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ABSTRACT
Mechanical loading plays a key role in the physiology o f bone, allowing bone to 
functionally adapt to its environment. A screen for genes associated with mechanical 
load-induced bone formation identified the glutamate transporter GLAST, implicating 
the excitatory amino acid glutamate in the mechanoresponse. Bone cells express 
functional components from each stage of the glutamate signalling pathway.
Five high affinity Na+-dependent excitatory amino acid transporters (EAATs) 
terminate glutamatergic signalling. EAAT1 (GLAST) is expressed by osteocytes and 
bone-forming osteoblasts in vivo, and may influence osteogenesis by regulating 
glutamate uptake, glutamate release, glutamate-gated ion channel activity or through 
activation of intracellular signalling pathways. The aim was to assess EAAT 
expression and function in osteoblasts and determine whether modulation o f EAAT 
activities in osteoblasts influences differentiation and bone forming activity through 
measurement of cell number, gene expression, alkaline phosphatase (ALP) activity 
and mineralisation.
QRT-PCR revealed mRNA expression o f EAATs 1-3 and both splice variants of 
EAAT1 (EAATla and EAATlex9skip) in human osteoblast-like cell lines (MG-63 
and SaOS-2) and human primary osteoblasts. 14C-glutamate uptake assays revealed 
Na+-dependent glutamate transport in osteoblasts, consistent with functional EAAT 
activity. Over-expression o f EAAT la  and EAATlex9skip in MG-63 and SaOS-2 by 
antisense mediated exon skipping reduced Na+-dependent glutamate uptake, 
indicating decreased transport function of these variants.
EAAT activity was modulated in osteoblasts at OpM or 500pM extracellular 
glutamate concentrations by inhibitors of EAATs 1-5 (/-PDC and TBOA), over- 
expression of EAAT 1 splice variants and through transient transfection o f expression 
vectors encoding competing peptides to EAAT1 intracellular domains. In the absence 
of glutamate, EAAT inhibitors increased osteoblast-like cell number and inhibited 
SaOS-2 ALP activity and mineralisation. In contrast, TBOA increased ALP activity in 
primary human osteoblasts cultured for 5 days in the presence of exogenous 
glutamate. EAAT inhibitors also significantly affected mRNA expression of 
osteocalcin, osteonectin, osteoprotegerin and ALP. Overexpression of EAATlex9skip 
increased SaOS-2 ALP activity at OpM glutamate while overexpression of EAAT la  
decreased SaOS-2 osteocalcin mRNA levels at both glutamate concentrations. 
Overexpression of EAAT 1 splice variants also affected cell number o f each cell line 
analysed and competing peptides to EAAT1 C-terminal domain increased MG-63 cell 
number at 500pM glutamate. Inhibition of EAAT 1 intracellular interactions regulated 
expression of osteocalcin mRNA in both osteoblast-like cell lines and decreased OPG 
mRNA expression in SaOS-2 cells. Overall, specific EAAT modulation could 
increase both osteoblast cell number and differentiation.
These data show for the first time that EAATs are functional in human osteoblasts and 
that inhibition of their activity can modulate the osteoblast bone-forming phenotype. 
Manipulation of these mechanically regulated glutamate transporters may represent a 
new therapeutic approach for the treatment of fractures and disorders such as 
osteoporosis where the bone is biologically and structurally compromised.
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Chapter 1: 
Introduction
Chapter 1
1. Introduction
There is a pressing need to identify new targets for anabolic bone therapies. This 
thesis will examine the role of the glutamate signalling pathway, with specific 
attention to the glutamate transporters, in the regulation of bone formation, and 
investigate mechanisms to modulate this pathway to achieve increased bone 
formation. The following introduction provides an overview of bone tissue, discussing 
its structure, composition, formation and associated pathologies. The glutamate 
signalling pathway, with emphasis on the glutamate transporters, is then introduced 
and the literature regarding the role of glutamate in bone reviewed.
1.1 Bone physiology and function
Bones are rigid organs that form the human skeletal system and are responsible for a 
diverse range o f functions including haematopoiesis, mineral homeostasis (most 
notably calcium and phosphorus), protection o f the body’s organs, attachment sites 
for muscles to generate movement and determinants of our size and shape (Dempster 
2006).
The human skeleton is formed of 206 bones which are grouped into the axial and the 
appendicular skeletons (reviewed in (Standring 2004) and discussed below). The axial 
skeleton forms the long axis o f the body and consists of bones o f the skull, vertebral 
column and rib cage which are primarily responsible for support and protection. The 
appendicular skeleton is comprised of bones of the upper and lower limbs, and the 
girdles that attach the limbs to the axial skeleton. 126 bones form the appendicular 
skeleton and its main function is movement.
The bones within the body can be categorised into five types: long, short, flat, 
irregular and sesamoid. Long bones (e.g. humerus, tibia, femur, ulna, metacarpals) 
contain a shaft (the diaphysis) that is longer than it is wide, and these bones often 
work as levers in the upper and lower extremeties (Figure 1.1). They are mainly 
composed of compact bone with some trabecular bone and marrow within the 
medullary cavity. Short bones are cube-shaped and have a thin layer of compact bone 
surrounding a trabecular interior. Short bones are located in the wrist and ankle. Flat 
bones are thin and often curved, with parallel layers of compact bone sandwiching a
1
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Bone Structure
Figure 1.1. Main features o f  a long bone. Long bones contain a hard outer layer o f 
cortical bone and spongy trabecular bone at the epiphysis and metaphysis. The 
Haversian system is the main functional unit o f compact bone and comprises 
concentric layers o f  bone (lamellae) surrounding a central Harversian canal which 
contains nerve and blood supplies for the bone. Osteoblasts become trapped within 
the matrix, forming osteocytes that live within their own small space (lacuna) and 
connect with one another via a network of canals (canaliculi). Figure source: 
Anatomy and Physiology by (Pack 2001). Figure reprinted with permission o f John 
Wiley & Sons, Inc. Copyright (John Wiley & Sons, Inc. 2010).
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layer of trabecular bone. Flat bones have broad surfaces for protecting organs and the 
attachment of muscles and are common within the skull and the sternum. Irregular 
bones do not fit into the above categories; they are of varied shapes and sizes and 
include bones of the vertebrae, hips and some in the skull. Sesamoid bones e.g. the 
patella, are special types of short bone that are embedded in tendons and hold the 
tendon away from the joint, increasing its angle and therefore increasing the force of 
the muscle.
1.1.1 Bone composition
Two forms of bone exist within the human skeleton; trabecular and cortical. Cortical 
bone accounts for about 80% of the skeletal mass (Parfitt 1983) and is highly resistant 
to bending and torsion, providing strength to the skull and the shafts o f long bones. 
Trabecular bone, also known as cancellous or spongy bone, is more porous, and is 
found in the epiphyseal and metaphyseal regions o f long bones (Figure 1.1), the 
interior o f short bones and constitutes the majority of the bone tissue in the axial 
skeleton (Johnson 1964). Trabecular bone forms 20% of the skeletal mass (Parfitt 
1983) but accounts for 80% of its surface area due to its spongy structure which is 
formed from bundles of short, parallel strands of bone fused together (Jee 1983). 
Plates and rods (trabeculae) represent the two basic microarchitechtural features of 
trabecular bone and are important in determining its mechanical properties. Plates 
have a flat structure while rods are cylindrical. Trabecular plates play an important 
role in determining the yield strength of human trabecular bone and the arrangement 
of trabeculae is highly adapted to the mechanical environment (Liu et al. 2006; 
Stauber et al. 2006; Liu et al. 2008; Liu et al. 2009). A recent study of femoral, tibial 
and vertebral trabecular bone demonstrated that the majority o f plates aligned with the 
longitudinal axis and the rods primarily aligned with the transverse plane (Liu et al. 
2008). Compressive loading o f vertebral trabecular bone indicates that longitudinal 
plates withstand the majority of axial loading and transverse rods act as links to 
stabilise the structure (Liu et al. 2009).
Bone is deposited first as disorganised woven bone, or primary bone, that forms 
quickly but is weak and contains small amounts of randomly orientated collagen 
fibres which convey isotropic mechanical properties to the tissue i.e. it adapts to 
forces from any direction in a similar fashion (Smith 1960; Su et al. 1997; Su et al.
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2003). Woven bone contains a high number of cells per unit volume that are randomly 
arranged. In humans, woven bone is resorbed by one year of age and replaced by 
lamellar bone which is highly organised, stronger and contains many highly organised 
collagen fibres within parallel columns called osteons (Bullough 1992; Buckwalter et 
al. 1996a). The osteon (or Haversian system) is the main functional unit of compact 
bone (Figure 1.1) (Parfitt 1983; Buckwalter et al. 1996a). Compact bone tissue forms 
concentric layers (lamellae) surrounding a central Harversian canal which contains 
nerve and blood supplies for the bone. The bone-forming cells, osteoblasts, form the 
osteon externally to internally and some become trapped within the matrix, forming 
osteocytes that live within their own small space (lacuna) (Mundy 1999) and connect 
with one another via extended cell processes within a network of canals (canaliculi). 
In each lamella, the collagen fibres run parallel to one another, but at an angle to 
fibres within adjacent lamellae (Giraud-Guille 1988). The organised, stress-orientated 
alignment of collagen fibres in lamellar bone gives it anisotropic properties which 
allow different mechanical responses to the orientation of an applied force. Osteons 
are separated from one another by cement lines (Schaffler et al. 1987; Burr et al. 
1988) and Volkmann’s canals which run perpendicular to Harversian canals and are 
responsible for connecting osteons to each other and connecting the blood vessels o f 
the Haversian canals with the periosteum
Bone is composed o f primarily four types of cells; osteoblasts, osteoclasts, osteocytes 
and bone lining cells in conjunction with an acellular matrix (Buckwalter et al. 1996b,
a)
1.1.1.1 Osteoblasts
Osteoblasts are mononucleated bone cells that differentiate from mesenchymal stem 
cells (MSCs) o f the bone marrow. MSCs are also capable of differentiating into cells 
of the adipocyte, myocyte and chondrocytic lineages (Owen and Friedenstein 1988; 
Aubin et al. 1995; Gimble et al. 1996; Prockop 1997). The transcription factors runt- 
related transcription factor-2 (Runx2), distal-less homeobox-5 (Dlx5) and msh 
homeobox homologue-2 (Msx2) are required to direct the stem cells towards to the 
osteoblast lineage (Ducy et al. 1997; Komori et al. 1997; Bendall and Abate-Shen
2000). Pre-osteoblasts express type I collagen and bone sialoprotein and require the 
expression of Runx2, osterix (Osx) and components of the Wnt signalling pathway to
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further differentiate into the mature bone-forming osteoblast phenotype (Ducy et al. 
1997; Nakashima et al. 2002; Glass et al. 2005; Hu et al. 2005). Osteoblasts are 
morphologically characterised as plump, cuboidal cells with a prominent rough 
endoplasmic reticulum and Golgi complex, reflecting high metabolic activity and 
secretion. Mature osteoblasts are present at the bone surface where they produce the 
osteoid (unmineralised bone matrix) and alkaline phosphatase (ALP), an enzyme that 
has a role in mineralisation of bone (Robison 1923; Moss et al. 1967; Majeska and 
Wuthier 1975; Fallon et al. 1980; Rezende et al. 1994). Osteoblasts are also able to 
produce cytokines and hormones such as prostaglandins that regulate bone growth 
and the activity o f neighbouring bone-resorbing osteoclasts (Vaes 1988; Suda et al. 
1992). Mature osteoblasts have one of three fates; they may die, become embedded 
within the bone matrix as osteocytes, or cease bone matrix synthesis and become bone 
lining cells (Parfitt 1987; Miller et al. 1989).
1.1.1.2 Osteoclasts
Osteoclasts are large, multinucleated cells derived from a monocyte-cell lineage and 
are located on the bone surface where they form resorption pits. Fusion of 
mononuclear cells to form multinuclear immature pre-osteoclasts requires the 
presence of macrophage colony-stimulating factor (M-CSF) and a member of the 
tumour-necrosis factor family, the receptor activator of nuclear factor kB ligand 
(RANK-L) (Felix et al. 1990; Kodama et al. 1991; Suda et al. 1992; Nakagawa et al. 
1998). RANK-L is expressed at the cell surface of osteoblasts and interacts with the 
osteoclast cell-surface receptor RANK (Fuller et al. 1998; Lacey et al. 1998). 
Osteoprotegerin (OPG), a soluble decoy receptor for RANK-L, is secreted by 
osteoblasts and competes with osteoclast RANK for binding sites (Yasuda et al. 
1998a; Yasuda et al. 1998b). Osteoblasts are therefore able to regulate 
osteoclastogenesis both positively and negatively by altering the balance o f OPG and 
RANK-L expression (Simonet et al. 1997; Yasuda et al. 1998b). The continued 
presence of osteoblast RANK-L is necessary for further osteoclast differentiation to a 
mature osteoclast, and regulation of its bone-resorbing activity and survival (Burgess 
et al. 1999; Udagawa et al. 1999). Activated pre-osteoclasts migrate and attach to the 
matrix, forming a compartment into which they pump hydrogen ions to solubilise the 
mineral substrate and secrete proteases that digest the organic component (Delaisse et
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al. 1991; Blair et al. 1993; Delaisse et al. 1993; Goto et al. 1993; Wucherpfennig et al. 
1994; Holliday et al. 1997). Osteoclasts are highly polarised when physiologically 
active, with an apical membrane at the contact with bone and a basolateral membrane 
at its opposite (Mulari et al. 2003). Actively resorbing osteoclasts are typified by a 
characteristic organisation o f F-actin into a ring called the sealing zone, which 
restricts proton and enzyme secretions to the resorption lacuna (Vaananen et al. 2000).
1.1.1.3 Osteocytes
Osteocytes are the most abundant cell type in bone (Parfitt 1977) and are 
differentiated from osteoblasts that have become trapped within the bone matrix and 
begin to express the early osteocyte marker E l 1 (Wetterwald et al. 1996). Osteocytes 
are smaller than osteoblasts and have lost many of their cytoplasmic organelles (Jande 
and Belanger 1973; Irie 2000). These cells occupy non-mineralised spaces called 
lacunae and have a dendritic morphology with many cellular processes extending 
within canaliculi that reach out to meet neighbouring osteocytes, surface bone cells 
(Doty 1981; Menton et al. 1984; Bonewald 1999) and bone marrow (Kamioka et al.
2001), facilitating communication (Palumbo et al. 1990). Contact of osteocytes with 
the bone marrow gives this cell type the potential to recruit osteoclast precursors to 
stimulate bone resorption (Baylink et al. 1973; Zhao et al. 2002) and regulate 
mesenchymal stem cell differentiation (Hartmann 2006). Apoptosis o f osteocytes in 
the vicinity of microcracks has been shown to act as an activator o f osteoclastogenesis 
and stimulate resorption of the deteriorated bone in that area (Noble et al. 2003; Gu et 
al. 2005; Kurata et al. 2006; Seeman and Delmas 2006). Mature osteocytes express 
dentin matrix protein-1 (DMP-1), matrix extracellular phosphoglycoprotein (MEPE) 
and sclerostin (SOST) (Feng et al. 2003; Nampei et al. 2004; van Bezooijen et al.
2004). Proposed osteocyte functions include matrix maintainance, calcium and 
phosphate homeostasis (Belanger 1969; Feng et al. 2006; Lorenz-Depiereux et al.
2006) and regulation of the bones response to mechanical load (Skerry et al. 1989; 
Mullender and Huiskes 1995; Lanyon 1996; Noble et al. 1997; Burger and Klein- 
Nulend 1999; Bonewald 2006).
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1.1.1.4 Bone lining cells
Bone lining cells are the second most abundant cell type in bone and cover more than 
90% of the surfaces o f adult bone (Parfitt 1983), connecting to osteocytes and 
osteoblasts via gap junctions (Doty 1981; Menton et al. 1984; Bonewald 1999). Bone
lining cells have a flattened morphology with few cellular organelles suggesting that
these cells do not actively produce matrix (reviewed in (Nakamura 2007)). They line 
bone surfaces that are not undergoing modelling or remodelling and are thought to be 
inactive osteoblasts which have ceased matrix synthesis (Miller et al. 1989; Miller 
1992). Bone lining cells form a thin continuous sheet that may have a role regulating 
the movement o f calcium and phosphate into and out of bone (Miller et al. 1989). 
Removal o f bone lining cells is necessary for osteoclastic bone resorption to 
commence (Jones and Boyde 1976; Zambonin Zallone et al. 1984), exposing the 
underlying bone matrix (Chambers and Fuller 1985).
1.1.1.5 Bone matrix
The cellular component of bone makes up only a small proportion o f its mass, with 
the rest composed of extracellular matrix. Bone matrix consists o f both inorganic and 
organic parts. Crystalline mineral salts and calcium in the form of hydroxyapatite 
make up the inorganic component while type I collagen forms 95% of the organic 
element (Burgeson 1988). Collagen fibrils in bone are extensively cross-linked, both 
intra- and intermolecularly, making them highly insoluble (Glimcher and Katz 1965). 
Non-collagenous proteins are also present; growth factors such as transforming 
growth factor-beta (TGF-P) and insulin-like growth factors (IGFs), cell attachment 
factors, proteoglycans and serum-derived y-carboxylated proteins that bind to the 
mineral component of bone (reviewed in (Heinegard and Oldberg 1989; Canalis 1993; 
Sommerfeldt and Rubin 2001)). Cell attachment factors include fibronectin, 
thrombospondin, osteopontin and bone sialoprotein (Oldberg et al. 1986; Somerman 
et al. 1988; Robey et al. 1989). Some of the non-collagenous proteins known to be 
present within bone are discussed below.
Osteopontin is a glycophosphoprotein secreted by osteoblasts, osteoclasts and 
osteocytes (Merry et al. 1993; Yamate et al. 1997) and is capable o f binding to cells 
and the hydroxyapatite matrix. Osteopontin influences bone homeostasis by inhibiting
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mineralisation (Hunter et al. 1996; Steitz et al. 2002; Pampena et al. 2004) and by 
promoting differentiation and activation of osteoclasts (Tani-Ishii et al. 1997; Faccio 
et al. 1998; Yoshitake et al. 1999; Ihara et al. 2001; Ishijima et al. 2001; Faccio et al. 
2002; Chellaiah et al. 2003).
Bone sialoprotien is found exclusively in mineralised tissues such as bone and dentin 
(reviewed in (Ganss et al. 1999)) and there is much evidence to suggest bone 
sialoprotien is a marker o f osteoblast differentiation and the onset of mineralisation 
(Chen et al. 1992; Chen et al. 1994; Cooper et al. 1998; Mizuno et al. 2000; Gordon et 
al. 2007).
Osteonectin is one of the most abundant non-collagenous proteins produced by 
osteoblasts and is a phosphorylated glycoprotein with a high affinity for Ca2+, 
hydroxyapatite, collagen (Termine et al. 1981), and thrombospondin (Clezardin et al. 
1988).
Osteocalcin is a y-caiboxylated protein found in bone (Glowacki and Lian 1987; 
Robey et al. 1989). Expression o f osteocalcin is restricted to late osteoblasts and its 
serum level is commonly used as a marker of bone turnover in metabolic disease 
(Price et al. 1980; Watts 1999).
Proteoglycans comprise o f a central core protein and polysaccharide side chains 
called glycosaminoglycans. In bone, various proteoglycans have been detected 
including small leucine-rich proteoglycans (SLRPs), heparan sulphate, aggregan and 
hyaluronic acid (reviewed in (Lamoureux et al. 2007)). In bone tissue, proteoglycans 
have structural roles, controlling collagen fibrillogenesis, and also act as co-receptors 
for some cytokines.
1.1.2 Bone formation
Two major mechanisms of osteogenesis exist and both involve the conversion of 
mesenchymal tissue into bone tissue. Intramembranous ossification is the direct 
transformation o f mesenchymal tissue to bone whereas formation of endochondral 
bone occurs via a hyaline cartilage model that is formed by differentiated 
mesenchymal cells (Cancedda et al. 2000; Karsenty and Wagner 2002; Eames et al. 
2003).
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1.1.2.1 Intramembranous ossification
In the human body, bones formed by intramembranous ossification include flat bones 
of the skull, the clavicle and the pelvis. During intramembranous ossification, 
mesenchymal cells proliferate and condense into compact nodules (Hall and Miyake 
1992; Huang et al. 1997). Some mesenchymal cells become osteoblasts that secrete 
bone matrix while others develop into fibroblasts and blood vessels (reviewed in 
(Buckwalter et al. 1996a)). As the secreted matrix calcifies, bony spicules radiate out 
from the point o f ossification to become surrounded by compact mesenchymal cells 
forming the periosteum (Buckwalter et al. 1996a; Gilbert 2006). Beneath the 
periosteum, osteoblasts deposit matrix parallel to existing spicules, forming many 
layers o f bone (Cohen 2006; Gilbert 2006).
1.1.2.2 Endochondral ossification
Endochondral ossification (Figure 1.2) replaces a hyaline cartilage model with bone 
tissue to form long bones, increase the length of long bones and represents an 
essential process for the healing of bone fractures (reviewed in (Erlebacher et al. 
1995)). Mesenchymal tissue differentiates to form a hyaline cartilage model bordered 
by a perichondrium. Chondrocytes secrete a matrix rich in type II collagen and the 
proteoglycan aggrecan. Chondrocytes within the central region of the cartilage stop 
proliferating, enlarge and mature to hypertrophic chondrocytes that secrete a different 
extracellular matrix to that of proliferating chondrocytes i.e. a greater amount of type 
X collagen over type II collagen (Iyama et al. 1991). Hypertrophic chondrocytes also 
secrete angiogenic factors, such as vascular endothelial growth factor (VEGF) 
(Geiber et al. 1999), that induce sprouting angiogenesis from the perichondrium 
(called the periosteol bud) during the third month of human fetal development 
(Karsenty 1999; Olsen et al. 2000). The periosteal bud consists of lymph vessels, 
nerves, and blood vessels, which are a source of haematopoietic cells, osteoblasts and 
osteoclasts (Olsen et al. 2000; Colnot and Helms 2001). This results in the formation 
of primary ossification centres. The cartilage perichondrium becomes the periosteum 
which contains a layer of undifferentiated cells that go on to become osteoblasts (Hall 
and Miyake 2000; Eames et al. 2003; Colnot et al. 2004). These osteoblasts generate a 
collar of compact bone around the primary ossification centre.
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Figure 1.2. Schematic diagram o f  endochondral ossification. (A) Mesenchymal 
cells condense and commit to the chondrocyte lineage and (B) form a cartilaginous 
model o f  the bone. (C,D) Chondrocytes proliferate and the cells in the centre o f the 
diaphysis become hypertrophic and apoptose as they mineralise their matrix. (E) 
Blood vessels invade the space left by the chondrocytes and provide a source o f 
osteoblasts which attach to the cartilaginous matrix and begin to deposit osteoid. 
(F,G) Bone formation and growth occurs via cycles o f proliferating, hypertrophic and 
mineralising chondrocytes. Secondary ossification centres form at the tips o f  bone to 
promote lengthening o f  bones. Figure source: Developmental Biology, 8th edition by 
(Gilbert 2006). Figure reprinted with permission of Sinauer Associates, Inc. 
Copyright (Sinauer Associates, Inc. 2010).
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Within primary ossification centres, hypertrophic cartilage is degraded, the 
hypertrophic chondorcytes undergo apoptosis and osteoblasts secrete osteoid to 
replace the disintegrating cartilage which calcifies to form trabecular bone.
While these events occur in the centre of the cartilage mould, chondrocytes continue 
to proliferate, enlarging the mould. Ossification continues from the centre towards the 
ends of bones, and osteoclasts break down newly formed trabecular bone within the 
diaphysis to open up the medullary cavity (Roach and Shearer 1989; Colnot and 
Helms 2001). Haematopoeitic stem cells interact with the stroma to establish the bone 
marrow which constitutes the main site for haematopoieisis in post-natal life.
As the cartilage at the epiphysis continues to grow, the developing bone increases in 
length and secondary ossification centres form postnatally. Trabecular bone is 
retained at secondary ossification centres and no medullary cavity is formed. When 
secondary ossification is complete, hyaline cartilage remains in only two areas, over 
the surface o f the epiphysis as articular cartilage and between the epiphysis and the 
diaphysis forming the epiphyseal plate (or growth plate).
1.1.2.3 Bone growth
Bone growth is driven by growth hormone and sex hormones. The cartilage at the 
epiphyseal plate continues to grow by mitosis, and as the chondrocytes adjacent to the 
diaphysis age and die, they are replaced by osteoblasts and bone matrix (Hunziker 
1994). This process continues into adolescence at which point cartilage growth slows 
and stops, and the epiphyseal plate ossifies to leave a thin epiphyseal line. At this 
stage, bones can no longer grow in length. However, bones can continue to thicken 
and widen by appositional growth throughout life. Appositional growth occurs 
through deposition of bone by osteoblasts beneath the periosteum and degradation of 
bone within the medullary cavity by osteoclasts.
1.2 Bone remodelling
Bone is a dynamic tissue that is continuously self-renewing and responding to 
environmental cues by remodelling itself. Bone remodelling is the making o f cavities 
by osteoclasts and the subsequent filling o f these cavities by osteoblasts to maintain
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skeletal integrity. At any one time, this process is occurring at multiple places 
throughout the skeleton. In normal young adults, equilibrium exists between bone 
resorption and bone formation and this depends on the coordinated differentiation and 
activation of osteoblasts and osteoclasts (Frost 1964). The team o f cells involved in 
bone remodelling are collectively termed the basic multicellular unit (BMU). The 
BMU is a distinct, temporary, 3-dimensional form that moves along bone, with 
osteoclasts lining the leading edge, followed by a group of mononuclear cells that line 
the resorption pit during the period between resorption and formation (reversal phase) 
(Parfitt 1983, 1994). Rows of osteoblasts then adhere to the reversal zone and deposit 
layers o f unmineralised bone matrix (osteoid) (Figure 1.3). The BMU is covered by a 
canopy of cells, which are most likely bone-lining cells connected to bone-lining cells 
on the quiescent bone surface (Hauge et al. 2001). Hague et al. have also shown that 
capillaries penetrate the canopy of bone-lining cells and presumably provide the 
vascular supply to the BMU as well as possibly providing the cells required for the 
remodeling process (Kassem et al. 1991b; Kassem et al. 1991a; Hauge et al. 2001; 
Eghbali-Fatourechi et al. 2005). Therefore, the BMU exists within a bone remodelling 
compartment (BRC) which consists of the BMU, the cell canopy and capillaries, and 
the BRC has been shown to exist in both cortical and cancellous bone (Hauge et al. 
2001).
The resorption and formation processes are said to be coupled to one another (Frost 
1964) and this coupling is a controlled process that ensures new bone is restored after 
old bone is removed, maintaining the bone balance (Parfitt 2000). This balance is 
achieved locally through the action of cytokines and growth factors such as TGF-P, 
bone morphogenetic proteins (BMPs), platelet-derived growth factor (PDGF), and 
IGF, and systemically by hormones such as oestrogen and parathyroid hormone 
(PTH) (Canalis 1983; Canalis et al. 1989; Canalis 1993). Within the BMU, osteoclast 
differentiation and resorption is also regulated by osteoblasts via the 
OPG/RANK/RANK-L system (Yasuda et al. 1998a; Yasuda et al. 1998b) and it is 
also thought that osteoclasts can enhance osteoblast differentiation and function 
(Martin and Sims 2005). Most skeletal disorders are caused by uncoupling of this 
remodelling process, favouring either bone resorption (osteoporosis) or bone 
formation (osteopetrosis) (Mundy et al. 2001).
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Figure 1.3. Normal bone remodelling The bone remodelling compartment (BRC) 
comprises the cells o f the basic multicellular unit (BMU) i.e. osteoclasts, osteoblasts 
and osteocytes as well as a cover o f bone-lining cells and the associated vasculature 
(i) Activation: osteoclast precursors differentiate into mature bone-resorbing cells in 
response to activating factors. Osteoclasts resorb bone mineral and matrix, creating an 
erosion cavity, (ii) Reversal: osteoclasts apoptose and mononuclear cells prepare the 
bone surface for osteoblast bone formation, (iii) Formation: osteoblasts synthesise an 
organic matrix to fill the cavity, which is then mineralised, (iv) Resting: the bone 
surface is covered with flattened lining cells. OC, osteoclast; OB, osteoblast. Adapted 
from (Eriksen et al. 2007) and the MRC human research unit, bone and calcium 
metabolism webpage (last accessed 23 May 2010) <http://www.mrc- 
hnr.cam.ac.uk/researclVbone health/bcm.html>.
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1.2.1 Uncoupled bone remodelling
Abnormalities in bone remodelling are common in many disease states such as 
osteopetrosis and osteoporosis (Table 1.1). A change in BMU dynamics, either 
activation or the speed of remodelling, can have significant effects on the bone 
balance. Furthermore, determining the etiology of diseases characterised by 
uncoupled bone remodelling may help to identify the normal factors that are 
responsible for controlling bone remodelling. For example, the importance of 
sclerostin as a negative regulator of bone formation was discovered through research 
into the high bone mass disorder sclerosteosis (Balemans et al. 1999; Balemans et al. 
2001; Brunkow et al. 2001; Winkler et al. 2003; van Bezooijen et al. 2004).
1.2.1.1 Osteosclerosis
Sclerosing bone dysplasias are characterised by an increase in bone density and are 
inherited heterogeneously.
1.2.1.1.1 Osteopetrosis
Osteopetrosis is a family o f sclerosing bone dysplasias characterised by defective 
osteoclast function and impaired bone resorption without an alteration in overall bone 
shape (Van Hul et al. 2001; Whyte 2002). The lethal form and several intermediate
Table 1.1. Uncoupled bone remodelling in human disorders (adapted from  (Raisz 
1999))
Bone resorption Bone formation
Osteoporosis t t t
Disuse osteoporosis i 14
Inflammation Tt 1
Osteopetrosis U T
Sclerosteosis T TT
Van Buchems T TT
14
Chapter 1
forms are inherited as autosomal recessive traits whereas the mild form is inherited as 
an autosomal dominant trait (Johnston et al. 1968; Beighton et al. 1979; Bollerslev 
and Andersen 1988). A primary abnormality in the osteoclast or its stem cell 
precursor has been proposed as the underlying cause of osteopetrosis (Marks 1984; 
Rouleau et al. 1986). Studies o f mammalian osteopetrosis suggest that genetic 
abnormalities are present in osteoclast precursor cells (Van Slyke and Marks 1987). 
Experimental models of the disease have been successfully treated by bone marrow 
transplantation (Walker 1993), a procedure that has been translated to humans in the 
severest of cases (Driessen et al. 2003).
1.2.1.1.2 Sclerosteosis
Sclerosteosis is a rare bone disorder characterised by sclerosis of the skeleton, 
particularly the skull and mandible resulting in facial distortion, raised intracranial 
pressure and entrapment o f cranial nerves (Beighton et al. 1976; Beighton and 
Hamersma 1979; Beighton 1988; Hamersma et al. 2003). Sudden death can occur as a 
result of impaction o f raised intracranial pressure. Sclerosteosis is due to loss of 
function mutations in the SOST gene and inherited as an autosomal recessive trait 
with heterozygotes clinically normal (Balemans et al. 1999; Balemans et al. 2001; 
Brunkow et al. 2001; Winkler et al. 2003; van Bezooijen et al. 2004). Sclerosteosis is 
the result o f increased bone formation and unaffected bone resorption leading to 
increased bone mass (van Bezooijen et al. 2005).
1.2.1.1.3 Van Buchem disease
Van Buchem disease is inherited as an autosomal recessive trait and clinically 
presents very similarly to sclerosteosis, with thickening of the skull, mandible, 
clavicles and diaphysis o f long bones (Van Buchem et al. 1962; van Buchem 1971). 
However, in contrast to sclerosteosis sufferers, patients with van Buchem disease 
have a large stature and hand malformations (Beighton et al. 1984). Sclerosteosis and 
van Buchem disease are both characterised by increased bone formation and map to 
the same chromosomal 17ql2-q21 region (Van Hul et al. 1998; Balemans et al. 1999). 
Patients with van Buchem disease were not found to have mutation in the SOST gene, 
but had a deletion downstream of the SOST gene (Balemans et al. 2002; Staehling-
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Hampton et al. 2002) that was later found to include an enhancer element that drives 
SOST expression (Loots et al. 2005).
1.2.1.2 Osteoporosis
Osteoporosis is the most common metabolic disorder of the skeleton (Raisz 1997). 
One in two women and one in five men over the age of 50 in the UK will fracture a 
bone as a result o f osteoporosis (van Staa et al. 2001). Osteoporosis is characterised 
by low bone mass and structural deterioration of bone tissue, resulting in bone 
fragility and increased risk o f fracture. The costs of osteoporosis are both health- 
related and financial. In the UK, the mortality following a hip fracture is 18% (Todd 
et al. 1995) and osteoporosis related fractures cost the health service an annual sum of 
over £1 billion (Torgensen 2001; PRODIGY 2006). Osteoporotic risk is dependent 
upon peak bone mass which declines with age, making osteoporosis a problem that 
accompanies the ageing population (Maravic et al. 2005) (Figure 1.4). Indeed, the 
number of hip fractures worldwide is expected to increase from 1.7 million in 1990 to
6.3 million in 2050 (Johnell 1997). Peak bone mass is reached by the age of about 20, 
after which bone is resorbed more rapidly than it is formed. Males and females are 
affected differently; by old age, women tend to have lost half their trabecular bone 
and one third o f their cortical bone whereas men typically lose one third of their 
trabecular bone and one fifth of cortical bone (Goldberg 2004). Bone mass in women 
also declines sharply for 5 years during the menopause as a result of decreased 
oestrogen production (Riggs et al. 1986; Wark 1993) and oestrogen deficiency is 
relevant to the pathogenesis of osteoporosis in both men and women (Riggs et al. 
1998). Optimising peak bone mass is therefore key in reducing the risk of 
osteoporosis in later life.
Skeletal fragility can be the result of (1) failure to generate a skeleton of appropriate 
mass and strength during early development; (2) disproportionate bone resorption 
leading to decreased bone mass and a loss of skeletal microarchitechture; or (3) an 
insufficient formation response to increased bone resorption during remodelling 
(reviewed in (Raisz 2005)). Experimental evidence suggests that at menopause there 
is accelerated bone remodelling, and that while bone formation increases overall, it is 
insufficient to replace the bone lost by resorption (reviewed in (Raisz 2005)). This
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defect in osteoblast function may be due to cellular senescence or the result of a 
decrease in the synthesis or activity of systemic and local growth factors (Raisz 2005).
1.2.1.3 Disuse osteoporosis
Mechanical loading of the skeleton directs bone remodelling (Robling 2006). Bone 
loss as a result o f reduced mechanical loading of the skeleton is termed disuse 
osteoporosis. Disuse results in bone loss due to bone resorption exceeding formation 
(Weinreb et al. 1989; Bain and Rubin 1990; Zerwekh et al. 1998; Rantakokko et al. 
1999; Li etal. 2005b).
Disuse osteoporosis affects astronauts and chronically immobilised patients, such as 
those suffering from spinal cord injury or stroke (Szollar et al. 1998; Kanis et al. 
2001; Wang et al. 2001). Disuse results in an increased fracture risk (Vestergaard et 
al. 1998; Kanis et al. 2001) as a result of decreased mineral density (Kaneps et al. 
1997; Lang et al. 2004) and a loss o f trabecular architecture (Li et al. 2005a) and bone 
strength (Kaneps et al. 1997; Li et al. 2005b).
1.2.1.4 Treatments for osteoporosis
The majority o f currently available therapeutics for osteoporosis target bone 
resorption. Anti-resorptives such as oestrogen, selective oestrogen receptor 
modulators, calcitonin and the bisphosphonates have had a major impact on 
osteoporosis treatment; however no dramatic increases in bone mass are achieved. 
Bisphosphonates are the first line o f treatment for osteoporosis and this class of drugs 
are stable structural analogues of inorganic pyrophosphate that selectively adsorb to 
mineral surfaces (Jung et al. 1973). Bisphosphonates are internalised by bone 
resorbing osteoclasts and interfere with various biochemical processes within these 
cells to inhibit bone resorption (reviewed in (Russell 2007)). Bisphosphonates 
accumulate in bone, for years after treatment is discontinued (Lin 1996; Khan et al. 
1997; Papapoulos and Cremers 2007), and the stored drug can be released by 
continued remodelling allowing for persistent metabolic effects (Rodan 1997). This 
chronic suppression o f bone remodelling has led to concerns surrounding the long­
term use of these drugs. Furthermore, there is some evidence to suggest that 
bisphosponate treatment is linked to osteonecrosis of the jaw (Marx 2003; Ruggiero et
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al. 2004; Marx et al. 2005). Though, this has been more commonly reported for 
cancer patients receiving bisphosphonate treatment than patients with postmenepausal 
osteoporosis or Paget’s disease receiving the same therapy (reviewed in (Silverman 
and Landesberg 2009)).
Growth hormone, PTH and the statins represent potentially important anabolic agents 
(Rosen and Bilezikian 2001). Teriparatide (Forteo) marketed by Eli Lilly is the only 
anabolic agent currently approved by the food and drug administration (FDA) for the 
treatment of osteoporosis. It is a recombinant portion of human PTH (rhPTHl-34) 
which is a major regulator o f calcium and phosphate metabolism in bone and kidney. 
Teriparatide stimulates new bone formation (Dempster et al. 2001; Neer et al. 2001; 
Rubin and Bilezikian 2003; Sato et al. 2004) however it is only used for the treatment 
of advanced osteoporosis, requires daily injection and is very expensive. Furthermore, 
its use is restricted to 18 months in Europe as a result o f studies in rats that indicated 
an increased risk of osteosarcoma, and other animal studies that have demonstrated 
increased growth of tumours following treatment with PTH (Vahle et al. 2004; 
Schneider et al. 2005; Tashjian and Gagel 2006).
Promising new anabolic agents that encourage bone formation are under 
development, such as antibodies to RANK-L and sclerostin (McClung 2006; Ominsky 
2006; Padhi 2007).
Denosumab is a human monoclonal antibody to RANK-L that mimics the action of 
OPG by binding RANK-L and preventing the activation of osteoclasts. In published 
phase II and phase m  trials, denosumab was tested for safety and efficacy in 
postmenopausal women with low bone density and found to inhibit bone resorption 
and remodelling as measured by decreased markers of bone turnover and increased 
bone mineral density, particularly of the lumbar spine (McClung 2006; Lewiecki et al. 
2007; Bone et al. 2008; Miller et al. 2008; Brown et al. 2009).
Sclerostin is an osteocyte-specific glycoprotein and acts as a negative regulator of 
bone formation by inhibiting osteoblast differentiation (Winkler et al. 2003; van 
Bezooijen et al. 2004; Poole et al. 2005). The Wnt signalling pathway promotes the 
differentiation of osteoblasts and sclerostin blocks this pathway by binding to low 
density lipoprotein receptor-related protein 5/6 (LRP5/6) (Li et al. 2005c; Semenov et 
al. 2005; Semenov and He 2006). Sclereostosis and Van Buchem are diseases of very 
high bone mass characterised by mutations in the SOST gene which reduce the levels 
of the biologically active protein sclerostin (section 1.2.1.1.2-3) (Balemans et al.
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2001; Brunkow et al. 2001). Monoclonal antibodies to sclerostin aim to mimic its 
down-regulation in response to conditions that promote bone formation i.e. 
mechanical load and PTH (Bellido et al. 2005; Keller and Kneissel 2005; Robling et 
al. 2006). Studies with a humanised monoclonal antibody to sclerostin in 
ovariectomised female rats, postmenopausal women and primates have shown 
anabolic bone activity and increased bone mass (Ominsky 2006; Padhi 2007; 
Ominsky et al. 2010).
Since teriparatide is currently the only FDA-approved anabolic therapy for 
osteoporosis and its window o f use is limited, there is a clear clinical need for the 
development o f new anabolic bone agents. Understanding the molecular pathways 
that regulate osteoblast bone formation and therefore bone density and resistance to 
fracture is critical for the identification o f  new approaches to treat osteoporosis. The 
glutamate signalling pathway in bone has been proposed as a novel target for anabolic 
bone therapies (Mason et al. 1997; Spencer et al. 2004). Glutamate signalling has 
been implicated in the mechanoresponse (Mason et al. 1997) and modulation o f this 
pathway may offer the opportunity to prime the skeleton to mimic or enhance the
Age (years)
Figure 1.4. Decrease in bone mass and increase in fracture risk with age. The 
reduction in bone mass with age means that our ageing demographic will lead to an 
increased number o f individuals at risk o f fracture. Figure adapted from (Valsamis et 
al. 2006)
Bone mass _
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appropriate osteogenic response to mechanical stimulation (Mason 2004b; Spencer et 
al. 2004). Mechanisms to modulate the glutamate signalling pathway to this end will 
be addressed in the experimental portions of this thesis.
1.2.1.5 Fracture
1.2.1.5.1 Normal bom  repair
During normal bone repair following fracture, the mechanisms regulating 
osteogenesis during embryological development are recapitulated (section 1.1.2.2) 
(Ferguson et al. 1999). The majority o f fractures heal by indirect repair involving 
endochondral ossification and the formation of a callus (Einhom 1998). There are 
three main phases o f normal bone healing: inflammation, repair and remodelling 
(reviewed in (Greenbaum and Kanat 1993; Gerstenfeld et al. 2003) and summarised 
below). Inflammation occurs during the first two weeks after injury and is initiated 
after haemorrhage due to vascular injury and the formation of a haematoma. The 
haematoma provides a small amount of mechanical stability to the fracture site and 
also allows inflammatory cells and fibroblasts to infiltrate into the area. 
Vascularisation then occurs and granulation tissue forms at the fracture site (the 
procallus). The haematoma and the disrupted periosteum provide a source of 
osteoblast and chondrocyte precursors which differentiate and start to produce matrix. 
The repair phase begins with continued vascularisation, secretion of osteoid and the 
generation of a temporary callus across the fracture gap consisting of cartilage, 4-6 
weeks after injury. This callus has limited mechanical stability and immobilisation of 
the fracture site is often appropriate. A hard callus of woven trabecular bone is then 
formed by osteoblasts after 6-12 weeks, which is high in mass but has lower strength 
and stability than mature lamellar bone; the callus is ultimately reduced in size and 
remodelled to cortical lamellar bone. This process can take months to years and yields 
bone of normal size, strength and shape.
1.2.1.5.2 Non-union fracture
More than one million fractures occur in the UK each year and 5-10% of these 
experience problems in healing (Gaston and Simpson 2007). This percentage is likely
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to increase as the population ages and fragility fractures become more common 
(Gaston and Simpson 2007). Fractures that are slow to heal (delayed union) or fail to 
heal (non-union) can occur in any bone but are most likely in the tibia, talus, humerus 
and fifth metatarsal bone. Several factors contribute to a non-union including 
infection, mechanical instability, inadequate vascularity at the fracture site and 
systemic causes such as malnutrition, comorbidities, smoking and medications 
(Venkatachalapathy et al. 2007).
Non-unions are typically classified as hypertrophic or atrophic according to 
radiographic information. Hypertrophic non-union presents with decreased callus 
formation and an elephant-foot configuration at the fracture site. This type of non­
union appears to have an appropriate healing response and blood supply but is linked 
to inadequate immobilisation (Megas 2005). Atrophic non-unions show little callus 
formation surrounding a fracture gap filled with fibrous tissue. Atrophic non-unions 
are typified by inadequate vascularisation or insufficient availability o f bone forming 
cells or both, preventing normal bone healing from occurring (Megas 2005). This type 
of non-union is common following a high-energy injury, an open fracture, an infected 
fracture or following multiple failed internal fixation procedures (Dagrenat 2002).
1.2.1.5.2.1 Treatment fo r  non-union fracture
Treatment of hypertrophic non-unions involves the placement of stable fixation (nail, 
plate, or an external fixator) to provide stability and improve the mechanical 
environment without disrupting the blood supply. Atrophic non-unions require both 
mechanical stability and an adequate biological environment at the fracture site. 
Autologous bone grafts are commonly employed and represent a source of MSCs, 
scaffolding and growth factors e.g. BMPs, to enhance bone formation (Canalis et al. 
1989; Megas 2005; Phieffer and Goulet 2006). However, this strategy is restricted by 
donor site morbidity (Younger and Chapman 1989) and limited availability. 
Recombinant human BMP-2 (rhBMP-2; INFUSE® Bone Graft, Medtronic Spinal and 
Biologies) and BMP-7 (rhBMP-7; OP-1, Stryker) represent commercially available 
bone graft substitutes that are osteoinductive and have therapeutic application to 
treating non-union fracture. Both proteins are delivered on an absorbable collagen 
sponge and rhBMP-2 is currently FDA approved for use in spinal fusion, fresh tibial
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fractures, and oral maxillofacial bone grafting procedures whereas BMP-7 is FDA 
approved for long bone non-union and spinal fusion.
Non-invasive stimulation such as low-intensity pulsed ultrasound (Heckman et al. 
1994; Gebauer et al. 2005; Rutten et al. 2007) and electrical stimulation (Brighton et 
al. 1975; Connolly 1981) can also provide alternative treatments for non-union.
1.3 Mechanical loading
The importance of mechanical strain on the maintenance of bone architecture and 
adequate bone mass has been demonstrated by numerous animal and human studies. 
There is a dynamic relationship between bone structure and its mechanical 
environment allowing bone to functionally adapt. This is most notable in examples o f 
load-bearing exercise-induced increases in bone mass (Jones et al. 1977; Smith and 
Gilligan 1996) and the reduction in bone mass associated with reduced load-bearing 
typical of astronauts in weightless environments for extended periods of time 
(Donaldson et al. 1970; Smith and Gilligan 1996). High strain rates and short periods 
of loading have been identified as the mechanical loading parameters required to 
achieve a maximal osteogenic response (reviewed in (Skerry 1997; Burr et al. 2002)). 
The mechanoresponsive signalling pathways which convert mechanical load to 
cellular signals to account for this biological phenomenon are unclear, although there 
is evidence to suggest that osteocytes are the mechosensory cells in bone (Skerry et al. 
1989; Klein-Nulend et al. 1995; Mullender and Huiskes 1995; Lanyon 1996; Noble et 
al. 1997; Burger and Klein-Nulend 1999). Osteocytes are ideally situated to respond 
to mechanical load by transmitting osteogenic signals through their canalicular 
syncytium to cells at the bone surface which then release paracrine factors such as 
prostaglandins, nitric oxide (NO) and IGFs that signal progenitor cells to differentiate 
into bone-forming osteoblasts and inhibit osteoclastogenesis (Duncan 1995; Duncan 
and Turner 1995; Pitsillides et al. 1995; Burger and Klein-Nulend 1999; Ehrlich and 
Lanyon 2002; Rubin et al. 2003). Blockade of the gap junctions that exist between 
osteocytes and osteoblasts (Doty 1981) affects the response of bone to mechanical 
load (Li et al. 2006).
Osteocytes respond to short periods of load in vivo by increasing transcriptional and 
metabolic activities (Pead et al. 1988; Skerry et al. 1989). The physical signal that
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prompts these responses is not known; strain resulting from stress or stress induced 
canalicular fluid flow or both might activate bone cells (Piekarski and Munro 1977; 
Weinbaum et al. 1994). Chicken calvarial osteocytes experimentally exposed to fluid 
flow stress respond by releasing prostaglandins and NO (Klein-Nulend et al. 1995; 
Ajubi et al. 1999; Burger and Klein-Nulend 1999). Fluid flow stress may activate 
stretch activated channels (i.e. potassium channels), cell surface G-protein coupled 
receptors (GPCRs) or integrin receptors on osteocytes to stimulate 
mechanotransduction pathways (Duncan 1995).
In vivo, inhibition o f prostaglandin production in rats has indicated that prostaglandins 
represent an essential component of the mechanotransduction pathway leading to 
bone formation (Chow and Chambers 1994). Both primary osteocytes and the 
osteocyte-like MLO-Y4 cells can be mechanically induced to synthesise and release 
prostaglandin E2 (PGE2) (Ajubi et al. 1999; Cherian et al. 2005) which increases the 
cell surface expression of connexin (Cx) 43 protein and the formation of 
hemichannels (Cherian et al. 2005). PGE2 achieves this response by signalling through 
the prostaglandin EP2 receptor and the subsequent activation of cyclic adenosine 3',5'- 
monophosphate (cAMP)-dependent protein kinase A (PKA) (Cherian et al. 2005). 
Prostaglandin up-regulation in primary avian osteocytes following fluid flow stress 
appears to be dependent upon increased release of NO (Klein-Nulend et al. 1995). 
Human primary bone cell cultures constitutively express endothelial nitric oxide 
synthase (eNOS) (Klein-Nulend et al. 1998), and in vivo studies have linked increased 
NO production to the mechanoresponse (Fox et al. 1996; Turner et al. 1996). 
Expression o f eNOS in endothelial cells is related to the sensitivity o f these cells to 
blood fluid shear stress and causes NO release, up-regulated expression of 
prostaglandins, and induction o f c-fos (Uematsu et al. 1995; Busse and Fleming 1998; 
Chien et al. 1998; Davies et al. 1999) indicating that endothelial and bone cells use 
similar mechanisms for sensing fluid flow stress. The eNOS gene contains several 
promoter elements that respond to shear stress and oestrogen (Hayashi et al. 1995) 
and expression of eNOS is upregulated in human osteoblast-like cells exposed to 
oestrogen (Armour and Ralston 1998). Oestrogen is known to suppress bone 
resorption (Christiansen et al. 1982; Wronski et al. 1988) and its loss is therefore 
thought to play an important role in post-menopausal osteoporosis. Oestrogen has also 
been implicated as a direct stimulant of osteoblast function (Samuels et al. 1999a; 
Tobias and Compston 1999) and its osteogenic activity can be partially suppressed by
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inhibitors of NOS (Wimalawansa et al. 1996; Samuels et al. 2001) and prostaglandin 
synthesis (Samuels et al. 1999b). In vivo studies indicate that the oestrogen receptor 
alpha (ERa) is involved in the response of bone to mechanical strain, since primary 
osteoblast-like cells from ERa^' mice do not proliferate in response to mechanical 
load and rescue of this response requires transfection of a fully functional ERa (Lee et 
al. 2003)
The ubiquitous amino acid glutamate has been implicated in the mechanoresponse 
through a gene-screening experiment designed to identify osteogenic signalling 
components following mechanical loading in rat ulna (Mason et al. 1997). Expression 
of the glutamate-aspartate transporter (GLAST) was observed to be down-regulated in 
osteocytes after loading (Mason et al. 1997) and during recent years the glutamate 
signalling pathway has received attention as a mechanism that may link mechanical 
loading to bone formation.
1.4 Innervation of bone
Bone marrow, mineralised bone and periosteum are densely innervated (Calvo and 
Forteza-Vila 1969; Bjurholm et al. 1988a; Hill and Elde 1991; Serre et al. 1999). 
Direct contact between nerve fibers and bone cells has been demonstrated however no 
typical synapses were detected (Serre et al. 1999). Some nerve fibers terminate in 
varicosities at the bone/periosteum interface while others run within the Haversian 
and Volkmann’s canals of cortical bone (Hill and Elde 1991; Hukkanen et al. 1992) 
and are abundant along the epiphyseal trabeculae facing the growth plate and the 
metaphysis of long bones (Hara-Irie et al. 1996; Serre et al. 1999). Bone contains both 
sensory and sympathetic nerve fibers and a variety of neurotransmitters have been 
identified in bone by immuohistochemistry including the neuropeptides vasoactive 
intestinal polypeptide (VIP) (Lundberg et al. 1979; Hohmann et al. 1986; Bjurholm et 
al. 1988b), calcitonin gene-related peptide (CGRP) (Bjurholm et al. 1988a), pituitary 
adenylate cyclase activating peptides (PACAP), neuropeptide Y (Bjurholm et al. 
1988b), substance P (SP) (Bjurholm et al. 1988a) and the classic neurotransmitters 
noradrenalin (Duncan and Shim 1977), serotonin (Bliziotes et al. 2001) and glutamate 
(Serre et al. 1999). Functional receptors for many of these neurotransmitters have also 
been detected in bone cells in vitro (Hohmann and Tashjian 1984; Bjurholm et al.
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1992; Chenu et al. 1998; Serre et al. 1999; Westbroek et al. 2001; Elefteriou et al. 
2005; Bliziotes et al. 2006). Many studies have demonstrated that the nervous system, 
particularly the sympathetic nervous system (SNS), influences the regulation o f bone 
metabolism ((Takeda et al. 2002; Elefteriou et al. 2005), reviewed in (Chenu 2002; 
Takeda et al. 2002; Chenu 2004; Spencer et al. 2004; Elefteriou et al. 2005; Patel and 
Elefteriou 2007)). For example, denervation inhibits developmental skeletal growth in 
the rat foot (Edoff et al. 1997) and modulates the number of activated osteoclasts in 
the rat mandible and gerbil middle ear bulla bone (Hill and Elde 1991; Sherman and 
Chole 2000). Furthermore, changes in bone innervation have been associated with 
various skeletal pathologies including osteoarthritis, heterotopic bone formation and 
fracture repair (Bjurholm et al. 1990; Hukkanen et al. 1992; Hukkanen et al. 1993; 
Hukkanen et al. 1995; Li et al. 2001).
A central control o f skeletal homeostais via the hypothalamus has been proposed 
(Ducy et al. 2000; Takeda et al. 2002; Elefteriou et al. 2005; Sato et al. 2007). The fat- 
derived hormone leptin can control bone formation through a hypothalamic relay and 
mice deficient in leptin display increased bone formation leading to high bone mass 
(Ducy et al. 2000). Binding of leptin to its hypothalamic receptor is sufficient to 
stimulate sympathetic nerves to release noradrenalin into the bone microenvironment 
and activate p2-adrenergic recpetors on osteoblasts, inhibiting their osteogenic 
activity and resulting in bone loss (Ducy et al. 2000; Takeda et al. 2002). Similarly, 
mice deficient in Y2 receptors for neuropeptide Y display a two-fold increase in 
trabecular bone volume and intracerebroventricular administration of neuropeptide Y 
leads to bone loss (Baldock et al. 2002).
However, the adaption o f bone to mechanical load is highly site specific (Rubin and 
Lanyon 1984) and therefore unlikely to be centrally controlled (Hert et al. 1971; 
Pitsillides et al. 1995; Cheng et al. 1996). Innervated and denervated limbs have been 
shown to react to loading in the same way (Hert et al. 1971) and bone explants as well 
as isolated bone cells display sensitivity to mechanical stimuli, excluding the 
requirement of central connections (Pitsillides et al. 1995; Wada et al. 2001). 
Nevertheless, the expression of some of the neurotransmitter receptors in bone has 
been shown to be modulated by mechanical load (Chenu et al. 1998; Westbroek et al. 
2001; Szczesniak et al. 2005; Bliziotes et al. 2006), supporting a role for innervation 
in the response of bone to mechanical stress. The direct regulation of bone by the 
paracrine release o f neurotransmitters by nerve terminals non-synaptically is therefore
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possible and gap junctions between osteoblasts and osteocytes have been proposed as 
a means of transmission of neuronal signals (Serre et al. 1999; Spencer and Genever 
2003; Patel and Elefteriou 2007). Furthermore, bone cells are known to release 
glutamate in a regulated manner (Genever and Skerry 2001; Hinoi et al. 2002b) 
indicating that this signalling molecule might also act in an autocrine or paracrine 
capacity within bone.
1.5 Glutamate as a signalling mediator in bone
Functional components from each stage of the glutamate signalling pathway have 
been identified within bone, including proteins necessary for calcium-mediated 
glutamate exocytosis, receptors, transporters and signal propagation (Mason et al. 
1997; Laketic-Ljubojevic et al. 1999; Gu and Publicover 2000; Genever and Skerry 
2001; Hinoi et al. 2001; Gu et al. 2002; Hinoi et al. 2002b; Bhangu 2003; Mason 
2004a; Takarada et al. 2004). Furthermore, glutamatergic nerves have been identified 
in the vicinity of bone cells expressing glutamate receptors in vivo (Chenu et al. 1998; 
Patton et al. 1998; Serre et al. 1999).
It is not yet known how a glutamate signalling event is initiated in bone or its 
physiological significance, however the regulation of the glutamate transporter in 
response to mechanical loading in vivo has implicated glutamate signalling in the 
osteogenic response to mechanical loading (reviewed in (Mason 2004a)). Glutamate 
signalling mechanisms are able to detect very fast stimulatory signals and self-modify, 
making them well-suited for responding to mechanical signalling in bone (Skerry 
2002; Turner et al. 2002; Spencer and Genever 2003; Bowe and Skerry 2005). 
Glutamate receptor and transporter activation are modulated by previous glutamate 
signals, so that maximal responses can be achieved by relatively few signalling events 
(Gonzalez and Ortega 2000; Riedel et al. 2003; Persson et al. 2005); this potential 
mechanism could explain why short periods of high strain rates are all that is required 
for the maximal osteogenic response in bone (Skerry 1997; Burr et al. 2002).
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1.5.1 dutamatergic signalling in the central nervous system (CNS)
Upon stimulation of a pre-synaptic neuron, voltage sensitive calcium channels 
(VSCC) open and the ensuing Ca2+ influx triggers the release of glutamate into the 
synaptic cleft by binding to protein complexes associated with primed synaptic 
vesicles tethered to the pre-synaptic membrane. Glutamate acts on a variety o f 
receptors at the post-synaptic membrane resulting in an influx of Ca2+ into the post- 
synaptic neuron and propagation of the depolarising signal. Glutamate receptors 
(GluRs) can be categorised into ionotropic (iGluRs) and metabotropic (mGluRs). 
Post-synaptic glutamate release can be inhibited by the opening of K+ channels and 
the inhibitory activities of some mGluR subtypes on VSCCs. Glutamate transporters 
(excitatory amino acid transporters; EAATs) at the pre-synaptic and post-synaptic 
membrane and neighbouring glial cells terminate the signalling event by removing 
glutamate from the synaptic cleft. In glial cells, glutamate is converted to glutamine 
by glutamine synthetase (GS) for metabolic purposes or for transport to neurons 
where glutamine is then converted back to glutamate for excitatory signalling (Figure 
1.5).
1.5.2 Glutamate signalling in peripheral tissues
There is strong evidence to suggest that glutamate signalling pathways are functional 
in several sites of the body besides the CNS, such as bone, skin, 0-islet cells of the 
pancreas and megakaryocytes of the bone marrow (reviewed in (Skerry and Genever 
2001; Hinoi et al. 2004)). Furthermore, expression of proteins associated with 
glutamatergic signalling has been identified in a variety of other tissues (e.g. intestine, 
heart, synovial joint, thymus, testis, kidney and lung). EAAT expression in peripheral 
tissues is summarised in Table 1.2.
Various iGluR and mGluR subunit mRNA has been detected in the patella, fat pad, 
cartilage and meniscus of the rat knee and in human articular cartilage (Salter et al. 
2004; Hinoi et al. 2005b; Flood et al. 2007). Glutamate and iGluR agonists elicit 
increases in intracellular Ca2+ in fibroblast-like synoviocytes from rheumatoid 
arthritis (RA) patients, demonstrating functional acitivity of iGluRs (Flood et al.
2007).
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Recent studies implicate peripheral glutamatergic signalling in arthritis, gout and 
cancer (McNeamey et al. 2000; Rzeski et al. 2002; McNearney et al. 2004; Hinoi et 
al. 2005b; Jean et al. 2008; Sharma et al. 2009). Glutamate concentrations increase in 
the synovial fluid o f arthritic patients (McNearney et al. 2000) and in the dialysates of 
osteoarthritic (OA) rat knees (Jean et al. 2005). Glutamate is present in human 
synovial fluid at 6pM (Plaitakis et al. 1982; McNearney et al. 2000)), however, 
glutamate concentrations in the synovial fluid from human patients with RA, gout and 
OA can reach 332.3 ± 29.3, 364.21 ± 50.19 and 240 ± 38 pM respectively 
(McNeamey et al. 2004). EAAT1 and 2 protein expression is significantly increased
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Figure 1.5. Glutamatergic signalling in the CNS. In response to depolarisation of the 
pre-synaptic neuron, glutamate is released into the synaptic cleft where it acts on 
glutamate sensitive ionotropic (NMD A, AMP A) and metabotropic receptors (mGluR) 
present on the post-synaptic cell. Glutamate release also triggers transporters located 
on the pre-synaptic cell and neighbouring glial cells, which actively remove glutamate 
from the synaptic cleft, terminating the signalling episode (VSCC; voltage sensitive 
calcium channel, EAAT; excitatory amino acid transporter, cAMP; cyclic adenosine 
monophosphate, DAG; diacylglycerol, PKC; protein kinase C, IP3; inositol 
triphosphate). Adapted from (Mason 2004a).
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Table l.Z  EAAT expression in peripheral tissues. R, mRNA; P, Protein.
T ransporter
Human/Rodent
nomenclature
T issue  d istribu tion
EAAT1/
GLAST
Bone"9 (Mason et ai. 1997; Huggett et al. 2000)
RetinaR (Rauen et al. 1996; Lehre et al. 1997; Pow and Barnett 1999) 
TestisR (Tanaka 1993)
Mammary gland*9 (Martinez-Lopez et al. 1998)
Placenta*9 (Matthews et al. 1998)
Pancreas*9 (Howell et al. 2001)
Heart*9 (Nakayama et al. 1996; Ralphe et al. 2004)
Synovial fibroblasts*9 (Hinoi et al. 2005b)
Cartilage*9 (Hinoi et al. 2005a; Jean et al. 2008)
EAATIa/
GLAST-1a
BoneR (Huggett et al. 2000) 
Retinap (Macnab et al. 2006)
EAAT2/ 
GLT-1
Bone" (Mason et al. 1997; Huggett et al. 2000) 
Retina (Rauen and Kanner 1994)
Liver" (Howell et al. 2001)
Mammary glandR,p (Martinez-Lopez et al. 1998) 
Keratinocytesp (Genever et al. 1999)
Heart*9 (Kugler 2004)
Rat testisR (Hinoi et al. 2004)
Pancreasp (Howell et al. 2001)
Placenta*9 (Matthews et al. 1998)
EAAT3/
EAAC1
Bone" (Takarada et al. 2004)
lntestinep (Kanai and Hediger 1992; Howell et al. 2001; Fan et al. 2004) 
Kidney*9 (Kanai and Hediger 1992; Shayakul et al. 1997; Howell et al. 2001) 
Retina" (Rauen et al. 1996; Schniepp et al. 2004)
Heart" 9 (Nakayama et al. 1996; Kugler 2004)
Liver*9 (Shashidharan et al. 1994; Howell et al. 2001)
Mouse testis" (Wagenfeld et al. 2002)
Keratinocytes9 (Genever et al. 1999)
Placenta*9 (Matthews et al. 1998)
EAAT4
Placenta" (Matthews et al. 1998)
Bone*9 (Hinoi et al. 2007; Takarada and Yoneda 2008)
EAAT5
Retina*9 (Arriza et al. 1997) 
Liver* (Arriza et al. 1997)
Rat testis" (Hinoi et al. 2004)
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in chondrocytes of rabbit knee joints upon induction of OA (Jean et al. 2008) and 
EAAT uptake activity is increased in synovial fibroblasts from rats with collagen- 
induced arthritis (CIA) (Hinoi et al. 2005b). Cancer cell lines, including breast and 
prostate cancer cell lines, are known to release glutamate (Carrascosa et al. 1984; 
Collins et al. 1998; Sharma et al. 2009) and iGluR antagonists can inhibit tumour 
growth (Rzeski et al. 2001; Rzeski et al. 2002; Abdul and Hoosein 2005).
1.5.3 Glutamate signalling in bone
1.5.3.1 Glutamate release in bone
Osteoblasts express the functional components required for neuronal glutamate 
release including molecules involved in synaptic vesicle packaging, targeting and 
fusion (Bhangu et al. 2001; Bhangu 2003). Osteoblasts spontaneously release 
glutamate in vitro (Genever and Skerry 2001; Hinoi et al. 2002b) and glutamate 
release by rat calvarial osteoblasts is increased following depolarisation with 50mM 
KC1 or activation o f iGluRs with DL-a-amino-3-hydroxy-5-methylisoxasole-4- 
propionate (AMPA) (Hinoi et al. 2002b). There are some discrepancies in these
studies and glutamate release appears to vary with differentiation (Bhangu et al. 2001)
and the phenotype o f the osteoblast-like cell (Genever and Skerry 2001). 
Depolarisation of the osteoblast-like cell lines MG-63 and SaOS-2 with 60mM KC1 
inhibits glutamate release but does not affect glutamate release by the murine 
calvarial-derived cell line MC3T3-E1 (Genever and Skerry 2001). The initiating 
stimulus for glutamate release in osteoblasts remains unclear, though a model 
suggested by Mason proposes that mechanical load induces opening of stretch 
sensitive calcium channels (SSCCs) in osteocytes, which in turn, may trigger 
glutamate release by osteocytes to act on receptors on surface osteoblasts (Mason 
2004a).
Mature osteoclasts, but not pre-osteoclasts, release glutamate and bone degradation 
products from transcytotic vesicles following depolarisation with 50mM KC1 and this 
release is dependent on extracellular Ca2+ (Morimoto et al. 2006).
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1.5.3.2 Glutamate receptors in bone
Glutamate is the primary excitatory neurotransmitter in the central CNS and signals 
through glutamate receptors. These receptors can be categorised into two major 
groups based on sequence homologies and intracellular signalling mechanisms 
(Reynolds and Miller 1988; Hollmann et al. 1989; Nakanishi et al. 1999; Yoneda et 
al. 2001); ionotropic and metabotropic (Figure 1.6). Ionotropic GluRs can be further 
classified by sequence homology and agonist preference as AMP A, kainate (KA) and 
N-methyl-D-aspartate (NMDA) which are associated with ion channels permeable to 
particular cations (Wisden and Seeburg 1993; Hollmann and Heinemann 1994). 
Cloning studies have revealed the existence of a variety of different subtypes within 
each receptor family, allowing the formation of heteromeric receptors, with the 
precise function of the receptor being determined by its subunit composition 
(Monaghan et al. 1989). Furthermore, the diversity of glutamate receptor subunits is 
considerably increased by adenosine-to-inosine RNA editing (Higuchi et al. 1993; 
Bass 1995; Seeburg 1996; Seeburg et al. 1998) and alternative splicing (Pin et al. 
1992; Tanabe et al. 1992; Gregor et al. 1993; Hollmann et al. 1993; Kohler et al. 
1994; Pin and Duvoisin 1995; Barbon et al. 2001). This mode of regulation can yield 
receptor subtypes with altered expression patterns, pharmacology and signal 
transduction mechanisms (Sommer et al. 1990; Verdoom et al. 1991; Bumashev et al. 
1992; Kohler et al. 1993; Lomeli et al. 1994; Flor et al. 1996).
Metabotropic GluRs are G-protein coupled and are categorised into three functional 
groups based on their sensitivity to exogenous agonists and intracellular signalling 
mechanisms; group I (mGluR 1 and mGluR5), group II (mGluR2 and mGluR3), and 
group HI (mGluR4, mGluR6, mGluR7 and mGluR8) (Masu et al. 1991; Tanabe et al. 
1992; Wisden and Seeburg 1993). Group I mGluRs stimulate the formation of inositol 
1,4,5-triphosphate (IP3) and diacylglycerol (DAG) whereas both group II and group 
IE mGluRs inhibit the production of intracellular cAMP. At least four splice variants 
have been identified for mGluRl, termed mGluRla to mGluRd (Mary et al. 1998). 
Various glutamate receptor subunits are expressed and functional in bone cells (Table 
1.3). Both glutamate and NMDA elicit significant increases in membrane currents in 
MG-63 and SaOS-2 osteoblast-like cells (Laketic-Ljubojevic et al. 1999) and in rabbit 
primary osteoclasts (Espinosa et al. 1999; Peet et al. 1999), which can be inhibited by 
the NMDA receptor antagonist MK-801. Electrophysiological studies further
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Figure 1.6. The glutamate receptor fam ily. Glutamate receptors are classified into 
two major groups according to sequence homology and intracellular signalling 
mechanisms; ionotropic (iGluRs) and metabotropic (mGluRs). There are three 
subgroups of iGluRs; NMDA, AMPA and KA receptors, each of which is ion channel 
associated. iGluRs are divided into subtypes by sequence homology and sensitivity to 
exogenous agonists. mGluRs are subclassified into groups 1, II and m  on the basis o f 
sensitivity to exogenous agonists and intracellular signalling mechanisms. (Adapted 
from (Hinoi et al. 2004)).
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demonstrate that NMDA receptors are expressed and functional in primary cultures of 
rat osteoblasts, with electrophysiological and pharmacological characteristics similar 
to neuronal NMDA receptors (Gu et al. 2002). MG-63 osteoblast NMDA receptors 
are blocked by Mg2+ in a voltage-insensitive manner (Laketic-Ljubojevic et al. 1999) 
in contrast to primary osteoblasts, which display a ‘classical’ voltage sensitive Mg2+ 
block, typical of neuronal NMDA receptors (Gu et al. 2002).
Transcripts for mGluR lb have been detected in rat femoral osteoblasts (Gu and 
Publicover 2000) and transcripts for mGluR4 and 8 have been detected in rat calvarial 
osteoblasts (Hinoi 2001). Upon exposure of rat femoral osteoblasts to \S,3R-ACPD, 
an mGluR agonist, elevated levels of intracelullar Ca2+ were observed, indicating 
functional group I mGluR expression (Gu and Publicover 2000). The initial phase of 
this response was not dependent on extracellular Ca2+ levels, reflecting mobilisation 
of Ca2+ from intracellular stores (Gu and Publicover 2000). In rat calvarial 
osteoblasts, the group HI mGluR agonist L-AP4 significantly inhibited forskolin- 
induced cAMP accumulation in a manner that could be prevented by cotreatment with 
the group m  mGluR antagonist CPPG, indicating functional group m  mGluR 
expression (Hinoi 2001). Interestingly, NMDA currents in rat femoral osteoblasts that 
were lost upon treatment with glutamate could be restored by blockade o f mGluRs 
with a-methyl-4-carboxyphenylglycine (MCPG), indicating that inhibitory cross talk 
occurs between mGluRs and NMDA receptors in osteoblasts (Gu and Publicover
2000). This crosstalk has not been demonstrated in osteoclasts indicating different 
glutamate-induced signalling pathways.
Expression of mGluR6 has also been detected by western blotting and RT-PCR in rat 
bone marrow stromal cells (Foreman et al. 2005). In these cells, treatment with 
glutamate resulted in inhibition of Ca2+ influx and subsequent membrane 
hyperpolarisation (Foreman et al. 2005). These effects were sensitive to the group HI 
mGluR antagonist (s)-MAP4, suggesting that activation of mGluR6 inhibits a Ca2+- 
permeable membrane channel (Foreman et al. 2005).
1.5.3.3 Glutamate signal propagation in bone
Expression of iGluR subunits is regulated by mechanical load in bone (Szczesniak et 
al 2005). Long bones (radius/ulna, tibia/fibula) of young adult rats that were subject 
to cyclic compressive load for four consecutive days displayed a load-induced loss of
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Table 1.3. Reported expression o f glutamate receptors in bone. Transcript/protein 
detected (black) or not detected (red) or not investigated (-).
Osteoblast Osteoclast Osteocyte
mRNA Protein mRNA Protein mRNA Protein
NMDAR1
(Patton et al. 
1998; Hinoi et 
al. 2001; 
Itzstein et al. 
2001; Hinoi et 
al. 2003)
(Chenu et 
al. 1998; 
Patton et al. 
1998; Hinoi 
et al. 2003)
(Patton et al. 
1998;
Itzstein et al. 
2001; Merle 
et al. 2003)
(Chenu et al. 
1998; Patton 
et al. 1998)
(Patton 
et al. 
1998)
(Chenu et al. 
1998)
(Patton et al. 
1998)
NMDAR2A
(Itzstein et al. 
2001)
(Hinoi et al. 
2003)
(Itzstein et 
al. 2001)
(Szczesniak 
et al. 2005)
- -(Hinoi et al 
2001; Hinoi et 
al. 2003)
(Merle et al. 
2003)
NMDAR2B
(Itzstein et al. 
2001)
(Hinoi et al. 
2003)
(Itzstein et 
al. 2001; 
Merle et al. 
2003)
(Szczesniak 
et al. 2005)
- -(Hinoi et al 
2001; Hinoi et 
al. 2003)
NMDAR2C
(Gu and 
Publicover 
2000) (Hinoi et al. 
2003)
(Itzstein et 
al. 2001)
(Szczesniak 
et al. 2005)
- -
(Hinoi et al 
2001; Hinoi et 
al. 2003)
NMDAR2D
(Patton et al. 
1998; Hinoi et 
al. 2001; 
Itzstein et al. 
2001; Hinoi et 
al. 2003)
(Itzstein et 
al. 2001; 
Hinoi et al. 
2003; Ho et 
al. 2005)
(Itzstein et 
al. 2001; 
Merle et al. 
2003)
(Itzstein et al. 
2001; Ho et 
al. 2005)
- -
AMPA
GluR1
(Hinoi et al. 
2002c)
(Chenu et 
al. 1998)
- (Szczesniak 
et al. 2005)
- (Chenu et al. 
1998)
AMPA
GluR2
(Hinoi et al. 
2002c)
(Chenu et 
al. 1998)
- (Szczesniak 
et al. 2005)
- (Chenu et al. 
1998)
AMPA
GluR3
(Hinoi et al. 
2002c)
- - (Szczesniak 
et al. 2005)
- -
AMPA
GluR4
(Hinoi et al. 
2002c)
- - (Szczesniak 
et al. 2005)
- -
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Osteoblast Osteoclast Osteocyte
mRNA Protein mRNA Protein mRNA Protein
KA1
(Hinoi et al. 
2002b)
- - - - -
KA2
(Hinoi et al. 
2002b)
- - - - -
Kainate
GluR5
(Hinoi et al. 
2002c)
- - (Szczesniak 
et al. 2005)
- -
Kainate
GluR6
(Hinoi et al 
2002c)
- - (Szczesniak 
et al. 2005)
- -
Kainate
GluR7
(Hinoi et al 
2002c)
- - (Szczesniak 
et al. 2005)
- -
mGluRla
(Gu and 
Publicover 
2000)
- - - - -
mGluRIb
(Gu and 
Publicover 
2000)
- - - - -
mGluR2
(Gu and 
Publicover 
2000; Hinoi et 
al. 2001)
- - - - -
mGluR3
(Gu and 
Publicover 
2000; Hinoi et 
al. 2001)
- (Morimoto et 
al. 2006)
(Morimoto et 
al. 2006)
- -
mGluR4
(Hinoi et al. 
2001)
- (Morimoto et 
al. 2006)
(Morimoto et 
al. 2006)
- -(Gu and 
Publicover 
2000)
mGluR5
(Gu and 
Publicover 
2000; Hinoi et 
al. 2001)
- (Morimoto et 
al. 2006)
- - -
mGluR6
(Gu and 
Publicover 
2000; Hinoi et 
al. 2001)
- - - - -
mGluR7
(Hinoi et al 
2001)
- - - - -
mGluR8
(Hinoi et al. 
2001)
- (Morimoto et 
al. 2006)
(Morimoto et 
al. 2006)
- -
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Table 1.4. Reported expression o f glutamate transporters in bone. Transcript/protein 
detected (black) or not detected (red) or not investigated (-).
O s te o b la s t O s te o c la s t O steo c y te
mRNA Protein mRNA Protein mRNA Protein
EAAT1/
GLAST
(Mason et al. 
1997; Huggett et 
al. 2000; Kalariti 
et al. 2004; 
Takarada et al. 
2004; Kalariti et 
al. 2007)
(Mason et al. 
1997; Kalariti 
et al. 2004; 
Kalariti et al. 
2007)
(Takarada 
and Yoneda 
2008)
-
(Mason et 
al. 1997; 
Huggett et 
al. 2000)
(Mason et 
al. 1997)
EAAT2/
GLT-1
(Mason et al. 
1997; Huggett et 
al. 2000; 
Takarada et al. 
2004)
-
(Hinoi et al. 
2007; 
Takarada 
and Yoneda 
2008)
-
(Mason et 
al. 1997; 
Huggett et 
al. 2000; 
Hinoi et al. 
2004)
-
EAAT3/
EAAC1
(Takarada et al. 
2004)
-
(Takarada 
and Yoneda 
2008)
- - -
EAAT4
(Takarada et al. 
2004)
-
(Hinoi et al. 
2007; 
Takarada 
and Yoneda 
2008)
(Hinoi et al. 
2007; 
Takarada 
and Yoneda 
2008)
- -
EAAT5
(Takarada et al. 
2004)
-
(Takarada 
and Yoneda 
2008)
- - -
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immunoreactivity to GluR2/3, GluR4, GluR5/6/7 and NMDAR2A on osteoclasts and 
NMDAR2A, NMDAR2B, GluR2/3 and GluR4 on bone lining cells (Szczesniak et al. 
2005). However, Ho et al. have reported downregulation of NMDAR1 and 
NMDAR2D mRNA and protein expression in osteoblasts, but not osteoclasts, in 
association with disuse-induced bone loss in rats following a three-week tail 
suspension (Ho et al. 2005). Expression of mGluR5 and the glutamate transporter 
EAAT1 have also been shown to be upregulated by glucocorticoid treatment in 
osteoblast-like cells (Kalariti et al. 2007).
The secondary signalling pathways following glutamate receptor activation of 
osteoblasts have not been well characterised, although activation o f receptor 
associated protein kinases and translocation of the transcription factor activator 
protein-1 (AP-1) has been demonstrated (Taylor 2002; Lin et al. 2008). Antagonists to 
NMDA receptors down-regulate the transcription factor Runx2 and inhibit alkaline 
phosphatase activity and osteocalcin expression in rat primary osteoblasts (Hinoi et al. 
2003; Ho et al. 2005). More recent studies have shown that the AMPA receptor 
antagonist 6-cyano-7-nitroquinoxaline-2,3-dione (CNQX) and the NMDA receptor 
antagonist MK-801 inhibit rat calvarial osteoblast activity and mineralisation in 
510pM extracellular glutamate and that AMPA and NMDA up-regulate osteocalcin 
expression and mineralisation of osteoblasts in glutamate-free medium (Lin et al. 
2008). The authors also demonstrated that injection of AMPA locally into the tibia of 
young rats increased bone volume and that this was antagonised by CNQX (Lin et al. 
2008).
In mice treated with the AMPA receptor antagonist NBQX or the NMDA receptor 
antagonist AP5 by osmotic minipumps over 8 days, differences were observed in 
trabecular and cortical thickness (Burford et al. 2004). Trabecular thickness was 
reduced by 50% in NBQX-treated mice but not in AP5-treated mice whereas cortical 
thickness at midshaft sites was reduced by 40% in AP5-treated mice and increased by 
30% in NBQX-treated mice (Burford et al. 2004), indicating different roles for 
NMDA and AMPA receptors in the regulation of trabecular and cortical bone mass 
(Burford et al. 2004; Skerry 2008). Skerry has also reported the generation of tissue 
specific NMDAR1 knockout mice under the control of the osteocalcin promoter 
(Skerry 2008). These mice fail to express functional NMDA receptors in osteoblasts 
and are bom with stunted skeletons (Skerry 2008), indicative of a role for glutamate 
signalling in skeletal development.
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Modulation of NMDA receptors in osteoclasts can also modify the cellular phenotype 
in vitro. In cocultures of mouse bone marrow leukocytes and osteoblasts in which 
osteoclasts differentiate, the NMDA receptor antagonist MK-801 suppressed 
osteoclast differentiation and reduced resorption pit formation in dentine (Peet et al. 
1999). No significant effects of MK-801 upon mature osteoclast activity could be 
discerned in this study (Peet et al. 1999), although others have reported that MK-801 
inhibits mature rabbit osteoclast activity (Chenu et al. 1998; Itzstein et al. 2000) and 
promotes apoptosis, via decreased NO production (Mentaverri et al. 2003). Glutamate 
and NMDA receptor agonists induced nuclear translocation of nuclear factor-kappaB 
(NF-kB) in osteoclast precursor cell lines, and this was inhibited by MK-801 (Merle 
et al. 2003) indicating that activation of this pathway is involved in osteoclastogenesis 
in response to glutamate receptor signalling.
1.5.3.4 Glutamate transporters
1.5.3.4.1 General overview
A variety o f proteins with the capacity to transport glutamate have been described. 
These include the high affinity transporters, low affinity transporters, 
cystine/glutamate antiporters and vesicular glutamate transporters (reviewed in 
(Danbolt 2001)). The high affinity glutamate transporters (K m l-100pM) are termed 
excitatory amino acid transporters (EAATs) and are sodium dependent. EAATs 
exhibit a preference for L-glutamate, D- and L-aspartate and are classified into five 
subtypes in human (EAAT 1, EAAT2, EAAT3, EAAT4, and EAAT5) (Arriza et al. 
1994; Fairman et al. 1995; Arriza et al. 1997). Rodent homologues to EAATs 1-3 are 
termed GLAST, glutamate transporter-1 (GLT-1) and excitatory amino acid carrier 
(EAAC1) respectively (Kanai and Hediger 1992; Pines et al. 1992; Storck et al. 1992; 
Tanaka 1993), and studies performed in human or rodent will be described here using 
the appropriate nomenclature for the species. Sodium-dependent transport systems are 
referred to by capital letters, which for dicarboxylic amino acid transporters such as 
the EAATs is ‘X’ (Bannai et al. 1984; Danbolt 2001). Sodium-independent uptake 
systems are instead referred to by lower case letters (Bannai et al. 1984; Danbolt 
2001). The charge of the amino acid transported is indicated by +/- as superscript and 
the letters A, G or C in subscript denote the preferred substrates aspartate, glutamate
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or cystine respectively. Therefore EAATs can be referred to as X " a g ,  while the 
sodium-independent cystine/glutamate antiporter is referred to as x ' c  (or x 'c g ) .  The 
EAAT subtypes display heterologous spatial and cellular expression profiles (Danbolt
2001) indicating a complex and finely tuned control over extracellular glutamate 
levels. This thesis will focus on the role of EAATs in bone and EAAT expression 
profiles, activity, and structure will be described in subsequent sections.
Low-affinity glutamate transporters (Km > 500pM) (Johnston 1981) have been 
described as sodium-independent and sensitive to inhibition by D-glutamate 
(Benjamin and Quastel 1976) and L-homocysteic acid (Cox et al. 1977). These 
transporters may provide cells with amino acids for metabolic purposes (reviewed in 
(Erecinska and Silver 1990)) though the existence of these transporters as separate 
entities remains controversial (Wheeler 1987; Robinson et al. 1991; Robinson et al. 
1993).
Cystine/glutamate antiporters are sodium-independent, chloride-dependent high- 
affinity glutamate transporters that have been described in a variety of tissues 
including bone (Bannai and Kitamura 1980, 1981; Waniewski and Martin 1984; 
Bannai 1986; Cho and Bannai 1990; Sato et al. 1999). The transporter is a 
heterodimer of the CD38 heavy chain (also called 4F2hc) and the x'c (referred to as 
xCT) light chain which determines the substrate specificity. Cystine (the dimeric form 
of cysteine) is necessary for the generation of the tripeptide antioxidant glutathione (y- 
Glu-Cys-Gly; GSH) (reviewed in (Cooper and Kristal 1997; Dringen 2000)).
Vesicular glutamate transporters (VGLUTs) are necessary for the condensation of 
glutamate into vesicular compartments for exocytic release. Within the CNS, 
VGLUT1 (also called brain-specific Na+-dependent inorganic phosphate transporter, 
BNPI) and VGLUT2 (also called differentiation-associated Na+-dependent inorganic 
phosphate cotransporter, DNPI) are restricted to glutamatergic neurons (Fremeau et 
al. 2001; Herzog et al. 2001) and heterologous expression of either is capable of 
converting inhibitory neurons into excitatory ones (Takamori et al. 2000, 2001; 
Kaneko and Fujiyama 2002). VGLUT3 is expressed by a variety of cell types that 
reportedly release glutamate via exocytosis such as dopaminergic, gamma- 
aminobutyric acid (GABA)-ergic and serotonergic neurons and astrocytes (Fremeau 
et al. 2002; Schafer et al. 2002).
A sodium-dependent transporter for cystine, glutamate and aspartate has also been 
detected in rat alveolar type 2 cells and in astrocytes (Bukowski et al. 1995; Bender et
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al. 2000) and high affinity sodium-dependent heterocarriers have been identified for 
glutamate and ascorbate (Grunewald 1993), for glutamate and GAB A and for 
glutamate and glycine, however these have not been fully characterised (Levi et al. 
1976; Bonanno et al. 1993; Bonanno and Raiteri 1994).
1.5.3.4.2 Role o f glutamate transporters in bone
Despite EAATs being the first component of glutamatergic signalling to be identified 
in bone, studies elucidating their role within this tissue have been limited.
The cystine/glutamate antiporter is expressed and functionally required for the cellular 
differentiation of pre-osteoblasts, pre-osteoclastic RAW264.7 cells and primary 
osteoclasts differentiated from bone marrow precursor cells (Hinoi et al. 2007; 
Takarada-Iemata et al. 2010). Differentiation was inhibited by high glutamate 
concentrations (over 500pM) in a manner that was sensitive to inhibitors of the 
antiporter (Hinoi et al. 2007; Takarada-Iemata et al. 2010). High concentrations of 
extracellular glutamate are likely to result in cystine being released from the cell, 
which will result in reduced levels of cystine available to generate GSH. Reduced 
levels o f GSH can also lead to cell death due to oxidative stress (Murphy et al. 1989; 
Cho and Bannai 1990). Indeed, expression of the cystine/glutamate antiporter has also 
been reported in MC3T3-E1 osteoblast-like cells where it is thought to mediate the 
suppression of proliferation following treatment with exogenous glutamate in 
association with decreased levels of intracellular GSH (Uno et al. 2007).
Expression of VGLUT1, but not VGLUT2, has been detected in rat calviarial 
osteoblasts (Hinoi et al. 2002b) and glutamate release in these cells was Ca2+ 
dependent and sensitive to AMPA antagonists (Hinoi et al. 2002b). VGLUT1 is also 
expressed by mature osteoclasts derived from bone marrow and is thought to 
accumulate glutamate into transcytotic vesicles for release, with bone degradation 
products, upon stimulation with 50mM KC1 or ATP in a Ca2+ dependent manner 
(Morimoto et al. 2006). Glutamate released from osteoclasts by transcytosis may be 
autoregulatory, since agonists to osteoclastic mGluR8 inhibits secretion of glutamate 
and bone degradation products whereas mGluR8 antagonists stimulate bone 
resorption (Morimoto et al. 2006).
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1.5.3.4.3 EAATs in bone
GLAST was the first glutamate transporter to be isolated from bone, leading to the 
hypothesis that glutamate may act as a signalling molecule in the skeleton (Mason et 
al. 1997). GLAST and GLT-1 are expressed in bone in vivo (Mason et al. 1997) and 
EAAT3 has been detected in rat primary osteoblasts in vitro (Takarada et al. 2004). 
Reported expression of EAAT subtypes in bone is summarised in Table 1.4.
GLAST is expressed by osteocytes and bone-forming osteoblasts in vivo and its 
expression in osteocytes is down-regulated following mechanical load (Mason et al. 
1997). The GLAST proteins in bone and brain are identical in sequence and 
monomers have been identified of the same molecular weight in both tissues (Huggett 
et al. 2000; Huggett et al. 2002; Mason and Huggett 2002).
In 2001, Gray et al. reported that GLAST knockout mice displayed little difference to 
wild-type siblings in mandibular and long bone length and thickness at two weeks, 
three months and six months old. The study also claimed that long bones from 
knockout mice at the age of three months could not be distinguished morphologically 
from wild-type mice by scanning electron microscopy on the basis of trabeculation 
within the marrow cavity, cortical thickness, or areas of formation versus resorption 
on the midshaft, however these assessments were carried out on only one mouse from 
each genotype. High resolution x-ray tomography was used to image femora from two 
knockout and one wild-type mouse at the age of three months and no differences in 
cortical thickness, trabecular distribution or density were observed between the two 
genotypes. These assessments contributed to the authors1 conclusion that glutamate 
does not play a major role in controlling bone growth. Chenu et al. and Skerry et al. 
argued that the lack of an abnormal bone phenotype in these knockout mice was not 
necessarily indicative of a minor role for glutamate in bone, and that functional 
studies would be more informative. One example of this would be to analyse GLAST 
knockout mice with reference to their mechanoresponse since glutamate has been 
implicated in bone cell signalling following mechanical load (Mason et al. 1997; 
Szczesniak et al. 2005). Furthermore, the expression of a variety of different 
glutamate transporters and receptors in bone suggests that several glutamatergic 
signalling pathways exist and so the likelihood of redundancy in this system is high 
(Mason et al. 1997; Gu and Publicover 2000; Itzstein et al. 2001). For example, in 
GLAST knockout mice, a compensatory role for GLT-1 was discovered which
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resulted in a lack of neurodegeneration or a behavioural phenotype in these mice 
(Stoffel et al. 2004).
Various studies have shown that glutamatergic signalling can influence bone cell 
phenotype (Itzstein et al. 2000; Taylor 2002; Hinoi et al. 2003; Merle et al. 2003; Lin 
et al. 2008) and this signalling pathway has been associated with mechanically- 
induced osteogenesis (Mason et al. 1997; Szczesniak et al. 2005) and increased 
osteoblast bone-forming activity (Hinoi et al. 2003; Lin et al. 2008). While the 
specific role of the EAATs in bone remains controversial (Chenu et al. 2001; Gray et 
al. 2001; Skerry et al. 2001), the regulation of EAAT expression by mechanical load 
indicates that the transport system may represent a new target for anabolic bone 
therapies (Mason et al. 1997; Chenu 2002; Mason 2004a; Spencer et al. 2004).
1.5.3.4.4 EAAT function
In the CNS, extracellular glutamate concentrations are tightly controlled by high 
affinity, sodium-dependent glutamate transporters. Glutamate uptake terminates a 
glutamatergic signalling event and prevents glutamate reaching excitotoxic 
concentrations (Marcaggi and Attwell 2004). Defective EAAT function and 
excitotoxicity leading to neuronal cell death are thought to underlie the pathogenesis 
of stroke-induced ischemic brain damage (Kuwahara et al. 1992; Rossi et al. 2000), 
epilepsy (Meldrum 1994; Tanaka et al. 1997; Meldrum et al. 1999; Guo et al. 2010) 
and a number o f neurodegenerative disorders of the CNS including amylotrophic 
lateral sclerosis (ALS) (Rothstein et al. 1995; Rothstein et al. 1996; Howland et al.
2002), Alzheimer’s disease (Scott et al. 1995; Scott et al. 2002; Maragakis and 
Rothstein 2004) and Parkinson’s disease (Blandini et al. 1996; Chase et al. 2000). 
EAATs transport glutamate against its concentration gradient. Three sodium ions and 
one proton are co-transported with glutamate and one potassium ion is counter­
transported leading to a net positive charge moving into the cell (Figure 1.7) 
(Zerangue and Kavanaugh 1996). Transport is therefore dependent upon the 
maintenance of an electrochemical gradient across the cell membrane by ion 
exchange pumps such as Na+/K+-ATPase (Schousboe and Divac 1979; Danbolt 2001). 
EAATs are also able to function as ion channels whereby sodium-dependent 
glutamate binding initiates an uncoupled anion conductance (Seal and Amara 1999; 
Slotboom et al. 2001b) that is physiologically measurable at some synapses (Billups
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et al. 1996; Eliasof and Jahr 1996). Both NaT and glutamate binding is necessary for 
anion conductance, although transport is unecessary (Fairman et al. 1995; Wadiche et 
al. 1995; Billups et al. 1996; Wadiche and Kavanaugh 1998; Slotboom et al. 2001b). 
A chloride leak conductance has also been reported for the EAATs that is independent 
of glutamate and Na+ binding (Otis and Jahr 1998; Wadiche and Kavanaugh 1998; 
Grewer et al. 2000). The physiological role o f the glutamate- and Na+-dependent 
anion conductance is unclear, though it has been suggested that it may function as a 
voltage clamp (Billups et al. 1996; Eliasof and Jahr 1996), whereby the flow of 
chloride ions may compensate for the membrane potential changes due to electrogenic 
glutamate uptake by EAAT s. The net positive charge
r  &\u & 3Na*
Figure 1.7. Glutamate transport by EAATs. Extracellular glutamate binds to the 
EAAT and is transported against its concentration gradient. Three sodium ions and 
one hydrogen ion are co-transported with the glutamate and one potassium ion is 
counter transported, resulting in a net positive charge moving into the cell. Glutamate 
transport is therefore driven by an electrochemical gradient across the cell membrane 
which is primarily maintained by the sodium/potassium ATPase pump. (Figure from 
(Mason 2004a)).
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moving into the cell upon glutamate transport by EAATs will induce depolarisation of 
the cell membrane and chloride ion entry could provide a hyperpolarising influence 
on the cell membrane that counters this effect. The chloride conductance may also 
modulate glutamate receptor activity and therefore the excitatory responses of the cell 
or operate more like a receptor, activating intracellular signalling cascades in response 
to glutamate binding (Danbolt 2001; Mason and Huggett 2002). Chloride channel 
activity varies between different members of the EAAT family, with anion 
conductance particularly prominent in EAAT4 and EAAT5 and almost nonexistent in 
EAAT2 (reviewed in (Danbolt 2001)).
In addition to transport and ion channel activities, protein-protein interactions with 
both N- and C- terminal domains o f the EAATs suggest a potential receptor-like 
function for the EAATs. Interactions with the actin cytoskeleton and other signalling 
pathways including components of the mitogen activated protein-kinase (MAPK) 
cascade have been reported (Jackson et al. 2001; Lin et al. 2001; Macnab et al. 2006). 
These interactions are discussed further in Chapter 6 of this thesis.
The role of EAAT 1 in bone may be a function o f any one of its activities; glutamate 
uptake, glutamate release, glutamate-gated ion channel or activation of intracellular 
signalling pathways (Mason 2004a).
1.5.3.4.5 EAAT structure
The EAATs display considerable homology to each other at the amino acid level (50- 
60%) and share some homology to the neutral amino acid transporters ASCT1 and 
ASCT2 and bacterial glutamate and dicarboxylate transporters ((Slotboom et al.
1999), reviewed in (Ryan and Vandenberg 2005)). Hydropathy analyses of the 
EAATs have indicated cytoplasmic N- and C- termini and six hydrophobic stretches 
of sequences at the N-terminal thought to be membrane-spanning alpha-helices 
(Slotboom et al. 2001a). Little is known regarding the topology of the C-terminal 
region, however its sequence is highly conserved and it contains a number of residues 
that are important for glutamate binding and ion transport (Vandenberg et al. 1995; 
Grunewald et al. 1998; Seal and Amara 1999; Bendahan et al. 2000; Grunewald and 
Kanner 2000; Seal et al. 2000; Borre et al. 2002; Ryan and Vandenberg 2002). Figure 
1.8 displays a proposed transmembrane topology of the EAATs which follows the 
Grunewald and Kanner model o f two re-entrant loops at the C-terminus that forms a
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Figure 1.8. EAAT1 topology and amino acid sequence. Hydropathy and mutational 
studies have proposed a topological model for EAAT1 with intracellular N- and C- 
terminals, 8 transmembrane alpha-helices and two re-entrant loops at the C-terminus 
(Figure adapted from Yemool et al., 2004). (A) Transmembrane topology model of 
EAAT1 according to (Grunewald and Kanner 2000; Yemool et al. 2004). (B) EAAT1 
amino acid sequence taken from GenBank data base under the accession number 
NP 004163.3. The boxes above the sequence correspond to the transmembrane 
domains, as determined by (Wahle and Stoffel 1996; Yemool et al. 2004) and are 
colour-coded according to (A). Residues implicated in glutamate transport are 
highlighted red (Conradt and Stoffel 1995; Pines et al. 1995; Seal et al. 2001; 
Leighton et al. 2002; Ryan and Vandenberg 2002; Leighton et al. 2006) and residues 
implicated in anion conductance are highlighted in blue (Ryan et al. 2004). Filled 
symbols below the sequence mark residues involved in glutamate binding (circles; 
(Leighton et al. 2006)) or sodium binding (triangles; (Zhang and Kanner 1999; Borre 
and Kanner 2001; Yemool et al. 2004; Tao et al. 2006)). Exons 2-10 (exon 1 is fully 
contained within the 5’ UTR) are in alternating colours and residues that overlap 
splice sites are in red. Potential phosphorylation sites for protein kinase C (PKC) and 
cAMP-dependent protein kinase (PKA) are identified by searching for consensus 
motifs (S/T-X-K/R for PKC and (R/K)2-X-(S/T) for PKA) and are denoted by stars 
with the appropriate subscript i.e. C and A respectively.
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pore-like structure (Grunewald and Kanner 2000). Residues within transmembrane 
(TM) domain 2 are crucial for ion channel activity (Leighton et al. 2002; Ryan et al. 
2004) and mutational studies of EAAT1 and structural analysis of the homologous 
prokaryotic amino acid transporter (Gltph) has placed these residues in close spatial 
proximity to regions involved in glutamate binding (Ryan et al. 2004; Yemool et al. 
2004). However, mutational studies of EAATs have also demonstrated that it is 
possible to influence one of the functions (transporter/ion channel) without affecting 
the other, suggesting that separate molecular determinants exist (Seal et al. 2000; 
Borre et al. 2002; Ryan and Vandenberg 2002, 2005). Freeze fracture electron 
microscopy indicated that the transporter functioned as a pentamer (Eskandari et al.
2000), however later molecular and biophysical analyses suggested that the 
transporter in fact functions as a trimer (Gendreau et al. 2004; Yemool et al. 2004; 
Grewer et al. 2005). The crystal structure of the glutamate transporter homologue 
from Pyrococcus horikoshii shows a bowl-shaped trimer with a solvent-filled 
extracellular baisin (Yemool et al. 2004) consistent with the idea that EAAT activity 
is exemplified by the altemating-access model (Yemool et al. 2004; Beart and O'Shea 
2007).
1.5.3.4.6 EAA T splice variants
There have been reports of the existence of several splice variants of EAATs 1-3 (Lin 
et al. 1998; Nagai et al. 1998; Matsumoto et al. 1999; Meyer et al. 1999) and this is 
further discussed in chapter 5. Two splice variants of EAAT 1 have been identified; 
GLAST-la (EAATla) (Huggett et al. 2000) and EAATlex9skip (Vallejo- 
Illarramendi et al. 2005), both of which are expressed as proteins in vivo (Huggett et 
al. 2000; Vallejo-Illarramendi et al. 2005; Macnab et al. 2006; Macnab and Pow 
2007a). Most EAAT2 and 3 splice variants exhibit little or no glutamate transport 
activity although they do interfere with the normal translation or post-translational 
processing of full-length EAATs (Lin et al. 1998; Nagai et al. 1998; Matsumoto et al. 
1999; Meyer et al. 1999). Some studies report that aberrant RNA processing of 
EAAT2 is linked to the pathogenesis of ALS (Bai and Lipton 1998; Lin et al. 1998), 
whereas evidence also exists to dispute this and instead suggests that EAAT2 splice 
variants may have a physiological role (Nagai et al. 1998; Meyer et al. 1999; Honig et 
al. 2000; Flowers et al. 2001; Macnab and Pow 2007b) .
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1.53.4.6.1 EAATla
EAATla is an alternatively spliced form of EAAT1 which lacks exon 3, and was first 
cloned from bone in vivo (Huggett et al. 2000). Exon 3 of the gene encoding EAAT1, 
solute carrier family 1 member 3 (SLC1A3), consists o f 138 bases which encode 47 
amino acids (61-107) (Figure 1.8) and its removal does not disrupt the open reading 
frame of the gene. GLAST-la encodes a functional transporter (Mason, Huggett, 
Daniels, unpublished) but lacks residues encoded by exon 3 that are known to be 
important for ion channel activity (Ryan et al. 2004). GLAST-la is expressed at low 
levels in brain, retina and bone in vivo (Huggett et al. 2000; Macnab et al. 2006) with 
higher levels of expression observed in MLO-Y4 osteocytes indicating an important 
role for the variant in this cell type (Huggett et al. 2002). A theoretical model of 
GLAST-la topology proposes a reorientation of the protein in the membrane 
following the splice site, leading to an extracellular rather than an intracellular C- 
terminus (Huggett et al. 2000).
1.5.3.4.6.1 EAATlex9skip
EAATlex9skip, which lacks exon 9, is expressed at the mRNA level throughout the 
human brain at levels between 10% and 20% of the full-length EAAT1 form (Vallejo- 
Illarramendi et al. 2005). Of the brain tissues analysed, EAATlex9skip mRNA was 
present at highest levels in the hippocampus and at lowest levels within the cortex 
(Vallejo-Illarramendi et al. 2005). Exon 9 of SLC1A3 comprises 135bp and its 
omission does not alter the RNA reading frame, yielding a predicted amino acid 
sequence that differs only from full length EAAT1 by 45 amino acids (430-474) 
located just prior to the last TM domain at the C-terminus (Figure 1.8) (Vallejo- 
Illarramendi et al. 2005). EAATlex9skip is translated in human embryonic kidney 
(HEK) cells into a protein that is retained in the endoplasmic reticulum (ER) and 
exerts a dominant negative effect over full-length EAAT1 function, possibly by 
protein-protein interactions at the ER which reduce the expression of full-length 
EAAT1 at the plasma membrane (Vallejo-Illarramendi et al. 2005). EAATlex9skip 
has also been detected by immunohistochemistry within the human brain, particularly 
cortical and collicular neurons (Macnab and Pow 2007a).
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1.5.4 Therapeutic targeting of glutamate transport
In the CNS, glutamate excitotoxicity is linked to a variety of disorders and diseases 
including epilepsy, ischemic stroke, post-traumatic lesions, ALS, Parkinson’s and 
Alzheimer’s disease (reviewed in (Obrenovitch et al. 2000)). Drug discovery in the 
field of glutamate receptor antagonists has been very active over recent years, with the 
largest clinical trials for selective NMDA antagonists in stroke and traumatic brain 
injury (reviewed in (Muir 2006)). However both uncompetitive and competitive 
NMDA antagonists, which target the ion channel site and the glutamate binding site 
respectively, have exhibited adverse side effects including psychomimetic effects and 
increased blood pressure due to global effects on NMDA receptors throughout the 
CNS (Muir and Lees 1995; Menniti et al. 2000b; Menniti et al. 2000a; Lipton 2006). 
Therapeutic targeting of the EAATs is in its early stages in contrast to glutamate 
receptors. However, regulating glutamate transport has the potential to limit these side 
effects, as it may be possible to reduce the pathological effects of high extracellular 
glutamate while still maintaining the physiological signalling role of glutamate.
The development of novel therapeutics capable of up-regulating transporter function 
has been proposed for the treatment of neurodegenerative diseases in which glutamate 
excitotoxicity has been implicated. Rothstein et al. discovered that P-lactam 
antibiotics were able to induce increases in EAAT2 protein levels of up to 6-fold 
(Rothstein et al. 2005). Of the antibiotics tested, ceftriaxone increased EAAT2 protein 
levels in a mouse model of ALS and prolonged survival of these mice compared to 
untreated animals (Rothstein et al. 2005).
Aberrant glutamate signalling is thought to be involved in the pathogenesis of 
schizophrenia and the expression of a number of proteins associated with the 
glutamatergic synapse have been found to be altered in the disease (McCullumsmith 
and Meador-Woodruff 2002). Levels of EAAT3 are decreased in response to 
antipsychotic medicines (Schmitt et al. 2003) and in the striatum in post-mortem 
studies of schizophrenic patients (McCullumsmith and Meador-Woodruff 2002), 
highlighting its role as a possible therapeutic target.
Targeted manipulation of EAATs has been proposed as a potential treatment for bone 
pathologies, such as osteoporosis or non-union fracture (Mason 2004a, b). Modulation 
of the glutamate signalling pathway in bone may offer the opportunity to activate 
mechanoresponsive bone formation in mechanically compromised tissue (Mason
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2004b). Bone retains a ‘strain memory’ whereby maximal anabolic responses are 
induced by a limited number of loading cycles (reviewed in (Skerry 1997; Burr et al. 
2002; Robling et al. 2002)). Proteins underlying the molecular mechanisms of 
memory in the CNS are also present in bone cells (Skerry 2002; Turner et al. 2002; 
Spencer and Genever 2003), suggesting that bone cells are capable of adapting their 
response to mechanically-induced glutamate signalling based on previous mechanical 
episodes (Spencer et al. 2001; Bowe and Skerry 2005). Modulation of glutamatergic 
signalling could artificially activate the cells to become more responsive to low levels 
of load, with clinical applications for increasing bone mass at mechanically 
compromised sites of the skeleton, such as fractures or osteoporotic tissues (Mason 
2004a, b).
1.6 Hypothesis and Aims 
Hypothesis:
Inhibition of glutamate transporter activity in bone cells can be used to mimic 
mechanical stimulation and enhance osteoblast differentiation and/or bone 
forming activity.
To investigate this hypothesis, the specific aims of the project were as follows:
1. To determine EAAT expression profile and glutamate transport activity in 
osteoblasts in vitro.
2. To determine whether inhibition of EAAT transport, ion channel, or N 
and C terminal interactions increases osteoblast differentiation and/or 
activity in vitro.
3. To determine whether increased expression of EAATla or 
EAATlex9skip mRNA splice variants increases osteoblast differentiation 
and/or activity in vitro.
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2. Materials and Methods
2.1 Materials
All reagents were from Sigma unless otherwise stated. All primers and 
oligonucleotides were synthesised and purified by MWG unless otherwise stated. 
GAPDH and 18S rRNA primer pairs were a kind donation from Dr Sophie Gilbert 
(Cardiff University, UK). All plasticware and consumables were certified 
ribonuclease (RNase)/deoxyribonuclease (DNase) free as appropriate. Dulbecco’s 
modified Eagle’s medium (DMEM), fetal bovine serum (FBS) and supplements were 
obtained from Gibco BRL (Invitrogen, Paisley, UK) unless otherwise stated. DMEM 
does not contain glutamate but does contain Glutamax® which is a more stable source 
of L-glutamine and so less likely to decompose to glutamate during storage, therefore 
minimising any potential source of exogenous glutamate. DMEM also contains 
pyruvate which has been shown to be essential for MC3T3-E1 osteoblast survival 
when cultured in DMEM (Hinoi et al. 2002a). Dialysed FBS (dFBS; 0.1pm filter, 
10,000 MWt cut-off) to exclude exogenous glutamate was obtained from Sera 
Laboratories Ltd (Crawley, UK). Full composition of all solutions used can be found 
within Appendix 9.1.
2.2 Cell lines and cell culture
2.2.1 MG-63
MG-63 cells (ATCC CRL-1427) were a kind gift from Dr Bronwen Evans (Cardiff 
University, UK). The cells are derived from bone osteosarcoma of a 14-year old 
Caucasian male (Billiau et al. 1977) and exhibit an osteoblast phenotype with
fibroblastic morphology. MG-63 propagation and subculture conditions were adapted
from the American Type Culture Collection (ATCC) guidelines and DMEM was 
chosen as maintenance medium over the recommended Eagle’s Minimum Essential 
Medium to ensure the presence of pyruvate and the minimisation of exogenous 
glutamate concentrations. MG-63 cells were routinely maintained in 75cm2 culture 
flasks in DMEM containing Glutamax® and pyruvate and supplemented with
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lOOU/ml penicillin, lOOpg/ml streptomycin and 5% FBS at 37°C in 5% COtJ9S% air 
atmosphere. Medium was renewed twice a week. Cells were passaged once a week by 
rinsing the cell layer with 0.25% (w/v) trypsin and ethylenediaminetetraacetic acid 
(EDTA), and subsequent incubation at 37 °C for 5 min. Cells were collected by 
centrifugation and seeded with splitting ratios of approximately 1:5. Passages 18-35 
were used for experiments.
2.2.2 SaOS-2
SaOS-2 cells (ATCC HTB-85) were a kind gift from Dr Bronwen Evans (Cardiff 
University, UK). The cells are derived from bone osteosarcoma of a 11-year old 
Caucasian female (Fogh et al. 1977) and exhibit an osteoblast phenotype with 
epithelial morphology. SaOS-2 propagation and subculture conditions were adapted 
from the ATCC guidelines and DMEM was chosen as maintenance medium over the 
recommended McCoy’s 5a Medium Modified to ensure the presence of pyruvate and 
the minimisation of exogenous glutamate concentrations. SaOS-2 cells were routinely 
maintained in 75cm2 culture flasks in DMEM containing Glutamax® and pyruvate and 
supplemented with lOOU/ml penicillin, lOOpg/ml streptomycin and 5% FBS at 37°C 
in 5% CC>2/95% air atmosphere. Medium was renewed twice a week. Cells were 
passaged once a week by rinsing the cell layer with 0.25% (w/v) trypsin and EDTA, 
and subsequent incubation at 37 °C for 5 min. Cells were collected by centrifugation 
and seeded with splitting ratios of approximately 1:4. Passages 18-35 were used for 
experiments.
2.2.3 Primary osteoblasts
Normal Human Osteoblasts (NHOBs) were a kind gift from Dr Bronwen Evans 
(Cardiff University, UK) (NHOB1 and NHOB3; Lonza, Walkersville, MD, US) and 
from Smith & Nephew (NHOB2; S&N, York, UK reference HS697/BC/01, provided 
by Promocell under Agreement Reference RC1341882Z). NHOBs have been named 
in the text to denote both cell line (NHOB1-3) and passage (NHOBP4-12). NHOBs 
were maintained in specialised basal media for osteoblast growth (Lonza Osteoblast 
Growth Medium and associated supplements and growth factors (NHOB1 and 3) and 
Promocell Osteoblast Growth Medium containing Promocell Osteoblast Supplement
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Mix (NHOB2)) in 75cm2 culture flasks at 37°C in 5% CC>2/95% air atmosphere. At 
80% confluency, NHOBs were subcultured by rinsing the cell layer with 0.25% (w/v) 
trypsin and EDTA, and subsequent incubation at 37 °C for 10 min. Cells were 
collected by centrifugation and seeded at 5000 cells/cm2. For experiments, NHOB1 
was plated in Lonza Osteoblast Growth Medium and associated supplements and 
growth factors. However the specialised basal medium for osteoblast growth from 
both companies was subsequently found to contain glutamate, therefore experiments 
on NHOB2 and NHOB3 were performed in DMEM containing Glutamax® and 
pyruvate and supplemented with lOOU/ml penicillin, lOOpg/ml streptomycin and 10% 
FBS. Passages 4-12 were used for experiments.
2.3 RNA P repara tion
RNA was extracted from cells in monolayer using RNase/DNase-free plasticware and 
molecular biology grade reagents.
2.3.1 Isolation of total RNA
Total RNA from cells grown in monolayer was isolated using an adaptation of 
(Chomczynski and Sacchi 1987) method. Cells were homogenised by pipetting up and 
down for 5 min with 1ml of TRIzol® reagent (Invitrogen, Paisley, UK) per 10cm2. 
0.2ml chloroform was then added per 1ml TRIzol® reagent and the samples shaken 
vigorously and centrifuged at 12,000g for 15 min at 4°C to separate the aqueous 
(RNA containing) and organic phases (protein containing). RNA from the aqueous 
phase was precipitated with 2-propanol (0.5ml per 1ml TRIzol® reagent) at room 
temperature for 10 min. The RNA precipitate was pelleted at 12,000g for 10 min at 
4°C and washed once with 75% ethanol before air-drying and resuspension in 44pl 
RNase/DNase-free water.
2.3.2 DNase treatment
qni
Isolated total RNA was subjected to DNAse treatment (UNA-free kit, Ambion, 
Huntington, UK) according to the manufacturer’s protocol in order to eliminate any
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residual genomic DNA. To 44pl total RNA, 5 pi 10X DNase I buffer (final 
concentration of lOmM Tris-HCl pH 7.5, 2.5mM MgCh, 0.5mM CaCb) and lpl 
recombinant DNase I were added and samples incubated at 37°C for 30 min. rDNase I 
was inactivated by the addition of 5pi DNase Inactivation Reagent and incubation at 
room temperature for 2 min with occasional mixing. Samples were centrifuged at 
10,000g for 1.5 min and RNA supernatant transferred to a fresh tube.
2.3.3 Precipitation
To ensure the eradication of all organic contaminants, total RNA was re-precipitated 
with 0.1 volumes 3M sodium acetate (pH 5.5) and 2.5 volumes of 100% ethanol at 
-20°C overnight or at -80°C for 30 min. Precipitates were then centrifuged at 12,000g 
for lOmin at 4°C and pellets washed once with 75% ethanol before air-drying and 
resuspension in 20pl RNase- and DNase-free molecular biology grade water. Total 
RNA was stored at -80°C.
2.3.4 Estimation of RNA concentration and purity
Total RNA was quantified by measuring the absorbance at 260nm in a NanoDrop® 
ND-1000 Spectrophotometer with associated NanoDrop 3.0.1 software (NanoDrop 
Technologies, UK) against a blank of molecular biology grade water. One unit of 
absorbance at 260nm corresponds to 40pg RNA per ml. The ratio of absorbance at 
260nm and 280nm (A260/A280) indicates the purity of the RNA with respect to 
contaminants that absorb in the UV spectrum i.e. proteins. Pure RNA has a A260/A280  
ratio of -2.0. The ratio of absorbance at 260nm and 230nm (A260/A230) indicates the 
purity of the RNA with respect to contaminants such as carbohydrates, salts, and 
phenol. Pure RNA has a A260/A230 ratio of 2.0-2.2. Samples with A260/A280 of >1.9 and 
A260/A230 o f >1.8 were deemed of suitable purity to continue to reverse transcription. 
Figure 2.1 shows a representative agarose gel of total RNA extracted by this 
procedure. Approximately 1 pg total RNA isolated from MG-63 and SaOS-2 cells and 
500ng isolated from human primary osteoblasts was resolved on a 1% agarose gel 
according to section 2.4.3. The 18S and 28S ribosomal RNA bands are clearly visible 
demonstrating that the isolated RNA has not degraded during the extraction process.
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1 2 3::  <----  28S <----  18S
Figure 2.1. Agarose gel o f  RNA isolated by T R Izo l method from  human 
osteoblasts. RNA extracted from 1. MG-63 cells (lpg), 2. SaOS-2 cells (lpg ) and 3. 
human primary osteoblasts (500ng) was resolved on a 1% agarose gel and visualised 
under UV light in conjunction with SafeView nucleic acid stain. The 28S and 18S 
ribosomal RNA bands are clearly visible in the extracted RNA showing that no 
degradation had occurred during the extraction process.
2.3.5 Reverse Transcription
Total RNA was reverse transcribed to prepare complementary DNA (cDNA). The 
mass o f RNA reverse transcribed was kept constant where possible within an 
experiment, but varied between experiments within a range of 100-500ng. The exact 
RNA mass that was reverse transcribed is detailed in the appropriate experimental 
chapter. Reverse transcription was carried out in a 20pl reaction volume and reaction
q n  /
conditions were defined by the manufacturers’ protocol for Superscript HI reverse 
transcriptase (Invitrogen, Paisley, UK). Total RNA was mixed with 4pl 
deoxyribonucleotide triphosphate (dNTPs) (at 2.5mM) (Promega, Southampton, UK), 
250ng random primers (hexadeoxynucleotides) (Promega, Southampton, UK) and 
water was added to 13 pi. The samples were then incubated at 65°C for 5 min followed 
by incubation on ice for 2 min and the addition of 4pl 5X first strand synthesis buffer 
(to yield IX buffer in a 20pl final reaction volume containing 50mM Tris-HCl, pH 
8.3, 75mM KC1, 3mM MgCl2) and lp l dithiothreitol (DTT) (0.1M), both supplied
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with the Superscript™ III reverse transcriptase (Invitrogen, Paisley, UK). 40 units 
RNase inhibitor RNasin® (Promega, Southampton, UK) and 200 units Superscript™ 
HI reverse transcriptase were then added. Reverse transcription reaction was mixed 
and incubated at 25°C for 5 min, 50°C for 50 min, and 70°C for 15 min on a Techne 
TC-312 Thermal Cycler (Techne, Cambridge, UK). Samples were held at 4°C before 
storage at -20°C until cDNA was required.
2.4 Real Time-Polymerase Chain Reaction (RT-PCR)
2.4.1 Prim er design
Primers were designed against known gene sequences 
(http://www.ncbi.nlm.nih.gov/nucleotide) using the Primer 3 web-based program 
(http://primer3.sourceforge.net/) to ensure similar melting temperatures (Tm), 
minimal internal structure (i.e. primer-dimer formation) and exclude 3’ end 
complementation. The total gene specificity of the nucleotide sequences chosen for 
the primers was confirmed by nBLAST (nucleotide basic local alignment search tool) 
searches (GenBank database sequences). Primers were positioned in either separate 
exons, or at the junction between two exons to ensure specificity to cDNA and not 
genomic DNA sequences. Exon boundaries were viewed in Ensembl 
(www.ensembl.org). Primers were synthesised by MWG Biotech AG (Milton Keynes, 
UK). The accession number, nucleotide sequences, Tm, amplicon size (base pairs, bp) 
and source of the primers for housekeeping, phenotypic and glutamate transporter 
genes of interest are shown in Table 2.1. A diagram showing the binding sites of 
primers to EAAT1 and its splice variants EAATla and EAATlex9skip is shown in 
Figure 2.2.
2.4.2 Standard RT-PCR
Standard PCR amplification of cDNAs of interest was carried out in a reaction 
containing 2.5mM MgCh, 200nM of each forward and reverse primer, GoTaq Flexi 
buffer, pH 8.5, and 1 unit of GoTaq Flexi DNA polymerase (Promega, Southampton,
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Table 2.1. Primer details for housekeeping genes (GAPDH, 18S rRNA and HPRT1), 
osteoblast markers (osteocalcin, osteonectin, osteoprotegerin, alkaline phosphatase,
runx2 and type I collagen) and glutamate transporters (EAATs).
Gene Primers (5’-3’) TmC 9
Amplicort 
size (bp) Source
GAPDH 
NM 002046
Fwd - GGT ATC GTG GAA GGA CTC ATG A (Exon 7)
60 68
Dr
Sophie
GilbertRev - GGC CAT CCA CAG TCT TCT G (Exon 8)
18S ribosomal 
RNA
NR 003286.1
Fwd - GCA ATT ATT CCC CAT GAA CG
60 125
Dr
Sophie
GilbertRev - GGC CTC ACT AAA CCA TCC AA
HPRT1 
NMOOO 194.2
Fwd - GCA GAC TIT GCT TTC CTT GG (Exon 6)
60 80 Primer3
Rev - GTG GGG TCC TTT TCA CCA G (Exon 7)
Osteocalcin
NM_199173.2
Fwd - GGC AGC GAG GTA GTG AAG AG (Exon 3)
60 73 Primer3
Rev - GAT CCG GGT AGG GGA CTG (Exon 4)
Osteonectin 
NM 003118.2
Fwd - AAA TAC ATC CCC CCT TGC CT (Exon6/7)
60 78
Dr
Philippa
ParsonsRev - CCA GGA CGT TCT TGA GCC AG (Exon 7)
Osteoprotegerin 
NM 002546.3
Fwd - GGA AGG GCG CTA CCT TGA G (Exon 2)
60 97 Primer3
Rev - TGT AIT TCG CTC TGG GGT TC (Exon 3)
Runx2
NM 004348.3
Fwd - GTG GAC GAG GCA AGA GTT TC (Exon3/4)
60 107 Primer3
Rev - TTC CCG AGG TCC ATC TAC TG (Exon 4)
Type I Collagen 
NM 000088.2
Fwd - CAG CCG CTT CAC CTA CAG C (Exon 50)
60 83 (Frank et al. 2002)Rev - TTT TGT ATT CAA TCA CTG TCT TGC C (Exon 51)
Alkaline 
Phosphatase 
NM 000478.2
Fwd - GGC TGG AGA TGG AC A AGT TC (Exon 4)
60 111 Primer3
Rev - CCT TCA CCC CAC ACA GGT AG (Exon 5)
EAAT1 (+ 
lex9skip) 
NM 004172
Fwd - ACC GCT GTC ATT GTG GGT A (Exon 2/3)
60 94 Primer3
Rev - GTT CCC CAG GAA AGG AGA AG (Exon 3)
EAAT1 (+ la) 
NM 004172
Fwd - CATTAACATGGATGGGACTGC (Exon 8)
60 119 Primer3
Rev - CAGCTGTGGCTGTGATGC (Exon 8/9)
EAAT1 (span 
exon 9)
NM 004172
Fwd - CTG CCC TCT ATG AGG CTT TG (Exon 8)
60
256
(EAAT1),
121
(ex9skip)
Primer3
Rev - TCT CCC AGT ACG TTG GTG GT (Exon 10)
EAAT1 (span 
exon 3) 
NM_004172
Fwd -  TTT GGC CAA GAA GAA AGT GC (Exon 2)
60
278
(EAAT1),
140
(EAATla)
Primer3
Rev - CCA TCT TCC CTG ATG CCT TA (Exon 4)
EAATla
Fwd - CGC TGT CAT TGT GGG AAT (Exon 2/4)
60 100 Primer3
Rev - CAC AGC AAT GAT GGT GGT AG (Exon 4)
EAATlex9skip
Fwd - CGG ACA AAT TAT TAC AAT CAG GGA (Exon 8/10)
60 93 Primer3
Rev - CGT GAC AAG TGC TCC ACA AT (Exon 10)
EAAT2
NM_004171
Fwd - ACC CTG ACG GTG TIT GGT G (Exon 2/3)
60 106 Primer3
Rev - CCC CTG GGA AGG CTA TTA AC (Exon 3)
EAAT3
NM4170
Fwd - AAT TCT ACT TTG CTT TTC CTG GAG (Exon 2/3)
60 102 Primer3
Rev - CCA GTG CAG CAA CAC CTG TA (Exon 3)
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- -
1 2 3 4 5 6 7 8 9 10 EAAT1
1 2 4 5 6 7 8 9 10 EAATla
1 2 3 4 5 6 7 8 10 EAAT1ex9skip
-  -
EAAT1 (+1ex9skip) 
EAAT1 (+1a)
EAAT 1 (span exon 3)
—* EAAT 1 (span exon 9) 
EAATla 
—* EAAT1ex9skip
Figure 2.2. Binding sites o f  primers to EAAT1, EAATla and EAATlex9skip. The 
exons o f EAAT 1, EA A Tla and EAATlex9skip are indicated by the shaded boxes and 
the sites o f hybridisation o f the primer pairs in Table 2.1 are shown by coloured 
arrows.
UK) in the presence o f 200nM dNTPs. Reaction volumes were scaled as appropriate 
to 12.5pi or 25pi. Samples were initially denatured at 95°C for 3 min then amplified 
for 40 cycles at 95°C for 30s, Tm for 30s (annealing, Table 2.1) and 72°C for 30s 
(extension) with a final extension at 72°C for 10 min. Samples were held at 4°C 
before analysis of products by agarose gel electrophoresis.
2.4.3 Agarose gel electrophoresis
Nucleic acid was resolved on agarose gels of the appropriate percentage agarose 
(Table 2.2) containing SafeView nucleic acid stain (NBS Biologicals, 
Cambridgeshire, UK) at 5pl/100ml. Gel electrophoresis was carried out in IX Tris 
Borate EDTA (TBE) buffer (Promega, Southampton, UK) alongside a DNA ladder. 
DNA ladders used were a lOObp DNA ladder spanning 100-l,500bp (Promega, 
Southampton, UK) and a low molecular weight DNA ladder spanning 25-766bp (New 
England BioLabs, Herts, UK). Gels were visualised under UV light and images taken 
using a GelDoc system (BioRad). For densitometry o f PCR products, gel pictures 
were scanned UMAX MagicScan DA software and bands of interest quantified by 
densitometry using NTH Image 6.2.
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Table 2.2. Percentage agarose (wA>) required to efficiently separate linear DNA o f  
different molecular weights by gel electrophoresis.
Amount of agarose 
in gel (% w/v)
Range of linear DNA fragment 
molecular sizes for efficient resolution
2 100-200bp
1.5 200-500bp
1 500bp-lkb
0.7 >lkb
2.4.4 Quantitative RT-PCR (QRT-PCR)
QRT-PCR assays were carried out using SYBR® Green I dye. SYBR® Green I dye 
specifically binds to double stranded DNA and fluorescence of the dye increases as 
PCR product accumulates during PCR cycles (Figure 2.3). The threshold was set so 
that it was in the centre of the logarithmic phase of the amplification curve for each 
gene and this yielded the cycle threshold value (Ct) which is defined as the cycle 
number at which the fluorescence curve crosses the threshold. Results were exported 
and either absolute (2.4.4.4) or relative (2.4.4.5) quantification was used.
2.4.4.1 Instruments and consumables
QRT-PCR assays were carried out on two separate instruments. The primer sets used, 
their concentrations and annealing temperatures were kept constant across 
instruments, as was the utilisation of SYBR® Green I dye in the assay and the 
employment of a dissociation thermal step to determine the melting point of the 
product at the end of the 40 cycles. A valid QRT-PCR assay was defined as one that 
generated a melt curve with a single peak (an example melt curve for each gene assay 
can be found in Appendix 9.2). Standard curves were assessed for each assay on each 
instrument and a standard curve with an efficiency of 90-110% and an R2 of >0.99 
were accepted as valid. Details of the construction of standard curves are found in 
section 2.4.4.2 and examples of standard curves for each instrument can be found in 
Appendix 9.2.
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Fluorescence
(ARxn)
Ct Ct
Figure 2.3. QRT-PCR amplification cur\’es. Each amplification curve is 
representative of the change in fluorescence (ARxn) for one sample after each 
PCR cycle. The threshold is automatically set in the logarithmic region of all 
curves. The cycle threshold value (Ct) is the cycle number at which the curve 
crosses the threshold.
2.4.4.1.1 Stratagene (Cardiff University)
QRT-PCR reactions were performed using RNase/DNase-free 96-well plates and strip 
caps (both from Stratagene, Cambridge, UK) and a Stratagene MX3000P™ Real- 
Time PCR system and monitored using MxPro QPCR Software (Stratagene, 
Cambridge, UK). cDNA samples were analysed in 25pi reaction volumes containing
TTV/f200nM o f each forward and reverse primer, and 12.5pi 2X JumpStart Taq 
ReadyMix™ containing SYBR® Green I dye. After an initial denaturation step at 
95°C for 2 min, the cDNAs were amplified with 40 PCR cycles. PCR cycles consisted 
o f a denaturation step at 95°C for 20s, an annealing step at Tm for 40s (Table 2.1) and 
an extension step at 72°C for 20s.
2 .4.4.1.2 Applied Biosystems (Smith & Nephew Research Centre, York)
QRT-PCR reactions were performed using RNase/DNase-free 96-well plates and ABI 
Prism™ optical adhesive covers (both from Applied Biosystems, Warrington, UK)
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and an Applied Biosystems 7900HT Fast Real-Time PCR system and monitored 
using standard SDS Software (Applied Biosystems, Warrington, UK). cDNA samples 
were analysed in 20pl reaction volumes containing 200nM of each forward and 
reverse primer, and lOpl 2X Power SYBR® Green PCR Master Mix (Applied 
Biosystems, Warrington, UK). After an initial denaturation step at 95°C for 10 min, 
the cDNAs were amplified with 40 PCR cycles. PCR cycles consisted of a 
denaturation step at 95°C for 15s, and a combined annealing/extension step at 60°C 
for 60s.
2.4 4.2 Generation of QRT-PCR standard curves
To assess the efficiency and linear range of detection for the designed primers, 
standard curves of the cloned amplicon or a stock osteoblast cDNA sample were 
generated and assayed by QRT-PCR. These standard curves were also employed for 
quantification of expressed genes under experimental conditions by comparing the Ct 
values of unknowns to the standard curve.
Plasmid standard curves were used to assess linearity and efficiency of the assays on 
the Stratagene MX3000P™ Real-Time PCR system (section 2.4.4.1.1) whereas 
cDNA standard curves were used with the Applied Biosystems 7900HT Fast Real- 
Time PCR system (section 2.4.4.1.2). Plasmid standard curves were required for 
optimisation of the assays on the Stratagene MX3000P™ Real-Time PCR system 
because this system was used for absolute quantification (section 2.4.4.4) of EAATs 
in osteoblast cell lines whereas relative quantification (section 2.4.4.5) using cDNA 
standard curves was employed with the Applied Biosystems 7900HT Fast Real-Time 
PCR system which was used to assess changes in osteoblast gene expression in 
response to experimental treatments.
2.4.4.2.1 Plasmid standard curves
Human osteoblast cDNA samples were amplified by PCR using the primers detailed 
in Table 2.1 and the PCR product was resolved on an agarose gel (section 2.4.3) to 
confirm that a single product of the correct size was generated with each primer set. 
PCR products from each gene amplification assay were excised from agarose gels, 
purified and cloned into PGEM®-T vector (Promega, Southampton, UK).
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2.4.4.2.1.1 Purification o f DNA from gel
DNA bands were excised from agarose gels using sterile scalpels under UV light and 
weighed. The DNA was then purified from the gel using a Qiagen QLAquick gel 
extraction kit (Qiagen, Crawley, UK) according to the manufacturer’s guidelines. 
DNA was eluted in 30pl molecular biology grade water.
2.4.4.2.1.2 TA cloning into PGEA^-T vector
DNA was TA cloned into 50ng PGEM®-T vector (Promega, Southampton, UK) in the 
presence of 3 units T4 DNA ligase (Promega, Southampton, UK) in rapid ligation 
buffer (containing 30mM Tris-HCl pH 7.8, lOmM MgCh, lOmM DTT, ImM ATP, 
5% polyethylene glycol) at room temperature for 3 hrs in a lOpl reaction volume. For 
PGEM®-T vector map and sequence of cloning site see Appendix 9.3.
2.4.4.2.1.3 Transformation into competent cells
The entire ligation reaction was transformed into 50pl ampicillin-resistant JM109 
competent Escherichia coli (Promega, Southampton, UK) by incubation on ice for 
20s followed by heat-shocking at exactly 42°C for 45s. 950pl S.O.C medium 
(Invitrogen, Paisley, UK) was then added and the transformation reactions incubated 
at 37°C for 1.5 hrs with shaking (150 revolutions per minute, rpm). lOOpl of the 
reaction was then spread onto lysogeny broth (LB) agar plates with lOOpg/ml 
ampicillin (Bioline, London, UK), 0.5mM Isopropyl P-D-l-thiogalactopyranoside 
(IPTG) and 40pg/ml X-Gal (Promega, Southampton, UK) and incubated overnight at 
37°C. Recombinant (white) colonies were selected and inoculated in 5ml LB broth 
(containing lOOpg/ml ampicillin) overnight at 37°C with shaking (150rpm).
2.4.4.2.1.4 Plasmid DNA minipreps
Plasmid DNA was extracted using Wizard® plus SV miniprep kit (Promega, 
Southampton, UK) according to the manufacturer’s instructions. DNA was eluted in 
lOOpl molecular biology grade water.
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2.4.4.2.1.5 Sequencing
PGEM®-T vector insert DNA sequence was determined by the Cardiff University 
Molecular Biology Unit DNA sequencing core facility using T7 forward and SP6 
reverse primers. The vector insert sequence was confirmed to be correct by displaying 
100% identity with the target sequence in nBLAST.
2.4.4.2.1.6 Plasmid standard curve dilution
The concentration of plasmid DNA was measured spectrophotometrically (NanoDrop 
Spectrophotometer, ND-1000, NanoDrop Technologies, UK) by measuring the 
absorbance at 260nm. One unit of absorbance at 260nm corresponds to 50pg DNA 
per ml. Copy numbers were determined according to the molecular weight of the 
respective inserts (based on methodology from (Whelan et al. 2003) (for insert size 
see Table 2.1, for calculation see Appendix 9.4). Plasmids were diluted 10-fold in 
molecular biology grade water to generate standard curves for QRT-PCR analysis 
over a range of lOMo8 plasmid DNA copies/pl. Stock plasmid DNA was stored at - 
20°C in RNase- and DNase-free no-stick microcentrifuge tubes (Alpha Laboratories, 
Eastleigh, UK).
2.4.4.2.2 cDNA standard curves
Stock concentrated cDNA (2-5 pg RNA reverse transcribed) from osteoblasts (MG-63 
or SaOS-2) was serially diluted in molecular biology grade water to generate standard 
curves. Standard curves generated in this way were over a narrower range than 
plasmid standard curves but were still able to demonstrate that the Ct values for 
unknown samples occurred in the linear and efficient range of the assay. For each 
gene assay, the stock cDNA sample and the standard curve set-up was kept constant 
across experiments.
2.4.4.3 Housekeeping genes
Numerous studies have reported considerable variation in housekeeping gene 
expression (Thellin et al. 1999; Bustin 2000; Suzuki et al. 2000; Warrington et al.
63
Chapter 2
2000) and therefore validation of stable housekeeping genes should be considered for 
each different experimental condition. Where possible, QRT-PCR analysis was 
carried out in conjunction with three housekeeping genes (18S rRNA, GAPDH and 
HPRT1). In this case, transcript data were normalised to the most stable housekeeping 
gene under each condition as determined using geNorm software which compares the 
pair-wise variation for each housekeeping gene (Vandesompele et al. 2002). Raw 
expression data for each housekeeping gene in an experiment (calculated from a 
standard curve) were loaded into the geNorm programme and the gene expression 
stability measure M  was generated. M  is the average pair-wise variation for that gene 
with all other tested genes and the most stable housekeeping gene is that with the 
lowest M  value. The housekeeping gene used for each experiment is stated in the 
appropriate experimental chapters of this thesis, as well as the relevant figure legend.
2.4.4.4 Absolute QRT-PCR
Absolute QRT-PCR analysis of experimental gene expression was carried out in 
conjunction with a standard curve generated from serial dilutions of plasmid vectors 
containing the specific amplicon under analysis (section 2.4 4.2.1). This method 
quantitates unknowns based on a known quantity standard curve and therefore 
absolute copy numbers of the transcript of interest can be determined. EAAT1 
primers amplify both EAAT1 and EAATlex9skip, therefore the absolute copy 
numbers obtained for EAAT1 (+lex9skip) were corrected by subtracting the absolute 
copy numbers obtained when the same samples were amplified using EAATlex9skip 
specific primers (Table 2.1). This method of determining expression levels of splice 
variants is only appropriate when there is near to equal abundance of the variants 
because the difference in Ct-values of both PCR products must be significantly higher 
than the inherent inter-well and inter-assay variation of real-time PCR 
(Vandenbroucke et al. 2001).
2.4.4.5 Relative QRT-PCR
In relative quantification, changes in expression of the gene of interest are normalised 
to the appropriate housekeeping gene in a given sample and expressed relative to a 
reference sample i.e. untreated control sample. The experimental sample group used
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as the reference sample is clearly stated in the methods and figure legend for each 
experiment. A requirement for this method of expression analysis is that the primer 
set for the endogenous control and the primer set for the gene of interest are of 
comparable efficiencies (90-110%). Relative QRT-PCR analysis of gene expression 
for the housekeeping gene and gene of interest was carried out in conjunction with a 
plasmid standard curve (section 2.4.4.2.1) or a cDNA standard curve (section
2.4.4.2.2) to determine expression quantities. The appropriate housekeeping gene was 
determined (as outlined in section 2.4.4.3) and for each experimental sample, the 
amount of gene of interest (measured against the standard curve) was divided by the 
amount of the housekeeping gene (also measured against a standard curve) to obtain a 
normalised value. Each of the normalised values was then divided by the mean of the 
normalised values from the reference sample group and the relative expression levels 
expressed as a percentage.
2.5 Protein preparation
2.5.1 General method for cell lysis
Entire cell lysate was obtained by washing the cell monolayer with cold phosphate 
buffered saline (PBS) and homogenising cells in lysis buffer (cold 0.9% (v/v) Triton® 
X-100 in PBS containing Sigma protease inhibitor cocktail (2mM 4-(2- 
aminoethyl)benzenesulfonyl fluoride (AEBSF), ImM EDTA, 130pM bestatin, 14pM 
E-64, lpM  leupeptin, 0.3 pM aprotinin)). For analysis of cell death in the culture
supernatant (section 2.5.3), the culture supernatant was incubated with 0.1 volume 9%
(v/v) Triton® X-100 in PBS to ensure lysis of all dead or dying cells.
2.5.2 BCA protein assay
Protein concentration of cell lysate was determined by Bicinchoninic acid (BCA™) 
assay kit (Pierce, Cheshire, UK) according to the manufacturers’ instructions and in 
comparison to a bovine serum albumin (BSA) standard curve (0-2mg/ml). Briefly, 
25 pi lysate/standard/lysis buffer blank was added to 200pl BCA™ working reagent 
(50:1, BCA™ Reagents A:B) in a 96-well plate and mixed on a plate shaker for 30s.
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The plate was then covered and incubated at 37°C for 30 min and cooled to room 
temperature prior to measuring the absorbance at 562nm on a FLUOstar OPTIMA 
microplate reader (BMG Labtech, Aylesury, UK).
2.5.3 LDH assay of cell number and cell death
Cytotoxicity assay was carried out immediately on cell lysate and/or culture 
supernatant according to the Cytotox96 kit protocol (Promega, Southampton, UK). 
Lactate dehydrogenase (LDH) is an abundant intracellular enzyme (Lipton et al.
1993). LDH was quantified colourimetrically with a coupled enzymatic assay which 
results in the conversion of a tetrazolium salt to a red formazan dye product, using 
Cytotox96 (Promega, Southampton, UK) according to the manufacturer’s 
instructions. Briefly, cell lysate or culture supernatant (diluted with distilled water if 
necessary to a total volume of 50jil) was incubated with 50pl Substrate Mix (prepared 
according to the manufacturer’s instructions) for 10 min in the dark. 50pl Stop 
Solution was then added to each well and absorbance at 490nm measured using a 
FLUOstar OPTIMA microplate reader (BMG Labtech, Aylesury, UK). LDH activity 
in the lysed cell monolayer represents viable adherent cells whereas LDH activity in 
the culture supernatant represents dead or dying cells.
2.5.4 Alkaline phosphatase activity
Alkaline phosphatase (ALP) activity was quantified in cell lysates by 
spectrophotometric measurement of /7-nitrophenol (pNP) release from /?-nitrophenyl 
phosphate (pNPP) using Sigma Fast /?-nitrophenyl phosphate tablet sets according to 
the instructions of the manufacturer. Cell lysates (diluted with distilled water if 
necessary to a total volume of 25pi) were incubated with 200pl pNPP substrate 
(1 mg/ml) in alkaline buffer. Release of pNP was determined by measuring the 
absorbance at 405 nm after a defined incubation time (in the dark) using a FLUOstar 
OPTIMA microplate reader (BMG Labtech, Aylesury, UK). The incubation time 
varied across cell line and was chosen to ensure absorbance values were within the 
linear range of the spectrophotometer (5 min for SaOS-2, lhr for primary osteoblasts). 
ALP activity was normalised to total cell number as determined by LDH assay
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(section 2.5.3) and expressed as nmoles pNPP converted per minute per cell (see 
Appendix 9.5 for calculation).
2.6 Immunofluorescence of EAATs
MG-63, SaOS-2 and human primary osteoblasts (NHOB2P12) were seeded in eight- 
well Lab-Tek™ II Chamber Slides™ (Nunc, Naperville, IL) in normal growth 
medium. MG-63 and SaOS-2 cells were seeded at 2.5 x 104 cells/cm2 and human 
primary osteoblasts were seeded at 1.25 x 103 cells/cm2. At 70% confluency, cells 
were washed with PBS and fixed with ice cold methanol 5 min. The slides were air- 
dried and washed with 3 x 5  min PBS prior to 20 min incubation with 0.2% Triton® 
X-100 in PBS. The cells were then washed with PBS followed by 1-hour incubation 
at room temperature with PBS containing 5% normal goat serum and incubation 
overnight at 4°C with rabbit-anti-GLASTl 1-S (15 amino acid (aa) C-terminal epitope) 
at 1:500 (Alpha Diagnostics, San Antonio, TX) or rabbit-anti-EAAT3 (14aa 
cytoplasmic C-terminal epitope) at 6pg/ml (Alpha Diagnostics, San Antonio, TX) in 
PBS with 0.1% Tween®-20. Cells were washed with PBS and primary antibody 
localised using goat-anti-rabbit IgG-fluorescein isothiocyanate (FITC) conjugate at 
1:160 or goat-anti-rabbit IgG-rhodamine isothiocyanate (TRITC) conjugate at 1:250 
in PBS with 0.1% Tween®-20. Surplus antibody was removed through extensive 
washing with PBS containing 0.1% Tween®-20 and coverslips mounted with 
Vectashield mounting medium with DAPI (4,6-diamidino-2-phenylindole) (Vector 
Laboratories, Burlingame, CA). Labelled cells were visualised using an Olympus 
BX61 fluorescent microscope and attached Olympus SIS F-view digital camera 
(Olympus UK, London, UK) in association with AnalySIS® imaging software v3.2 
(Olympus UK, London, UK). Primary negative controls were performed to confirm 
that staining was not a result of non-specific binding of the secondary antibody. 
Nonim mu no serum-only controls were not carried out.
2.7 EAAT inhibitors
L-/raras-Pyrrolidine-2,4-dicarboxylic acid (/-PDC) and DL-threo-P-benzyloxyaspartic 
acid (TBOA) are glutamate analogues which inhibit glutamate transport in a broad 
range of EAATs whilst displaying weak or no affinity to glutamate receptors (Bridges
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et al. 1991; Maki et al. 1994; Shimamoto et al. 1998; Bridges and Esslinger 2005). 
The IC50 values for each EAAT inhibitor with respect to specific EAAT subtypes are 
displayed in Table 2.3. The IC50 value for an inhibitor represents the inhibitor 
concentration at which the activity of each EAAT subtype was reduced by half. 
Where IC50 values were not available in the literature, Ki values are shown which 
represent the dissociation constant for inhibitor binding, or Km values which represent 
the affinity of the inhibitor for the transporter.
7-PDC is a competitive transportable inhibitor of EAATs 1-4 (Arriza et al. 1994; 
Fairman et al. 1995) and a competitive non-transportable inhibitor of EAAT5 (Arriza 
et al. 1997). TBOA is a competitive non-transportable inhibitor of EAATs 1-5, 
displaying Ki and IC 50 values in the range of 1-1 OpM (Arriza et al. 1994; Shimamoto 
et al. 1998; Jabaudon et al. 1999; Shigeri et al. 2001). TBOA displays similar 
affinities for EAAT1 and EAAT2 as /-PDC, but a much higher affinity for EAAT3. T- 
PDC and TBOA were purchased from Tocris Bioscience (Bristol, UK). Inhibitors 
were dissolved in distilled water to lOmM, frozen at -20°C and used within 8 weeks. 
For the structure of /-PDC and TBOA in comparison to glutamate, see Figure 2.4.
Table 2.3. IC50 (or K/Km values i f  IC50 not available) fo r  EAAT inhibitors with 
respect to specific EAAT subtypes. /-PDC; L-/raws-Pyrrolidine-2,4-dicarboxylic acid, 
TBOA; DL-threo-p-benzyloxyaspartic acid.
EAAT1 EAAT2 EAAT3 EAAT4 EAAT5
f-PDC Transportable IC5oU= 6 5 1K“=792
IC5oU= 1 4 1
KjU=82 KjU=612 KmE=33 KjE=6.24
TBOA Non-transportable IC5oU= 6 7 1 IC5oU= 5 .5 1 IC5oU= 8 5 K,e=46 KjE=36
All values are expressed as mean (in pM) and assessed by electrophysiological study 
(E) or by uptake inhibition study (U).
lln EAAT expressing COS-1 kidney cell line (Shimamoto et al. 1998)
2In EAAT expressing COS-7 kidney cell line (Arriza et al. 1994)
3In EAAT expressing Xenopus laevis oocytes (Fairman et al. 1995)
4In EAAT expressing Xenopus laevis oocytes (Arriza et al. 1997)
5In EAAT expressing COS-1 kidney cell line (Shimamoto et al. 2000)
6In EAAT expressing Xenopus laevis oocytes (Shigeri et al. 2001)
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TBOAf-PDCL-Glutamic acid
Figure 2.4. Glutamate and its analogues. Abbreviations h-trans-2,4-pyrrolidine 
dicarboxylate (/-PDC); DL-threo-p-benzyloxyaspartic acid (TBOA).
2.8 Radiolabelled glutamate uptake assay
Glutamate uptake assays were carried out in 24-well plates according to the described 
methods of (Takarada et al. 2004) to assess EAAT function. Cultured cells were 
washed twice with warm Krebs-Ringer HEPES (KRH) buffer (for composition see 
Appendix 9.1) and incubated with 250p 1/well KRH buffer for lhr at 37°C. For 
inhibitor experiments, KRH buffer was supplemented with 2.5pl/well of 100X EAAT 
inhibitor (Table 2.3) over a range of concentrations. After 1 hour, KRH buffer on cells 
was then replaced with 250pl of KRH buffer (± Na4)  containing a mix of cold and 
14C-labelled glutamate (± EAAT inhibitor for inhibitor experiments). For sodium-free 
experiments, sodium chloride in the KRH buffer was replaced with equimolar choline 
chloride. The specific activities of 14C-labelled glutamate were adjusted across 
glutamate concentration ranges (Table 2.4) based on data from this lab (Flood, 
Duance and Mason, unpublished observations). Cells were incubated with Re­
labelled glutamate at 37°C or 4°C for 10 min (osteoblast-like cell lines) or 20 min 
(primary human osteoblasts). Assay time for osteoblast-like cell lines was based on a 
preliminary optimisation experiment following lOpM glutamate uptake in SaOS-2 
and primary human osteoblasts (NHOB2P9) over time which showed that the 
glutamate transporters had not reached saturation even after 30 min (Appendix 9.6). 
Assay time was longer for primary osteoblasts since this study indicated that these
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cells transported glutamate at a slower rate than observed with osteoblast-like cells. 
Buffer was then aspirated and cells washed briefly with ice-cold KRH buffer 
containing 1.5mM unlabelled glutamate to ensure that 14C-labelled glutamate 
accumulation is derived from uptake o f labelled glutamate into cultured cells as 
opposed to adsorption and/or binding to the cell surface (Takarada et al. 2004). 
Washing with high concentrations o f unlabelled glutamate had no effect on 3H- 
labelled glutamate accumulation in cultured rat calvarial osteoblasts (Takarada et al. 
2004). Cells were then lysed in lOOpl 0.1M NaOH and uptake assessed by 
scintillation counting.
Table 2.4. Specific activity o f glutamate concentrations used in glutamate uptake 
assays, p d  is picocuries
Final glutamate Specific activity
conc“ (pM) (pCi/pmol)
0.1 100
1 50
5 20
10 20
50 10
100 10
250 4.5
2.8.1 Scintillation counting
90pl cell lysate in 0.1M NaOH from the glutamate uptake assay was added to 10ml 
scintillation cocktail (Emulsifier safe™, Perkin-Elmer, Beaconsfield, UK). Each 
sample was counted for 2 min on an LS6500 Multi-purpose scintillation counter 
(Beckman-Coulter, High Wycombe, UK). Radioactivity o f samples is given in 
disintegrations per minute (d.p.m) which can be converted to pmol o f 14C-glutamate 
by the following calculations:
Becquerels (Bq) = d.p.m/60 
Picocuries (pCi) = Bq x 27
Picomoles (pmol) = pCi/Specific Activity o f 14C-glutamate (pCi/pmol)
70
Chapter 2
2.8.2 Normalisation to total protein
Protein content of lysates equivalent to the 90pl taken for scintillation counting from 
glutamate uptake assays was determined using parallel cultures (lysed following the 
methods outlined in section 2.5.1). Protein concentration was determined using a 
Pierce BCA™ protein assay kit in conjunction with a BSA standard curve (section
2.5.2). Glutamate uptake is expressed, where possible, as pmol of glutamate per hour 
per mg total protein. For calculation of sodium-dependent glutamate uptake, uptake in 
KRH in the absence of sodium was subtracted from uptake in KRH in the presence of 
sodium.
2.9 Alizarin red staining for mineralisation
Mineralisation of osteoblasts can be assessed by alizarin red S staining of calcium 
(Putchler 1969; Lievremont et al. 1982; Stanford et al. 1995b). Cells were washed 
twice with cold PBS then fixed with 70% ethanol for lhr at 4°C before staining 
calcium deposits with 1 mg/ml alizarin red S solution in distilled water, pH 4.2 at 
room temperature for 15 min with gentle agitation. Cultures were washed with tap 
water until excess dye had been removed. Representative images from stained wells 
were captured using a Canon IXUS digital camera (Canon, Japan) or by Nikon 
Eclipse TS100 inverted light microscope (Nikon UK ltd, UK) and attached Canon 
400D digital camera (Canon, Japan) under 10X and 20X objectives. To quantify 
mineralisation, cells were de-stained overnight in 300pl of 5% perchloric acid and the 
total volume then transferred to a 96-well plate. Absorbance was measured at 450nm 
in conjunction with a standard curve of alizarin red S dissolved in 5% perchloric acid 
(an example standard curve can be found in Appendix 9.7). Bound alizarin red S was 
expressed in micrograms per well.
2.10 Antisense mediated exon skipping
Antisense oligoribonucleotides (AON) were used to overexpress EAATla and
EAATlex9skip splice variants. AONs used here mediate exon skipping independently 
of RNase-H mediated degradation (Kole and Sazani 2001; Kurreck 2003). AONs can
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mediate exon skipping by sterically blocking splice signals (Kole and Sazani 2001) by 
targeting specific sequences including the donor and acceptor splice sites, the branch 
point sequence and also exonic splice enhancer (ESE) sequences which are discrete 
sequences within exons that promote both constitutive and regulated splicing.
2.10.1 Antisense oligoribonucleotide design
AONs complimentary to EAAT1 pre-mRNA (GenBank Accession no. NM_004172, 
encoded by the gene SLC1A3) intron2/exon3 (ex3skip) and intron8/exon9 (ex9skip) 
boundaries were designed according to published methods (Stein 2001; Aartsma-Rus 
et al. 2004; Aartsma-Rus and van Ommen 2007). AONs were designed by identifying 
sequences positioned across the splice acceptor site i.e. 5’ end of exon to be spliced 
out and the adjacent intronic sequence. AON length was designed to be ~ 20 
nucleotides (Stein 2001). AON locations relative to full-length EAAT1 pre-mRNA 
sequence are depicted in Figure 2.5. The total specificity of the nucleotide sequences 
chosen for the AONs was confirmed by nBLAST searches (GenBank database 
sequences). A scrambled control oligo was generated from the ex9skip AON. 
nBLAST searches confirmed that the scrambled sequence was unlikely to result in 
non-specific effects. AONs were synthesised by MWG (high-performace liquid 
chromatography (HPLC) purified). All AONs were labelled with fluorescent 5- 
carboxy fluorescein (FAM) at the 5’ end to allow for observation of transfection 
efficiency. AON backbone chemistry was modified to include 2’-O-methyl modified 
RNA which renders the AON RNase-H resistant and increases its affinity for target 
RNA (Mayeda et al. 1990; Wang and Kool 1995; Kurreck 2003). Stability o f bases at 
each end of the AON was enhanced by phosphorothioate backbones which inhibit 
AON breakdown by endo- and exonucleases (Campbell et al. 1990; Sands et al.
1994). 2’-0-methyl-phosphorothioate AONs are very sensitive to mismatches in the 
target sequence, making them very specific (Aartsma-Rus and van Ommen 2007). 
AONs were dissolved in molecular biology grade water to lpg/pl.
2.10.2 DNA transfection
Cells were transfected at 80% confluence in antibiotic-free DMEM containing 5% 
dFBS and 50pg/ml ascorbate. Cells were transfected with a previously optimised 5:2
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EAAT1
nnn5'UTR ■0- 3 'U T R
Splice 
acceptor site
I Exon 3Intron 2
5’UCUUUUUCUU UUUUUUUUUU UUUCCUUCAGlg u a c a a u c c u  u g g a u u u a c c  c u c c g a c c a u
3'-aggAAGUC CAUGUUAGGA acC-FAM-5'
3’ Pre-mRNA 
AON Ex3skip
Splice 
acceptor site
Intron 8 I  Exon 9
* 3 ’ Pre-mRNA5* UGUUUUCUGU UCUGGUACITU CUGUUAACAG CAUCACAGCC ACAGCUGCCA GUAUTJGGGGC
3' -acaAUUGUC GUAGUGUCgg U-FAM-5' AON Ex9skip
Scrambled AON Ex9skip:5'-FAM- UauAGUAUUAGCCUGGGugc-3' 
AON Upper case - 2'-O-methyl RNA
AON Lower case - 2'-O-methyl RNA-Phosphorothioate 
FAM - 5-carboxy fluorescein
Figure 2.5. Sequences and relative binding sites o f  AONs. The 5’ sequence of exons 
3 and 9 of human EAAT1 pre-mRNA are indicated by the shaded boxes, whereas the 
intronic sequences neighbouring the exon are indicated by no shading. The sequence 
and orientation o f all the AONs used in this study are indicated, except for Scrambled 
AON Ex9skip, which was designed not to hybridize to any known human sequence as 
validated by a database search.
ratio o f FugeneHD transfection agent (Roche Applied Science, UK) and DNA in 
DMEM according to the manufacturer’s protocol. Per well o f a 24-well plate, lpl 
FugeneHD was added to 18.6pl DMEM, mixed by flicking, then incubated at room 
temperature for 5 min. 0.4pg DNA was then added and mixed by flicking. 
Transfection mix was then incubated at room temperature for 30-45 min before being 
added to cells drop-wise. For smaller culture areas, the transfection mix was scaled 
down appropriately i.e. for 8-well chamber slides and 48-well plates, 0.4pl FugeneHD 
and 0.17pg DNA was combined in 8pl DMEM.
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2.10.3 Analysis of AON transfection efficiency
Cells were plated onto 8-well chamber slides and transfected with FAM-labelled 
AONs. 24hrs post-transfection, cells were washed and fixed in 4% paraformaldehyde 
(PFA) in PBS for 15 min. The cell monolayer was washed with PBS prior to 20 min 
permeabilisation with 0.2% Triton® X-100 in PBS. The cells were then washed with 
PBS and coverslips mounted with Vectashield mounting medium with DAPI (Vector 
Laboratories, Burlingame, CA). Cells were visualised using an Olympus BX61 
fluorescent microscope and attached Olympus SIS F-view digital camera (Olympus 
UK, London, UK) in association with AnalySIS® imaging software v3.2 (Olympus 
UK, London, UK). Transfection efficiency was expressed as the percentage of nuclei 
associated with FAM fluorescence compared to total nuclei in a field of vision at 20X 
magnification. Four random fields of vision were assessed per well and 3 wells 
assessed per experimental group.
2.11 Subcloning of EAAT1 intracellular domains into pcDNA3.1/V5- 
Hise-TOPO® expression vector
Areas of EAAT1 were identified that may be involved in protein-protein interactions 
within the cell. These portions included the entire intracellular portions of the N- and 
C-termini and the intracellular stretch of amino acids between transmembrane 
domains 6 and 7 (Gegelashvili and Schousboe 1998) (Figure 1.8 and Appendix 9.8). 
The sequences corresponding to these domains in the EAAT1 transcript were cloned 
into pcDNA3.1/V5-His°-TOPO® expression vector (Invitrogen, Paisley, UK) (Figure 
2.6, Appendix 9.3 for vector map and sequence of cloning site).
2.11.1 PCR and subcloning of amplicon into PGEM®-T vector
2.11.1.1 Primer design
Primers were designed to amplify sequences within the EAAT1 transcript that 
correspond to the intracellular domains detailed above (Table 2.5). Primers were 
designed by the methods outlined in section 2.4.1. Domains amplified for cloning
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T4 DNA ligase
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E1-ID
E c o R VpGEM-T
B am H I
E c o R V
pcDNA3.1
Transformation into E.coli strain JM109
Purification of plasmid from E.coli (miniprep)
Restriction digestion with BamHI and EcoRV 
and gel purification
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pcDNA3.1
E c o R V
E1-ID
I + I  ----1
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T4 DNA ligase
B am H I
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E c o R VPCDNA3.1
Transformation into E.coli strain JM109
Purification of plasmid from E.coli 
(Endo-free maxi prep)
Figure 2.6 Diagramatic representation o f the protocol followed to generate 
pcDNA3.1/V5-His®-TOPO® vector expressing EAAT1 intracellular domains (E l- 
ID).
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correspond to residues 1-47, 369-390 and 495-542 of EAAT1 amino acid sequence 
shown in Figure 1.8. Forward primers were designed to generate a BamHI restriction 
site and to contain a Kozak consensus sequence which comprises an ATG initiation 
codon ((G/A)NNATGG) where this was not already present i.e. within the sequence 
for the N-terminus. The reverse primers generated an EcoRV restriction site. Primers 
were generated to ensure that subcloning of the BamHI/EcoRV double digested insert 
into pcDNA3.1/V5-Hise-TOPO® would be in frame with the V5 epitope and 
polyhistidine tag. 3 nucleotides were added at either end to ensure recognition of 
restriction site sequence by the restriction enzyme.
BamHI site
5’...GGATCC ...3
3’...CCTAGG...5
▲
EcoRV
S’-.GATATC.S'
3’...CTATAG...5’
Table 2.5. Primers fo r  amplification o f EAAT1 intracellular domains. Restriction 
sites are shown in bold italics. ATG start codon is underlined. Kozak consensus 
sequence is shown in brackets.
EAATl
domain
NM 004172
Primers (5*-3 *) TmCQ
Ampticon size 
0>p)
N-terminus 
(aa 1-47)
Fwd -  GTAGGA TCCGATATGACTAAAAGC AATGG 66
162
Rev -  TAC GA TA TCCCG AAAC AGGTAACTTTTAAC 64
TM6-7 
(aa 369-390)
Fwd -  GTAGGA TCC[GATATGG] GCCTACCCATCACCT 74
93
Rev -  TACGL4 TA TCC ACGAATCTGGTGACGCGCTTG 76
C-terminus 
(aa 495-542)
Fwd -  ATAGGA TCCTGATATGG1TGGAGCACTTG T 68
174
Rev -  TKCGATArCCTACATCTTGGTTTCACTGTCG 68
2.11.1.2 Cloning PCR
Osteoblast-like cell line cDNA (MG-63 and SaOS-2) was amplified using the primers 
in Table 2.5. PCR was carried out in a 25jil reaction volume containing 2.5mM 
MgCh, 200nM of each forward and reverse primer, Phusion High Fidelity buffer and 
0.4units Phusion High Fidelity DNA polymerase (Finnzymes, Espoo, Finland) in the 
presence of 200nM dNTPs. Samples were denatured for 30s at 98°C and then 
amplified for 40 cycles at 98°C for 10s, Tm for 30s (annealing) and 72°C for 30s
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(extension) with a final extension at 72°C for 10 min. Annealing temperatures for 
each primer pair are shown in Table 2.6. Samples were held at 4°C before analysis of 
products by agarose gel electrophoresis.
Table 2.6. Cycling parameters used with primers designed fo r  amplification o f 
EAAT1 intracellular domains.
T m (0Q Cycles
N-terminus 65 x 40
TM6-7
72 x 2
70 x 2
68 x 2
66 x 2
68 x 32
C-terminus 68 x40
2.11.1.3 Purification of amplicon
PCR products were resolved on agarose gels and visualised as outlined in section 
2.4.3. DNA was excised and purified from the gel as outlined in section 2.4.4.2.1.1.
2.11.1.4 Addition of A overhangs
Purified PCR products were incubated with 1 unit of GoTaq Flexi DNA polymerase 
(Promega, Southampton, UK) in the presence of 200nM dATP, 2.5mM MgCb and 
GoTaq Flexi buffer at 72°C for 20 min. Inserts were then immediately TA cloned into 
PGEM®-T vector.
2.11.1.5 TA cloning into PGEM®-T vector
TA cloning, transformation, purification and sequencing of PGEM®-T plasmid 
minipreps containing nucleotide sequences for EAAT1 intracellular domains was 
carried out as outlined in section 2.4.4.2.1.2 to 2.4.4.2.I.5. Those with 100% identity
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to the N-terminus, TM 6-7, and C-terminus sequences of EAAT1 were subcloned into 
pcDNA3.1/V 5-Hisc-TOPO®.
2.11.2 Subcloning of amplicon into pcDNA3.1/V5Hisc-TOPO® vector
2.11.2.1 Restriction digests
Inserts from PGEM®-T plasmid minipreps were removed using the BamHI and 
EcoRV  sites engineered into the forward and reverse primers respectively. Plasmid 
DNA was digested in a 20pl reaction with 5 units of BamHI and EcoRV  (Promega, 
Southampton, UK), and 2pg acetylated BSA in the presence of IX Multi-Core 
restriction enzyme buffer (containing 25mM Tris-Acetate, pH 9.5, lOOmM potassium 
acetate, lOmM magnesium acetate, ImM DTT) (Promega, Southampton, UK). 
Reactions were incubated at 37°C for 2hrs. The expression vector pcDNA3.1/V5- 
His°-TOPO® was digested using the same protocol.
2.11.2.2 Purification of excised inserts
Digest reactions were resolved on 2% (for excision of insert) or 0.7% (for excision of 
pcDNA3.1/V5-His°-TOPO®) agarose gels and visualised under UV exposure as 
outlined in section 2.4.3. Expected sizes of digested inserts are detailed in Table 2.7. 
Digested inserts and pcDNA3.1/V5-His°-TOPO® were excised and purified as 
outlined in section 2.4.4.2.I.2.
Table 2 .7. Expected size o f digested insert
Digested insert (bp)
N-terminus 152
TM6-7 83
C-terminus 164
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2.11.2.3 Ligation into pcDNA3.1 /V5-His®-TOPO® vector
Digested vector and insert were ligated at a ratio of 1:3 vector:insert based on the 
strength of the DNA bands using agarose gel electrophoresis (section 2.4.3). Purified 
digested insert was incubated at 65°C for 5 min in the presence of purified digested 
pcDNA3.1/V5-Hise-TOPO® vector to reduce self-association. 3 units of T4 DNA 
ligase (Promega, Southampton, UK) and rapid ligation buffer (containing 30mM Tris- 
HC1 pH 7.8, lOmM MgCh, lOmM DTT, ImM ATP, 5% polyethylene glycol) were 
then added in a lOpl reaction volume and incubated at room temperature for 3hrs. 
Ligated plasmids were transformed into JM109 chemically competent cells following 
the manufacturers (Promega, Southampton, UK) instructions (as per section
2.4 4.2.1.3). Transformations were grown overnight on LB agar plates containing 
lOOpg/ml ampicillin (Bioline, London, UK) at 37°C.
2.11.2.4 Screening for recombinant clones and determination of insert orientation
Positive colonies were identified by direct PCR of bacterial colonies using primers to 
pcDNA3.1/V5-Hise-TOPO® vector (Table 2.8 and binding sites shown in Appendix 
9.3) and the primers used to generate the insert (Table 2.5). Colonies were amplified 
using either vector forward primer and insert reverse primer, or vice versa, to confirm 
the presence of insert and correct orientation. Samples were denatured for 5-10 min at 
95°C to lyse the cells prior to PCR amplification (section 2.4.2). Annealing 
temperatures, cycling parameters and expected product sizes are outlined in Table 2.9. 
Positive colonies with correct orientation were cultured overnight in 5ml LB broth 
(containing lOOpg/ml ampicillin) at 37°C with shaking (150rpm).
Table 2.8. pcDNA3.1/V5-His®-TOPO9 vector primers spanning the cloning site.
Primers (S’-3>) Tm
C 9
Position in vector 
sequence
pcDNA3.1/V 5-His°- 
TOPO® vector
Fwd -
GAACCC ACTGCTT ACTGGCTTATCG 66 834-858
Rev -
ACTAGAAGGCACAGTCGAGGCTGAT 66 1,106-1,130
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Table 2.9. Cycling parameters and expected product sizes fo r  each primer 
combination used to screen fo r recombinant clones o f pcDNA3.1/V5-Hise-TOPO® 
vector containing N-terminus, TM 6-7 or C-terminus DNA insert
Vectorfwd + 
Insert rev
Insert fw d+ 
Vector rev
Vector fwd + 
Vector rev
EAAT domain
Tm
CQ
Cycles
Product size 
(bp)
Product size 
(bp)
Product size 
(bp)
N-terminus (entire) 66 x 40 245 315 398
TM6-7
75 x 2
176 246 329
73 x 2
71 x 2
69 x 2
67 x 2
66 x 30
C-terminus (entire) 66 x 40 257 327 410
Self ligated BamHI/EcoR V 
dbl digested vector
66 x 40 - - 246
2.11.2.5 Endo-free Plasmid DNA purification
Plasmid DNA was extracted using Endo-free plasmid maxiprep kit (Qiagen, Crawley, 
UK) according to the manufacturer's instructions. DNA was eluted in 500pl 
endotoxin-free tris-EDTA (TE) buffer. DNA was quantified by measuring the 
absorbance at 260nm in a NanoDrop® ND-1000 Spectrophotometer with associated 
NanoDrop 3.0.1 software (NanoDrop Technologies, UK) against a blank of buffer 
TE. One unit of absorbance at 260nm corresponds to 50pg DNA per ml. The ratio of 
absorbance at 260nm and 280nm (A260/A280) indicates the purity of the DNA with 
respect to contaminants that absorb in the UV spectrum i.e. proteins. Pure DNA has a 
A260/A280 ratio of -1.8. The ratio of absorbance at 260nm and 230nm (A260/A230) 
indicates the purity of the DNA with respect to contaminants such as carbohydrates, 
salts, and phenol. Pure DNA has a A260/A230 ratio of 2.0-2.2. Plasmid maxipreps with 
A260/A280 of >1.7 and A260/A230 of >1.8 were deemed of suitable purity to continue to 
transfection.
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2.11.2.6 Sequencing
Insert DNA sequence of pcDNA3.1 /V5 -Hi se-TOPO® vector was determined by the 
Cardiff University Molecular Biology Unit DNA sequencing core facility using T7 
forward primers.
2.11.2.7 Empty vector control
Control cells were treated with a self-ligated pcDNA3. l/V5-Hise-TOPO® vector that 
was sequenced and found not to contain an ATG initiation codon and therefore will 
not express a peptide within the cell.
2.14 Statistical analysis
All statistical comparisons were performed using Minitab 15 software. Results are 
presented graphically as the mean ± S.E.M of replicate samples. The number of 
experimental samples and replicates is indicated in the relevant figure legend. Outliers 
were identified as data points that were >2 standard deviations away from the mean 
and discounted from the analysis. Data were analysed for normality (Anderson- 
Darling) and equal variance (Bartletts and Levenes tests) to satisfy the assumptions of 
a one-way analysis of variance (ANOVA) or General Linear Model (GLM; for 
unbalanced two-factor tests). Data that violated these assumptions were transformed 
(log transform or rank). Data with significant P-values for the ANOVA or GLM were 
analysed by a post-hoc Fisher’s comparison test (one-way ANOVA) or Tukey’s 
comparison test (GLM). Non parametric tests were applied (Kruskal-Wallis in place 
of one-way ANOVA or Shierer-Ray test in place of GLM) when data could not be 
normalised and if significant P-values obtained, 2-tailed Mann-Whitney U tests were 
employed for post-hoc pair-wise comparisons. Data are significantly different at 
P< 0.05.
Much of the data from primary human cells are from single preliminary experiments 
and in these cases, statistical analyses were carried out to identify trends in the data 
set for comparison with cell lines, however increased repeats would be necessary to 
statistically validate any effects of the experimental treatments on these cells.
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3. Investigation of EAAT expression and function in human
osteoblasts
3.1 Background
Glutamate mediates excitatory signalling in the CNS. However, there is now 
considerable evidence to suggest that glutamate may also act as a signalling molecule 
in several peripheral tissues, including bone (Skerry and Genever 2001; Hinoi et al. 
2004).
Full length mRNA for GLAST and the splice variant GLAST-la have been cloned 
from rat tibia (Huggett et al. 2000) and western blotting has revealed bands of 
~69kDa corresponding to the molecular weight for GLAST in rat long bone (Huggett 
et al. 2000). Transcript and protein expression for EAAT1 have also been detected in 
human MG-63 osteoblast-like cells (Kalariti et al. 2004) and EAAT1 and EAAT la 
transcripts have been detected in human SaOS-2 osteoblast-like cells (Huggett et al. 
2002). Expression of transcripts for GLAST, GLT-1 and EAAC1, but not EAAT4 or 
EAAT5 have been demonstrated in primary cultured rat calvarial osteoblasts and, 
although expression of the corresponding proteins could not be confirmed by 
immunoblotting, temperature- and sodium- dependent glutamate uptake was 
observed, indicative of functional EAAT expression (Takarada et al. 2004). EAATs 
transport glutamate in a sodium dependent manner (reviewed in more detail in section
1.5.3.4.4) and thus far, sodium-dependent glutamate uptake activity has only been 
reported for osteoblasts in one instance (Takarada et al. 2004). Accumulation of 
radiolabelled glutamate in primary cultured rat calvarial osteoblasts was found to 
consist of a single kinetic component within a substrate range of l-250pM with a Km 
of 26pM and 42pM a Vmax of 960 pmol/min/mg protein and 290 pmol/min/mg protein 
in osteoblasts cultured for 7 and 21 days respectively (Takarada et al. 2004). 
Furthermore, glutamate uptake was inhibited by the EAAT inhibitors l -(-)-threo-3- 
hydroxyaspartic acid (THA), /-PDC and (2S ,rS ,2’R)-2-(carboxycyclopropyl)glycine 
(CCGHI) at lpM-lmM and the glutamate receptor agonists kainate and NMD A at 
lmM (Takarada et al. 2004).
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3.1.1 Aims
EAAT function comprises both sodium-dependent glutamate uptake and anion 
conductance. Glutamate uptake activity can be measured in vitro by adding 
extracellular radiolabelled glutamate and monitoring movement of the labelled 
glutamate into the cell. The objectives of the experiments described in this chapter 
were to profile EAAT expression at the mRNA and protein level in human primary 
osteoblasts and human osteoblast-like cell lines and also to determine the sodium- 
dependence, kinetic components and pharmacological profile of glutamate uptake in 
these cells.
3.2 Methods
3.2.1 RT-PCR analysis of EAAT mRNA expression
Total RNA was extracted from MG-63 and SaOS-2 osteoblast-like cells, primary 
human osteoblasts (NHOB1P5 and NHOB2P7), and human bone obtained from total 
knee replacements (with informed consent and full ethical approval). Extracted RNA 
(50-500ng) was reverse transcribed in a 20pl volume which was subsequently diluted 
to lOOpl with RNase- and DNase-free molecular biology grade water. Human 
cerebellum total RNA (2pg) (Clontech, Oxford, UK) was reverse transcribed by Dr 
Cleo Bonnet in 20pl volume which was subsequently diluted to 100pi with RNase- 
and DNase-free molecular biology grade water. 5pi cDNA was then used in each RT- 
PCR reaction using primers against EAAT 1+E AAT1 ex9skip, EAATl+EAATla, 
EAAT2, EAAT3, EAATlex9skip and EAAT la  (Table 2.1 and Figure 2.2). RNA 
extraction, reverse transcription, RT-PCR and resolution of PCR products by agarose 
gel electrophoresis was carried out as outlined in section 2.3, 2.4.2 and 2.4.3. PCR 
product cloning and sequencing was carried out as outlined in section 2.4.4.2.1.
3.2.1.1 QRT-PCR analysis of EAAT mRNA expression
500ng MG-63 and SaOS-2 RNA and 50ng primary human osteoblast (NHOB1P5) 
RNA was reverse transcribed in 20pl volume which was subsequently diluted to
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100(j.l with RNase- and DNase-free molecular biology grade water. 5 pi cDNA was 
then used in each QRT-PCR reaction. Transcript expression levels of 
EAATl+EAATlex9skip, EAATlex9skip, and the housekeeping gene 18S rRNA 
were quantified in each cell line by absolute QRT-PCR (section 2.4.4.4). Expression 
of EAAT3 was also quantified in MG-63 and SaOS-2 cells. Expression levels of 
EAAT1 were calculated by subtracting the absolute copy numbers obtained when the 
same samples were amplified using EAATlex9skip specific primers from the 
absolute copy numbers obtained for EAAT1 + EAATlex9skip. QRT-PCR was 
carried out using the Stratagene MX3000P™ Real-Time PCR system (section
2.4.4.1.1) in conjunction with plasmid standard curves (section 2.4.4.2.1). Absolute 
copy numbers of EAAT transcripts were normalised to 18S rRNA transcript copy 
numbers.
3.2.1.2 Effect of extracellular glutamate concentration on EAAT mRNA 
expression
MG-63 cells were seeded at 2.6 x 104 cells/cm2 of a 24-well plate and SaOS-2 cells 
were seeded at 4.2 x 104 cells/cm2 of a 24-well plate in normal growth medium 
(section 2.2.1 and 2.2.2) and allowed to adhere overnight. Cells were then incubated 
with DMEM, 5% dFBS, and 50pg/ml ascorbate in the presence or absence of 500pM 
glutamate for 24hrs. Medium was then aspirated, cells rinsed with cold PBS and 
homogenised with 0.2ml TRIzol® reagent per well for 5 min. The plates were stored 
at -80°C until RNA extractions, reverse transcription and absolute QRT-PCR for 
EAAT 1+E AAT lex9skip, EAATlex9skip, and EAAT3 expression was carried out in 
conjunction with the housekeeping gene 18S rRNA as outlined above (section
3.2.1.1).
3.2.2 Immunofluorescent staining of EAATs
MG-63 and SaOS-2 osteoblast-like cells and primary human osteoblasts 
(NHOB2P12) were immunostained for expression of EAAT1 and EAAT3 using 
specific antibodies (section 2.6).
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3.2.3 Glutamate uptake
EAAT activity was assessed in MG-63 and SaOS-2 osteoblast-like cells and primary 
osteoblasts (NHOB2P9) (section 2.8).
3.2.3.1 Kinetics of glutamate uptake in osteoblasts
Cells were pre-incubated with KRH buffer (+ Na+) for lhr. The buffer was then 
aspirated and replaced with KRH buffer (± Na+) containing a mix of labelled 14C- 
glutamate and unlabelled glutamate over a concentration range of l-250pM (Table
2.4) for 10 min (MG-63 and SaOS-2) or 20 min (primary human osteoblasts). 
Lineweaver-Burk graphs were plotted (Lineweaver and Burk 1934). Briefly, the 
reciprocal of glutamate uptake rate was plotted against the reciprocal of glutamate 
concentration to yield a straight line when data conforms to Michaelis-Menten 
kinetics. The y-intercept is equivalent to the inverse of Vmax and the x-intercept is 
equivalent to -1/Km, however this plot can distort the errors in measurement. 
Therefore, Km and Vmax values were also determined where possible by non-linear 
regression analysis of the uptake saturation curves using a curve fitting program 
followed by the application of a one-site or two-site binding (hyperbola) equation to 
the data, using GraphPad Prism 2 software (GraphPad Prism Software Inc, San Diego, 
CA).
3.2.3.2 Effect of EAAT inhibitors on Na+-dependent glutamate uptake
Cells were pre-incubated with KRH buffer (+ Na*) supplemented with EAAT 
inhibitors (/-PDC and TBOA) over a concentration range of lfiM to ImM for lhr. 
After the pre-incubation period, KRH buffer was replaced with KRH buffer (± Na+) 
containing a mix of labelled 14C-glutamate and unlabelled glutamate and the inhibitor 
at the appropriate concentration for 10 min.
3.2.3.2.1 EAA T inhibitors
EAAT inhibitors (section 2.7) were added to KRH to yield concentrations in the range 
of lpM  to ImM. These concentrations were chosen to span the I C 5 0  and Ki values
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reported in the literature (Table 2.3). Inhibitors were dissolved in water and diluted in 
each well with KRH buffer.
3.2.3.3 Effect of extracellular glutamate concentration on Na+-dependent 
glutamate uptake
MG-63 cells were seeded at 2.6 x 104 cells/cm2 of a 24-well plate and SaOS-2 cells 
were seeded at 4.2 x 104 cells/cm2 of a 24-well plate in normal growth medium 
(section 2.2.1 and 2.2.2) and allowed to adhere overnight. Cells were then incubated 
with DMEM, 5% dFBS, and 50pg/ml ascorbate in the presence or absence of 
glutamate (10 or 500pM). After 24hrs, medium was replaced with KRH buffer (+ 
Na+) in the presence or absence of glutamate (10 or 500pM) for a further 1 hour. 
Some cells were incubated with glutamate for the 1 hour pre-incubation period only in 
order to observe both the short-term (lhr) and long-term (24hrs) effect of extracellular 
glutamate on EAAT activity. After the pre-incubation period, KRH buffer was 
replaced with KRH buffer (± Na+) containing a mix of labelled 14C-glutamate and 
unlabelled glutamate at lOpM for 10 min.
3.3 Results
3.3.1 Expression of EAAT transcripts in human osteoblasts
Total RNA was extracted from MG-63 and SaOS-2 osteoblast-like cells, primary 
human osteoblasts, human bone and human cerebellum for subsequent analysis by 
RT-PCR using primers against specific EAAT sequences. Transcripts for EAATs 1-3 
and the splice variants of EAAT 1 - EAAT la and EAATlex9skip - were detected in 
all samples and sequencing verified the correct RT-PCR amplification products for 
each primer pair in MG-63 and SaOS-2 cells (Figure 3.1).
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Figure 3.1. Various EAATs are expressed in human bone and brain. Expression of 
EAATs 1-3 and both EAAT1 splice variants (EAATIa and EAATlex9skip) was 
shown to be expressed by RT-PCR in human brain, primary osteoblasts, osteoblast­
like cells (MG63 and SaOS-2) and bone tissue. 1. Human cerebellum, 2. Human 
primary osteoblast (NHOB2P7), 3. MG-63, 4. SaOS-2, 5. Human bone, 6. Water 
blank.
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3.3.1.1 Quantification of EAAT transcripts in osteoblast-like cells by QRT-PCR
Expression levels of EAAT1 and EAATlex9skip were quantified in MG-63 and 
SaOS-2 osteoblast-like cells and primary human osteoblasts (NHOB1P5) by absolute 
QRT-PCR and expressed as a ratio of the housekeeping gene 18S rRNA (the ratio 
value was then multiplied by 108 to yield whole numbers) (Figure 3.2). Expression of 
EAAT3 was also quantified in MG-63 and SaOS-2 osteoblasts but not in primary 
human osteoblasts due to inadequate sample quantity. Presented data are from three 
independent experiments where n=4 (MG-63 and SaOS-2) or from a single 
preliminary experiment where n=4 (NHOB1P5).
Expression levels of EAAT 1 and its splice variant EAATlex9skip were far higher in 
SaOS-2 cells compared to MG-63 cells (Figure 3.2A and B). However, analysis of 
EAAT3 expression showed higher expression of the transcript in MG-63 cells 
compared to SaOS-2 cells (Figure 3.2C). Expression levels of EAATlex9skip were 
approximately 13% those of full length EAAT1 in MG-63 cells, 2% in SaOS-2 cells 
and, from preliminary data, 12% in primary human osteoblasts. The relative 
expression levels of EAATs varied for each osteoblast-like cell line although 
generally EAAT1>EAAT3>EAAT2. The expression of EAAT2 and EAATIa were 
too low to be accurately quantified by this method.
3.3.1.2 Effect of glutamate on EAAT transcript expression in osteoblast-like cells
MG-63 and SaOS-2 osteoblast-like cells were incubated for 24hrs in the presence or 
absence of 500pM glutamate and expression levels of EAAT1, EAATlex9skip, 
EAAT3 were quantified by absolute QRT-PCR, normalised to the housekeeping gene 
18S rRNA and expressed as a percentage of control expression for each EAAT, i.e. 
expression of cells at OpM glutamate (Figure 3.3). Presented data are from three 
independent experiments where n=4.
Exposure of MG-63 and SaOS-2 cells to 500pM glutamate for 24hrs did not 
significantly affect expression of EAAT1 (in MG-63 Kruskal-Wallis 0.525; in 
SaOS-2 one-way ANOVA with log data P=0.982), EAATlex9skip (in MG-63 one­
way ANOVA P=0.703; in SaOS-2 one-way ANOVA P=0.430) orEAAT3 (in MG-63 
one-way ANOVA with log data P=0.150; in SaOS-2 Kruskal-Wallis P=0.902). MG- 
63 cells did however show a trend toward increasing EAAT3 expression in response
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Figure 3.2. MG-63, SaOS-2 and primary human osteoblasts express EAATs at 
differential levels. Expression of (A) EAAT1, (B) EAATlex9skip and (C) EAAT3 
were analysed by QRT-PCR, normalised to 18S rRNA expression and expressed as a 
ratio (xlO8). Values are mean ± S.E.M from three independent experiments, n=4 
(MG-63 and SaOS-2) or a single preliminary experiment, n=4 (NHOB1P5). 
Expression of EAAT3 was not assessed by QRT-PCR in primary human osteoblasts.
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Figure 3.3. 24hr incubation with SOOpM glutamate does not significantly affect 
EAAT transcript levels in MG-63 and SaOS-2 osteoblasts. EAAT expression was 
analysed by QRT-PCR in each cell line following 24hr culture at 0 and 500pM 
glutamate, normalised to 18S rRNA expression and expressed as the mean percentage 
of expression in control cells (OpM glutamate) ± S.E.M from three independent 
experiments, n=4.
to 24hrs pre-incubation with 500pM glutamate. Under these conditions mean EAAT3 
mRNA levels were increased to 122 ± 11 % of untreated control cells.
3.3.2 Expression of EAAT protein in human osteoblasts
3.3.2.1 Immunofluorescence
MG-63, SaOS-2 and human primary osteoblasts (NHOB2P12) were immunostained 
for EAAT1 (Figures 3.4 and 3.6) and EAAT3 (Figures 3.5 and 3.6) expression using 
specific antibodies. Primary negative control tests displayed negligible non-specific 
staining with either the FITC-conjugated (Figure 3.4C,D; Figure 3.5C,D; Figure 3.6B) 
or the TRITC-conjugated (Figure 3 .6D) goat-anti-rabbit secondary antibody under
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Figure 3.4. Immunofluorescence o f EAAT1 in human osteoblast-like cell lines. 
MG-63 and SaOS-2 cells were immunofluorescently probed with rabbit-anti-EAATl 
antibody and a corresponding FITC tagged goat-anti-rabbit secondary antibody. 
Control cells (C,D) were probed with secondary antibody alone to determine levels o f 
non-specific staining. Pictures were taken under 800ms exposure.
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Figure 3.5. Immunofluorescence o f EAAT3 in human osteoblast-like cell lines. 
MG-63 and SaOS-2 cells were immunofluorescently probed with rabbit-anti-EAAT3 
antibody and a corresponding FITC tagged goat-anti-rabbit secondary antibody. 
Control cells (C,D) were probed with secondary antibody alone to determine levels of 
non-specific staining. Pictures were taken under Is exposure.
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Figure 3.6. Immunofluorescence o f EAAT1 and EAAT3 in primary human 
osteoblasts (NHOB2P12). Cells were immunofluorescently probed with specific 
primary antibodies (A, rabbit-anti-EAATl; C, rabbit-anti-EAAT3) and the 
corresponding fluorescently tagged goat-anti-rabbit secondary antibodies (A, FITC; 
C, TRITC). Control cells (B,D) were probed with goat-anti-rabbit secondary antibody 
alone to determine levels o f non-specific staining (B, FITC; D, TRITC). Pictures were 
taken under 1.3s (A,B) and 1.6s (C,D) exposure.
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the same conditions. EAAT1 and EAAT3 specific staining was detectable in both 
osteoblast-like cell lines (Figure 3.4A,B; Figure 3.5A,B) and human primary 
osteoblasts (Figure 3.6A,C).
3.3.3 Glutamate uptake
3.3.3.1 Na+-dependent glutamate uptake
3.3.3.1.1 Osteoblast-like cells
Incubation o f  the human osteoblast-like cell lines MG-63 and SaOS-2 with 10 or 
250pM mix o f  radiolabelled and unlabelled glutamate at 37°C for 10 min in KRH (+ 
Na+) buffer led to the accumulation o f glutamate in these cells (Figure 3.7 A  and Table
3.1). Presented data are from three independent experiments where n=4. MG-63 cells 
accumulated lOpM glutamate at a rate o f 4087 ± 274 pmol/hr/mg and 250pM at a rate 
o f 49941 ± 4795 pmol/hr/mg. Replacement o f sodium chloride with choline chloride 
significantly reduced MG-63 glutamate uptake by -35% , to 2739 ± 227 pmol/hr/mg 
at lOfiM (one-way ANOVA P=0.001) and by -30%  to 35944 ± 5157 pmol/hr/mg at 
250pM, however this was not significant (one-way ANOVA P=0.059). In SaOS-2 
cells, lOpM glutamate was accumulated at a rate o f 32190 ± 1185 pmol/hr/mg and 
250pM glutamate at a rate o f  102922 ± 3971 pmol/hr/mg. Replacement o f sodium 
chloride with equimolar choline chloride significantly reduced glutamate 
accumulation by -90%  (to 3355 ± 1 5 8  pmol/hr/mg) at lOpM (one-way ANOVA  
PO.OOl) and by -50%  (to 53191 ± 2965 pmol/hr/mg) at 250pM (one-way ANOVA 
^ < 0.001).
These graphs show that both cell lines display Na+-dependent glutamate uptake 
activity, characteristic o f  EAATs, and that compared to MG-63 cells, SaOS-2 cells 
display 8-fold greater Na+-dependent glutamate uptake activity at lOpM glutamate but 
only 2-fold greater Na+-dependent glutamate uptake activity at 250pM glutamate.
3.3.3.1.2 Primary osteoblasts
Human primary osteoblasts (NHOB2P9) were incubated with 10pM mix o f  
radiolabelled and unlabelled glutamate at 37°C for 20 min in KRH buffer containing
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Figure 3.7. Glutamate accumulation in cultured (A) human osteoblast-like cell lines 
and (B) human primary osteoblasts (NHOB2P9). Osteoblasts were incubated with 10 or 
250|iM  14C-glutamate at 4 or 37°C for 10 min (in A) or 20 min (in B) in KRH buffer, 
followed by aspiration of buffer and rinsing with cold KRH containing 1.5mM 
unlabelled glutamate. To determine the Na+-dependent component o f glutamate uptake, 
sodium chloride was replaced with equimolar choline chloride. Values are mean ± S.E M 
from three independent experiments, n=4 in (A) or a single preliminary experiment, n=4 
in (B). **P<0.01, ***P<0.001 significantly different from control value obtained with 
normal KRH buffer (containing N a^  shown by one-way ANOVA. Abbreviations: Cl, 
chloride.
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sodium chloride and also in KRH buffer where sodium chloride was replaced with 
equimolar choline chloride. Presented data are from a single preliminary experiment 
where n=4. Replacement of sodium chloride with choline chloride reduced 
accumulation of glutamate by 50% from 60 ± 2.5 pmol/hr to 27.5 ±2.8 pmol/hr (one­
way ANOVA PO.OOl) (Figure 3.7B and Table 3.1). Incubation of human primary 
osteoblasts with lOpM mix of radiolabelled and unlabelled glutamate at 4°C for 20 
min in KRH buffer with sodium chloride led to a 70% reduction in glutamate uptake 
compared to uptake at 37°C (n=l, Figure 3.7B). These findings may indicate that this 
NHOB cell line (NHOB2P9) displays Na+-dependent glutamate uptake activity, 
characteristic of EAATs, however this experiment was not repeated.
Table 3.1. Glutamate uptake in osteoblast-like cells (MG-63 and SaOS-2) and 
human primary osteoblasts (NHOB2P9). Uptake of glutamate at lOpM and 250pM 
was measured in the presence and absence of Na+. The Na+-dependent component of 
glutamate uptake was determined by subtracting the glutamate uptake in the absence 
of Na+ from total glutamate uptake in KRH with Na+. Abbreviations; Cl, chloride.
Glutamate uptake
Cell line Glutamate(pM)
Sodium
Cl
Choline
Cl
Sodium-
dependent Unit
MG-63
10 4087 ± 274 2739 ± 227 1348 pmol/hr/mg250 49941 ± 4795 35944 ±5157 13997
SaOS-2
10
250
32190± 1185 
102922 ±3971
3355± 158 
53191± 2965
28835
49731 pmol/hr/mg
Primary
osteoblasts
(NHOB2P9)
10 60 ± 2.5 27.5 ± 2.8 32.5 pmol/hr
3.3.32 Kinetics of Na+-dependent glutamate uptake
3.3.3.2.1 Osteoblast-like cells
Osteoblast-like cell lines were incubated with l-250pM mix of radiolabelled and 
unlabelled glutamate at 37°C for 10 min in KRH buffer (± Na+) for kinetic 
characterisation of glutamate uptake (Figures 3.8 and 3.9). Presented data are from 
three independent experiments where n=4.
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Figure 3.8. Glutamate accumulation in MG-63 cells. (A) MG-63 cells were 
incubated with l-250pM mix of radiolabelled and unlabelled glutamate at 37°C for 10 
min in KRH buffer ± Na+, followed by aspiration of buffer and rinsing with cold KRH 
containing 1.5mM unlabelled glutamate. (B) Sodium-dependent glutamate uptake was 
determined by subtracting the glutamate uptake in the absence of sodium from total 
glutamate uptake in KRH with sodium. Values are mean ± S.E.M from three 
independent experiments, n=4. Abbreviations: ChoCI, choline chloride.
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Figure 3.9. Glutamate accumulation in SaOS-2 cells. (A) SaOS-2 cells were 
incubated with l-250pM mix of radiolabelled and unlabelled glutamate at 37°C for 10 
min in KRH buffer ± Na+, followed by aspiration of buffer and rinsing with cold KRH 
containing 1.5mM unlabelled glutamate. (B) Sodium-dependent glutamate uptake was 
determined by subtracting the glutamate uptake in the absence of sodium from total 
glutamate uptake in KRH with sodium. Values are mean ± S.E.M from three 
independent experiments, n=4. Abbreviations: ChoCI, choline chloride.
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In MG-63 cells, glutamate uptake increased as the concentration of glutamate was 
increased, however no point of saturation was observed up to 250pM glutamate, both 
in the presence and absence of Na+ (Figure 3.8A). Na+-dependent glutamate uptake 
also increased dose-dependently in MG-63 cells and uptake was not saturated by 
250pM glutamate (Figure 3.8B). Interestingly, Na+-dependent glutamate uptake 
appeared to saturate between 50pM and lOOpM glutamate before then continuing to 
increase between IOOjiM and 250pM glutamate suggesting that there may be two 
components to the Na+-dependent glutamate uptake curve in MG-63 cells.
In SaOS-2 cells, glutamate accumulation increased as glutamate concentration 
increased, both in the presence and absence of sodium (Figure 3.9A). On analysis of 
the Na+-dependent component of glutamate accumulation, a typical saturation curve 
was observed (Figure 3.9B). SaOS-2 cells increased Na+-dependent glutamate uptake 
as the glutamate concentration increased, followed by saturation at a concentration 
above 50pM within a concentration range of up to 250pM.
3.3.3.2.1.1 Determination o f kinetic constants
Lineweaver-Burk plots graphically display kinetic data and when this plot yields a 
straight line the data conforms to Michaelis-Menten kinetics. When this is the case, 
the y-intercept is equivalent to the inverse of Vmax (the maximal glutamate uptake 
rate) and the x-intercept is equivalent to -1/Km (-1/the affinity of the glutamate 
transporter).
Na+-dependent glutamate accumulation in MG-63 cells does not yield a typical 
saturation curve (Figure 3.8B) and a Lineweaver-Burk plot of these data does not 
generate a straight line, as shown by a goodness of fit value (R2) of 0.7747 (Figure 
3.10A), further indicating that Na+-dependent glutamate accumulation in MG-63 cells 
does not adhere to typical Michaelis-Menten kinetics.
Since Lineweaver-Burk analysis can distort errors in the data, non-linear regression 
analysis was also carried out using a curve fitting program with GraphPad Prism 
software. The shape of the uptake curve in Figure 3.8B suggests that there may be two 
components to Na+-dependent glutamate uptake in MG-63 cells since uptake appears 
to saturate between 50pM and 100pM glutamate before then continuing to increase 
between lOOpM and 250pM glutamate. These components may represent a low- and 
a high-affinity transporter. However, there are too few data points in each
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B. Curve fitting of MG-63 Na*-dependent glutamate uptake by GraphPad 
Prism to a (i) one-site or (ii) two-site binding equation
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Figure 3.10. Kinetic analysis o f Na -dependent glutamate accumulation in MG-63 
cells. (A) Lineweaver-Burk analysis was carried out using data from Figure 3.8B. The 
reciprocal of glutamate uptake rate (in pmol/hr/mg protein) was plotted against the 
reciprocal of glutamate concentration (in jjM). The goodness of fit (R2) value 
generated by Microsoft Excel (0.7747) shows that these data do not yield a straight 
line indicating that the data deviates from Michaelis-Menten kinetic principles. (B) 
The data from Figure 3.8B was fitted to (i) one-site and (ii) two-site binding equations 
by GraphPad Prism software. The R2 values generated are presented on the graph. 
Both curves deviate from the data points and have similarly poor R2 values ((i) 0.5591 
and (ii) 0.5691). Values are mean ± S.E.M from three independent experiments, n=4.
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component for them to be analysed separately, therefore to investigate this hypothesis, 
GraphPad Prism was used to fit the data to either a one-site or two-site binding 
equation and compare the goodness of fit to these two models (Figure 3.1 OB). The 
curves generated in both cases do not pass through all data points and display 
similarly poor R2 values, i.e. 0.5591 for a one-site binding hypothesis (Figure 
3.10B(i)) and 0.5691 for a two-site binding hypothesis (Figure 3.10B(ii)). However, 
F-test comparison by GraphPad Prism indicated that a one-site binding model was the 
best fit to the data. Using this model, non-linear regression analysis of Na+-dependent 
uptake in MG-63 cells by GraphPad Prism indicated that glutamate was accumulated 
with a KM of 241 ± 151 pM and a Vmax of 26,940 ± 9,804 pmol/hr/mg (Table 3.2). 
The large errors associated with these constants and the fact that the data does not 
strongly conform to a known model indicates that these results must be interpreted 
with caution. Repeating the experiment over a more comprehensive range of 
glutamate concentrations, particularly within the 100-250pM range, might help reveal 
the best kinetic model to fit the data.
In contrast, Lineweaver-Burk plot analysis indicated that Na+-dependent glutamate 
accumulation in SaOS-2 cells (using data from Figure 3.9B) consisted of a single 
component within a substrate concentration of l-250pM with a straight line R2 value 
of 0.99 (Figure 3.11 A). Using this graph to estimate kinetic constants resulted in a Km 
of lOpM and a Vmax of 50,000 pmol/hr/mg.
Comparison of a one-site or two-site binding (hyperbola) model by F-test using 
GraphPad Prism recommended that a one-site binding model is the best fit to the data 
with a R2 value of 0.795 (Figure 3.1 IB). The curve fitted to this model by passing 
through every data point. Non-linear regression analysis of Na+-dependent uptake in 
SaOS-2 cells by GraphPad Prism indicated that glutamate was accumulated with a Km 
of 7.4 ±1.2 pM and a Vmax of 48,510 ± 1,700 pmol/hr/mg (Table 3.2).
Table 3.2. Kinetic components o f glutamate uptake in
osteoblast-like cells.
Km (p M) Vmax (pmol/hr/mg)
MG-63 241± 151 26.940 ± 9,804
SaOS-2 7.4 ± 1.2 48,510 ± 1,700
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Figure 3.11. Kinetic analysis o f Na+~dependent glutamate accumulation in SaOS-2 
cells. (A) Lineweaver-Burk analysis was carried out using data from Figure 3.9B. The 
reciprocal of glutamate uptake rate (in pmol/hr/mg protein) was plotted against the 
reciprocal of glutamate concentration (in pM). The goodness of fit (R2) value 
generated by Microsoft Excel (0.9986) shows that these data yield a straight line 
indicating that the data conforms to Michaelis-Menten kinetic principles. The y- 
intercept of the plot is equivalent to the inverse of Vmax and the x-intercept is 
equivalent to -1/K m (shown inset). (B) The data from Figure 3.9B was fitted to a one- 
site binding equation by GraphPad Prism software. The curve fits all the data points 
with a good R2 value (0.795). GraphPad Prism estimates the kinetic parameters (Km 
and Vmax) from the data (shown inset). Values are mean ± S.E.M from three 
independent experiments, n=4.
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3.3.3.2.2 Primary osteoblasts
Primary human osteoblasts (NHOB2P9) were incubated with l-500pM mix of 
radiolabelled and unlabelled glutamate at 37°C for 20 min in KRH buffer (+ Na+) 
(Figure 3.12). Presented data are from a single preliminary experiment where n=4. In 
these cells, glutamate uptake increased as the concentration of glutamate was 
increased. Due to insufficient cell number, parallel cultures could not be used for Na+- 
free uptake controls or for assaying protein content and therefore uptake is expressed 
as pmol/hr rather than pmol/hr/mg. Since there were no experimental treatments, all 
uptake values would be normalised to the same protein concentration, thus the trends 
are unaffected by lack of protein normalisation. The lack of Na+-free uptake controls 
unfortunately prevents the calculation of the Na+-dependent component of glutamate 
uptake and therefore the data represent a total of all glutamate uptake systems in these 
cells.
3.3.3.3 Pharmacology of glutamate uptake in osteoblast-like cells
MG-63 and SaOS-2 cells were pre-incubated with KRH buffer (+ Na+) containing 
EAAT inhibitors (f-PDC or TBOA) at a concentration range of lpM  to lmM for lhr 
at 3 7 ° C .  These concentrations were chosen to span the I C 50 and Ki values reported in 
the literature (Table 2.3). Glutamate uptake was then determined by supplementing 
the buffer with lOpM (MG-63) or lpM  (SaOS-2) mix of radiolabelled and unlabelled 
glutamate in KRH (± Na+) to determine the effect of EAAT inhibitors on the Na+- 
dependent component of uptake. Glutamate uptake is expressed as a percentage of 
control uptake (no EAAT inhibitor) over a range of inhibitor concentrations (Figure 
3 . 1 3  and 3 . 1 4 ) .  Presented data are from a single experiment where n=4. GraphPad 
Prism 2  was used to determine I C 50 values for each inhibitor (Table 3.3). TBOA, a 
competitive inhibitor of a wide range of EAATs, was the most potent inhibitor of 
glutamate uptake ( I C 5 o = 0 . 9 2 p M  and 7 . 4 p M  in MG-63 and SaOS-2 cells respectively) 
and the competitive EAAT inhibitor t-PDC was a less potent inhibitor ( I C 5 o = 3 1 8 . 6 p M  
and 5 1 . 6 p M  in MG-63 and SaOS-2 cells respectively).
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Figure 3,12. Glutamate accumulation in cultured human primary osteoblasts. 
Human primary osteoblasts (NHOB2P9) were incubated with l-500|iM mix of 
radiolabelled and unlabelled glutamate at 37°C for 20 min in KRH buffer + Na+, 
followed by aspiration of buffer and rinsing with cold KRH containing 1.5mM 
unlabelled glutamate. Values are mean ± S.E.M from a single preliminary experiment, 
n=4.
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Figure 3.13. Pharmacological inhibition o f glutamate accumulation in MG-63 
osteoblasts. MG-63 osteoblasts were pre-incubated with KRH buffer + Na+ in the 
presence and absence of lpM-lmM EAAT inhibitor for lhr. Osteoblasts were then 
incubated with lOpM mix of radiolabelled and unlabelled glutamate at 37°C for 10 
min in KRH buffer ± Na+, followed by aspiration of buffer and rinsing with cold KRH 
containing 1.5mM unlabelled glutamate. To determine the sodium-dependent 
component of glutamate uptake, sodium chloride was replaced with equimolar choline 
chloride. Values represent sodium-dependent uptake as a percentage of sodium- 
dependent uptake in untreated control cells. Values are mean ± S.E.M from a single 
experiment, n=4. /-PDC; L-fraw5-Pyrrolidine-2,4-dicarboxylic acid, TBOA; DL- 
threo-b-benzyloxyaspartic acid.
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Figure 3.14. Pharmacological inhibition o f glutamate accumulation in SaOS-2 
osteoblasts. SaOS-2 osteoblasts were pre-incubated with KRH buffer + Na+ in the 
presence and absence o f  lpM -250pM  EAAT inhibitor for lhr. Osteoblasts were then 
incubated with lpM  mix o f  radiolabelled and unlabelled glutamate at 37°C for 10 min 
in KRH buffer ± Na+, followed by aspiration o f buffer and rinsing with cold KRH 
containing 1.5mM unlabelled glutamate. To determine the sodium dependent 
component o f glutamate uptake, sodium chloride was replaced with equimolar choline 
chloride. Values represent sodium-dependent uptake as a percentage o f sodium- 
dependent uptake in untreated control cells. Values are mean ± S.E.M from a single 
experiment, n=4. /-PDC; L-fra/is-Pyrrolidine-2,4-dicarboxylic acid, TBOA; DL- 
threo-b-benzyloxyaspartic acid.
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Table 3.3. ICso values and confidence intervals fo r  the effect o f EAAT inhibitors 
on Na+-dependent glutamate uptake in MG-63 and SaOS-2 cells. /-PDC; L-trans- 
Pyrrolidine-2,4-dicarboxylic acid, TBOA; DL-threo-b-benzyloxyaspartic acid
Cell line Inhibitors ICso(mM) IC5 0  95% confidence intervals (pM)
MG-63
-O-t-PDC
-*-TBO A
318.6
0.92
202 -  502 
0.73-1 .16
SaOS-2 -O-t-PDC-■-TBOA
51.6
7.4
25.3-105.1
4 .9 -11 .4
3.3.3.4 The effect of glutamate on Na+-dependent glutamate uptake in osteoblast­
like cells
The effect of short-term (lhr) and long-term (24hr) pre-treatment with glutamate on 
Na+-dependent glutamate uptake was assessed in MG-63 and SaOS-2 osteoblast-like 
cells. Pre-incubations were carried out at both physiological (lOpM) and pathological 
(500pM) glutamate concentrations (section 1.5.2). Na+-dependent glutamate uptake is 
expressed as a percentage of control Na+-dependent glutamate uptake measured in 
cells that were incubated in glutamate-free medium/KRH buffer (Figure 3.15 and 
3 .16). Presented data are from three independent experiments where n=4. 
Na+-dependent glutamate uptake in MG-63 cells was not significantly affected by lhr 
or 24hr pre-incubation with lOpM or 500pM glutamate (Figure 3.15) as shown by 
Shierer-Ray test for the effect of pre-incubation time (P=0.300), glutamate 
concentration (P=0.667) and interaction effects (P=0.104).
Na+-dependent glutamate uptake in SaOS-2 cells was significantly affected by pre­
incubation time (PO.OOl), glutamate concentration (P<0.001) and interaction effects 
(P<0.001) as shown by GLM (Figure 3.16). Post-hoc pair-wise Tukey’s comparisons 
revealed that Na+-dependent glutamate uptake was not significantly affected by lhr 
pre-incubation with lOpM glutamate (P=0.1142); however a significant reduction in 
Na+-dependent glutamate uptake was detectable after lhr pre-incubation with 500pM 
glutamate to 85 ± 2 % of control cells (P=0.0014). 24hr pre-incubation with lOpM 
glutamate did not significantly affect Na+-dependent glutamate uptake (P=0.8931),
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Figure 3.15. Effect o f  glutamate pre-incubation on Na -dependent glutamate
uptake in MG-63 cells. MG-63 cells were pre-incubated with 0, 10 or 500pM 
unlabelled glutamate for 1 or 24hrs. MG-63 cells were then incubated with lOpM mix 
of radiolabelled and unlabelled glutamate at 37°C for 10 min in KRH buffer ± Na+, 
followed by aspiration o f the buffer and rinsing with cold KRH containing 1.5mM 
unlabelled glutamate. Na+-dependent glutamate uptake was normalised to total 
cellular protein (mg) and expressed as a percentage of untreated cells (no pre­
incubation with glutamate). Values are mean ± S.E.M from three independent 
experiments where n=4. Na+-dependent glutamate uptake in MG-63 cells was not 
significantly affected by lh r or 24hr pre-incubation with lOpM or 500pM glutamate 
(Shierer Ray test).
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Figure 3.16. Effect o f  glutamate pre-incubation on Na+-dependent glutamate 
uptake in SaOS-2 cells. SaOS-2 cells were pre-incubated with 0, 10 or 500pM 
unlabelled glutamate for 1 or 24hrs. SaOS-2 cells were then incubated with lOpM 
mix o f radiolabelled and unlabelled glutamate at 37°C for 10 min in KRH buffer ± 
Na+, followed by aspiration of the buffer and rinsing with cold KRH containing 
1.5mM unlabelled glutamate. Na~-dependent glutamate uptake was normalised to 
total cellular protein (mg) and expressed as a percentage of untreated cells (no pre­
incubation with glutamate). Values are mean ± S.E.M from three independent 
experiments where n=4. Na"-dependent glutamate uptake in SaOS-2 cells was 
significantly affected by pre-incubation time (P<0.001), glutamate concentration 
(P<0.001) and interaction effects (P<0.001) as shown by GLM. Post-hoc Tukey’s 
tests revealed that Na+-dependent glutamate uptake was significantly decreased 
following lhr and 24hr pre-incubation with 500pM glutamate compared to untreated 
cells and cells incubated with lOpM glutamate for 24hrs. This decrease was 
significantly greater at 24hrs compared to lhr. **P<0.01, ***P<0.001 significantly 
different from untreated cells or from values indicated by lines.
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however 24hr pre-incubation with 500pM glutamate resulted in a significant decrease 
in Na+-dependent glutamate uptake to 63 ± 2 % of control cells (PO.OOl). The 
reduction of Na+-dependent glutamate uptake in SaOS-2 cells following pre­
incubation with 500pM glutamate was significantly greater at 24hrs compared to lhr
with 500|iM glutamate (P<0.001) and also compared to 24hr pre-incubation with 
lOgM glutamate (F^O.OOl).
3.4 Discussion
3.4.1 EAATs are expressed in human osteoblasts
The experiments presented in this chapter have shown that transcripts for EAATs 1-3 
and two splice variants of EAAT 1 (EAATla and EAATlex9skip) are expressed in 
human bone, human primary osteoblasts and human osteoblast-like cell lines. 
Furthermore, expression of EAAT1 and EAAT3 protein has been confirmed by 
immunofluoresence in human primary osteoblasts and human osteoblast-like cell 
lines. Since both splice variants of EAAT 1 are expressed as proteins in vivo (Huggett 
et al. 2000; Vallejo-Illarramendi et al. 2005; Macnab et al. 2006; Macnab and Pow 
2007a) and the antibody used here detects a 15aa C-terminal epitope, a sequence 
common to EAAT1, EAAT la  and possibly EAATlex9skip, it is likely that the 
immunostaining shown here for EAAT1 represents a pool of the 3 known EAAT1 
variants. Expression of EAAT1 protein has been previously described for MG-63 
cells (Kalariti et al. 2004; Kalariti et al. 2007) and bone-forming osteoblasts in vivo 
(Mason et al. 1997) and EAAT1 mRNA has been previously detected in SaOS-2 cells 
(Huggett et al. 2002; Mason and Huggett 2002).
Expression of EAAT-la mRNA has been detected at low levels in bone in vivo, and 
also in SaOS-2 osteoblasts and MLO-Y4 osteocytes (Huggett et al. 2002). However, 
this is the first reported detection of EAATlex9skip in human bone, human primary 
osteoblasts and human osteoblast-like cells. In the human brain, EAATlex9skip 
mRNA is expressed at levels of 10-20% of full-length EAAT1 and acts in a dominant 
negative capacity over full-length EAAT1 glutamate transport function in transiently 
transfected HEK293 cells (Vallejo-Illarramendi et al. 2005). In MG-63 osteoblast-like
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cells and primary human osteoblasts, the expression levels of EAATlex9skip relative 
to full-length EAAT1 are 13% and 12% respectively, which is comparable to the 
proportion of the variant in human brain. However quantitative analysis of primary 
human osteoblast EAAT expression was not repeated. Expression of EAATlex9skip 
was far lower in SaOS-2 osteoblast-like cells (2%). Interestingly, the experiments in 
this chapter have shown that MG-63 cells have a reduced capacity for Na+-dependent 
glutamate compared to SaOS-2 cells (Figure 3.7). The higher proportion of the 
dominant negative splice variant EAATlex9skip in MG-63 cells compared to SaOS-2 
cells may play a role in reducing Na+-dependent transport activity. High expression 
levels of the EAATlex9skip transcript in MG-63 cells and human brain suggest a 
possible physiological role for this splice variant in glutamate homeostasis or 
signalling. EAATlex9skip has been detected by immunohistochemistry within the 
human brain, particularly cortical and collicular neurons, in contrast to the primarily 
glial expression of full-length EAAT1 (Macnab and Pow 2007a). Furthermore, 
EAATlex9skip is expressed in neurons and in regions that are susceptible to damage 
in the hypoxic pig brain, such as the CA1 region of the hippocampus, supporting the 
suggestion that expression of EAATlex9skip may indicate neurons that are subject to 
abnormal glutamate-mediated excitation and at risk of dying in response to insult 
(Sullivan et al. 2007a). A provisional patent for the use of EAATlex9skip (also 
referred to as GLASTlb) as a biomarker for the detection of hypoxia-induced 
neuronal damage was filed in 2008 (Pow 2008). Information regarding the regulation 
of EAATlex9skip expression in osteoblasts will be important for elucidating the role 
of this variant in bone.
Expression of GLT-1 and EAAC1 transcripts have previously been detected in rat 
calvarial osteoblasts (Takarada et al. 2004) and GLT-1 protein expression has been 
detected in mononuclear cells from rat bone marrow, though EAAC1 protein could 
not be detected in bone in vivo (Mason et al. 1997). However, transcript expression 
for EAAT2 and EAAT3 has not previously detected in human bone, human primary 
osteoblasts or human osteoblast-like cells.
3.4.1.1 EAATs are expressed at differential levels in human osteoblasts
Differences in EAAT expression levels observed between the osteoblast-like cell lines 
may reflect altered regulation of the transporters during osteoblast differentiation
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since SaOS-2 cells represent a more mature phenotype compared to MG-63 cells 
(Jukkola et al. 1993; Chaudhary and Avioli 1994; Pautke et al. 2004; Shapira and 
Halabi 2009). EAATs 1-3 act as high-affinity glutamate transporters and function in 
the CNS to rapidly clear synaptically released glutamate (reviewed in (Danbolt 
2001)). EAATs also function as glutamate gated ion channels and the anion 
permeability of EAATs 1-3 decreases in the order EAAT1>EAAT3>EAAT2 
(Wadiche et al. 1995). The anion conductance of EAATs may therefore be of 
relevance to osteoblasts since the data presented here demonstrate that transcript 
levels for EAATs in human osteoblast-like cell lines decrease in magnitude in the 
order of EAAT 1>EAAT3>EAAT2.
EAAT1 and EAAT2 are expressed by astrocytes in the CNS (Kanai and Hediger 
2004), with EAAT1 displaying strong expression in Bergmann glia of the cerebellum 
and EAAT2 predominantly expressed in astrocytes of the cerebral cortex and 
hippocampus (Kanai and Hediger 2004). EAAT3 is primarily expressed in neurons 
and epithelial cells (Kanai and Hediger 1992). In the brain, EAAT3 is strongly 
expressed in neurons in the cerebral cortex, striatum, hippocampus, superior 
colliculus, olfactory bulb, and thalamus (Rothstein et al. 1994; Kanai et al. 1995b; 
Berger and Hediger 1998). Interestingly, despite EAAT1 and EAAT2 being expressed 
by the same astrocyte cells in the CNS (Kanai and Hediger 2004), they have been 
reported to display different distribution patterns in rat peripheral tissues at both the 
transcript and protein level (Berger and Hediger 2006). GLAST expression was most 
commonly found in epithelial cells of tissues including the tongue, urinary bladder, 
ovaries and prostate gland whereas GLT-1 localised primarily to glandular tissues 
such as mammary glands, salivary glands and lacrimal glands (Berger and Hediger
2006). These observations are consistent with the low expression of EAAT2 found in 
osteoblast-like cell lines and primary human osteoblasts compared to high expression 
levels of EAAT 1.
3.4.1.2 Extracellular glutamate does not significantly affect EAAT mRNA 
expression in human osteoblasts
Expression levels of EAAT1, EAATlex9skip and EAAT3 were not changed 
following 24hrs exposure to 500pM glutamate in MG-63 or SaOS-2 osteoblasts. The 
glutamate-mediated regulation of EAAT 1 expression has been previously investigated
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in astrocytes of the CNS but not in cells of the peripheral tissues where glutamate 
signalling has been implicated. Gegelashvili et al. found that 7 day incubation of 
murine primary cortical astrocytes with ImM glutamate had no effect on GLAST 
mRNA levels (Gegelashvili et al. 1996). Glutamate concentrations can reach as high 
as 3mM in the small volume of the synaptic cleft following neuronal depolarisation 
and glutamate release (Clements 1996; Diamond and Jahr 1997), however the 
glutamate concentration rapidly decreases as a result of diffusion and through binding 
and/or transport by EAATs (Diamond and Jahr 1997; Wadiche and Jahr 2005). In the 
absence of a signalling event, extracellular glutamate concentrations within the CNS 
are maintained at a low nanomolar range (Zerangue and Kavanaugh 1996; Herman 
and Jahr 2007). Therefore this study reflects the prolonged incubation of cells at 
glutamate concentrations typical of a synaptic signalling event i.e. pathological 
situation and no assessments of GLAST mRNA expression were made at earlier time- 
points in this study.
Other studies have observed that long-term exposure (6-24hrs) of chick cerebellar 
Bergmann glia to glutamate (l-1000pM) results in a reduction of GLAST 
transcription, which can be mimicked by AMPA and kainate and is sensitive to 
inhibition of PKC, suggesting that transcriptional regulation of GLAST is 
AMPA/kainate receptor-mediated (Lopez-Bayghen et al. 2003; Lopez-Bayghen and 
Ortega 2004; Rosas et al. 2007). Glutamate receptor activation increases DNA 
binding of the transcription factor AP-1 in neurons and glia (Gallo and Ghiani 2000) 
and partial analysis of the murine GLAST gene promoter has identified an AP-1 
consensus sequence (Hagiwara et al. 1996) suggesting one mechanism whereby 
extracellular glutamate could regulate EAAT transcription in chick Bergmann glia. 
Interestingly the activation of AP-1 has been shown to be regulated by iGluR activity 
in osteoblasts in a similar manner to that observed in neurons (Taylor 2002).
These reported studies in chick Bergmann glia most closely resemble the 
experimental conditions used here with human osteoblasts. The differences in 
findings are likely to be the result of the different cell types studied. Astrocytes 
express EAAT1 and EAAT2 whereas human osteoblast-like cells express quantifiable 
levels of EAAT 1 and EAAT3 but unquantifiable levels of EAAT2 (section 3.3.1). 
Furthermore, there are likely to be differences in glutamate receptor activation 
between the two cell types since extracellular glutamate concentrations within the 
CNS are maintained within a low nanomolar range (Zerangue and Kavanaugh 1996;
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Herman and Jahr 2007) and glutamate is present in human synovial fluid at 6pM 
(Plaitakis et al. 1982; McNeamey et al. 2000) suggesting that bone cells might be 
exposed to higher basal levels of glutamate than cells within the CNS.
Long term regulation of EAAT expression can occur at the level of the gene promoter 
or by alternative splicing of mRNA transcripts. The regulation of EAATlex9skip 
transcription has not been previously investigated in any cell type and the results 
shown here indicate that in osteoblasts, long-term exposure to 500pM glutamate does 
not significantly affect expression of this splice variant. Interestingly, 5 days exposure 
of SaOS-2 cells to lOpM glutamate, but not 1, 100 or lOOOpM glutamate, has been 
shown to increase expression of EAAT la  relative to full-length EAAT1 (Huggett et 
al. 2002). Expression levels of full-length EAAT1 were not significantly affected by 
long-term exposure to 500pM glutamate in the experiments shown in this thesis, 
however this does not mean that the ratio of EAAT 1 to EAAT la was unaffected since 
this cannot be determined without also quantifying EAAT la expression, which is very 
low in these cells.
EAAT3 expression appeared to be slightly up-regulated in MG-63 cells, but not 
SaOS-2 cells, following 24hrs exposure to 500pM glutamate, however this was not 
significant. This increase in expression may represent a compensatory change in 
response to increased extracellular glutamate. Glutamate transport activity does 
appear to be increased in MG-63 cells following 24hrs exposure to 500pM glutamate 
(Figure 3.15), although this also did not reach significance. However EAAT3 is 
expressed in MG-63 cells at much lower levels than EAAT1 and EAATex9skip, so a 
small, but significant, change in transcription seems unlikely to have a major effect on 
glutamate uptake activity.
3.4.2 EAATs are functional in human osteoblasts
MG-63 and SaOS-2 cells displayed Na+-dependent glutamate uptake, consistent with 
functional EAAT activity. Prelimary findings also indicated Na+-dependent glutamate 
uptake activity in human primary osteoblasts, however these experiments were not 
repeated. This is the first report of functional EAATs in human osteoblasts. 
Replacement of sodium chloride with equimolar choline chloride reduced lOpM 
glutamate uptake by 50% in human primary osteoblasts, by 35% in MG-63 cells and 
by 90% in SaOS-2 cells revealing the existence of a Na+-dependent component of
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glutamate uptake in these cells. At 250pM glutamate, uptake was reduced in MG-63 
cells by 30% and in SaOS-2 cells by 50% following removal of sodium. These 
differences indicate that glutamate uptake in SaOS-2 cells occurs primarily via Na+- 
dependent mechanisms whereas the majority of glutamate uptake in MG-63 cells 
appears to be Na+-independent.
Na+-dependent glutamate uptake activity has previously been reported in cells from 
various peripheral and musculoskeletal tissues including rat calvarial osteoblasts 
(Takarada et al. 2004), rat costal chondrocytes (Hinoi et al. 2005b), and human 
synovial fibroblasts (unpublished data, Flood, Duance and Mason). Replacement of 
sodium chloride with choline chloride almost entirely abolished glutamate uptake in 
rat calvarial osteoblasts and chondrocytes (Takarada et al. 2004; Hinoi et al. 2005b). 
The higher levels of Na+-independent glutamate transport reported in this thesis in 
MG-63 cells may be due to variances in the assay protocol or due to increased activity 
of a Na+-independent glutamate transporter such as the cystine/glutamate antiporter 
which has been reported to be expressed in MC3T3-E1 osteoblast-like cells (Uno et 
al. 2007) or the poorly characterised Na+-independent low-affinity glutamate 
transporter (reviewed in (Erecinska and Silver 1990; Danbolt 2001)). Interestingly the 
majority of glutamate uptake in MG-63 osteoblasts appears to occur independently of 
sodium indicating that the dominant glutamate transport machinery in these cells is 
Na+-independent. Therefore it is possible that in these cells the other potential EAAT 
functions besides glutamate transport, i.e. ion channel and receptor-like function, may 
have a more prominent role. The differences observed in the proportion of Na+- 
dependent to Na+-independent glutamate transport are clearly cell type, species and 
differentiation stage specific and an important consideration in the context of 
modulating glutamatergic signalling for therapeutic effect in human musculoskeletal 
disorders.
Glutamate uptake in primary osteoblasts also appeared to be temperature-dependent, 
in agreement with previous studies of glutamate transporters (Stallcup et al. 1979), 
suggesting that the transport mechanism involves steps that must overcome large 
energy barriers such as conformational transitions of the transporter and/or the 
requirement of energy for the maintenance of the Na+/K+ membrane gradients 
(Grunewald and Kanner 1995; Wadiche and Kavanaugh 1998).
115
Chapter 3
3.4.2.1 Kinetic characterisation of glutamate uptake in human osteoblast-like cells
Kinetic characterisation of the osteoblast cell lines provides information relating to 
the affinity of the EAATs expressed for glutamate (K m) as well as the maximum 
capacity of these cells to transport glutamate ( V m a x ) -  These constants can then be used 
to detect differences associated with the phenotypic maturity of the cell lines. 
Na+-dependent glutamate uptake in SaOS-2 cells displayed a typical saturation curve 
with a high affinity for glutamate (KM = 7.4 ± 1.2pM) and a large maximal uptake 
capacity ( V m a x  = 48,510 ± 1,700 pmol/hr/mg). SaOS-2 cells express much higher 
levels of EAAT1 mRNA than any other EAAT expressed in this cell type (section
3.3.1), indicating that this transporter subtype might be responsible for the bulk of 
glutamate uptake in these cells.
In contrast, Na+-dependent glutamate uptake in MG-63 cells does not display a typical 
saturation curve. It is possible that this reflects the presence of a low- and a high- 
affinity transporter; and similar uptake curves have been previously reported for 
glutamate uptake in human platelets (Mangano and Schwarcz 1981) and for 
endogenous Na+-dependent glutamate uptake in Xenopus Laevis oocytes (Steffgen et 
al. 1991). However statistical comparison of a one- and two-site binding model 
indicated that the MG-63 uptake data fitted a one-site binding model better, despite 
both models fitting the data poorly. It is still plausible that the shape of the curve 
represents two components from two different transporters or differential regulation 
of the same transporter at increasing substrate concentrations, and that this is not 
mathematically detectable because transport was not measured across a broad enough 
range of glutamate concentrations. If this is the case then the second component 
transports glutamate with a high Vmax but a low affinity which is not characteristic of 
the EAATs. EAATs transport glutamate with Km values ranging from 18-42pM in 
Xenopus oocytes and HEK293 cells (Arriza et al. 1994; Jensen and Brauner-Osbome 
2004), which fit better to the first component of the curve. A number of other Na+- 
dependent glutamate transporters have been identified which might be responsible for 
the second component in the curve, however these are poorly characterised and none 
have been studied in osteoblasts to date (Levi et al. 1976; Bonanno et al. 1993; 
Bonanno and Raiteri 1994; Bukowski et al. 1995; Bender et al. 2000).
It is also possible that the non-hyberbolic shape of the curve can be explained by 
some glutamate-mediated effects on glutamate transporter activity and/or expression
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that are occurring in MG-63 cells within the 10 min incubation period. Section 3.3.3.4 
shows that lhr pre-incubation with IO j iM  or 500pM glutamate had no effect on 
uptake of lOpM glutamate in MG-63 cells, however the effect of the same pre­
incubations on uptake of higher concentrations of glutamate (i.e. 250pM) were not 
studied.
Km values for glutamate uptake in HEK293 cells stably expressing human EAAT1, 
EAAT2, and EAAT3 were 20 ± 3 pM, 25 ± 3 pM, and 42 ± 13 pM respectively 
(Jensen and Brauner-Osbome 2004) and similar values were obtained in Xenopus 
Laevis oocytes expressing EAAT1, 2 and 3 (20 ± 3 pM, 18 ± 3 pM, and 28 ± 6 pM 
respectively) (Arriza et al. 1994). The Km value for SaOS-2 cells observed here is ~3- 
fold lower than those detected in HEK293 cells or oocytes, whereas the Km value for 
MG-63 cells is ~ 10-fold higher. These variations could be attributed to differences 
between experimental systems testing a single EAAT, and the combined values that 
arise from osteoblasts expressing different EAATs that are, in turn, likely to be 
differentially regulated within the cell.
In rat calvarial osteoblasts cultured for 7 or 21 days, the observed Km values for 
glutamate uptake were 26 ± 6 pM and 42 ± 11 pM respectively and the Vmax values 
were 57,600 ± 7320 pmol/hr/mg protein and 17,400 ± 1980 pmol/hr/mg protein 
respectively (Takarada et al. 2004). These findings suggest that as osteoblasts mature 
in culture, their maximal capacity to transport glutamate and the affinity of the 
transporters for glutamate decreases. The phenotype of the osteoblast-like cells used 
in the experiments presented in this thesis are widely accepted to reflect that of a pre- 
osteoblast (MG-63) and a late osteoblast (SaOS-2) (Jukkola et al. 1993; Chaudhary 
and Avioli 1994; Pautke et al. 2004; Shapira and Halabi 2009). In these studies, the 
more mature osteoblast (SaOS-2) in fact exhibits a much higher maximal glutamate 
capacity and higher affinity over the less mature osteoblast (MG-63) in contrast to the 
published findings with rat calvarial osteoblasts (Takarada et al. 2004). These 
inconsistencies might be attributable to species-specific differences, differences in the 
cell phenotypes used or simply a reflection of the short-comings of using cell lines in 
contrast to primary cells. However Takarada et al. maintained calvarial osteoblasts in 
medium containing glutamate at 510pM, a concentration which we have shown can 
decrease EAAT activity in a short- and long-term capacity in SaOS-2 cells (Figure 
3.16). The authors also mentioned as a point of discussion that the possibility that 
radiolabelled glutamate might be unable to gain access to EAATs due to
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mineralisation during maturation had not been ruled out (Takarada et al. 2004). It is 
also relevant to note that calvarial osteoblasts do not exhibit the same responses to 
mechanical stimulation as osteoblasts from load bearing regions of the body i.e. ulna 
(Rawlinson et al. 1995), and so regulation of glutamate signalling in these cells, a 
signalling pathway that has been implicated in the mechanoresponse, may not be 
comparable to osteoblasts from other sources.
3.4.2.2 Pharmacology of glutamate uptake in human osteoblast-like cells
Na+-dependent glutamate uptake in M G - 6 3  and SaOS-2 cells was dose-dependently 
inhibited by the non-selective competitive E A A T  inhibitors T B O A  and / - P D C  
(Figures 3 . 1 3  and 3 . 1 4 ) .  Na+-dependent glutamate uptake was most potently inhibited 
by T B O A  ( I C 5 o = 0 . 9 2  pM and 7 . 4  pM in M G - 6 3  and SaOS-2 cells respectively) and 
to a lesser extent by / - P D C  ( I C 5 o = 3 1 8 . 6  pM and 5 1 . 6  pM in M G - 6 3  and SaOS-2 cells 
respectively). Both E A A T 1  and E A A T 3  are expressed in M G - 6 3  and SaOS-2 cells 
and the lack of an E A A T 1 -  or E A A T 3 -selective uptake inhibitor makes it difficult to 
discern if a single E A A T  subtype is responsible for glutamate accumulation in these 
cell lines.
Inhibition of EAAT activity by /-PDC in MG-63 cells appeared to generate a biphasic 
dose-response curve suggesting the presence of more than one Na+-dependent 
glutamate transporter responsible for glutamate uptake activity, consistent with kinetic 
findings of glutamate uptake in these cells (section 3.3.3.2.1). Table 2.3 shows the 
reported inhibition constants for /-PDC across the EAATs and these values indicate 
that the inhibitor is more potent for EAAT2, EAAT4 and EAAT5 than for EAAT1 
and EAAT3. MG-63 cells express quantifiable levels of EAAT 1 and EAAT3 mRNA 
but these EAATs have similar IC50 values for /-PDC (Arriza et al. 1994; Shimamoto 
et al. 1998) so it is unlikely that they are responsible for the two phases of the dose- 
response curve, unless post-translational regulation of the transporters modulates their 
sensitivity to inhibition by /-PDC. MG-63 cells express unquantifiable levels of 
EAAT2 mRNA and expression levels of EAAT4 and EAAT5 mRNA were not 
assessed. To determine whether any of these EAATs might be responsible for Na+- 
dependent glutamate uptake in MG-63 cells, specific inhibitors could be used such as 
the EAAT2-specific inhibitor dihydrokainic acid.
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Repeating the experiments over a wider range of inhibitor concentrations would also 
be advantageous in revealing more accurate IC50 values, since the determined IC50 
values for TBOA in MG-63 and SaOS-2 cells are at concentrations below or in the 
lower range of those measured. Furthermore, a more comprehensive view of the dose- 
response curves for TBOA in each cell line would reveal any deviations from a simple 
sigmoidal curve. TBOA is 10X less potent for EAAT1 than for other EAATs (Table 
2.3) so a biphasic dose-response curve for TBOA might indicate that more than one 
EAAT is responsible for glutamate uptake.
These experiments have however confirmed the presence of functional EAATs in 
osteoblast-like cell lines and informed decisions for further experiments assessing the 
effects of EAAT inhibitors on osteoblast bone-forming activity, which form the basis 
of chapter 4 of this thesis.
3 .4.2.3 Extracellular glutamate regulates EAAT activity in human osteoblasts
Short-term (lhr) and long-term (24hr) pre-incubation of SaOS-2 cells with 
pathological (500pM) concentrations of glutamate significantly decreased Na+- 
dependent glutamate uptake in these cells. The same pre-incubation periods with 
physiological concentrations of glutamate (lOpM) had no effect on Na+-dependent 
glutamate uptake. No significant effects upon Na+-dependent glutamate uptake were 
observed following any of these pre-incubations in MG-63 cells.
These data may indicate that uptake is inhibited in SaOS-2 cells that are subject to 
excessive glutamate concentrations. The concentrated glutamate uptake activity 
occurring in SaOS-2 cells treated with 500pM glutamate, compared to those treated 
with lOpM glutamate, may result in depolarisation of the cell membrane due to the 
net positive charge moving into the cell which would then result in a reduction in the 
electrochemical gradients that drive transport, and so eventually slowing the rate of 
transport. Alternatively, the substrate-induced decrease in SaOS-2 Na+-dependent 
glutamate uptake rate may be due to feedback signalling mechanisms via the receptors 
or transporters themselves.
Other studies have demonstrated a substrate induced inhibition of transport activity in 
microglial cultures expressing GLT-1 but not GLAST (12hrs with 0.1 and ImM 
glutamate) (Persson et al. 2005) and in chick Bergmann glia expressing high levels of 
GLAST (30-60 min with 0.2 and ImM glutamate) (Gonzalez and Ortega 2000). In
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Bergamnn glia, inhibition was found to be due to a reduction in affinity of the 
transporter rather than a loss of available transporters at the cell surface, and was 
independent of receptor activation but sensitive to PKC inhibition (Gonzalez and 
Ortega 2000). This is in contrast to the effects of glutamate on EAAT transcription in 
Bergmann glia which are thought to be dependent upon AMPA/kainate receptor 
activation (Lopez-Bayghen et al. 2003; Lopez-Bayghen and Ortega 2004; Rosas et al.
2007). PKC phosphorylation has previously been shown to have an inhibitory effect 
upon GLAST activity (Conradt and Stoffel 1997; Gonzalez and Ortega 1997); yet 
PKC regulates GLT-1 and EAAC1 to increase transport (Casado et al. 1991; Dowd 
and Robinson 1996), suggesting that the response to pre-incubation with glutamate 
will alter depending on which EAAT subtypes are expressed and will therefore be 
cell-type specific.
Pre-incubation of primary astrocyte cultures and human platelets with 100pM 
glutamate for lhr significantly increased glutamate uptake activity and increased 
GLAST protein expression (Duan et al. 1999; Begni et al. 2005) and this substrate- 
induced increase in transporter activity was also found to occur independently of 
receptor activation (Duan et al. 1999; Gonzalez and Ortega 2000; Munir et al. 2000; 
Begni et al. 2005). Long-term pre-incubation (7 days) of murine primary cortical 
astrocytes with ImM glutamate also significantly increased glutamate uptake activity 
and increased GLAST protein expression (Gegelashvili et al. 1996). Pre-incubation of 
‘astrocyte-poor’ neuronal cultures with lOOpM glutamate for 30 min significantly 
increased glutamate uptake activity but had no detectable effects on transporter 
protein levels or cell surface expression (Munir et al. 2000).
The regulation of transporter activity by its substrate is not limited to the EAATs. The 
transport of norepinephrine is down-regulated by the long-term application (3 days) of 
the transporter antagonist, desipramine (Zhu et a l 1998) and the function of the 
GAB A transporter is up-regulated by extracellular GAB A (at lOOpM for lhr) in a 
receptor-independent fashion (Bernstein and Quick 1999).
The activity of expressed EAATs can be regulated at several levels, including 
phosphorylation (Casado et al. 1991; Conradt and Stoffel 1997) and intracellular 
protein-protein interactions (discussed further in chapter 6 of this thesis). Kinetic 
characterisation of Na+-dependent glutamate uptake in SaOS-2 cells pre-incubated 
with glutamate would reveal whether the reduction in glutamate uptake was the result 
of decreased transporter expressed at the plasma membrane (decreased Vmax) or a
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decrease in transporter affinity for glutamate (increased K m). Furthermore, pre­
incubation o f osteoblast-like cells with glutamate in the presence o f  receptor, 
transporter or kinase inhibitors may elucidate whether the substrate-induced inhibition 
o f transporter activity observed in SaOS-2 cells is receptor-, transporter- and/or 
kinase-mediated. Alternatively, conducting the same pre-incubation conditions but in 
the absence o f sodium would indicate whether transport o f glutamate was necessary 
for the observed effects.
3.4.3 Knowledge of EAAT expression and function in human osteoblasts 
can inform methods to therapeutically target EAATs for bone repair
The experiments presented here have profiled EAAT expression and function in 
human osteoblasts, and provided some insight into the regulation o f  these 
transporters. In order to understand the role EAATs play in modulating the glutamate 
signalling pathway in bone, particularly during the mechanoresponse, and how these 
proteins can be therapeutically targeted, it is important to ascertain information 
regarding the expression and activity o f the EAAT family in this tissue. Furthermore, 
these data have been important for informing and interpreting experiments presented 
in this thesis where EAAT activity has been modulated in osteoblasts.
These experiments have shown that EAATs are differentially expressed and regulated 
in cell lines that reflect early and late stages o f osteoblast differentiation, suggesting 
that these cell lines will not respond similarly to modulation o f EAAT activity. 
Therefore, methods to therapeutically modulate EAAT activity may differ depending 
on which stage o f  osteoblast maturation towards bone formation represents the most 
appropriate target. Analysis o f EAAT expression and activity during osteoblastic 
differentiation o f  MSCs would be particularly informative in this respect.
These studies have also validated the use of osteoblast-like cell lines to compensate 
for primary human osteoblasts, which are expensive to obtain and can be variable. 
MG-63 and SaOS-2 cells display a similar EAAT expression pattern to primary 
human osteoblasts and both osteoblast-like cells and primary human osteoblasts 
exhibit Na+-dependent glutamate uptake suggesting that these cell lines represent 
appropriate models to investigate the role o f EAATs in osteoblasts.
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3.4.4 Summary
In summary, the experiments shown here have demonstrated that human osteoblasts 
express EAATs 1-3 at differential levels, including two splice variants o f  EAAT 1. 
Human osteoblasts transport glutamate in a Na+-dependent manner that is sensitive to 
pharmacological inhibition o f EAATs. An essential step towards understanding the 
contribution o f  EAATs to the modulation o f glutamate signalling in osteoblasts is the 
analysis o f the regulation o f their activity. These experiments have shown that 
glutamate regulates its own uptake in osteoblast cell lines through effects on EAAT 
activity, suggestive o f feedback mechanisms via either the transporter or receptors 
present at the cell surface. Differences exist between MG-63 cells and SaOS-2 cells in 
EAAT expression levels and the kinetics o f Na+-dependent glutamate uptake, as well 
as the glutamate-mediated regulation o f  these processes indicating differentiation 
specific influences. Such differences may be used to inform therapeutic targeting o f  
glutamate uptake in bone since pre-osteoblast differentiation and mature osteoblast 
bone formation are likely to be regulated differentially by glutamate.
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4. Pharmacological inhibition of EAATs in human osteoblasts
4.1 Background
4.1.1 Pharmacological EAAT inhibitors
A number o f  pharmacological molecules have been developed to investigate and 
modulate properties o f the glutamate transporters. Most o f the compounds developed 
to date are competitive transportable substrate inhibitors (Gegelashvili and Schousboe
1998), generating a transport current and a substrate-dependent anion conductance 
(Shigeri et al. 2004). Competitive substrate inhibitors can also induce an efflux of 
glutamate due to heteroexchange, increasing the extracellular glutamate concentration 
(Nicholls and Attwell 1990; Dunlop et al. 1992; Blitzblau et al. 1996; Koch et al.
1999). Heteroexchange occurs when the addition o f  one substrate e.g. /-PDC 
stimulates the efflux o f  a second substrate that has been accumulated within the cell 
e.g. glutamate (Koch et al. 1999). Therefore, substrate inhibitors are able to mimic 
reversed operation o f  the transporter. The transporters are driven by ionic gradients 
across the membrane (K+, Na+) which are maintained by the sodium pump which 
requires ATP for activity. ATP levels drop in ischemia and the electrochemical 
gradients cannot be maintained, leading to reversed operation o f the transporter and 
glutamate release (Rossi et al. 2000). This is a major contributor to neurotoxicity 
associated with stroke-induced ischemic brain damage (Kuwahara et al. 1992; Rossi 
et al. 2000), transportable EAAT inhibitors have consequently been used to 
investigate the role o f  reversed glutamate uptake in ischemia (Danbolt 2001; 
Maragakis and Rothstein 2004; Re et al. 2006).
L-/ra«s-2,4-pyrrolidine dicarboxylate (f-PDC) is a conformationally restricted 
glutamate analogue and functions as an inhibitor o f EAATs 1-5, exhibiting little 
cross-reactivity with iGluRs (Bridges et al. 1991; Garlin et al. 1995) and no reported 
cross-reactivity with mGluRs. T-PDC is transported slowly by EAATs 1-4 (Sarantis et 
al. 1993) but is a non-transportable inhibitor o f EAAT5 and acts most potently on 
EAATs 2, 4, and 5 (Bridges et al. 1999). T-PDC activates the uncoupled anion 
conductance in EAATs 1-4 (Wadiche and Kavanaugh 1998; Shigeri et al. 2004).
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A number o f non-transportable EAAT inhibitors have been developed more recently 
including dihydrokainic acid (DHK) and DL-threo-P-benzyloxyaspartic acid (TBOA), 
allowing distinction between binding and translocation o f the transporter. DHK is a 
derivative o f  the glutamate receptor agonist kainate and acts as a non-transportable, 
EAAT2 selective inhibitor of L-glutamate uptake and also binds to kainate receptors 
with low affinity (Arriza et al. 1994; Shimamoto et al. 1998). TBOA is an O- 
substituted hydroxyaspartate and is a non-transportable inhibitor o f EAATs 1-5 with 
Ki and IC50 values in the 1-lOpM range (Table 2.3). TBOA inhibits glutamate 
transport and also glutamate gated anion conductance (Shimamoto et al. 1998; Seal et 
al. 2001; Ryan and Vandenberg 2002). Non-transportable inhibitors o f the EAATs, 
such as TBOA (and f-PDC with respect to EAAT5), are substrate analogues but do 
not by themselves elicit anion conductance (Arriza et al. 1997; Shimamoto et al. 
1998; Seal et al. 2001; Ryan and Vandenberg 2002) and yet it is known that 
conductance is independent o f substrate transport (Fairman et al. 1995; Wadiche et al. 
1995; Billups et al. 1996; Wadiche and Kavanaugh 1998; Seal et al. 2001; Slotboom 
et al. 2001b). Seal et al. suggest that the EAAT bound substrates might undergo 
additional steps to activate anion conductance and that non-transportable inhibitors 
stabilise the transporter in a conformation that prevents the entrance into this anion 
conducting state (Seal et al. 2001). Indeed, lithium can support the transport o f  
glutamate by EAAC1, but not the substrate gated anion conductance, suggesting that 
different conformations o f  the transporter are required for anion conductance and 
glutamate transport (Borre and Kanner 2001).
Most o f the subtype selective EAAT inhibitors developed to date are specific to 
EAAT2, possibly due to the use o f synaptosomal model systems which express high 
levels o f  EAAT2 (Koch et al. 1999). EAAT2 selective inhibitors include DHK, L- 
trans-2,3-PDC, (ftS)-2-amino-3-(3-hydroxy-l,2,5-thiadiazol-4-yl)propionic acid 
(TDPA), L-anti-endo-3,4-PDC and WAY-855 (Arriza et al. 1994; Bridges et al. 1994; 
Bridges et al. 1999; Dunlop et al. 1999; Brauner-Osbome et al. 2000; Campiani et al. 
2003). Selective inhibitors for the other EAATs are not available; however 4- 
methylglutamate and L-serine-O-sulfate are EAAT1 specific substrates with low 
potency (Arriza et al. 1994; Vandenberg et al. 1998).
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4.1.2 Inhibition of EAATs in vitro
4.1.2.1 EAAT inhibitors in the CNS
In the CNS, EAATs rapidly clear glutamate from the synaptic cleft, terminating 
glutamatergic signalling. Therefore, inhibition o f EAATs has the potential to increase 
the concentration o f  extracellular glutamate available for receptor binding (Tovar et 
al. 2009) and modulate the amplitude and duration o f  the signal. In organotypic 
hippocampal cultures, TBOA treatment resulted in a rapid build up o f extracellular 
glutamate (Jabaudon et al. 1999). EAAT inhibition can cause cell death in 
hippocampal neurons and slices (Bonde et al. 2003; Himi et al. 2003; Guiramand et 
al. 2005), cerebellar granule neurons (Estrada-Sanchez et al. 2007) and retinal Muller 
cells (Izumi et al. 2002) in a manner sensitive to NMDA and non-NMDA antagonists, 
indicative o f  a role for EAATs in the prevention o f  excitotoxicity. A build up o f  
extracellular glutamate can also lead to activation o f pre-synaptic inhibitory mGluRs, 
which would normally be prevented by active removal o f glutamate from the synaptic 
cleft (Maki 1994).
4.1.2.2 EAAT inhibitors and the cystine/glutamate antiporter
Inhibition o f  glutamate transporters can prevent the build up o f intracellular 
glutamate, therefore affecting its concentration gradient across the cell membrane. 
The glutamate concentration gradient, in turn, drives cystine uptake via the 
cystine/glutamate antiporter (Bannai and Kitamura 1980), which provides the cell 
with cystine required to form the antioxidant GSH (Meister 1983). Inhibition o f this 
mechanism has been proposed to cause cell death following EAAT inhibition due to 
the increased presence o f  reactive oxygen species (ROS) (Kato et al. 1992; Mawatari 
et al. 1996; Reichelt et al. 1997; Himi et al. 2003). Transportable inhibitors such as t- 
PDC can also induce an efflux o f glutamate due to heteroexchange, exacerbating the 
build up o f  ROS by increasing extracellular glutamate concentrations (Griffiths et al. 
1994; Volterra et al. 1996). Incubation o f astrocytes and hippocampal cultures with t- 
PDC has led to cell death, in association with GSH depletion and an increase in ROS 
(Himi et al. 2003; Re et al. 2003; Guiramand et al. 2005).
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4.1.2.3 EAAT inhibitors in osteoblasts
The role o f  the cystine/glutamate antiporter in osteoblasts has been highlighted by 
studies showing that the survival o f rat calvarial osteoblasts in glutamate-free medium 
was significantly improved by the addition o f pyruvate or cystine during the 
proliferative phase, and also by supplementation with GSH (Hinoi et al. 2002b). 
Furthermore, high concentrations o f glutamate can suppress osteoblast differentiation 
o f mouse bone marrow stromal cells through inhibition o f the cystine/glutamate 
antiporter and depletion o f GSH production (Takarada-Iemata et al. 2010).
EAAT inhibition by f-PDC in rat calvarial osteoblasts has also been reported to 
prevent bone formation in vitro and shift the cells from an osteoblastic to a more 
adipocytic phenotype (Taylor 2002).
4.1.2.4 EAAT inhibitors in chondrocytes
Cultured rodent chondrocytes express EAAT1 and EAAT2 mRNA and protein and 
transport glutamate in a temperature-, sodium- and time-dependent manner (Hinoi et 
al. 2005a; Piepoli et al. 2009). Incubation o f rodent chondrocytes with EAAT 
inhibitors at O.lpM-lmM for 5 min demonstrated that EAAT2 selective inhibitors 
(threo-3-Methylglutamic acid (T3MG) and DHK) were more potent in inhibiting 
1 pM glutamate uptake than the non-selective inhibitors CCGIH and fi-threo-hydroxy- 
aspartate (THA). This demonstrated that EAAT2 plays a more prominent role in 
mediating glutamate uptake in these cells than EAAT1 (Hinoi et al. 2005a).
4.1.2.5 EAAT inhibitors in synovial fibroblasts
In rat synovial fibroblasts (normal and with collagen-induced arthritis (CIA)), mRNA 
for EAATs 1-3 was detected and functional EAAT activity was confirmed by sodium- 
dependent glutamate uptake assays (Hinoi et al. 2005b). EAAT uptake activity was 
increased in CIA rats, most drastically at 7 days post-immunisation with type II 
collagen and declining up to 28 days despite second and third immunisations (Hinoi et 
al. 2005b). Incubation o f  rat synovial fibroblasts with EAAT inhibitors at lOOpM for 
20 min demonstrated that the non-selective EAAT inhibitors (THA, CCGID and /- 
PDC) were more potent in inhibiting lpM  glutamate uptake than the EAAT2-
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selective inhibitors T3MG and DHK in both normal and CIA rats, indicating that 
EAAT2 does not play a dominant role in mediating glutamate uptake in rat synovial 
fibroblasts (Hinoi et al. 2005b). Over 24hrs, 500pM glutamate significantly increased 
proliferation o f  synovial fibroblasts from CIA rats but not normal rats, and this was 
inhibited by co-incubation with the non-selective EAAT inhibitors THA and CCGID 
at lOOpM (Hinoi et al. 2005b). The authors suggest that intracellular glutamate 
accumulated through increased EAAT activity may prime the cellular proliferation in 
synovial fibroblasts, that leads to synovial hyperplasia, early in CIA rats (Hinoi et al. 
2005b).
4.1.3 Aims
The objectives o f  the experiments described in this chapter were to assess the 
importance o f  glutamate transport by EAATs in osteoblast differentiation and activity 
using small molecule inhibitors o f  EAATs. Since EAAT1 is the most highly 
expressed mRNA in human osteoblasts (section 3.3.1) and GLAST expression is 
regulated by osteogenic mechanical loading in vivo (Mason et al. 1997), the use o f an 
EAAT1 selective inhibitor would be favourable, however to date there are no potent 
EAAT1 specific inhibitors available. The non-selective inhibitors, f-PDC and TBOA 
target a broad range o f  EAATs, including EAAT1, with differing potencies and 
Chapter 3 showed that TBOA and /-PDC inhibit glutamate uptake in MG-63 and 
SaOS-2 osteoblast-like cells (section 3.3.3.3). These inhibitors were chosen due to 
their ability to target EAAT1 (Table 2.3) and their differing effects on EAAT anion 
conductance, allowing the importance o f the EAAT ion channel to also be assessed. 
The transportable inhibitor /-PDC inhibits EAAT glutamate uptake but activates 
EAAT anion conductance (in EAATs 1-4) (Shigeri et al. 2004) in contrast to the non- 
transportable inhibitor TBOA which inhibits both EAAT uptake and anion 
conductance activities (Shimamoto et al. 1998).
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4.2 M ethods
4.2.1 EAAT inhibitors
In cell culture experiments where the inhibitor concentration was kept constant, a 
concentration o f  lOOpM was chosen since /-PDC and TBOA are effective inhibitors 
o f each EAAT subtype at lOOpM (section 2.7 and Table 2.3). lOOpM TBOA inhibits 
Na+-dependent glutamate uptake by -100%  in MG-63 and SaOS-2 cells (Figures 3.13 
and 3.14). lOOpM /-PDC inhibits Na+-dependent glutamate uptake by 40% in MG-63 
and by 70% in SaOS-2 cells (Figures 3.13 and 3.14). The differences in the potency o f  
these inhibitors are due to the nature o f inhibition -  TBOA is a potent EAAT blocker 
whereas /-PDC is a competitive glutamate analogue and so will be a less effective 
inhibitor at the same concentration.
4.2.2 Inhibition of EAATs in human osteoblast-like cells
MG-63 and SaOS-2 cells were incubated with the transporter inhibitors /-PDC and 
TBOA at lOOpM ± 500pM glutamate in DMEM containing 5% dFBS and 50pg/ml 
ascorbate. Cells were treated with inhibitors for lhr prior to the addition o f glutamate 
to ensure glutamate uptake was inhibited to the levels reported in section 3.3.3.3.
4 .2.2.1 Effect o f EAAT inhibitors on cell number and alkaline phosphatase (ALP) 
activity
MG-63 osteoblasts were seeded at 2.6 x 104 cells/cm2 in 96-well plates and SaOS-2 
cells were seeded at 4.2 x 104 cells/cm2 in 96-well plates. Cells were allowed to 
adhere overnight before treatments were begun (cells were -80%  confluent). Cells 
were incubated with inhibitors ± 500pM glutamate for 24-72hrs and assayed for cell 
number (LDH Cytotox96 assay) and ALP activity (SaOS-2 cells only) at 24, 48 and 
72hrs (sections 2.5.3 and 2.5.4). Cells were also incubated with l-1000pM  EAAT 
inhibitor in the absence o f glutamate and assayed for cell number and ALP activity at 
24hrs. At each time-point, medium was removed and cells were lysed with 80 p 1/well 
o f lysis buffer (section 2.5.1) and 25pi o f  lysate was taken for each o f  the above
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assays. Cell death was not assayed in these cultures; however previous analyses (not 
shown) indicated that cell death represented no more than 10% o f total LDH activity 
in untreated cells and in cells treated with EAAT inhibitors ± 500pM glutamate over 
24hrs.
4.2.2.2 Effect o f  EAAT inhibitors on gene expression
MG-63 osteoblasts were seeded at 2.6 x 104 cells/cm2 in 24-well plates and SaOS-2 
cells were seeded at 4.2 x 104 cells/cm2 in 24-well plates. Cells were allowed to 
adhere overnight before treatments were begun (cells were -80%  confluent). Cells 
were incubated with inhibitors ± 500gM glutamate for 24hrs. The medium was then 
aspirated, cells rinsed with cold PBS and homogenised with 0.2ml TRIzol® reagent 
per well for 5 min. The plates were stored at -80°C until RNA extractions and reverse 
transcription were carried out (section 2.3). 500ng total RNA was reverse transcribed 
in a 20pl reaction which was then diluted to 100pi with RNase/DNase-ffee molecular 
biology grade water and lp l taken for QRT-PCR amplification. QRT-PCR was 
carried out (section 2.4.4) using primers against Runx2, osteocalcin, type I collagen, 
osteonectin, osteoprotegerin (OPG) and ALP in conjunction with the housekeeping 
genes 18S rRNA, GAPDH and HPRT1 (Table 2.1). Gene expression for MG-63 and 
SaOS-2 cells was normalised to GAPDH and HPRT1 respectively, the most stable 
housekeeping genes o f  the three as determined using geNorm software for each 
experiment (Vandesompele et al. 2002). Relative QRT-PCR (section 2.4.4.5) was 
carried out using the Applied Biosystems 7900HT Fast Real-Time PCR system 
(section 2.4.4.1.2) in conjunction with cDNA standard curves (section 2.4.4.2.2). All 
values were expressed relative to untreated cells (OpM inhibitor, OpM glutamate).
4.2.2.3 Effect o f  EAAT inhibitors on mineralisation
SaOS-2 cells were seeded at 4.2 x 104 cells/cm2 in 24-well plates. Cells were allowed 
to adhere overnight before treatments were begun (cells were -80%  confluent). Cells 
were incubated with inhibitors ± 500pM glutamate for 10 days in the presence of 
2mM p-glycerophosphate and treatments were refreshed every 2-3 days. SaOS-2 
osteoblasts were assessed for mineralisation by alizarin red staining (section 2.9).
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Parallel cultures were assayed for cell number (LDH Cytotox96 assay, section 2.5.3). 
Medium was removed from these cultures and cells were washed with cold PBS prior 
to cell lysis with 100 p 1/well o f lysis buffer (section 2.5.1) and 5pi taken for assay o f  
cell number.
4.2.3 Inhibition of EAATs in human primary osteoblasts
Human primary osteoblasts (NHOB1-3) were seeded at 2 x 104 cells/cm2 in 24-well 
plates and cultured until 70% confluent. Cells were serum starved for 24hrs and then 
treated for a further 24hrs with lOOpM glutamate transport inhibitors /-PDC and 
TBOA ± 500pM glutamate. For all experiments exceeding 24hrs, cells were 
incubated with fresh growth medium containing 5% dFBS, 50pg/ml ascorbate and 
supplemented with inhibitors ± glutamate. Medium was refreshed every 2-3 days.
4.2.3.1 Effect o f  EAAT inhibitors on cell number and ALP activity
The effect o f EAAT inhibitors on cell number (NHOB1P5, NHOB2P7 and 
NHOB3P5) and ALP activity (NHOB1P5) o f human primary osteoblasts was 
assessed at 24hrs and 5 days. At each time-point, medium was removed from cells 
and retained, and cells were washed with cold PBS prior to lysis with lOOpl/well of 
lysis buffer (section 2.5.1). 5pi cell lysate was assayed for adherent cell number 
(section 2.5.3) and 25pl cell lysate was assayed for ALP activity (section 2.5.4). Dead 
and dying cells in the culture supernatant from each medium change were also lysed 
according to methods outlined in section 2.5.1 and 50pl culture supernatant from each 
medium change was assayed for cell death (section 2.5.3). Values obtained for cell 
death in culture supernatant from each medium change over 5 days were combined to 
indicate total cell death over the 5 day period.
4.2.3.2 Effect o f  EAAT inhibitors on gene expression
The effect o f  EAAT inhibitors on gene expression o f human primary osteoblasts 
(NHOB2P7) was assessed at 24hrs and 5 days. The medium was aspirated, cells 
rinsed with cold PBS and homogenised with 0.2ml TRIzol® reagent per well for 5 
min. The plates were stored at -80°C until RNA extractions and reverse transcription
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were carried out (section 2.3). lOOng (24hrs) and 450ng (5 days) total RNA was 
reverse transcribed in a 20pl reaction which was then diluted to lOOpl with 
RNase/DNase-free molecular biology grade water and 5 pi taken for QRT-PCR 
amplification. QRT-PCR was carried out (section 2.4.4) using primers against Runx2, 
osteocalcin and osteonectin in conjunction with the housekeeping genes 18S rRNA, 
GAPDH and HPRT1 (Table 2.1). Absolute QRT-PCR was carried out with the 
Stratagene MX3000P™ Real-Time PCR system (section 2.4.4.1.1) in conjunction 
with plasmid standard curves generated from cloned template sequences (section 
2.4.4.2.1). Transcript copy numbers were normalised to 18S rRNA as this was the 
most stable housekeeping gene o f the three as determined using geNorm software for 
this experiment (Vandesompele et al. 2002), and expressed relative to untreated cells 
(OpM inhibitor, OpM glutamate).
4.2.3.3 Effect o f EAAT inhibitors on mineralisation
2mM p-glycerophosphate and 10'7M dexamethasone was added to experimental 
medium throughout the culture period for mineralisation experiments. Medium was 
changed every 2-3 days and primary osteoblasts (NHOB2P11) were assessed for 
mineralisation by alizarin red staining after 21 days (section 2.9).
4.3 Results
4.3.1 Viability of cells treated with different concentrations of EAAT
inhibitors
MG-63 and SaOS-2 osteoblasts were treated with the inhibitors /-PDC and TBOA at 
lpM -lm M  in the absence o f exogenous glutamate for 24hrs and adherent cell number 
determined by LDH activity in the lysed cell monolayer (Figure. 4.1). Presented data 
are from three independent experiments where n=4.
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Figure 4.1. Effect o f  24hr incubation with 1-1000/iM EAAT inhibitor at 0/iM  
glutamate on adherent cell number in (A) MG63 and (B) SaOS-2 osteoblasts. LDH 
released upon total lysis o f viable adherent cells is shown as the mean percentage of 
LDH activity o f viable adherent control cells (no inhibitor) ± S.E.M from three 
independent experiments, n=4. MG-63 cell number was not significantly affected by 
inhibitors (Kruskal-Wallis test). SaOS-2 cell number was significantly increased by 
lpM , 10gM, and lOOpM /-PDC (Kruskal-Wallis test with post-hoc Mann-Whitney U 
comparisons) and lOpM and lOOpM TBOA (one-way ANOVA with post-hoc Fisher’s 
comparisons). *P<0.05, **P<0.01, ***P<0.001 compared to untreated control cells.
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4.3.1.1 MG-63
MG-63 cell number (Figure. 4.1 A) was not significantly affected by /-PDC (Kruskal- 
Wallis .P=0.214) or TBOA (Kruskal-Wallis P=0.294) in comparison to control 
untreated cells over lpM -lmM .
4.3.1.2 SaOS-2
SaOS-2 cell number (Figure. 4. IB) was significantly affected by /-PDC (Kruskal- 
Wallis P<0.001) and TBOA (one-way ANOVA P=0.012) in comparison to control 
untreated cells over lpM -lm M . Post-hoc pair-wise comparisons (Mann Whitney U  
tests) revealed that cell number was significantly increased by /-PDC at lpM  (124 ±
11.5 % o f control, P=0.015), at lOpM (143 ± 12.9 % o f control, P=0.003) and at 
lOOpM (133 ± 6.8 % o f  control, PO.OOl). Fisher’s post-hoc tests revealed that 
TBOA significantly increased SaOS-2 cell number at lOpM and lOOpM to 133 ± 14.7 
% (P<0.0\) and 121 ± 7.3 % (P<0.05) o f control respectively.
4.3.2 Viability of cells treated with EAAT inhibitors over time
4.3.2.1 Osteoblast-like cells
Osteoblast-like cell lines (MG-63 and SaOS-2) were treated with the inhibitors /-PDC 
and TBOA at lOOpM for 72hrs and adherent cell number determined by LDH activity 
in the lysed cell layer at 24, 48 and 72hrs. The effect o f 500gM glutamate on adherent 
cell number was also assessed in these cells in the presence and absence o f  EAAT 
inhibitors. Presented data are from three independent experiments where n=4.
4.3.2.1.1 MG-63
Although MG-63 cell number was not significantly affected by glutamate alone 
(Shierer-Ray P=0.455) or by EAAT inhibitor treatment (Shierer-Ray P=0.312) at 
24hrs, there was a significant interaction between these factors (Shierer-Ray P=0.047) 
(Figure 4.2). Post-hoc pair-wise comparisons (Mann-Whitney U  tests) revealed that
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Figure 4.2. Effect o f  EAAT inhibitors on MG-63 osteoblast cell number over 72hrs. 
MG-63 cells were cultured with EAAT inhibitors ± 500|iM glutamate for 72hrs and 
cell number was assayed by measuring LDH released upon total lysis o f viable 
adherent cells at 24, 48 and 72hrs. LDH released is shown as the mean percentage of 
LDH released from viable adherent control cells (no inhibitor, no glutamate) ± S.E.M 
from three independent experiments, n=4. At 24hrs, there was a significant interaction 
between glutamate and EAAT inhibition on MG-63 cell number (Shierer-Ray 
P=0.047). 500pM glutamate significantly increased cell number compared to 
untreated control cells, and this was prevented by lOOpM TBOA (post-hoc Mann- 
Whitney U tests). At 48hrs, 500pM glutamate also significantly increased cell number 
(GLM with log data P=0.014), but no post-hoc pair-wise comparisons (Tukey’s test) 
were statistically significant. No significant effects on cell number were observed 
after 72hrs (Shierer-Ray test). Significance values *P<0.05, ***.P<0.001.
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500pM glutamate significantly increased cell number at 24hrs by 116 ± 4.9 % in the 
absence of EAAT inhibitor treatment (P<0.001), and this was attenuated by lOOpM 
TBOA (P=0.046). At 48hrs, 500|liM glutamate also significantly increased MG-63 
cell number (GLM with log data P=0.014), but no significant effects were found in 
response to EAAT inhibitors (GLM with log data P=0.307) or the interaction between 
the two factors (GLM with log data P=0.237). Post-hoc pair-wise comparisons 
(Tukey’s tests) did not reveal any significant pair-wise effects of 500pM glutamate, 
indicating that the significance was a result of an overall increase in cell number 
across groups in response to 500pM glutamate. No significant effects on cell number 
were observed after 72hrs (by Shierer-Ray test).
4.3.2.1.2 SaOS-2
SaOS-2 cell number was significantly affected by the presence of EAAT inhibitors at 
24hrs (GLM P=0.001), but not by the presence of 500pM glutamate (GLM P=0.142) 
or by the interaction between the two factors (GLM P=0.601) (Figure 4.3). Post-hoc 
Tukey’s tests showed that IOOjhM /-PDC significantly increased cell number 
compared to cells without EAAT inhibitor independently of glutamate concentration 
(P<0.001) and pair-wise comparisons indicated that lOOpM /-PDC significantly 
increased cell number to 133 ± 6.8 % of untreated control cells at OgM glutamate 
(P=0.008) and from 112 ± 8.0 % to 145 ± 8.4 % at 500pM glutamate (7MX301). No 
significant effects on cell number were observed after 48hrs (by Shierer-Ray test) or 
72hrs (by Shierer-Ray test).
4.3 2.2 Primary osteoblasts
Human primary osteoblasts (NHOB2P7 and NHOB3P5) were treated with the 
inhibitors /-PDC and TBOA at 100pM for 24hrs and 5 days. At each time-point, 
adherent cell number was determined by LDH activity in the lysed cell layer and cell 
death was determined by LDH activity in the lysed culture supernatant. The effect of 
500pM glutamate on adherent cell number was also assessed in these cells in the 
presence and absence of EAAT inhibitors. Presented data are from two independent 
experiments where n=4. Cell number data from NHOB1P5 is not
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Figure 4.3. Effect o f  EAAT inhibitors on SaOS-2 osteoblast cell number over 72hrs. 
SaOS-2 cells were cultured with EAAT inhibitors ± 500|iM glutamate for 72hrs and 
cell number was assayed by measuring LDH released upon total lysis o f viable 
adherent cells at 24, 48 and 72hrs. LDH released is shown as the mean percentage of 
LDH released from viable adherent control cells (no inhibitor, no glutamate) ± S.E.M 
from three independent experiments, n=4. Cell number was significantly affected by 
EAAT inhibition at 24hrs (GLM P=0.001) and post-hoc pair-wise Tukey’s 
comparisons revealed that lOOpM f-PDC significantly increased cell number in the 
absence o f glutamate. No significant effects on cell number were observed after 48hrs 
or 72hrs (Shierer-Ray tests). Significance values **P<0.01.
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presented since cells were plated in, and experiments carried out in, medium 
containing glutamate (section 2.2.3), therefore the methodology is not comparable.
4.3.2.2.1 Viable cell number
After 24hrs o f treatment with EAAT inhibitors in the presence or absence of 500pM 
glutamate, primary osteoblast cell number was significantly increased by 500pM 
glutamate (GLM P=0.046) but not affected by EAAT inhibition (GLM P=0.914) or 
by the interaction between the two factors (GLM P=0.449) (Figure 4.4). Post-hoc 
Tukey’s tests did not reveal any significant pair-wise comparisons between treatment 
groups in the presence and absence of 500pM glutamate.
After 5 days treatment, primary osteoblast cell number was not significantly affected 
by glutamate (GLM P=0.103), EAAT inhibitors (GLM P=0.068) or by the interaction 
between the two factors (GLM P=0.281) (Figure 4.4).
4.3.2.2.2 Cell death
Primary osteoblast cell death was determined by measuring LDH activity of dead or 
dying cells in the culture supernatant and this value was expressed as a percentage of 
total LDH activity in the culture well (i.e. adherent cell lysate + dead or dying cells in 
the supernatant) (Figure 4.5). Cell death accounted for 12-14 % of total LDH activity 
at both 24hrs and 5 days treatment. No significant effects of glutamate, EAAT 
inhibitors, or the interaction between the two factors on cell death were detected at 
24hrs (P=0.541, P=0.765 and P=0.885 respectively by GLM) or 5 days (P=0.142, 
P =0.112 and P=0.761 respectively by GLM of ranked data).
4.3.3 Effect of EAAT inhibition on osteoblast gene expression
Osteoblast-like cells and human primary osteoblasts (NHOB2P7) were incubated with 
lOOpM /-PDC or TBOA in the presence and absence of 500pM glutamate for 24hrs. 
Expression of transcripts for Runx2, osteocalcin, type I collagen, osteonectin, OPG 
and ALP were determined by QRT-PCR, normalised to expression of the appropriate 
housekeeping gene (section 2.4.4.3) and expressed as the mean percentage change 
from untreated control cells (OpM inhibitor, OpM glutamate) (Figures 4.6-4.11).
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Figure 4.4. Effect o f  EAA T inhibitors on primary osteoblast cell number at 24hrs 
and 5 days. Primary osteoblasts (NHOB2P7 and NHOB3P5) were cultured with 
EAAT inhibitors ± 500nM glutamate and cell number was assayed by measuring 
LDH released upon total lysis o f viable adherent cells at 24hrs and 5 days. LDH 
released is shown as the mean percentage of LDH released from viable adherent 
control cells (no inhibitor, no glutamate) at each time-point ± S.E.M from two 
independent experiments, n=4. At 24hrs, cell number was significantly increased by 
500pM glutamate (GLM P=0.046), however post-hoc Tukey’s tests did not reveal any 
significant pair-wise differences between individual treatment groups. No significant 
effects on cell number were observed at 5 days (GLM).
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Figure 4.5. Effect o f  EAAT inhibitors on primary osteoblast cell death at 24hrs and 
5 days. Primary osteoblasts (NHOB2P7 and NHOB3P5) were cultured with EAAT 
inhibitors ± 500pM glutamate and cell death assayed by measuring LDH released 
from dead or dying cells in the cell culture supernatant at 24hrs and 5 days. 
Supernatant from medium changes over 5 days was pooled. LDH activity of dead or 
dying cells in the supernatant is shown as the mean percentage of total LDH activity 
(i.e. adherent cell lysate + dead or dying cells in the supernatant) ± S.E.M from two 
independent experiments, n=4. Treatments had no significant effects on primary 
osteoblast cell death at 24hrs or 5 days (GLM).
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Presented data are from three independent experiments where n=4 (MG-63 and SaOS- 
2) or a single preliminary experiment where n=4 (NHOB2P7).
4.3.3.1 Runx2
433.1.1 MG-63
Expression of Runx2 mRNA in MG-63 cells was not significantly affected by EAAT 
inhibitors (GLM with log data P=0.087), glutamate (GLM with log data P=0.071) and 
there was no significant interaction between the two factors (GLM with log data 
P=0.074) (Figure 4.6A). The effects of each of these factors were close to significant 
at the 5% level, and this is probably a reflection of the decrease in Runx2 mRNA 
levels in cells treated with EAAT inhibitors in the presence of 500pM glutamate 
compared to cells treated with 500pM glutamate alone. Mean Runx2 expression was 
increased slightly by 500pM glutamate to 113 ± 11.7 % of untreated cells. The 
combination of 500pM glutamate and IOOjiM /-PDC or TBOA decreased mean 
Runx2 levels to 69 ± 13.5 % and 61 ± 8.5 % of untreated cells respectively.
4.3.3.1.2 SaOS-2
Expression of Runx2 mRNA in SaOS-2 cells was not significantly affected by EAAT 
inhibitors (GLM with log data P=0.828), glutamate (GLM with log data P=0.467) and 
there was no significant interaction between the two factors (GLM with log data 
P=0.839) (Figure 4.6B).
4.3.3.1.3 Primary osteoblasts (NHOB2P 7)
Preliminary findings indicated that primary osteoblast Runx2 expression was not 
significantly affected by EAAT inhibitors (at 24hrs GLM P =0.521; at 5 days GLM 
with log data P=0.106) or by the interaction between EAAT inhibitors and glutamate 
(at 24hrs GLM P=0.823; at 5 days GLM with log data P=0.269) (Figure 4.6C,D). 
However at 24hrs, glutamate significantly reduced expression of Runx2 (GLM 
P=0.042) and this effect was not detected after 5 days treatment (GLM with log data 
P=0.901). At 24hrs, 500pM glutamate decreased Runx2 mRNA levels from
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Figure 4.6. Effect o f  EAAT inhibitors on Runx2 mRNA expression in human 
osteoblasts. Human osteoblasts (A, MG-63; B, SaOS-2; C,D, NHOB2P7) were 
cultured with EAAT inhibitors ± 500|aM glutamate for 24hrs (A-C) or 5 days (D). 
Runx2 expression was assessed by QRT-PCR, normalised to housekeeping gene 
levels and expressed as the percentage change over control cells (OpM inhibitor, OpM 
glutamate). Values are mean ± S.E.M from three independent experiments, n=4 (MG- 
63 and SaOS-2) or a single preliminary experiment, n=4 (NHOB2P7). There were no 
significant effects o f EAAT inhibition or glutamate on expression of Runx2 in MG- 
63, SaOS-2 or in NHOB2P7 at 5 days (GLM). Runx2 expression was significantly 
reduced in NHOB2P7 at 24hrs by 500pM glutamate (GLM P=0.042), however no 
pair-wise Tukey’s comparisons were statistically significant.
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100 ± 37.8 % to 57 ± 14.4 % in untreated cells, from 98 ± 36.3 % to 55 ± 10.5 % in t- 
PDC treated cells and from 146 ± 45.7 % to 70 ± 20.1 % in TBOA treated cells. 
However, post-hoc Tukey’s tests revealed that none of these pair-wise comparisons 
were statistically significant at the 5% level (in untreated cells P=0.910; in f-PDC 
treated cells P=0.909; in TBOA treated cells P=0.503).
4.3.3.2 Osteocalcin
4.3.3.2.1 MG-63
Osteocalcin mRNA levels in MG-63 cells were not significantly affected by EAAT 
inhibitors (GLM with log data P=0.262) or by the interaction between glutamate and 
EAAT inhibitors (GLM with log data P=0.910) (Figure 4.7A). However, osteocalcin 
mRNA expression was significantly decreased in MG-63 cells in the presence of 
500pM glutamate compared to cells at OpM glutamate (GLM with log data 7M).004), 
though post-hoc Tukey’s comparisons did not reveal any pair-wise significance at the 
5% level. Osteocalcin expression was decreased in response to 500pM glutamate 
from 100 ± 14.3 % to 67 ± 7.7 % in untreated cells (P=0.514), from 129 ± 16 % to 80 
± 7.0 % in f-PDC treated cells (P=0.347) and from 99 ± 11.7 % to 81 ± 13.4 % in 
TBOA treated cells (P=0.729).
4.3.3.12 SaOS-2
SaOS-2 osteocalcin expression was significantly affected by EAAT inhibitors (GLM 
with log data P=0.032), glutamate (GLM with log data P=0.024) and the interaction 
between the two factors (GLM with log data T^O.039) (Figure 4.7B). Post-hoc pair- 
wise comparisons (Tukey’s test) revealed that osteocalcin levels were significantly 
increased to 204 ± 28.0 % of untreated control cells by treatment with lOOpM TBOA 
for 24hrs in the absence of glutamate (P=0.011). This increase appeared to be 
prevented by co-incubation with 500pM glutamate (P=0.140).
Since no other pair-wise comparisons were significant at the 5% level, the significant 
effect of 500pM glutamate detected by the GLM probably reflects a general trend
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Figure 4. 7. Effect o f  EAA T inhibitors on osteocalcin mRNA expression in human 
osteoblasts. Human osteoblasts (A, MG-63; B, SaOS-2; C,D, NHOB2P7) were 
cultured with EAAT inhibitors ± 500(iM glutamate for 24hrs (A-C) or 5 days (D). 
Osteocalcin expression was assessed by QRT-PCR, normalised to housekeeping gene 
levels and expressed as the percentage change over control cells (OpM inhibitor, OpM 
glutamate). Values are mean ± S.E.M from three independent experiments, n=4 (MG- 
63 and SaOS-2) or a single preliminary experiment, n=4 (NHOB2P7). MG-63 
osteocalcin expression was significantly reduced by 500pM glutamate (GLM 
P=0.004). SaOS-2 osteocalcin expression was significantly affected by EAAT 
inhibitors (P=0.032), glutamate (P=0.024), and the two factors interacted (P=0.039) 
(GLM). Tukey’s comparisons revealed that SaOS-2 osteocalcin levels were 
significantly increased by lOOpM TBOA at OpM glutamate. There were no significant 
effects o f EAAT inhibition or glutamate on expression o f osteocalcin in NHOB2P7 at 
24hrs or 5 days (Shierer-Ray test and GLM respectively). Significance values 
*P<0.05.
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across the inhibitor treated groups for decreased osteocalcin levels in response to 
500pM glutamate.
4.3.3.2.3 Primary osteoblasts (NHOB2P 7)
Preliminary findings indicated that primary osteoblast osteocalcin expression was not 
significantly affected by EAAT inhibitors (at 24hrs Shierer-Ray P=0.088; at 5 days 
GLM with ranked data P=0.120), glutamate (at 24hrs Shierer-Ray P =0.129; at 5 days 
GLM with ranked data P=0.819) or by the interaction between these factors (at 24hrs 
Shierer-Ray P=0.339; at 5 days GLM with ranked data P=0.852) (Figure 4.7 C,D). 
Interestingly, the effect of EAAT inhibitors on osteocalcin expression was close to 
significant at 24hrs, and this probably reflects the trend for decreased osteocalcin 
expression in cells treated with EAAT inhibitors in the presence of 500pM glutamate. 
Osteocalcin levels were decreased from 125 ± 12.0 % in untreated cells at 500pM 
glutamate to 83 ± 6.3 % by lOOpM /-PDC and to 85 ± 3.2 % by lOOpM TBOA.
4.3.3.3 Type I collagen
4.3.3.3.1 MG-63
Expression of type I collagen mRNA in MG-63 cells was not significantly affected by 
EAAT inhibitors (GLM P=0.322), glutamate (GLM P=0.797) and there was no 
significant interaction between the two factors (GLM P=0.290) (Figure 4.8A).
4.3.3.3.2 SaOS-2
Expression of type I collagen mRNA in SaOS-2 cells was not significantly affected by 
EAAT inhibitors (GLM P=0.628), glutamate (GLM P=0.376) and there was no 
significant interaction between the two factors (GLM P=0.246) (Figure 4.8B).
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Figure 4.8. Effect o f  EAAT inhibitors on type I  collagen mRNA expression in 
human osteoblasts. Human osteoblasts (A, MG-63; B, SaOS-2) were cultured with 
EAAT inhibitors ± 500pM glutamate for 24hrs. Type I collagen expression was 
assessed by QRT-PCR, normalised to housekeeping gene levels and expressed as the 
percentage change over control cells (OpM inhibitor, OpM glutamate). Values are 
mean ± S.E.M from three independent experiments, n=4. There were no significant 
effects of EAAT inhibition or glutamate on expression of type I collagen in MG-63 or 
SaOS-2 cells (GLM).
4.3.3.4 Osteonectin
4.3.3.4.1 MG-63
MG-63 osteonectin expression was significantly affected by EAAT inhibitors (GLM 
with log data P=0.002), but not by glutamate (GLM with log data .P=0.139) or by the 
interaction between these factors (GLM with log data / >=0.702) (Figure 4.9A). Post- 
hoc Tukey’s tests revealed that lOOpM TBOA significantly reduced expression of 
osteonectin independently o f glutamate concentration (P=0.010) and pair-wise 
comparisons revealed that lOOpM TBOA decreased osteonectin expression from 100 
± 9.8 % to 77 ± 7.1 % at OpM glutamate (P=0.071) and from 95 ± 7.2 % to 70 ± 9.3 
% at 500pM glutamate (.P=0.035).
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Figure 4.9. Effect o f  EAA T inhibitors on osteonectin mRNA expression in human 
osteoblasts. Human osteoblasts (A, MG-63; B, SaOS-2; C,D, NHOB2P7) were 
cultured with EAAT inhibitors ± 500pM glutamate for 24hrs (A-C) or 5 days (D). 
Osteonectin expression was assessed by QRT-PCR, normalised to housekeeping gene 
levels and expressed as the percentage change over control cells (OpM inhibitor, OpM 
glutamate). Values are mean ± S.E.M from three independent experiments, n=4 (MG- 
63 and SaOS-2) or a single preliminary experiment, n=4 (NHOB2P7). MG-63 
osteonectin expression was significantly reduced by EAAT inhibitors (GLM P=0.002) 
and pair-wise Tukey’s comparisons revealed that TBOA significantly reduced 
osteonectin expression in the presence of 500pM glutamate. There were no significant 
effects of EAAT inhibition or glutamate on expression of osteonectin in SaOS-2 cells 
or in NHOB2P7 at 24hrs and 5 days (GLM). Significance values *P<0.05.
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4.3.3.4.2 SaOS-2
SaOS-2 osteonectin expression was not significantly affected by EAAT inhibitors 
(GLM with log data P=0.069), glutamate (GLM with log data P=0.059) or by the 
interaction between these factors (GLM with log data P=0.106) (Figure 4.9B). The 
effect of EAAT inhibitors and glutamate were close to significant at the 5% level and 
this may reflect the increase in mean osteonectin expression in cells treated with 
EAAT inhibitors at both glutamate concentrations, and also the mean increase in 
osteonectin expression in response to 500pM glutamate in cells treated with lOOpM t- 
PDC.
4.3.3.4.3 Primary osteoblasts (NHOB2P 7)
Primary osteoblast osteonectin expression was not significantly affected by EAAT 
inhibitors (at 24hrs GLM with ranked data P=0.079; at 5 days GLM with log data 
P=0.808), glutamate (at 24hrs GLM with ranked data P = 0.722; at 5 days GLM with 
log data P=0.809) or by the interaction between these factors (at 24hrs GLM with 
ranked data P=0.600; at 5 days GLM with log data P=0.651) (Figure 4.9C,D). The 
effect of EAAT inhibitors on osteonectin expression was close to significance at 
24hrs, and this may reflect the trend for increased osteonectin expression in cells 
treated with EAAT inhibitors at both concentrations of glutamate.
4.33.5 OPG
4.3.3.5.1 MG-63
MG-63 OPG expression was not significantly affected by EAAT inhibitors (GLM 
P=0.094), glutamate (GLM P=0.549) or by the interaction between these factors 
(GLM P=0.291) (Figure 4.10A).
4.3.3.5.2 SaOS-2
SaOS-2 OPG expression was not significantly affected by EAAT inhibitors (GLM 
with log data P=0.249) or by glutamate (GLM with log data P=0.290) (Figure 4.10B).
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Figure 4.10. Effect o f  EAAT inhibitors on OPG mRNA expression in human 
osteoblasts. Human osteoblasts (A, MG-63; B, SaOS-2) were cultured with EAAT 
inhibitors ± 500pM glutamate for 24hrs. OPG expression was assessed by QRT-PCR, 
normalised to housekeeping gene levels and expressed as the percentage change over 
control cells (OpM inhibitor, OpM glutamate). Values are mean ± S.E.M from three 
independent experiments, n=4. There were no significant effects of EAAT inhibition 
or glutamate on expression o f OPG in MG-63 cells (GLM). SaOS-2 OPG levels 
revealed a significant interaction between EAAT inhibition and glutamate 
concentration (GLM P^O.010). Pair-wise Tukey’s comparisons revealed that OPG 
expression was significantly reduced by /-PDC in the presence o f 500pM glutamate 
but not at OpM glutamate. Significance values *P<0.05.
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However there was a significant interaction between these two factors (GLM with log 
data P=0.010). This interaction reflects the fact that t-PDC significantly decreased 
mean OPG expression at 500pM glutamate (Tukey’s P=0.016) but had no effect at 
OpM glutamate.
4.3.3.6 ALP
43.5.6.1 MG-63
MG-63 ALP expression was significantly affected by EAAT inhibitors (Shierer-Ray 
P=0.004), but not by glutamate (Shierer-Ray P=0.340) or by the interaction between 
the two factors (Shierer-Ray P=0.154) (Figure 4.11 A). Post-hoc pair-wise 
comparisons (Mann-Whitney U tests) revealed that ALP expression was significantly 
decreased by EAAT inhibitors at 500pM glutamate, but not at OpM glutamate. At 
500pM glutamate, ALP levels were decreased from 133 ± 18.1 % in untreated cells to 
62 ± 8.5 % by lOOpM /-PDC (P=0.006) and to 77 ± 5.7 % by lOOpM TBOA 
(P=0.030).
4.3.3.6.2 SaOS-2
SaOS-2 ALP expression was not significantly affected by EAAT inhibitors (GLM 
with log data P=0.876), glutamate (GLM with log data P=0.115) or by the interaction 
between these factors (GLM with log data P=0.253) (Figure 4.1 IB).
4.3.4 ALP activity of cells treated with different concentrations of EAAT 
inhibitors
SaOS-2 osteoblasts were treated with the inhibitors /-PDC and TBOA at lpM-lmM at 
OpM glutamate for 24hrs and ALP activity was determined and normalised to total 
cell number (total LDH activity within the adherent cell lysate) (Figure. 4.12). 
Presented data are from three independent experiments where n=4. ALP activity was 
significantly affected by both inhibitors over this concentration range (one-way 
ANOVA P=0.009 (/-PDC) and P=0.028 (TBOA). Post-hoc pair-wise comparisons
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Figure 4.11. Effect o f  EAAT inhibitors on ALP mRNA expression in human 
osteoblasts. Human osteoblasts (A, MG-63; B, SaOS-2) were cultured with EAAT 
inhibitors ± 500pM glutamate for 24hrs. ALP expression was assessed by QRT-PCR, 
normalised to housekeeping gene levels and expressed as the percentage change over 
control cells (OpM inhibitor, OpM glutamate). Values are mean ± S.E.M from three 
independent experiments, n=4. MG-63 ALP expression was significantly reduced by 
EAAT inhibitors (Shierer-Ray P =0.002) and pair-wise Mann-Whitney U tests 
revealed that both f-PDC and TBOA significantly reduced ALP expression in the 
presence o f 500pM glutamate. There were no significant effects of EAAT inhibition 
or glutamate on expression of ALP in SaOS-2 cells (GLM). Significance values 
*P<0.05, **P<0.01.
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Figure 4.12. Effect o f  24hr incubation with 1-1000/iM EAAT inhibitor at 0/iM  
glutamate on SaOS-2 ALP activity. Enzyme activity was measured colourimetrically 
and normalised to cell number (as measured by total cellular LDH activity). ALP 
activity is expressed as the mean percentage of ALP activity of control cells (no 
inhibitor) ± S.E.M from three independent experiments, n=4. ALP activity was 
significantly affected by both inhibitors over this concentration range (one-way 
ANOVA P=0.009 (7-PDC) and .P=0.028 (TBOA)). Post-hoc pair-wise comparisons 
(Fisher’s tests) revealed that ALP activity was significantly decreased in cells treated 
with 10 and lOOpM /-PDC and TBOA. *P<0.05, **P<0.01 significantly different 
from control cells (no inhibitor).
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(Fisher’s tests) with the untreated control revealed that ALP activity was significantly 
reduced by both inhibitors at lOpM and lOOpM. 10 and lOOgM /-PDC reduced ALP 
activity to 44 ± 8.2 % (P<0.001) and 62 ± 11.1 % (P<0.05) o f control cells 
respectively. 10 and lOOgM TBOA reduced ALP activity to 51 ± 10.4 % (P<0.001) 
and 58 ± 7.9 % (P<0.05) o f control cells respectively. lpM  /-PDC also reduced ALP 
activity non-significantly to 62 ± 13.5 % o f control cells whereas lpM  TBOA and 
both inhibitors at ImM had no effect on ALP activity.
4.3.5 ALP activity of cells treated with EAAT inhibitors over time
4.3.5.1 SaOS-2
ALP activity was assayed in SaOS-2 cell lysates following culture with 100pM 
EAAT inhibitors in the presence and absence o f  500pM glutamate at 24, 48 and 72hrs 
treatment (Figure 4.13). Enzyme activity was normalised to total cell number (total 
LDH activity within the adherent cell lysate). Presented data are from three 
independent experiments where n=4.
At 24hrs, ALP activity was significantly affected by EAAT inhibitors (GLM with log 
data P=0.011), but not by glutamate (GLM with log data P=0.378) or by the 
interaction between the two factors (GLM with log data P=0.372). Post-hoc pair-wise 
comparisons (Tukey’s tests) revealed that ALP activity was significantly reduced by 
IOOjiM /-PDC (P=0.018) and lOOpM TBOA (P=0.028) compared to untreated cells 
in the absence o f glutamate. EAAT inhibition did not significantly affect ALP activity 
compared to untreated cells at 500gM glutamate, given that 500pM glutamate alone 
also decreased ALP activity (to 79 ± 10.0 % o f untreated control cells). At 48hrs, 
glutamate concentration significantly influenced ALP activity (GLM with ranked data 
P=0.019). This reflects a reduction in ALP activity when inhibitors are combined with 
500pM glutamate, although no post-hoc pair-wise comparisons (Tukey’s tests) were 
statistically significant. EAAT inhibition (GLM with ranked data P=0.559) and the 
interaction between glutamate and EAAT inhibitors (GLM with ranked data P=0.161) 
had no significant effects on ALP activity at 48hrs. ALP activity was not significantly 
affected at 72hrs by EAAT inhibition (GLM with ranked data P=0.767), glutamate 
(GLM with ranked data P=0.991) or the interaction o f  the two factors (GLM with 
ranked data P=0.394).
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Figure 4.13. Effect o f  EAAT inhibitors on SaOS-2 osteoblast ALP activity over 
72hrs. SaOS-2 cells were cultured with EAAT inhibitors ± 500pM glutamate for 
72hrs. ALP activity was measured colourimetrically and normalised to cell number 
(as measured by total cellular LDH activity) at 24, 48 and 72hrs. ALP activity is 
expressed as the mean percentage o f ALP activity in control cells (no inhibitor, no 
glutamate) at each time-point ± S.E.M from three independent experiments, n=4. ALP 
activity was significantly affected by EAAT inhibition at 24hrs (GLM P=0.011) and 
post-hoc Tukey’s tests revealed reduced ALP activity in cells treated with lOOpM t- 
PDC and TBOA in the absence of glutamate. At 48hrs, ALP activity was significantly 
decreased across all groups by 500pM glutamate (GLM P=0.019), but no post-hoc 
pair-wise comparisons were statistically significant at the 5% level. ALP activity at 
72hrs was not significantly affected by experimental treatments. Significance values 
*P<0.05.
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4.3.5.2 Primary osteoblasts (NH0B1P5)
ALP activity was assayed in primary osteoblasts (NH0B1P5) following culture with 
lOOpM EAAT inhibitors for 24hrs and 5 days (Figure 4.14). For experiments, 
NHOB1 cells were plated in Lonza Osteoblast Growth Medium, however this 
medium was subsequently found to contain 510pM glutamate (section 2.2.3), and 
therefore the effects o f  the inhibitors in the absence o f  exogenous glutamate cannot be 
observed. ALP activity was not assayed in cell lysates from NHOB2P7 and 
NHOB3P5 due to low ALP activity in these cell lines and insufficient sample volume 
for accurate analysis. Enzyme activity was normalised to total cell number (total LDH 
activity within the adherent cell lysate). Presented data are from a single preliminary 
experiment where n=4. There was no significant effect o f  EAAT inhibitors on ALP 
activity in primary osteoblasts at 24hrs (one-way ANOVA P=0.076), however there 
was a trend for decreased ALP activity in cells treated with the EAAT inhibitors (79 ±
11.6 % and 49 ±  7.7 % o f  untreated cells with lOOpM /-PDC and TBOA 
respectively). At 5 days, inhibitors significantly influenced ALP activity (one-way 
ANOVA ^=0.037) and post-hoc Fisher’s tests revealed that ALP activity significantly 
increased to 256 ± 52.2 % o f  untreated cells in response to lOOpM TBOA for 5 days 
(P<0.05).
4.3.6 Alizarin red staining of mineralisation
4.3.6.1 SaOS-2
Mineralisation was determined in SaOS-2 cells following 10 days culture with EAAT 
inhibitors in the presence or absence o f  500pM glutamate (Figure. 4.15). 
Representative pictures from stained wells are shown in Figure 4.15. The number o f  
mineralised nodules stained by alizarin red appeared to be slightly reduced in cells 
treated with 500gM  glutamate alone and strongly reduced in cells treated with either 
/-PDC or TBOA in the presence and absence o f  500pM glutamate. To confirm this, 
bound alizarin red (pg) was extracted in 5% perchloric acid (section 2.9) and 
quantified against a standard curve (Figure 4.16A). Presented data are from three 
independent experiments where n=4. Alizarin red staining was significantly reduced 
by EAAT inhibitors (Shierer-Ray P<0.001) but not affected by glutamate (Shierer-
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Figure 4.14. Effect o f  EAAT inhibitors on primary osteoblast ALP activity at 24hrs 
and 5 days. Primary osteoblasts (NHOB1P5) were cultured with EAAT inhibitors at 
lOO^M in medium containing 510(iM glutamate and ALP activity measured 
colourimetrically and normalised to cell number (as measured by total cellular LDH 
activity) at 24hrs and 5 days. ALP activity is shown as the mean percentage o f ALP 
activity o f control cells (no inhibitor) ± S.E.M from a single preliminary experiment, 
n=4. ALP activity was not significantly affected by EAAT inhibitors at 24hrs, but was 
significantly increased by lOOpM TBOA at 5 days (one-way ANOVA P=0.037). 
Significance values *P<0.05.
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Figure 4.15. Effect o f  EAAT inhibition on SaOS-2 osteoblast mineralisation. 
SaOS-2 cells were cultured with EAAT inhibitors ± 500pM glutamate for 10 days 
in the presence o f 2mM P-glycerophosphate and stained with alizarin red. Pictures 
were taken of stained cells under 10X and 20X objectives.
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Figure 4.16. Effect o f  EAAT inhibition on SaOS-2 osteoblast mineralisation. SaOS-2 
cells were cultured with EAAT inhibitors ± 500pM glutamate for 10 days in the presence 
of 2mM P-glycerophosphate. (A) Cultures were stained with alizarin red. Bound alizarin 
red, extracted in 5% perchloric acid, was quantified spectrophotometrically and 
expressed as mean bound alizarin red (pg) per well ± S.E.M from three independent 
experiments, n=4. Alizarin red staining was significantly reduced by EAAT inhibitors 
(Shierer-Ray PO.OOl). Post-hoc pair-wise Mann-Whitney U tests revealed that 
treatment of cells with lOOpM /-PDC and TBOA significantly decreased bound alizarin 
red at OpM and 500pM glutamate compared to respective control cells. (B) Cells from 
parallel cultures were assayed for cell number by measuring LDH released upon total 
lysis o f viable adherent cells at 10 days. LDH released is shown as the mean percentage 
of LDH released from viable adherent control cells (no inhibitor, no glutamate) ± S.E.M 
from a single experiment, n=4. Cell number was significantly affected by glutamate 
(P<0.001) and EAAT inhibition (PO.OOl) (GLM). Post-hoc Tukey’s tests revealed a 
significant increase in cell number in response to 500pM glutamate, and this was 
prevented by EAAT inhibition. Significance values *P<0.05, **P<0.01, ***P<0.001.
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Ray P=0.935) and there was no interaction between the two factors (Shierer-Ray 
P=0.476). Post-hoc pair-wise comparisons (Mann-Whitney U tests) revealed that 
treatment of cells with lOOpM f-PDC significantly decreased bound alizarin red by 45 
± 0.9 jug per well in the absence of glutamate (P<0.001) and by 25 ± 1.2 pg per well 
in the presence of 500pM glutamate (P<0.001) compared to respective control cells. 
lOOpM TBOA also significantly decreased bound alizarin red by 40 ± 2.5 pg per well 
in the absence of glutamate (P<0.001) and by 19 ± 1.4 pg per well in the presence of 
500pM glutamate (P<0.001) compared to respective control cells. Both EAAT 
inhibitors consistently inhibited alizarin red staining of mineralised nodules in SaOS-2 
monolayers and this appeared to mimic the effect of 500pM glutamate which 
decreased mean bound alizarin red by 18 ± 5.5 pg per well, although this was not 
statistically significant.
Cell number was assayed in parallel cultures under the same experimental conditions 
after 10 days (Figure 4.16B). Presented data are from a single preliminary experiment 
where n=4. Cell number was significantly affected by glutamate (GLM P<0.001) and 
EAAT inhibition (GLMPO.OOl) but there was no significant interaction between the 
two factors (GLM -P=0.140). Post-hoc pair-wise comparisons (Tukey’s tests) revealed 
that cell number was significantly increased 8 ± 1.0 % by 500pM glutamate 
(P=0.006) and that this was prevented by f-PDC (P=0.048) and TBOA (P<0.001).
A trend for reduced SaOS-2 mineralisation upon treatment with EAAT inhibitors ± 
glutamate has been observed in 7 independent experiments and this has been found to 
be independent of cell passage (PI 8-30), cell confluence at initiation of treatment (50- 
100%), presence or absence of antibiotics (1% penicillin/streptomycin), presence or 
absence of dexamethasone (10'7M), pH changes associated with the treatments (tested 
by supplementing the medium with HEPES buffer during the 10 days treatment) or 
frequency of treatment replenishment (data not shown). However a further 3 
independent experiments have shown contrasting results and the possible variations in 
methodology responsible for this are investigated in the discussion of this chapter. 
These 3 experiments were not included in the replicates presented in this chapter since 
they did not conform exactly to the uniform experimental protocol.
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4.3.6.2 Primary osteoblasts (NH0B2P11)
Alizarin red staining of human primary osteoblasts (NH0B2P11) treated with EAAT 
inhibitors in the presence and absence of 500pM glutamate for 21 days is expressed as 
mean bound alizarin red (pg) per well (Figure. 4.17). Presented data are from a single 
preliminary experiment where n=4. 500pM glutamate significantly increased bound 
alizarin red (GLM with log data P =0.044), however no post-hoc pair-wise 
comparisons (Tukey’s test) were significant at the 5% level. In this preliminary 
experiment, bound alizarin red was increased by 500pM glutamate from 6 ± 2.0 pg to 
7 ± 1.2 pg in untreated cells (no inhibitor) (P=0.942), from 5 ± 0.9 pg to 7 ± 1.1 pg in 
/-PDC treated cells (P=0.905), and from 5 ± 0.8 pg to 11 ± 3.1 pg in TBOA treated 
cells (P=0.470). EAAT inhibition at 0 or 500pM glutamate did not significantly affect 
mineralisation (GLM with log data P - 0.782), and there was no interaction between 
the two factors (GLM with log data P=0.774).
4.4 Discussion
4.4.1 Background
Glutamate is present in human serum within the low micromolar range (Plaitakis et al. 
1982), detected to be 28.3 ± 2.5 pM by HPLC (Mally et al. 1996). Increased serum 
glutamate levels have been associated with autism (89.2pM) (Shinohe et al. 2006) and 
essential tremor (89.6pM) (Mally et al. 1996). Glutamate is present in human synovial 
fluid at 6pM (Plaitakis et al. 1982; McNeamey et al. 2000) and glutamate 
concentrations in the synovial fluid from human patients with rheumatoid arthritis 
(RA), gout and osteoarthritis (OA), can reach 332.3 ± 29.3, 364.21 ± 50.19 and 240 ± 
38 pM respectively (McNeamey et al. 2004). An experimental concentration of 
500pM glutamate was chosen here to reflect these pathological concentrations in the 
joint that osteoblasts may be exposed to. Glutamate-free medium was used as a 
control, however it is unlikely that the extracellular milieu remained glutamate-free 
for the duration of the experiment since osteoblasts (MG-63, SaOS-2, MC3T3-E1, 
primary mouse and human osteoblasts) spontaneously release glutamate
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Figure 4.17. Effect o f  EAAT inhibition on primary osteoblast mineralisation.
Osteoblasts (NHOB2P11) were cultured with EAAT inhibitors ± 500pM glutamate 
for 21 days in the presence o f 2mM (3-glycerophosphate and 10'7M dexamethasone 
and stained with alizarin red (A). Bound alizarin red, extracted in 5% perchloric acid, 
was quantified spectrophotometrically and is expressed as mean bound alizarin red 
(pg) per well ± S.E.M from a single preliminary experiment, n=4 (B). 500pM 
glutamate significantly increased bound alizarin red (GLM P = 0.044) however no 
pair-wise Tukey’s comparisons were significant.
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(~2-7 nmol/mg protein/day) (Genever and Skerry 2001).
The glutamate transporter inhibitors used here are glutamate analogues which bind to 
a broad range of EAATs and are either competitively transported into the cell (f-PDC 
with respect to EAATs 1-4) or block transport completely (TBOA). Inhibition of 
EAATs in osteoblasts has the potential to influence bone formation by a variety of 
mechanisms since EAAT activities include glutamate transport, glutamate gated Cl' 
conductance and potentially the activation of intracellular signalling pathways 
(reviewed in (Mason 2004a)). EAAT inhibitors bind to EAATs extracellularly and 
inhibit glutamate uptake into the cell, increasing the extracellular glutamate 
concentrations available to activate glutamate receptors (section 4.1.1 and 4.1.2.1) 
and/or inhibit the cystine/glutamate antiporter (section 4.1.2.2). The EAAT inhibitors 
used here (f-PDC and TBOA) differentially affect the EAAT glutamate gated Cl' 
conductance (section 4.1.1) and may differentially affect EAAT intracellular 
interactions. The effect o f glutamate binding/transport on EAAT intracellular 
interactions has not yet been fully investigated; however it is likely that any glutamate 
mediated effects on EAAT interactions within the cell might be modulated or 
mimicked by the EAAT inhibitors. Indeed, the transportable EAAT inhibitors THA 
and f-PDC can mimic glutamate signalling through EAATs in rat cortical astrocytes 
leading to increased MAPK phosphorylation in a time- and concentration-dependent 
manner (Abe and Saito 2001).
Since EAATs display a variety of activities and, as outlined above, the EAAT 
inhibitors have the potential to differentially modulate these activities, the effect of 
inhibitors and/or glutamate in osteoblasts is unlikely to be the product of a single 
common pathway. A summary o f the main effects of f-PDC and TBOA on MG-63 
and SaOS-2 cells are shown in tables 4.1-3. Data from human primary osteoblasts are 
not included since experiments on these cells were only carried out 1-2 times; but are 
discussed in the following sections where appropriate for comparison with cell line 
data.
4.4.1.1 EAAT inhibitors in storage and culture
The half-life of the inhibitors in culture is unknown and attempts to monitor the 
stability of the compounds over time by HPLC were hampered by the presence of 
many other small compounds in DMEM which gave overlapping peaks to the
161
Table 4.1. Summary o f  the effects o f  500fiM  glutamate on the osteoblast phenotype. Changes in the expression/activity o f  M G -63 (black) and 
SaOS-2 (grey) are shown as increases ( |) , decreases ( j)  or no change (-) relative to untreated cells (OpM inhibitor, OpM glutamate). NT, not tested. 
Significance values *P<0.05, **P<0.01, ***P<0.001, n.s (not significant). Trends non-significant by post-hoc test but significant by ANOVA are 
indicated in brackets.
Gene expression (24hrs)
Cell number Osteoblastdiff" Bone extracellular matrix
Bone
remodelling
Mineral­
isation Bone-forming activity
LDH activity in 
cell layer 
(24hrs)
Runx2 Osteocalcin Type I  collagen Osteonectin OPG ALP
ALP activity 
(24/48hrs)
Mineralisation
(10d)
500pM
glutamate
^  ***
"
^ n .s .(**) ^  n.s.
"
n.s.
^  n.s. 
^  n.s.
NT NT
^  n.s.
Table 4.2. Summary of the effects o f pharmacological EAAT inhibition at OpM glutamate on the osteoblast phenotype. Changes in the 
expression/activity o f MG-63 (black) and SaOS-2 (grey) are shown as increases ( |) , decreases (j)  or no change (-) relative to untreated cells (OpM 
inhibitor, OpM glutamate). NT, not tested. Significance values *P<0.05, ***P<0.001, n.s (not significant).
Gene expression (24hrs)
Inhibitor Cell number
Osteoblast
diff"
Bone extracellular matrix
Bone
remodelling
Mineral­
isation
Bone-forming activity
LDH activity in 
cell layer 
(24hrs)
Runx2 Osteocalcin Type 1 collagen Osteonectin OPG ALP
ALP activity 
(24/48hrs)
Mineralisation
(10d)
^  n.s. - - ^  n.s. - - ^  n.s. NT NT
t- PDC *** - ^  n.s. ^  n.s. - - - IV  ^ * * *
^  n.s. - - - n.s. II n s - - NT NT
TBOA t* - t* - - - - 17- j ***
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Table 4.3. Summary o f  the effects o f  pharmacological EAAT inhibition at SOOfiM glutamate on the osteoblast phenotype. Changes in the 
expression/activity of MG-63 (black) and SaOS-2 (grey) are shown as increases ( |) , decreases ( j)  or no change (-) relative to untreated cells (OpM 
inhibitor, 500pM glutamate). NT, not tested. Significance values *P<0.05, **P<0.01, ***P<0.001, n.s (not significant).
Gene expression (24hrs)
Inhibitor Cell number
Osteoblast
diff"
Bone extracellular matrix
Bone
remodelling
Mineral­
isation
Bone-forming activity
LDH activity in 
cell layer 
(24hrs)
Runx2 Osteocalcin Type I collagen Osteonectin OPG ALP
ALP activity 
(24/48hrs)
Mineralisation
(lOd)
 ^n.s.  ^n.s. m m m 1 n.s. ^  ** NT NT
f-PDC ^  n.s. -  ^n.s. 4 * - - / 4 ns ' | ***
1 n s- - - 4 * - 4 * NT NT
TBOA
- - - - - - / - j| ***
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inhibitors (data not shown). High concentrations of EAAT inhibitors (333pM and 
ImM), including /-PDC and TBOA, effectively increased extracellular glutamate 
concentrations in organotypic cultures o f rat hippocampus after 7 days in culture 
without medium refreshment, however lower inhibitor concentrations had no 
significant effects (O'Shea et al. 2002). Lower concentrations of these inhibitors (50- 
200pM) were able to increase extracellular glutamate concentration when medium 
was replaced twice weekly over a culture period of 14 days (O'Shea et al. 2002), 
suggesting that the inhibitors used in this thesis (lOOpM) will maintain activity for the 
time course used. In murine astrocyte cultures, TBOA significantly reduced D- 
aspartate uptake over 24-72hrs, however the inhibitor was less effective after 72hrs 
culture compared to 24hrs (Lau et al. 2010). These studies indicate that /-PDC and 
TBOA at lOOpM were able to inhibit glutamate uptake for up to 72hrs in the 
experiments presented here, but that effectiveness probably decreased with culture 
time.
Inhibitors used in these studies were dissolved in water; however the stability of the 
compounds during storage has not been robustly assessed. Since the stability of the 
stock inhibitor (10mM, stored at -20°C) over the 8 week usage period is unknown, 
this may represent a confounding variable in all the experiments presented in this 
chapter. However glutamate uptake assays have been carried out during the course of 
this PhD where the compounds have been shown to retain their inhibitory activity 
despite length of storage.
4.4.2 High concentrations of glutamate and EAAT inhibition influence 
osteoblast cell number
4.4.2.1 Glutamate
The addition of 500pM glutamate to the culture medium of MG-63 and human 
primary osteoblasts significantly increased adherent cell number in comparison to 
cells that were maintained in glutamate-free medium; however this experiment was 
only carried out twice in human primary osteoblasts and therefore needs to be further 
repeated to validate this finding. Increased cell number was detectable at 24hrs for 
both cell types and also at 48hrs for MG-63 cells and comprised a 10-20% increase in 
MG-63 cell number and a 5-15% increase in primary osteoblast cell number.
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Glutamate at 50pM-lmM has previously been shown to increase human primary 
osteoblast viable cell number (by 5-15% compared to cells cultured in glutamate-free 
medium) over 72hrs whereas very high glutamate concentrations (lOmM) resulted in 
a decrease in cell number (-7% compared to cells cultured in glutamate-free medium) 
(Genever and Skerry 2001). The authors hypothesised that glutamate in the range of 
50pM-lmM may represent a survival factor since the experiments were carried out in 
serum-free medium. In our experiments, MG-63 and SaOS-2 cell lines were cultured 
in the presence of 5% dialysed serum for the duration of glutamate treatment and 
primary osteoblasts were cultured serum-free for only the first 24hrs of treatment, 
after which 10% dialysed FBS was added to the medium. Glutamate did result in a 
significant overall increase in primary osteoblast cell number after 24hrs in serum-free 
medium in our studies, in agreement with the published findings from Genever and 
Skerry.
Investigation of which receptor could mediate the proliferative response to glutamate 
have yielded contrasting results. An antagonist to NMD A receptors (MK-801) had no 
effect on viable cell number of rat calvarial osteoblasts over 3-28 days (Hinoi et al. 
2003) suggesting that glutamate signalling through this receptor subtype does not 
influence cell number, however another study has shown that NMDA treatment of 
MC3T3-E1 osteoblast-like cells for up to lhr could increase viable cell number 
(Fatokun et al. 2006).
Glutamate has been implicated in the regulation of neuronal, cancer cell, chondrocyte­
like cell and synovial fibroblast proliferation (Contestabile 2000; Rzeski et al. 2001; 
Parada-Turska et al. 2006; Spitzer 2006; Piepoli et al. 2009). In early neuronal 
development, glutamate signalling is thought to play a key role in regulating 
proliferation of neural progenitor cells and neuronal migration (Komuro and Rakic 
1993; Contestabile 2000; Spitzer 2006). Activity of iGluRs can both reduce and 
increase neural progenitor cell proliferation in a manner that is specific to different 
brain regions (LoTurco et al. 1995; Haydar et al. 2000; Bai et al. 2003). Glutamate 
also critically regulates neuronal survival during synaptogenesis and blockade of 
NMDA receptors in the developing rodent brain can trigger massive apoptotic 
neuronal death (Ikonomidou et al. 1999).
Antagonists to NMDA and AMPA receptors limit the proliferation of a wide variety 
of non-neuronal cancer cells including colon, breast, lung and thyroid carcinoma, as a 
result of both decreased cell division and increased cell death (Rzeski et al. 2001).
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This proliferative effect of glutamate may be common to all cells but subject to 
altered regulation in cancer cell lines. The osteoblast-like cell lines used here, MG-63 
and SaOS-2, are osteosarcoma derived and so interpretation of their proliferative 
responses to the modulation of glutamate signalling might be complicated by the fact 
that they are both osteoblast-like and a cancer cell line.
NMDA receptor antagonists and knockdown of NR1 in SW1353 human 
chondrosarcoma cells suppressed proliferation without affecting cell death (Piepoli et 
al. 2009) and a variety of ionotropic and metabotropic glutamate receptor antagonists 
suppressed proliferation of HIG-82 cells (Parada-Turska et al. 2006), a rabbit 
synoviocyte cell line that shares many characteristics of activated human synovium 
(Georgescu et al. 1988).
In synovial fibroblasts from rats with collagen-induced arthritis (CIA) 500pM 
glutamate significantly increased proliferation over 24hrs and this was attenuated by 
co-incubation with the non-selective EAAT inhibitors THA and CCGHI at lOOpM 
(Hinoi et al. 2005b) indicating a role for the transporter in the proliferative activity of 
these cells. That an EAAT-mediated activity may underlie the proliferative response 
of these cells to glutamate is interesting since it is in contrast to the receptor-mediated 
effects of glutamate in neuronal cells, cancer cells and the chondrocyte and 
synoviocyte cell lines discussed above. Furthermore, the glutamate-mediated increase 
in MG-63 cell number at 24hrs could also be attenuated by EAAT inhibition. 
However EAAT inhibitors alone increased MG-63 cell number suggesting that the 
increase in cell number is not dependent on glutamate uptake by EAATs.
Since 500jiM glutamate did not reduce cell number in any of the assayed osteoblast 
cell lines, nor affect cell death in human primary osteoblasts, it can be inferred that 
glutamate-mediated toxicity does not occur in these cells as it does in mature cell 
populations of the CNS (reviewed in (Obrenovitch et al. 2000)). The resistance of 
bone to glutamate mediated toxicity at these concentrations has been previously 
reported (Genever and Skerry 2001), however some studies have shown that >500pM 
glutamate can suppress proliferation of the pre-osteoblast mouse MC3T3-E1 cell line 
and the pluripotent MSC line C3H10T1/2, with no effect upon cell death (Iemata et al. 
2007; Uno et al. 2007). This suppression of proliferation could be rescued by 
supplementation with cystine or GSH indicating that exogenous glutamate leads to 
retrograde operation of the cystine/glutamate antiporter and therefore reduced 
intracellular levels of the antioxidant GSH (Iemata et al. 2007; Uno et al. 2007). Hinoi
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et al, have also shown that cysteine is important for MC3T3-E1 cell survival when 
cultured in DMEM (glutamate-free) compared to a-minimum essential medium (a- 
MEM, 5 lOpM glutamate) (Hinoi et al. 2002a). However, the same study also showed 
that ImM pyruvate could exhibit antioxidant properties and prevent the cell death 
associated with replacement of a-MEM with DMEM (Hinoi et al. 2002a). MG-63, 
SaOS-2 and primary osteoblasts used in these experiments were protected from ROS- 
mediated cell death by culture in DMEM medium containing pyruvate.
Glutamate had no effect on adherent cell number in MG-63 or human primary 
osteoblasts at later time-points (72hrs for MG-63 or 5 days for primary osteoblasts). 
This may be the result of extracellular glutamate depletion by EAAT activity or 
feedback signalling mechanisms. That SaOS-2 cell number was neither increased nor 
decreased by the presence of 500pM glutamate at any of the measured time-points 
(24-72hrs) supports the former hypothesis since these cells have much higher basal 
EAAT activity compared to MG-63 cells (section 3.3.3) which could result in 
glutamate being rapidly bound or transported from the extracellular space.
4.4.2.2 EAAT inhibitors
In the absence of extracellular glutamate, 24hrs treatment with EAAT inhibitors over 
a concentration range of l-100pM increased osteoblast-like cell number. These 
effects were statistically significant in SaOS-2 cells for both /-PDC and TBOA but 
only an observed trend in MG-63 cells. Both inhibitors elicited the same response in 
SaOS-2 cells, suggesting a similar mode of action. Both /-PDC and TBOA inhibit 
EAAT glutamate transport but have differing effects on EAAT Cl' conductance 
(Arriza et al. 1997; Shimamoto et al. 1998; Wadiche and Kavanaugh 1998; Seal et al. 
2001; Ryan and Vandenberg 2002; Shigeri et al. 2004), suggesting that inhibition of 
the glutamate transport activity of EAATs is the more likely mode of action 
responsible for increasing cell number in these cells. EAAT inhibitors reduce 
glutamate uptake into the cell, preventing its intracellular accumulation and thus 
increasing extracellular glutamate concentrations, which we have shown can increase 
MG-63 cell number. This hypothesis is supported by the finding that /-PDC is more 
effective than TBOA at low concentrations in SaOS-2 cells, since /-PDC can also 
induce efflux of glutamate by heteroexchange (Nicholls and Attwell 1990; Dunlop et 
al. 1992; Blitzblau et al. 1996; Koch et al. 1999).
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EAAT inhibitors were more effective at increasing SaOS-2 cell number compared to 
MG-63 cells. SaOS-2 cells have a much higher rate of EAAT activity than MG-63 
cells (section 3.3.3) and a lower rate of glutamate release (Genever and Skerry 2001), 
suggesting that extracellular glutamate concentrations are more tightly regulated in 
SaOS-2 cells than in MG-63 cells. If so, SaOS-2 cells will experience the biggest 
change from basal conditions upon treatment with the inhibitors, providing one 
possible explanation as to why these are the most responsive cell line.
High concentrations of the inhibitors (lOOOpM) had no effect on SaOS-2 cell number 
and the peak increase in cell number occurred at inhibitor concentrations of lOpM, 
which inhibit SaOS-2 Na+-dependent uptake of lpM  glutamate (not tested at lOpM 
glutamate) by 25% (/-PDC) and 71% (TBOA) (section 3.3.3.3, Figure 3.14). Since t- 
PDC had the greatest effect on cell number, these findings suggest that partial, as 
opposed to complete, inhibition of glutamate uptake in SaOS-2 cells results in 
increased cell number. Complete inhibition of glutamate uptake might prevent the 
accumulation of intracellular glutamate required metabolically or increase the 
extracellular glutamate concentration to such an extent that feedback signalling occurs 
or inhibitory GluRs are activated, thus attenuating the response. The latter theory 
might also explain why treatment of SaOS-2 cells with 500pM glutamate in addition 
to lOOpM EAAT inhibitor for 24hrs does not potentiate the inhibitor-mediated 
increase in cell number or why the same treatment does not potentiate the glutamate- 
mediated increase in cell number in MG-63 cells.
EAAT inhibitors alone displayed a trend toward increasing MG-63 cell number. This 
effect was not observed at 48hrs, nor did EAAT inhibitors have any significant effects 
on MG-63 cell number at 72hrs or SaOS-2 cell number at 48 or 72hrs. The loss of 
EAAT-mediated effects on cell number after 24-48hrs may reflect instability of these 
compounds, suggesting that treatments should be regularly refreshed in long-term 
experiments, or that the inhibitors influence the osteoblast phenotype in a confluence- 
dependent manner.
The presented experiments have so far indicated that the increase in osteoblast cell 
number in response to EAAT inhibitors or 500pM glutamate is the result of increased 
concentrations of extracellular glutamate and subsequent activation of GluRs which 
are known to regulate proliferation of a number of different cell types, including 
osteoblast-like cells (Contestabile 2000; Rzeski et al. 2001; Fatokun et al. 2006; 
Parada-Turska et al. 2006; Spitzer 2006; Piepoli et al. 2009). From preliminary data,
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EAAT inhibitors did not have any significant effects on human primary osteoblast cell 
number or cell death at 24hrs or 5 days, in contrast to effects observed in the 
osteoblast-like cell lines. Primary osteoblasts release glutamate at a lower basal rate 
than MG-63 and SaOS-2 cells and contain lower levels of intracellular glutamate 
(Genever and Skerry 2001), therefore treatment of these cells with EAAT inhibitors 
alone may not result in a build up of extracellular glutamate to levels comparable to 
that of MG-63 and SaOS-2 cell lines. However, EAAT inhibitors in the presence of 
500pM glutamate might be expected to enhance the effect of glutamate on primary 
osteoblast cell number, and TBOA does seem to demonstrate this, though the data in 
this experimental group is very variable (Figure 4.4). Quantitative comparison of 
glutamate receptor expression in osteoblast-like cell lines and human primary 
osteoblasts has not previously been investigated; however since EAAT expression 
varies between the cell lines (section 3.3.1.1) it seems likely that differences will exist 
and this may represent an additional underlying factor in the proliferative response of 
these cells to glutamate.
4.4.3 EAAT inhibition and high concentrations of glutamate can influence 
markers of differentiation and bone formation in osteoblasts
4.4.3.1 Gene expression
The gene expression of a variety of markers of osteoblast differentiation, bone 
formation and remodelling were assessed in response to EAAT inhibition and 
glutamate. The proposed roles of these genes are summarised in Table 4.4 and their 
expression levels during osteoblast maturation are shown in Figure 4.18. Changes in 
the expression of a number of these genes were detected in response to the 
experimental treatments (Tables 4.1-4.3), revealing that modulation of the glutamate 
signalling pathway in osteoblasts can modify the cell phenotype. A number of the 
gene expression trends detected were cell line specific, suggesting that the 
differentiation stage of the osteoblast may regulate its response. Unfortunately, large 
variances in the gene expression data from primary osteoblasts and the fact that data 
were from a single preliminary experiment meant that significant differences were not 
detected in many cases. These variances were not a reflection of poor sensitivity or
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Figure 4.18. Temporal expression pattern o f  markers fo r  osteoblast growth and
differentiation. The growth and differentiation o f osteoblasts progresses through three 
general stages. Osteoblast proliferation is typified by the induction o f expression of 
various cell cycle markers including hi stones. Alkaline phosphatase, bone sialoprotein, 
type I collagen and osteonectin are expressed at high levels during the period of 
extracellular matrix deposition and maturation. Osteoblast matrix mineralisation is 
characterised by expression of osteocalcin, osteopontin and collagenase-3. Expression 
of many of these genes (underlined) are regulated in a Runx2-dependent manner and 
expression levels o f Runx2 are shown at the bottom. The thickness of the line represents 
the expression level o f Runx2 at the various stages o f differentiation. The phenotypes of 
the osteoblast-like cell lines MG-63 and SaOS-2 and primary osteoblasts have been 
matched to the appropriate stage o f osteoblast maturation and are shown on the diagram. 
Abbreviations, OP, osteopontin; ALP, alkaline phosphatase; BSP, bone sialoprotein; 
ON, osteonectin; OC, osteocalcin. Figure adapted from Stein et al. 2004.
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Table 4.4. Roles o f  bone proteins used as markers o f  the osteoblast phenotype.
O steob last m arker Role
Runx2
Transcription factor essential for osteoblast differentiation 
(Ducy et al. 1997; Komori et al. 1997). Regulates the 
expression o f many bone proteins including osteocalcin, 
type I collagen, and ALP.
Osteocalcin
Secreted y-carboxylated protein (Glowacki and Lian 1987; 
Robey et al. 1989). Its expression is restricted to late 
osteoblasts and its serum level is commonly used as a 
valuable marker o f  bone turnover in metabolic disease (Price 
et al. 1980; W atts 1999).
Type I collagen Forms 95% o f the organic element o f bone matrix (Burgeson 1988).
Osteonectin
Calcium binding glycoprotein. May play a role in bone 
remodelling and the maintenance o f bone mass (Delany et 
al. 2000). In vitro studies indicate the protein can regulate 
cell proliferation and cell-matrix interactions (Lane and Sage 
1994).
Osteoprotegerin
A soluble decoy receptor for RANK-L. Inhibits osteoclast 
differentiation and regulates activity o f mature osteoclasts 
(Simonet et al. 1997; Yasuda et al. 1998b).
Alkaline phosphatase Has a role in extracellular matrix mineralisation (Henthom and Whyte 1992).
accuracy o f the gene expression assay, but due to the low sample size preventing the 
removal o f outliers.
500pM glutamate significantly decreased MG-63 osteocalcin expression in both the 
presence and absence o f EAAT inhibitors indicative o f a receptor-mediated effect that 
was not potentiated by the sustained presence o f extracellular glutamate due to 
inhibition o f uptake. Glutamate also decreased mean Runx2 expression in MG-63 
cells; however this effect was only apparent in conjunction with EAAT inhibitor 
treatment, suggesting that either sustained exposure to extracellular glutamate was 
required for these effects or that the effects were mediated via glutamate transport i.e. 
that glutamate exerted an effect directly via the EAATs which was prevented by the 
inhibitors. Interestingly, preliminary data from human primary osteoblasts indicated 
that 500pM glutamate decreased Runx2 expression and that glutamate in conjunction 
with EAAT inhibitors decreased mean osteocalcin expression. The combination o f 
500pM glutamate and EAAT inhibitors also decreased expression o f osteonectin and 
ALP in MG-63 cells compared to treatment with 500pM  glutamate alone.
These effects on Runx2 and osteocalcin in MG-63 and primary human osteoblasts are 
surprising given that antagonists to NMDA receptors down-regulate the DNA binding
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activity, protein and mRNA expression of Runx2 and the mRNA expression of 
osteocalcin in rat calvarial osteoblasts (Hinoi et al. 2003) and inhibit Runx2 mRNA 
expression in bone marrow stromal cells (Ho et al. 2005). Furthermore, recent studies 
have shown that NMDA can up-regulate osteocalcin expression in glutamate free 
medium (Lin et al. 2008). A variety of NMDA receptor subunits, including NR1, have 
been identified at the mRNA and protein level in MG-63 and primary human and rat 
osteoblasts (Chenu et al. 1998; Patton et al. 1998; Hinoi et al. 2001; Itzstein et al. 
2001; Hinoi et al. 2003; Kalariti et al. 2004) and these receptors have been shown to 
be functional in MG-63 and primary rat osteoblasts (Laketic-Ljubojevic et al. 1999; 
Gu et al. 2002). The discrepancies between these and our studies could be a result of 
different treatment periods and variations in extracellular glutamate concentrations. 
For example, the studies from Hinoi et al. were carried out over a longer time period 
(7-28 days in vitro) than data presented in this chapter (24hrs) and the cells were 
cultured in a-MEM, which contains approximately 510pM glutamate, complicating a 
comparison with the results presented here (Hinoi et al. 2003).
In SaOS-2 cells, osteocalcin expression was significantly increased by TBOA at OpM 
glutamate and this effect was prevented by 500pM glutamate which might suggest 
that either the response was specific to low concentrations of glutamate achievable by 
preventing the uptake of endogenously released glutamate, or that glutamate 
signalling through the transporter itself negatively regulates osteocalcin expression 
and that this occurred in cells treated with exogenous glutamate despite co-treatment 
with EAAT inhibitors due to the high glutamate concentration competing for EAAT 
binding sites.
SaOS-2 OPG expression was significantly reduced by 7-PDC at 500pM glutamate and 
although 500pM glutamate increased the mean expression of OPG in SaOS-2 cells, 
these effects were not statistically significant at the 5% level. Regulation of OPG 
expression in SaOS-2 cells is indicative of an effect of these treatments on 
remodelling; however quantifying expression levels of RANKL in the same samples 
is necessary to confirm any such effects since it is the ratio of these two gene products 
that is important in the regulation of remodelling.
A similar expression pattern was observed for ALP in MG-63 cells. 500pM glutamate 
increased the mean expression of ALP in MG-63 cells while EAAT inhibitors in the 
presence of 500pM glutamate significantly decreased ALP expression. This pattern of
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gene expression suggests that glutamate alone exerts an effect that is prevented by the 
EAAT inhibitors, suggesting that the mechanism is EAAT-mediated.
The basis for using both a transportable and a non-transportable EAAT inhibitor was 
to allow for the possibility that other EAAT activities besides glutamate transport 
might be important in osteoblasts, such as the uncoupled anion conductance or a 
receptor-like function. In the majority of cases, gene expression was affected in a 
similar manner by each inhibitor although there were some conditions where this was 
not the case, suggesting that EAAT activities besides glutamate uptake may be 
important in modulating the osteoblast phenotype. For example, TBOA but not /-PDC 
decreased MG-63 osteonectin expression and f-PDC but not TBOA decreased SaOS-2 
OPG expression at 500pM glutamate. Differences in the effects of each inhibitor may 
also be a product of varying affinities for the EAAT subtypes expressed.
Overall, the effects of EAAT inhibition on osteoblast gene expression do not mimic 
the effects of exogenous glutamate, or potentiate these effects when added in 
combination. However the inhibitors alone do influence gene expression and 
modulate the response of the cells to 500pM glutamate suggesting that the 
transporters are important in regulating the osteoblast phenotype. Furthermore, 
different inhibitors have different effects on the same gene product, indicating the 
existence of more than one mechanism. Analysis of protein levels for these gene 
products would confirm that the changes observed at the mRNA level are translated to 
phenotypic changes.
4.4.3.2 ALP activity
Incubation of SaOS-2 cells with lOpM and lOOpM I-PDC and TBOA for 24hrs 
significantly decreased ALP activity. The same inhibitor concentrations also 
significantly increased cell number. An inverse relationship between osteoblast 
proliferation and phenotypic maturation is well documented (Lian and Stein 1995; 
Karsenty 2003). Osteoblasts display a regulated pattern of gene expression (Figure 
4.18) whereby the transition between proliferation and differentiation is characterised 
by the down-regulation of genes associated with proliferation and the up-regulation of 
genes associated with matrix maturation and mineralisation (Malaval et al. 1999; 
Karsenty 2003; Lian and Stein 2003; Stein et al. 2004). The decreased ALP activity of 
SaOS-2 cells treated with EAAT inhibitors may reflect prolonging of the proliferation
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stage, as has been observed in primary human and rat osteoblasts subjected to 
dynamic cell stretching (Stanford et al. 1995a; Kaspar et al. 2000) and TGF-P (Lian 
and Stein 1993).
500pM glutamate decreased mean ALP activity at 24hrs and, although not 
statistically significant, this suggests that EAAT inhibition mimics the effects of 
increasing extracellular glutamate concentrations. 500pM glutamate also decreased 
ALP activity at 48hrs; though this was only apparent in cells that were co-incubated 
with EAAT inhibitors. No effect of the inhibitors or glutamate was detected at 72hrs, 
which might be a reflection of extracellular glutamate depletion by EAATs and/or 
degradation of the inhibitors. Interestingly, inhibitor effects on ALP activity or cell 
number in SaOS-2 cells were only effective up to lOOpM suggesting that ImM 
inhibitor concentrations may sustain extracellular glutamate concentrations to the 
extent that inhibitory glutamate receptors are activated or feedback signalling occurs, 
attenuating the response.
Preliminary findings indicated that primary osteoblasts also reduced mean ALP 
activity after 24hrs treatment with both EAAT inhibitors. Conversely, TBOA 
increased ALP activity after 5 days suggesting that glutamate signalling may exert 
differential effects depending on the stage of osteoblast maturation. Antagonists to 
NMDA receptors have previously been shown to inhibit ALP activity in the presence 
of 510pM glutamate in rat calvarial osteoblasts cultured for 28 days (Hinoi et al. 
2003) and in osteoblasts derived from rat MSCs cultured for 7-11 days (Olkku and 
Mahonen 2008), implicating glutamate signalling through these receptors in 
regulating ALP activity. These findings correlate with the hypothesis that the 
increased ALP activity detected in human primary osteoblasts cultured with lOOpM 
TBOA for 5 days is a result of increased extracellular glutamate levels available to 
activate NMDA receptors. However, the data presented here are based on a single 
experiment where the cells were maintained in 510pM glutamate, which is reflective 
of chronic pathological conditions.
4.4.3.3 Mineralisation
Mineralisation of SaOS-2 cells was reduced following incubation with 500pM 
glutamate for 10 days. In contrast to these findings, mineralisation of human primary 
osteoblasts over 21 days was increased in the presence of 500pM glutamate, however
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this is preliminary data from a single experiment. Expression and activity of the 
glutamatergic signalling components (glutamate release, receptors and transporters) 
may alter as a result of time in culture in a way that differs between the SaOS-2 cell 
line and primary osteoblasts, providing one explanation for these contrasting effects 
of glutamate. The SaOS-2 cell line may be phenotypically restricted and unable to 
mature and regulate expression of glutamate signalling machinery in the same manner 
as primary osteoblasts.
The AMP A receptor antagonist CNQX and the NMDA receptor antagonist MK-801 
have been shown to inhibit rat calvarial osteoblast mineralisation in the presence of 
510pM glutamate over 12-18 days and that AMP A and NMDA up-regulate 
mineralisation over 16 days in glutamate-free medium (Lin et al. 2008). 
Mineralisation of osteoblasts derived from rat MSCs cultured in the presence of 
510pM glutamate was also inhibited by MK-801 over 7-11 days (Olkku and Mahonen 
2008). These findings are consistent with the experiments presented here in human 
primary osteoblasts which indicate that enhanced glutamate signalling through iGluRs 
may increase osteoblast mineralisation.
Mineralisation of SaOS-2 cells treated for 10 days with lOOpM EAAT inhibitor ± 
500pM glutamate was decreased by all treatment combinations. These changes in 
mineralisation occurred with very little effect on cell number (less than 10% 
difference in cell number in each experimental group from untreated control cells). 
EAAT inhibition in primary rat calvarial osteoblasts has previously been reported to 
prevent bone formation in vitro and shift the cells from an osteoblastic to a more 
adipocytic phenotype, however these experimental results by Spencer et al. were not 
published and only alluded to in a published review from the research group (Taylor 
2002), so it is not possible to directly compare methodology. The inhibitory effect of 
long-term EAAT inhibitor treatment on SaOS-2 mineralisation is in agreement with 
the down-regulation of ALP activity observed in these cells at 24hrs. However, this is 
in contrast to the significant increase in expression of osteocalcin, a marker of late 
osteoblasts, in SaOS-2 cells treated with TBOA for 24hrs. Furthermore, EAAT 
inhibitors decreased ALP activity of primary human osteoblasts at 24hrs but long­
term treatment increased ALP activity and had no effect upon mineralisation 
suggesting that primary osteoblasts might be differentially regulated by EAAT 
inhibitors during maturation in a way that does not occur in SaOS-2 cells.
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Over the course of the PhD, mineralisation assays in SaOS-2 cells have had variable 
outcomes. Three independent experiments (n=4) were carried out according to 
standardised methodology, analysed and presented in this chapter. A further four 
independent experiments designed to test modifications to the method have displayed 
similar trends. However three experiments carried out in 2007 showed contrasting 
results, with glutamate and/or EAAT inhibitors increasing SaOS-2 mineralisation. 
One methodological variable that may be responsible for these differences and that 
has not yet been tested is P-glycerophosphate concentration. Early experiments were 
carried out using lOmM p-glycerophosphate as opposed to the 2mM concentration 
that was used in the presented experiments. The concentration of P-glycerophosphate 
was reduced to 2mM due to findings that concentrations above this can lead to non- 
physiological mineral deposition in bone cell cultures (Chung et al. 1992), which 
might explain some of the inconsistencies observed between experiments. However, 
not all experiments showing increased mineralisation in response to treatments were 
carried out in the presence of lOmM P-glycerophosphate; therefore other variables 
must be investigated.
4.4.4 Inferences from these studies regarding glutamate signalling in 
osteoblasts
These studies have shown that modulation of EAAT activity can regulate each stage 
of osteoblast differentiation including proliferation, expression of genes associated 
with extracellular matrix production and remodelling, and mineralisation. These 
effects can vary in primary osteoblasts with time in culture and between the two 
osteoblast-like cell lines which display pre-osteoblast and late osteoblast phenotypes, 
indicating that glutamate signalling may have multiple effects in osteoblasts 
depending on the maturation stage (discussed in section 7.3.4), which might be 
expected given the complexity of the glutamate receptors. In addition, EAAT 
inhibitors do not always mimic or potentiate the effect of extracellular glutamate, 
suggesting that direct EAAT-mediated effects might be important in osteoblasts.
The majority of work in the field of glutamate signalling in bone has been carried out 
using receptor agonists or antagonists. Such experiments investigate the effects of 
activation of a particular receptor subtype if and when it is expressed in bone cells. 
Differences are therefore to be expected between the effects of specific glutamate
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receptor agonists/antagonists and the general effects of glutamate itself which have 
been investigated in the experiments presented here. Gu and Publicover have shown 
that NMDA currents in osteoblasts that were rapidly lost upon treatment with lOOpM 
glutamate could be restored by blockade of mGluRs with MCPG, indicating 
inhibitory cross talk occurs between mGluRs and NMDA receptors in osteoblasts and 
demonstrating that the effect of glutamate can differ from the effects of specific 
receptor subtype activation (Gu and Publicover 2000).
4.4.5 Chemical EAAT inhibitors as a therapeutic tool in bone
The aim of this thesis was to identify a means of inhibiting EAAT activity in bone 
cells that would mimic mechanical stimulation and enhance bone formation with an 
outlook to develop an anabolic therapeutic strategy in bone. A great deal of drug 
development targeting components of the glutamate signalling pathway has already 
been carried out in the neuronal field. A common problem in designing drugs to target 
the CNS is the difficulty in transporting these drugs across the blood-brain barrier 
(BBB) (Pardridge 2003). These compounds therefore represent particularly attractive 
therapeutics for use in bone, since such therapeutics targeted to the glutamate 
signalling system in bone would not have severe non-specific effects in the CNS.
In the experiments presented in this chapter, EAAT inhibitors have increased 
osteoblast proliferation and mRNA expression of markers of bone formation in 
osteoblast-like cells, and increased mineralisation of human primary osteoblasts 
indicating that further investigation of these molecules as therapeutic tools for 
increasing bone formation is warranted. However it is also apparent that in order to 
clarify the effects of these inhibitors further, experiments should be carried out to 
determine the maturation stage that these inhibitors can most potently influence bone 
formation and identify a way to specifically target this.
4.4.6 Summary
EAAT inhibition was investigated in osteoblast-like cells and human primary 
osteoblasts as a means of mimicking osteogenic mechanical loading and enhancing 
osteoblast bone-forming activity. EAAT inhibitors and high concentrations of 
extracellular glutamate increased osteoblast proliferation and regulated the expression
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of a variety of markers of osteoblast differentiation, bone formation and remodelling 
at the mRNA level. Mineralisation of SaOS-2 osteoblasts was inhibited by EAAT 
inhibitors, while preliminary data indicated that high concentrations of glutamate 
increased mineralisation of human primary osteoblasts, highlighting that differences 
exist between the osteoblast-like cell lines and primary cells in the response to long­
term treatments with glutamate and/or EAAT inhibitors.
The effect of EAAT inhibition on osteoblasts has not previously been fully 
investigated or reported in the literature, and these studies are the first to show that 
EAAT inhibition can significantly modify the osteoblast phenotype. Furthermore, 
these experiments have provided evidence that pharmacological regulation of 
glutamate transporters may be important in modulating bone formation.
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5. Use of antisense mediated exon skipping to modulate
EAAT1 activity in human osteoblasts
5.1 Background
5.1.1 Splicing of glutamate transporters
Various mRNA splice variants o f  EAATs 1-3 have been reported (Lin et al. 1998; 
Nagai et al. 1998; Matsumoto et al. 1999; Meyer et al. 1999; Huggett et al. 2000; 
Vallejo-Illarramendi et al. 2005). Furthermore, western blotting for EAATs often 
identifies a number o f  immunoreactive fragments smaller than the EAAT monomer 
suggesting that alternatively spliced EAAT variants exist at the protein level and are 
therefore potentially o f  physiological relevance (Lehre et al. 1995; Haugeto et al. 
1996; Huggett et al. 2000; Vallejo-Illarramendi et al. 2005; Macnab et al. 2006). 
Since EAATs are thought to form multimers (Yemool et al. 2004; Koch and Larsson 
2005), it is possible that different EAAT variants may combine together to confer 
different properties to the cell (Mason 2004a).
5.1.1.1 EAAT1
EAATs are thought to consist o f cytoplasmic N- and C- termini and eight membrane- 
spanning alpha-helices with two re-entrant loops at the C-terminus (Slotboom et al. 
2001a; Yemool et al. 2004) (Figure 5.1) and the molecular weight o f full-length 
glycosyltaed monomeric GLAST is ~ 70 kDa in rat brain (Conradt et al. 1995). Two 
splice variants o f EAAT1 have been identified; EAAT la  (rodent nomenclature 
GLAST-la) (Huggett et al. 2000) and EAATlex9skip (also referred to as GLAST-lb) 
(Vallejo-Illarramendi et al. 2005), both o f which are expressed as proteins in vivo 
(Huggett et al. 2000; Vallejo-Illarramendi et al. 2005; Macnab et al. 2006; Macnab 
and Pow 2007a). Furthermore, detection o f  mRNA for an EAAT1 splice variant 
lacking both exons 5 and 6 in hypoxic pig brain has been reported in abstract form 
(Lee et al. 2008). Exon 5 and 6 comprise TM domain 4 o f EAAT 1 as well as part of  
the large, glycosylated extracellular domain between TM3 and 4 (Figure 1.8).
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5.1.1.1.1 EAATla
5.1.1.1.1.1 Expression
EAATla is an alternatively spliced form o f  EAAT 1 which lacks exon 3, and was first 
cloned from bone in vivo (Huggett et al. 2000). EAATla is expressed at low levels in 
brain and bone in vivo (Huggett et al. 2000) and retina (Macnab et al. 2006). Exon 3 
o f EAAT 1 (Figure 5.1) consists o f  138 bases which encode 47 amino acids (61-107) 
in TM1 and TM2 and its removal does not disrupt the open reading frame (ORF) o f  
the gene. Exon 3 starts in phase 1 o f  the codon, between the first and second bases 
and the new codon formed at the exon 2/4 junction in EAATla does not alter the 
amino acid sequence.
The predicted molecular weight o f EA ATla is -5 4  kDa and an immunoreactive 
protein o f 55 kDa has been detected in rat cerebellum using a polyclonal antibody 
against the N-terminus o f  GLAST (Huggett et al. 2000) and in rat brain and retina 
using a GLAST-la-specific antibody targeted against the peptide sequence across the 
splice site (Macnab et al. 2006). GLAST-la was detected largely in the cerebellar 
Bergmann glia o f the rat brain with weaker staining detected in the retinal Muller cells 
(Macnab et al. 2006).
5.1.1.1.1.2 Structure
Hydropathy analysis o f  EAATla topology indicates a truncation o f  the first and 
second TM domains, resulting in the formation o f a single TM domain which has 
been proposed to re-orientate the remainder protein in the membrane (Figure 5 .IB) 
(Huggett et al. 2000). This re-orientation would result in an extracellular rather than 
intracellular C-terminus and a loss o f  glycosylation at N206 and N216 (Conradt et al. 
1995) between TM3 and 4 since these sites would no longer be presented for 
glycosylation in the ER (Huggett et al. 2000). A  loss o f  glycosylation is in agreement 
with a molecular weight for GLAST la  o f  55 kDa (Huggett et al. 2000) since 
glycosylation at both sites would add approximately 10 kDa (Conradt et al. 1995).
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A .  E A A T 1 4 3 0-SITATAASIGAAGIPQAGLVTMVIVLTSVGLPTDDITLIIAVDWFL-4 7 5
61-GTILGFTLRPY RMSYREVKYFSFPGELLMRMLQMLVLPLIISSLVTG-107
B. EAAT-la
out
Figure 5.1. Topological model o f  EAAT1 and EAATla. (A) Regions o f the EAAT1 
protein encoded by exons 3 and 9 are shown in red. Amino acids 61-107 are contained 
within exon 3 and located in the first two transmembrane domains and the intervening 
extracellular sequence. Amino acids 446-475 are contained within exon 9 of EAAT 1 
and thought to be located extracellularly at the C-terminal region o f the protein. Loss 
of exon 3 or exon 9 does not disrupt the open reading frame; the formation of a new 
codon at the exon2/4 splice boundary codes for Glycine and therefore does not alter 
the amino acid sequence, however Leucine 475 is converted to an Arginine in 
EAATlex9skip. Splicing o f exon 3 leads to the loss o f 46 amino acids and splicing of 
exon 9 leads to the loss of 45 amino acids (Figure adapted from Vallejo-Illarramendi 
et al. 2005). (B) Hydropathy analysis o f EA A Tla indicates a truncation of the first 
and the second transmembrane domains, resulting in the formation of a single 
transmembrane domain which re-orientates the remainder o f the protein in the 
membrane (Huggett et al. 2000). No topological model has been proposed for 
EAAT lex9 skip.
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5.1.1.1.1.3 Function
EAATla retains key residues from the C-terminal region o f  EAAT1 that are 
important for glutamate binding and ion transport (Vandenberg et al. 1995; 
Grunewald et al. 1998; Seal and Amara 1999; Bendahan et al. 2000; Grunewald and 
Kanner 2000; Seal et al. 2000; Borre et al. 2002; Ryan and Vandenberg 2002), 
although theoretically reversed in orientation (Huggett et al. 2000). EAAT1 can 
transport glutamate in either direction dependent upon the Na+/K+ gradient across the 
plasma membrane (Rossi et al. 2000), and consistent with this, EAATla is a 
functional glutamate transporter (Mason, Huggett, Daniels, unpublished). EAATs 1-5 
also exhibit an anion conductance that is dependent upon Na+ and glutamate binding 
(Wadiche et al. 1995; Wadiche and Kavanaugh 1998; Seal and Amara 1999) but is 
not thermodynamically linked to substrate translocation (Fairman et al. 1995; 
Wadiche et al. 1995; Billups et al. 1996; Wadiche and Kavanaugh 1998). Exon 3 
encodes parts o f  the first two TM domains and the intervening sequence o f  EAAT 1, a 
region thought to be involved in this glutamate-gated ion channel. Mutation o f  polar 
and charged residues contained within TM2 (P98, S102, S103, T106, D112, K114) to 
aliphatic residues alters anion permeability but not the rate o f  glutamate transport 
(Ryan et al. 2004), indicating that residues encoded by exon 3 may form part o f the 
chloride channel (these residues are shown in the EAAT1 sequence in Figure 1.8). 
Furthermore, many residues o f TM2 were shown to be accessible to the external 
aqueous environment by sulfhydryl modification o f cysteine mutants (R90, Q93, V96, 
L99, S I02, S I03), consistent with pore-lining residues o f  an ion channel (Ryan et al.
2004). Loss o f these residues in EA ATla as a result o f exon 3 splicing may confer 
altered ion channel properties to the protein or ion conductance may be lost 
completely (Mason, Huggett, Daniels, unpublished).
Residues within TM2 have also been suggested to be involved in formation o f the 
transporter trimerisation domain in a crystal structure o f  a glutamate transporter 
homologue from Pyrococcus horikoshii (Yemool et al. 2004). Eskandari et al (2000) 
hypothesized that EAAT monomers are capable o f  glutamate transport but that 
multimerisation o f  the transporter is necessary for the formation o f  a central pore for 
anion conductance, in a similar manner to multimeric ion channels (Eskandari et al. 
2000; Fu et al. 2000; Murata et al. 2000). If this were the case, loss o f part o f TM2 in 
EAATla may prevent the variant from multimerisation and the consequent formation
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of a central ion channel pore, without affecting glutamate transport activity. 
Furthermore, it is likely that EAATla is not glycosylated (Huggett et al. 2000) and 
there is evidence to suggest that loss o f  glycosylation prevents dimerisation in vitro, 
with no effect on transport activity (Conradt et al. 1995).
5.1.1.1.1.4 Bioinformatics
The structure o f  the gene encoding EAAT1 indicates that the potential to splice out an 
exon that encodes amino acids present within TM2 is retained in three other subtypes 
(EAAT2, EAAT3 and EAAT4) o f  the glutamate transporter family, lending weight to 
the notion that this splicing pattern is functionally significant (Mason, Huggett, Taylor 
unpublished). It is particularly interesting to note that EAAT5, which acts almost 
exclusively as an ion channel with very little transport activity (Arriza 1997), is 
encoded by a gene that does not retain the potential to generate a transport-only splice 
variant equivalent to EAATla (Mason, Huggett, Taylor unpublished).
Comparison o f  EAAT 1 exon 3 to equivalent domains in EAATs 2 (amino acids 57- 
104), 3 (amino acids 31-78), 4 (amino acids 69-115) and 5 (amino acids 30-76) show 
identities o f 53%, 53%, 79% and 62% respectively (Figure 5.2).
5.1.1.1.1.5 Localisation
In MLO-Y4 osteocyte-like cells and SaOS-2 osteoblasts transfected with GLAST and 
GLAST-la tagged with green fluorescent protein (GFP), GLAST was localised to the 
plasma membrane with some accumulation within intracellular vesicles (Huggett et 
al. 2002; Mason and Huggett 2002). GLAST-la was detected in internal vesicles 
surrounding the nucleus in MLO-Y4 osteocytes (Huggett et al. 2002) and some 
patchy distribution at the plasma membrane was observed in SaOS-2 osteoblasts 
(Mason and Huggett 2002). In MLO-Y4 osteocytes, 0.3mM extracellular glutamate 
redistributed GLAST into an internal expression pattern similar to GLAST-la 
whereas 1.3mM extracellular glutamate appeared to increase GLAST cell surface 
expression (Huggett et al. 2002). In retinal Muller cells GLAST and GLAST-la were 
differentially distributed within the cell, with G LAST-la preferentially targeted to the 
end feet (Macnab et al. 2006).
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EAA T1 exon 3
EAATl GTILGFTLRPYR-MSYREVKYFSFPGELLMRMLQMLVLPLIISSLVTG (61-107) 
EAAT2 GAVCGGLLRLASPIHPDWMLIAFPGDILMRMLKMLILPLIISSLITG (57-104) 
EAAT3 GITTGVLVREHSNLSTLEKFYFAFPGEILMRMLKLIILPLIISSMITG (31-78) 
EAAT4 GVSIAFALRPYQ-LTYRQIKYFSFPGELLMRMLQMLVLPLIVSSLVTG (69-115) 
EAAT5 GCLLGFFLRTRR-LSPQEISYFQFPGELLMRMLKMMILPLWSSLMSG (30-76)
EAATl exon 9
EAATl SITATAASIGAAGIPQAGLVTMVIVLTSVGLPTDDITLIIAVDWFL (430-4 75) 
EAAT2 SLTATLASVGAASIP SAGLVTMLLILTAVGLP TED IS LL.VAVDWLL (429-474) 
EAAT3 SITATSASIGAAGVPQAGLVTMVIVIjSAVGLPAEDVTLIIAVDWLL (398-443) 
EAAT4 SITATAASVGAAGIPQAGLVTMVTVLTSVGLPTEDI TLI IAVDWFL (455-500) 
EAAT 5 SI TATAAS IGAAGIPQAGLVTMVTVLTSVGLP TDD I TLI IAVDWAL (409-454)
Figure 5.2. Amino acid alignment o f EAATl exons 3 and 9 to homologous regions 
of EAATs 2-5. Amino acid residue numbers are detailed in brackets.
5.1.1.1.2 EAA Tlex9skip
5.1.1.1.2.1 Expression
EAATlex9skip, which lacks exon 9, was first cloned from human optic nerve and 
detected at the transcript level throughout the human brain at levels between 10 and 
20% of full-length EAATl (Vallejo-Illarramendi et al. 2005). Of the tissues analysed 
(cerebellum, corpus callosum, hippocampus, cortex and optic nerve), EAATlex9skip 
mRNA was present at highest levels in the hippocampus and at lowest within the 
cortex (Vallejo-Illarramendi et al. 2005). Exon 9 o f EAATl comprises 135 bp and its 
omission does not alter the RNA reading frame. The predicted amino acid sequence of 
EAATlex9skip differs from full length EAATl by exclusion o f 45 amino acids (430- 
474) located extracellularly at the C-terminus (Figure 5.1) (Vallejo-Illarramendi et al.
2005). Exon 9 starts between the second and third bases o f a codon (phase 2) and the 
new codon formed at the exon 8/10 junction results in the substitution o f leucine 475 
for an arginine residue (Vallejo-Illarramendi et al. 2005).
Western blotting using an EAATlex9skip specific antibody raised against a synthetic 
peptide that corresponds to the amino acids encoded by the splice site between exons 
8 and 10 detected a band o f 150-160 kDa, which may represent an EAATlex9skip 
trimer complex (Vallejo-Illarramendi et al. 2005; Sullivan et al. 2007a). Lower
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molecular weight bands were also detected in severely damaged hypoxic pig brains o f  
50-55 kDa which likely represents monomeric EAATlex9skip and -3 0  kDa which is 
a possible cleavage product o f  EAATlex9skip that retains immunoreactivity with 
EAATlex9skip specific antibodies and a C-terminus specific EAATl antibody 
(Sullivan et al. 2007a). Interestingly, an N-terminal specific EAATl antibody 
detected full-length EAATl at -6 7  kDa in hypoxic pig brain but failed to detect bands 
at 50-55 kDa or -3 0  kDa, suggesting that EAATlex9skip and EAATla may not 
contain the normal EAATl N-terminus or the specific antibody epitope, or that the 
antibody was not sensitive enough to detect expression o f the variants (Sullivan et al. 
2007a).
There is some evidence to suggest that EAATlex9skip mRNA or protein is unstable, 
since transfection o f  HEK293 cells with an EAATlex9skip expressing vector yielded 
less protein compared to HEK293 cells transfected with the same amount o f  EAATl 
expressing vector (Vallejo-Illarramendi et al. 2005).
5.1.1.1.2.2 Structure
Exon 9 is located at the C-terminus o f  EAATl (Figure 5.1). The topology o f  the C- 
terminal region o f the EAATs is not confirmed, however its sequence is highly 
conserved across transporter subtypes and it contains a number o f residues that are 
important for glutamate binding and transport (Vandenberg et al. 1995; Grunewald et 
al. 1998; Seal and Amara 1999; Bendahan et al. 2000; Grunewald and Kanner 2000; 
Seal et al. 2000; Borre et al. 2002; Ryan and Vandenberg 2002), many o f which are 
encoded by exon 9 (Figure 1.8). A proposed transmembrane topology o f the EAATs 
(Figures 1.8 and 5.1) places two re-entrant loops at the C-terminus that forms a pore­
like structure (Grunewald and Kanner 2000; Yemool et al. 2004) therefore loss o f  
exon 9 may produce a protein where the topology o f second o f  these re-entrant loops 
is compromised.
5.1.1.1.2.3 Function
Within exon 9 o f EAATl, specific residues (A446-G459) have been found to be 
important for glutamate transport but not glutamate binding or anion conductance 
(Seal et al. 2001; Leighton et al. 2002; Ryan and Vandenberg 2002). Cysteine
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scanning and sulphahydryl modification o f  amino acids 446-459 o f EAATl (Figure 
1.8) showed that access to these residues could be prevented by the presence o f  
substrates or inhibitors (Leighton et al. 2002). Interestingly, despite the hydrophobic 
nature o f this region, many o f  the residues were accessible to small, charged 
sulphahydryl reagents that react in an aqueous phase suggesting that this region may 
exist as a pore or binding pocket (Leighton et al. 2002). This region o f  EAATl has 
also been shown to be important in determining functional differences between 
EAATl and EAAT2 such as substrate selectivity, chloride permeability and blocker 
sensitivities (Mitrovic et al. 1998).
EAATlex9skip exerts a dominant negative effect over full-length EAATl as 
demonstrated by measuring Na+-dependent glutamate transport in HEK293 cells 
transiently transfected with either the fiill coding sequence o f  EAATl or 
EAATlex9skip or co-transfected with both (Vallejo-Illarramendi et al. 2005). In 
HEK293 cells expressing only EAATlex9skip, no glutamate uptake activity was 
detected above endogenous levels, and in cells expressing EAATl, glutamate uptake 
activity was dose-dependently decreased by increasing amounts o f  EAATlex9skip 
(Vallejo-Illarramendi et al. 2005). Furthermore, in HEK293 cells expressing both 
EAATlex9skip and EA ATl, less EAATl protein was detectable by western blot 
compared to cells expressing EAATl alone, suggesting that the splice variant might 
interfere with expression o f  full-length EAATl or target the protein for degradation 
(Vallejo-Illarramendi et al. 2005).
HEK293 cells transiently transfected with the coding sequence o f EAATlex9skip 
expressed a protein that was retained primarily within the ER (Vallejo-Illarramendi et 
al. 2005). The authors speculate that this occurs due to the loss o f suppression o f a 
diarginine motif (RXR) in exon 10 which appears to function as an ER retention 
signal in EAAT2 and is conserved in the sequence o f  EAATl (Kalandadze et al. 
2004; Vallejo-Illarramendi et al. 2005). A  leucine rich region o f  EAAT2 that is 
important for normal post-translational processing and suppression o f  the ER 
retention signal (Kalandadze et al. 2004) is partially conserved in EAATl exon 9 and 
would be lost in EAATlex9skip leading to retention o f the protein in the ER. Protein- 
protein interactions between EAATl and EAATlex9skip at the ER may reduce the 
expression o f full-length EAATl at the plasma membrane and possibly target the 
complex for degradation, thus inhibiting glutamate transport activity (Vallejo- 
Illarramendi et al. 2005).
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5.1.1.1.2.4 Bioinformatics
The amino acid sequence encoded by exon 9 o f  EAATl is highly conserved across 
the EAAT family indicating functional importance for this region. Exon 9 o f EAATl 
and EAAT2 share 70% conserved residues (amino acids 430-475 o f  EAATl, 429-474 
ofEAAT2), whereas comparison o f  EAATl exon 9 to equivalent domains in EAATs 
3 (amino acids 398-443), 4 (amino acids 455-500) and 5 (amino acids 409-454) show 
identities o f  83%, 96% and 98% respectively (Figure 5.2). These homologous regions 
of EAATs 2-5 can also be spliced out o f  the sequence in frame.
5.1.1.1.2.5 Localisation
HEK293 cells transiently transfected with the coding sequence o f EAATlex9skip 
expressed a protein that was retained primarily within the ER, but which was also 
detected at the plasma membrane, whereas EAATl was predominantly localised at 
the plasma membrane (Vallejo-Illarramendi et al. 2005). EAATlex9skip, detected in 
the human brain by immunohistochemistry using EAATlex9skip specific antibodies 
(Macnab and Pow 2007a), was localised intracellularly and at the plasma membrane 
of cortical and collicular neurons, in contrast to the primarily glial expression o f full- 
length EAATl (Macnab and Pow 2007a). The variant was found predominantly in 
abnormal appearing neuronal populations, suggesting that these cells were subject to 
abnormal glutamate-mediated excitation (Macnab and Pow 2007a). In the hypoxic pig 
brain, EAATlex9skip was detected in neurons and in regions that are susceptible to 
damage such as the CA1 region o f  the hippocampus, supporting the suggestion that 
expression o f EAAT lex9skip may indicate neurons that are at risk to dying in 
response to insult (Sullivan et al. 2007a).
5.1.1.2 EAAT2
At least 3 isoforms o f GLT-1 exist as proteins and are encoded by transcripts with 3’- 
untranslated regions (UTRs) o f  different lengths: GLT-1 a, GLT-lb (also called GLT- 
lv) and GLT-1 c (Pines et al. 1992; Utsunomiya-Tate et al. 1997; Chen et al. 2002; 
Reye et al. 2002; Schmitt et al. 2002; Rauen et al. 2004). These splice variants differ 
in the sequence o f  their C-terminus (Figure 6.1) and also in their expression patterns.
188
Chapter 5
GLT-1 a and GLT-lb are expressed in glia and neurons (Chen et al. 2002; Schmitt et 
al. 2002; Maragakis and Rothstein 2004; Sullivan et al. 2004; Berger et al. 2005) 
whereas GLT-1 c is expressed by photoreceptors in human and rat retina (Rauen et al. 
2004). Differential targeting o f GLT-1 splice variants has also been observed in 
astrocytes (Sullivan et al. 2004) and in retina (Reye et al. 2002). In astrocytes, 
expression o f GLT-lb is restricted to non-synaptic locations, whereas GLT-la is 
localised to astrocytic processes, which can be interposed between multiple synapses, 
suggesting GLT-lb may play a role in uptake o f general pools o f extracellular 
glutamate (Sullivan et al. 2004). In retina, GLT-lb was primarily localised to cone 
photoreceptors and subpopulations o f  both rod and cone bipolar cells, whereas GLT- 
la was generally associated with amacrine cells, bipolar cells, and rod photoreceptor 
cells (Reye et al. 2002).
Alternative splicing o f  the 5’-UTR has been detected at the transcript level in human, 
mouse and rat brain tissue with the potential to generate GLT-1 with different N- 
termini (Utsunomiya-Tate et al. 1997; Munch et al. 2001; Munch et al. 2002; Munch 
et al. 2003; Rozyczka and Engele 2005). Expression o f  some o f these variants has 
been shown to be increased under hypoxic conditions as well as in a transgenic model 
for ALS (Munch et al. 2002; Munch et al. 2003).
Other splice variants o f  EAAT2 have been cloned from human tissues including an 
exon 7 skipping variant (Honig et al. 2000), an exon 8 skipping variant (Nagai et al. 
1998), an intron 7 retention variant (Lin et al. 1998), an exon 9 skipping variant (Lin 
et al. 1998; Meyer et al. 1998) and a variant that lacks both exons 7 and 9 (Scott et al. 
2010). The exon 9 skipping variant o f  GLT-1 is homologous to EAATlex9skip, and 
lacks part o f the glutamate translocation site o f  GLT-1 (Gebhardt et al. 2010). 
Expression o f the GLT-1 exon 9 skipping variant in Xenopus laevis oocytes generated 
a protein that was expressed at the plasma membrane but was non-functional with 
respect to glutamate uptake (Scott et al. 2010), consistent with the loss o f  glutamate 
uptake activity detected in EAATlex9skip (Vallejo-Hlarramendi et al. 2005).
Intron 7 retention and exon 9 skipping splice variant transcripts o f EAAT2 were 
reported to be selectively present in brains from ALS patients (Lin et al. 1998), 
however other studies have shown that the variants are also present in normal brains 
(Meyer et al. 1999; Honig et al. 2000; Flowers et al. 2001). This was confirmed by 
exon-9 skipping EAAT2 protein expression in the normal adult rat brain and spinal 
cord (Macnab and Pow 2007b).
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5.1.1.3 EAAT3
A truncated form o f EAAT3 (EAAC1) termed tEAACl has been identified at the 
transcript level in the human renal carcinoma cell line, ACHN, in which EAAT3 is 
highly expressed (Matsumoto et al. 1999). The translated splice variant would lack 
amino acids G31-T77 (Matsumoto et al. 1999) which are encoded by EAAT3 exon 2; 
this region is homologous to exon 3 o f  EA ATl, therefore represents an equivalent 
splice variant to EAATla. The splice variant was detected in various human tumour 
cells including renal, bladder, cervical, breast and lymphoma but was not detectable in 
bladder carcinoma, hepatoma or glioma cells o f  rat origin or mammary carcinoma, 
hepatoma, melanoma or myeloma o f  mouse origin (Matsumoto et al. 1999).
5.1.2 Role of EAAT splice variants
Alternative splicing appears to be a common feature o f  at least 3 subtypes o f  the 
EAAT family, and protein expression for some o f  these splice variants has been 
detected (Huggett et al. 2000; Reye et al. 2002; Rauen et al. 2004; Sullivan et al. 
2004; Vallejo-Illarramendi et al. 2005) suggesting physiological relevance. The two 
identified splice variants o f  EAATl both lack regions that have been demonstrated to 
contain key residues for EAAT functions (ion channel activity and glutamate 
transport activity) supporting the hypothesis that the variants will display different 
functional properties to full-length EA ATl. Furthermore, EAATs 2-4 retain the 
ability to splice out equivalent domains to exon 3 o f EAATl, and this has been 
confirmed in EAAT3 (Matsumoto et al. 1999), indicating a functional significance for 
the EAATla variant (Huggett, Taylor and Mason, unpublished data). It seems 
possible therefore, that splice variant expression may be a means o f selectively 
regulating EAAT function.
5.1.3 Antisense mediated exon skipping
Antisense oligoribonucleotides (AONs) are able to interfere with RNA processing to 
modulate gene expression. AONs can knock down gene expression by mediating 
RNase H cleavage o f  RNA-AON duplexes (Hausen and Stein 1970; Zamecnik and 
Stephenson 1978) or manipulate pre-mRNA splicing by sterically hindering normal
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splice signals (Kole and Sazani 2001). With respect to the latter, AONs are able to 
induce the skipping o f specific exons to over-express a specific splice variant, or 
bypass ffame-shift mutations and restore protein synthesis (Sierakowska et al. 1996).
5.1.4 Aims
The objectives o f  the experiments described in this chapter were to manipulate the 
splicing ratios o f  EAATl in order to ascertain the importance o f  the domains encoded 
by the spliced out exons in EA ATla and EAATlex9skip. Exon 3 o f EAATl contains 
a number o f residues important for anion conductance, suggesting that EAATla may 
have altered or no ion channel activity. Furthermore, the potential reorientation o f the 
transporter in the membrane will prevent any intracellular interactions downstream o f  
the N-terminal. Exon 9 o f  EAATl encodes a portion o f  the transporter important for 
glutamate transport and expression o f  EAATl ex9skip in HEK293 cells indicates that 
this variant exerts a dominant negative effect over full-length EAATl (Vallejo- 
Illarramendi et al. 2005). Over-expression o f  EAATla and EAATlex9skip will 
delineate the importance o f each EAAT function (i.e. glutamate transport, anion 
conductance, intracellular interactions) in osteoblast differentiation and activity.
5.2 Methods
Design, sequence, modifications and relative binding sites o f AONs (scrambled, 
ex3skip, ex9skip) are detailed in section 2.10 and Figure 2.5. General methods for 
transfection and analysis o f  transfection efficiency are detailed in section 2.10.2 and 
2.10.3.
5.2.1 Cell culture and transfection
MG-63 osteoblasts were seeded at 2.5 x 104 cells/cm2 in 48-well and 24-well plates. 
SaOS-2 cells were seeded at 4.4 x 104 cells/cm2 in 48-well and 24-well plates. 
Primary human osteoblasts (NHOB2P11) were seeded at 5 x 102 cells/cm2 in 24-well 
plates. At 80% confluence, the cells were transfected with scrambled, ex3skip or
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ex9skip AONs as outlined in section 2.10.2, or left untransfected. No refreshment o f  
culture medium was carried out post-transfection. Transfection efficiency was 
determined at 24hrs post-transfection (section 2.10.3).
5.2.2 Efficiency of antisense mediated EAATl exon 9 skipping over time
For experiments assessing the efficiency o f  exon 9 skipping over time, transfections 
were carried out glutamate-free and glutamate was not added at any subsequent time- 
points.
RNA was extracted and reverse transcribed from transfected cells (MG-63, SaOS-2 
and human primary osteoblasts NHOB2P11) (section 2.3) and amplified using primer 
pairs against regions o f  EAATl spanning exon 3 or 9 (Table 2.1, Figure 2.2), as 
appropriate. Each primer pair yielded two products, the higher molecular weight full- 
length EAATl and the lower molecular weight splice variant.
5.2.2.1 RT-PCR
Cells were transfected in 48-well plates and RNA extractions, reverse transcription 
and RT-PCR were carried out as above (section 5.2.2) at 6hrs, 24hrs, 48hrs (MG-63 
and SaOS-2), and 72hrs (SaOS-2 cells only) post-transfection. RT-PCR was carried 
out using an optimised 30 cycles o f  amplification (section 2.4.2) to ensure that 
comparison o f  band densities by agarose gel electrophoresis (section 2.4.3) occurred 
during the linear increase in PCR product and thus the ratio o f  
EAATlex9skip:EAATl could be estimated.
5.2.22 QRT-PCR
MG-63, SaOS-2 and human primary osteoblasts were transfected in 24-well plates 
and RNA extractions were carried out as detailed in section 2.3. All cells were
assayed at 24 and 48hrs post-transfection, however only MG-63 and SaOS-2 cells
were also assayed at 72hrs post-transfection. 200ng (MG-63) and 400ng (SaOS-2) 
total RNA was reverse transcribed (section 2.3.5) in a 20pl reaction which was then 
diluted to lOOpl with RNase/DNase free molecular biology grade water and 5 pi taken 
for QRT-PCR amplification. As much total RNA as possible was reverse transcribed
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from primary osteoblasts i.e. 8.5pi o f  20pl total RNA. QRT-PCR was carried out 
(section 2.4.4) using primers against EAATl and EAATlex9skip in conjunction with 
the housekeeping gene 18S rRNA (Table 2.1). Absolute QRT-PCR was carried out 
with the Stratagene MX3000P™ Real-Time PCR system (section 2.4.4.1.1) in 
conjunction with plasmid standard curves generated from cloned template sequences 
(section 2.4.4.2.1). Transcript copy numbers were normalised to 18S rRNA and 
expressed relative to scrambled control cells.
5.2.3 Effect of antisense mediated EAATl exon skipping on glutamate
uptake
Cells were transfected in 24-well plates. At 48hrs post-transfection, glutamate uptake 
activity was assayed in the presence and absence o f Na+ to determine Na+-dependent 
uptake (section 2.8). Culture medium was aspirated and the cells pre-incubated with 
KRH buffer (+ Na+) for lhr and then the buffer aspirated and replaced with KRH 
buffer (± Na+) containing a mix o f radiolabelled and unlabelled glutamate at lOpM 
(Table 2.4) for 10 min. Uptake activity was normalised to total protein content 
determined by BCA assay from parallel cultures (sections 2.5.2 and 2.8.2).
5.2.4 Effect of antisense mediated EAATl exon skipping on gene
expression
5.2.4.1 Human osteoblast-like cells
MG-63 and SaOS-2 cells were transfected in 24-well plates. At 24hrs post­
transfection, the medium o f  replicate cultures was supplemented with 500pM  
glutamate. After a further 24hrs (i.e. 48hrs post-transfection) the medium was 
aspirated, cells rinsed with cold PBS and homogenised with 0.2ml TRIzol® reagent 
per well for 5 min. The plates were stored at -80°C for RNA extraction (section 2.3). 
500ng total RNA was reverse transcribed in a 20jil reaction, diluted to lOOpl with 
RNase/DNase-free water and lp l taken for QRT-PCR (section 2.4.4) using primers 
against osteocalcin, osteonectin, osteoprotegerin (OPG), alkaline phosphatase (ALP), 
18S rRNA, GAPDH and HPRT1 (Table 2.1). Gene expression for MG-63 and SaOS- 
2 cells was normalised to GAPDH and HPRT1 respectively, the most stable
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housekeeping genes o f  the three as determined using geNorm software for each 
experiment (Vandesompele et al. 2002). Relative QRT-PCR was carried out (section 
2.4.4.5) using the Applied Biosystems 7900HT Fast Real-Time PCR system (section 
2.4.4.1.2) in conjunction with cDNA standard curves (section 2.4.4.2.2). All values 
are expressed relative to scrambled control cells at OpM glutamate.
5.2.4.2 Human primary osteoblasts
Cells were transfected in 24-well plates at 0 and 500pM glutamate, with the addition 
of glutamate occurring at the point o f  transfection. Experimental set-up, RNA 
extraction and generation o f  cDNA are detailed in section 5.2.2.1.2. Absolute QRT- 
PCR was carried out using primers against osteocalcin, osteonectin and 18S rRNA 
(Table 2.1) on the Stratagene MX3000P™ Real-Time PCR system (section 2.4.4.1.1) 
in conjunction with plasmid standard curves (section 2.4.4.2.1). Transcript copy 
numbers were normalised to 18S rRNA, and expressed relative to scrambled control 
cells at OpM glutamate.
5.2.5 Effect of antisense mediated EAAT1 exon skipping on cell number,
cell death and ALP activity
5.2.5.1 Human osteoblast-like cells
MG-63 and SaOS-2 cells were transfected in 24-well plates. At 24hrs post­
transfection, the medium o f  replicate cultures was supplemented with 500pM  
glutamate. After a further 24hrs (i.e. 48hrs post-transfection) the medium was 
aspirated and the cells lysed with lOOpl/well lysis buffer (section 2.5.1). Plates were 
then incubated on ice for lhr to ensure adequate cell lysis and 5 pi lysate was taken for 
assays o f adherent cell number (LDH Cytotox96 assay) and ALP activity (SaOS-2 
cells only) (sections 2.5.3 and 2.5.4).
194
Chapter 5
5.2.5.2 Human primary osteoblasts
Primary osteoblasts (N H 0B2P11) were transfected in 24-well plates at 0 and 500pM  
glutamate, with the addition o f glutamate occurring at the point o f transfection. At 
48hrs post-transfection, the medium was retained for analysis o f  cell death and the 
cells lysed with lOOpl/well lysis buffer (section 2.5.1). Plates were then incubated on 
ice for lhr to ensure adequate cell lysis and 5pi lysate or 50pl culture supernatant was 
taken for LDH assay o f  cell number and cell death respectively (LDH Cytotox96 
assay, section 2.5.3),
5.2.6 Statistics
Cells transfected with AONs targeted against EAAT1 splice sites were compared to 
cells transfected with scrambled control oligoribonucleotides. Statistical comparison 
between untransfected and scrambled control cells was also carried out to display any 
non-specific effects o f  oligoribonucleotide transfection.
5.3 Results
5.3.1 AON transfection efficiency
MG-63 cells were transfected with scrambled control, ex3skip or ex9skip FAM- 
labelled AONs or left untransfected. In untransfected cells, no FAM fluorescence was 
observed (Figure 5.3A). In cells transfected with FAM-labelled AONs, most nuclei 
were surrounded by punctuate FAM fluorescence (Figure 5.3 B-D), confirming 
transfection o f  the AON into the cell. Transfection efficiency (Figure 5.3E) was 96% 
for scrambled AON, 94% for ex3skip AON and 94% for ex9skip AON.
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Figure 5.3. Transfection efficiency o f  antisense oligoribonucleotides (AONs). 
MG63 cells were left untransfected (A) or transfected for 24hrs with FAM labelled 
scrambled (B), ex3skip (C) and ex9skip (D) AONs. Nuclei were stained with DAPI 
and the number o f FAM associated nuclei counted from four fields o f view per 
sample using a fluorescent microscope (20X magnification) and expressed as a 
percentage of total nuclei (E). No significant FAM fluorescence was observed in 
untransfected cells. Values are mean ± S.E.M, n=3.
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5.3.2 Confirmation of antisense mediated EAAT1 exon skipping by RT-
PCR
Skipping of the appropriate exon was confirmed in MG-63, SaOS-2 and NHOB2P11 
cells transfected with ex3skip and ex9skip AONs by RT-PCR using primers that span 
the skipped exon. EAATla levels (140bp) were increased and EAAT1 levels (218bp) 
decreased in ex3skip AON transfected cells compared to scrambled control and 
untransfected cells, in which no bands were detected for EAATla (Figure 5.4). 
Ex9skip AON transfected cells displayed a weaker band corresponding to EAAT1 
(256bp) and stronger expression of EAATlex9skip (121 bp) compared to scrambled 
control and untransfected cells (Figure 5.5).
5.3.2.1 Efficiency o f antisense mediated EAAT1 exon 9 skipping over time
In order to define the optimum time post-transfection that assays for EAAT activity 
and bone formation should be carried out; the efficiency of exon skipping was 
observed over time by densitometric analysis o f PCR products resolved on agarose 
gels and also by QRT-PCR o f EAAT1 and EAATlex9skip expression in ex9skip 
AON transfected cells. Only the ex9skip AON was used to optimise assay time-points 
since it was assumed that similar conditions would apply to the ex3skip AON given 
that they both target the same transcript.
5.3.2.1.1 Densitometry o f RT-PCR
MG-63 and SaOS-2 cells were transfected with scrambled control or ex9skip AONs 
or left untransfected and total RNA was extracted at 6, 24, 48 (both cell lines) and 
72hrs (SaOS-2 cells only) for reverse transcription and amplification by RT-PCR 
using primers that span exons 8-10. Due to infection of the culture plate, no 72hr 
time-point was available for analysis with MG-63 cells. Products were resolved by 
agarose gel electrophoresis and density o f DNA bands for full-length EAAT1 and 
EAATlex9skip measured. The ratio of EAATlex9skip:EAATl was determined for 
each experimental condition and expressed as a percentage of 
EAAT 1 ex9skip:EAAT 1 ratio in scrambled control cells (Figure 5.6). No statistical 
analysis was carried out and the data were used merely to guide assay timings.
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Figure 5.4. Efficiency o f  antisense mediated EAAT1 exon 3 skipping in human 
osteoblast-like cells and prim ary human osteoblasts. Osteoblast-like cells ((A) MG- 
63 and (B) SaOS-2) and (C) primary human osteoblasts (NH0B2P11) were 
transfected with scrambled AON, ex3skip AON or left untransfected for 48hrs and 
changes in splicing ratios o f EAAT1 were determined by RT-PCR using primers that 
span exons 2-4.
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Figure 5.5. Efficiency o f  antisense mediated EAATl exon 9 skipping in human 
osteoblast-like cells and primary human osteoblasts. Osteoblast-like cells ((A) MG- 
63 and (B) SaOS-2) and (C) primary human osteoblasts (NHOB2P11) were 
transfected with scrambled AON, ex9skip AON or left untransfected for 48hrs and 
changes in splicing ratios o f EAATl were determined by RT-PCR using primers that 
span exons 8-10.
199
A. MG-63
Chapter 5
450
□ 24hrs
□  48hrs
Scram bled Ex9skip Untransfected
B. SaOS-2
_  4000
□  2 4 h r s
□  4 8 h r s
72hrs
Scrambled Ex9skip Untransfected
Figure 5.6. Expression ratio o f  EAATlex9skip:EAATl in (A) MG-63 and (B) 
SaOS-2 cells transfected with scrambled control or ex9skip AONs over time. MG-63 
and SaOS-2 cells were transfected with scrambled control or ex9skip AONs or left 
untransfected and total RNA extracted at 6, 24, 48 (both cell lines) and 72hrs (SaOS-2 
cells only) for reverse transcription and amplification by RT-PCR using primers that 
span exons 8-10. Products were resolved on an agarose gel, visualised under UV light 
and densitometry o f DNA bands was carried out. The ratio o f EAATl ex9skip:EAATl 
is expressed as a percentage o f  EAATlex9skip:EAATl ratio in scrambled control 
cells at each time-point.
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The ratio of EAATlex9skip to full-length EAATl did not appear to be different 
between untransfected and scrambled control cells, suggesting that the transfection 
procedure does not influence the regulation o f EAATl splicing. In both cell lines, the 
ratio of EAATl ex9skip to EAATl was increased in ex9skip AON transfected cells at 
each time-point assessed. The greatest increases in the ratio of EAATlex9skip to 
EAATl were detected at 24 and 48hrs in both cell lines, though the results at 24hrs 
were more variable than those detected at 48hrs. These results indicated that peak 
exon skipping occurs at between 24 and 48hrs in MG-63 and SaOS-2 cells.
5.3.2.1.2 QRT-PCR
The ratio of transcript levels for EAATl and EAATlex9skip was also assessed by 
QRT-PCR in osteoblast-like cells (MG-63 and SaOS-2) transfected with scrambled 
control and ex9skip AONs over time (Table 5.1). Data are presented as the percentage 
change over scrambled control cells at each time-point from a single preliminary 
experiment where n=4. In MG-63 cells, the EAATlex9skip:EAATl expression ratio 
was increased 856 ± 186 % at 24hrs, 646 ± 114 % at 48hrs, and 255 ± 37 % at 72hrs 
compared to scrambled controls at each time-point. In SaOS-2 cells, the 
EAATlex9skip:EAATl expression ratio was increased 381 ± 28% at 24hrs, 466 ± 58 
% at 48hrs, and 208 ± 32 % at 72hrs compared to scrambled controls at each time- 
point.
In primary human osteoblasts (NHOB2P11) transfected with scrambled and ex9skip 
AONs, only expression o f EAATlex9skip was measured by QRT-PCR at 24 and 
48hrs post-transfection (Figure 5.7). In these cells, EAATlex9skip expression was 
significantly increased 1399 ± 577 % at 24hrs (Kruskal-Wallis P=0.021) and 1647 ± 
391 % at 48hrs (Kruskal-Wallis P=0.021) compared to scrambled oligoribonucleotide 
transfected cells at each time-point.
The results o f the above experiments led to the decision to assess the effect of 
extracellular glutamate on cells overexpressing EAATla and EAATlex9skip by 
adding glutamate 24hrs post-transfection, when exon skipping is high, and to assay 
cells at 48hrs post-transfection, when exon skipping remains high.
201
Chapter 5
2500
■  Scrambled 
□  Ex9skip AON
24 48
Hrs post transfection
Figure 5.7. Efficiency o f  antisense mediated E A A Tl exon 9 skipping in primary 
human osteoblasts over time by QRT-PCR analysis. Osteoblasts were transfected 
with scrambled or ex9skip AONs and changes in expression of EAATlex9skip were 
determined by QRT-PCR at 24 and 48hrs post-transfection. Expression levels are 
normalised to 18S rRNA expression and shown as the percentage change over 
scrambled control cells at each time-point. Values are mean ± S.E.M from a single 
preliminary experiment where n=4. Expression of EAATlex9skip was significantly 
increased in ex9skip AON transfected cells at both time-points (Kruskal-Wallis 
P=0.021 (24hrs), P=0.021 (48hrs)). Significance values *P<0.05 relative to scrambled 
control.
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Table 5.1. Efficiency o f antisense mediated E A A Tl exon 9 skipping in osteoblast­
like cells over time. MG-63 and SaOS-2 cells were transfected with scrambled or 
ex9skip AONs and changes in expression of EAATl and EAATlex9skip were 
determined by QRT-PCR at 24, 48 and 72hrs post-transfection. The ratio of 
expression levels normalised to 18S rRNA expression are shown as the percentage 
change over scrambled control cells at each time-point. Values are mean ± S.E.M 
from a single preliminary experiment where n=4.
Hrs post­
transfection
EAATl ex9skip:EAAT1 mRNA levels in ex9skip AON 
transfected cells (% scrambled at each time-point)
24 856 ±186
MG-63 48 646 ±114
72 255 ± 37
24 381 ± 28
SaOS-2 48 466 ±58
72 208 ± 32
5.3.3 Effect of antisense mediated EAATl exon skipping on Na+-dependent
glutamate uptake
Na+-dependent glutamate uptake was measured in untransfected MG-63 and SaOS-2 
osteoblast-like cells and in the same cells 48hrs post-transfection with scrambled 
control or antisense oligoribonucleotides. Na+-dependent glutamate uptake was 
normalised to total cellular protein (mg) and expressed as a percentage of scrambled 
control cells. Presented data are from three independent experiments where n=3-4.
5.3.3.1 MG-63
In transfected MG-63 cells, Na+-dependent glutamate uptake was significantly 
affected by overexpression of EAATl splice variants (Kruskal-Wallis P—0.007) 
(Figure 5.8). Post-hoc pair-wise comparisons (Mann Whitney U tests) revealed that 
Na+-dependent glutamate uptake was significantly decreased by 23 ± 6.3 % in MG-63 
cells transfected with ex3skip AON (P=0.002) and by 17 ± 6.5 % in MG-63 cells 
transfected with ex9skip AON (P=0.045) compared to scrambled control cells.
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Figure 5.8. E ffect o f  antisense mediated E A A T l exon 3 and exon 9 skipping on 
Na*-dependent glutamate uptake in MG-63 cells. MG-63 cells were transfected with 
scrambled control, ex3skip or ex9skip AONs for 48hrs, or left untransfected. MG-63 
cells were then incubated with IOjiM mix o f radiolabelled and unlabelled glutamate at 
37°C for 10 min in KRH buffer ± Na+, followed by aspiration o f buffer and rinsing 
with cold KRH containing 1.5mM unlabelled glutamate. Na+-dependent glutamate 
uptake was normalised to total cellular protein (mg) and expressed as a percentage of 
scrambled control cells. Values are mean ± S.E.M from three independent 
experiments where n=3-4. Na+-dependent glutamate uptake was significantly affected 
by overexpression of EAATl splice variants (Kruskal-Wallis P=0.007) and post-hoc 
pair-wise comparisons (Mann Whitney U tests) revealed that uptake was significantly 
decreased in cells transfected with ex3 skip and ex9skip AONs compared to scrambled 
control cells. Na+-dependent glutamate uptake was significantly decreased in 
scrambled control cells relative to untransfected cells (one-way ANOVA P=0.040). 
Significance values *P<0.05, **P<0.01.
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Na+-dependent glutamate uptake was significantly decreased in scrambled control 
cells relative to untransfected cells (one-way ANOVA .P=0.040).
5.3.3.2 SaOS-2
In transfected SaOS-2 cells, Na+-dependent glutamate uptake was significantly 
affected by overexpression of EAATl splice variants (one-way ANOVA PO.OOl) 
(Figure 5.9). Post-hoc pair-wise comparisons (Fisher’s tests) revealed that Na+- 
dependent glutamate uptake was significantly decreased by 14 ± 2.1 % in SaOS-2 
cells transfected with ex3skip AON (P<0.001) and by 32 ± 2.9 % in SaOS-2 cells 
transfected with ex9skip AON (P<0.001) compared to scrambled control cells. 
Na+-dependent glutamate uptake was significantly increased in scrambled control 
cells relative to untransfected cells (one-way ANOVA P=0.003).
5.3.4 Effect of antisense mediated EAATl exon skipping on cell number
5.3.4.1 Osteoblast-like cells
MG-63 and SaOS-2 cells were transfected with scrambled control or antisense 
oligoribonucleotides for 48hrs, or left untransfected. 500pM glutamate was added to 
replicate cultures under each condition at 24hrs post-transfection. Adherent cell 
number was assayed by measuring LDH released upon total lysis of viable adherent 
cells and expressed as a percentage of LDH activity of viable adherent control cells 
(scrambled, OpM glutamate). Presented data are from two independent experiments 
where n=4 (MG-63) or three independent experiments where n=3 (SaOS-2).
5.3.4.L1 MG-63
In transfected MG-63 cells, cell number was significantly affected by overexpression 
of EAATl splice variants (GLM with ranked data .P=0.019) but not by 500pM 
glutamate (GLM with ranked data P=0.535) and there was no interaction between the 
two factors (GLM with ranked data P=0.144) (Figure 5.10). Post-hoc pair-wise 
comparisons (Tukey’s tests) revealed that, compared to scrambled control cells at 
OpM glutamate, cell number was significantly decreased by 5 ± 1.3 % in cells
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Figure 5.9. E ffect o f  antisense mediated E A A T l exon 3 and exon 9 skipping on 
Na+-dependent glutamate uptake in SaOS-2 cells. SaOS-2 cells were transfected 
with scrambled control, ex3skip or ex9skip AONs for 48hrs, or left untransfected. 
SaOS-2 cells were then incubated with lOpM mix of radiolabelled and unlabelled 
glutamate at 37°C for 10 min in KRH buffer ± Na+, followed by aspiration o f buffer 
and rinsing with cold KRH containing 1.5mM unlabelled glutamate. Na+-dependent 
glutamate uptake was normalised to total cellular protein (mg) and expressed as a 
percentage of scrambled control cells. Values are mean ± S.E.M from three
independent experiments where n=3. Na+-dependent glutamate uptake was
significantly affected by overexpression o f EAATl splice variants (one-way ANOVA 
P<0.001) and post-hoc pair-wise comparisons (Fisher’s tests) revealed that uptake 
was significantly decreased in cells transfected with ex3skip and ex9skip AONs 
compared to scrambled control cells. Na+-dependent glutamate uptake was
significantly increased in scrambled control cells relative to untransfected cells (one­
way ANOVA P=0.003). Significance values **P<0.01, ***P<0.001.
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Figure 5.10. E ffect o f  antisense mediated E A A T l exon 3 and exon 9 skipping on 
MG-63 cell number at 48hrs post-transfection. MG-63 cells were transfected with 
scrambled control, ex3skip or ex9skip AONs for 48hrs, or left untransfected (± 
500pM glutamate for last 24hrs). Adherent cell number was assayed by measuring 
LDH released upon total lysis of viable adherent cells and expressed as the mean 
percentage of LDH activity o f viable adherent control cells (scrambled, no glutamate) 
± S.E.M from two independent experiments, n=4. Cell number was significantly 
affected by overexpression o f EAATl splice variants (GLM .P=0.019) and post-hoc 
Tukey’s tests revealed a significant reduction in cell number at OpM glutamate in 
cells overexpressing EAATlex9skip. Cell number was significantly increased by 
transfection with scrambled control oligoribonucleotides compared to untransfected 
cells (GLM PcO.OOl) and this was apparent at both glutamate concentrations. 
Significance values *P<0.05, **P<0.01.
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transfected with ex9skip AONs (P=0.016), though such a small effect is unlikely to be 
biologically significant. No effect of ex9skip AONs on cell number was detected at 
500pM glutamate (P=0.983).
Transfection with scrambled control oligoribonucleotides significantly increased MG- 
63 cell number relative to untransfected cells (GLM /*<0.001) and post-hoc 
comparisons (Tukey’s tests) revealed that this occurred at both OpM and 500pM 
glutamate (P=0.009 and P=0.029 respectively).
5.3.4.1.2 SaOS-2
In transfected SaOS-2 cells, cell number was significantly affected by overexpression 
of EAATl splice variants (GLM P=0.001) but not by 500pM glutamate (GLM 
P=0.185) and there was no interaction between the two factors (GLM P=0.070) 
(Figure 5.11). Post-hoc pair-wise comparisons (Tukey’s tests) revealed that, compared 
to scrambled control cells at 500pM glutamate, cell number was significantly 
increased from 97 ± 1 .5% to 113 ± 2.0 % in cells transfected with ex3skip AONs 
(P=0.001). This increase in cell number was quite large and therefore potentially 
biologically significant. No effect of ex3skip AONs on cell number was detected at 
OpM glutamate (P=0.879).
Transfection with scrambled control oligoribonucleotides had no significant effect on 
SaOS-2 cell number relative to untransfected cells (GLM P=0.156).
5.3.4.2 Primary osteoblasts
Cell number and cell death were measured in untransfected primary human 
osteoblasts (NHOB2P11) and in the same cells 48hrs post-transfection with scrambled 
control or antisense oligoribonucleotides. 500pM glutamate was added to replicate 
cultures under each condition at the point o f transfection. Adherent cell number was 
assayed by measuring LDH released upon total lysis of viable adherent cells and 
expressed as a percentage of LDH activity in viable adherent control cells (scrambled, 
no glutamate) (Figure 5.12). Cell death was assayed by measuring LDH released upon 
lysis o f dead and dying cells in the culture supernatant and expressed as the 
percentage of total LDH activity in the cell lysate and culture supernatant combined 
(Figure 5.13). Presented data are from a single preliminary experiment where n=4.
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Figure 5.11. E ffect o f  antisense mediated E A A T l exon 3 and exon 9 skipping on 
SaOS-2 cell number at 48hrs post-transfection. SaOS-2 cells were transfected with 
scrambled control, ex3skip or ex9skip AONs for 48hrs, or left untransfected (± 
500pM glutamate for last 24hrs). Adherent cell number was assayed by measuring 
LDH released upon total lysis o f viable adherent cells and expressed as the mean 
percentage of LDH activity of viable adherent control cells (scrambled, no glutamate) 
± S.E.M from three independent experiments, n=3. Cell number was significantly 
affected by overexpression of EAATl splice variants (GLM P=0.001) and post-hoc 
Tukey’s tests revealed that cell number was significantly increased in cells 
overexpressing EAATla compared to scrambled control cells at 500pM glutamate. 
SaOS-2 cell number was not significantly different in scrambled control cells 
compared to untransfected cells (GLM). Significance values **P<0.01.
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Figure 5.12. E ffect o f  antisense mediated E A A Tl exon 3 and exon 9 skipping on 
primary osteoblast cell number at 48hrs post-transfection. Primary osteoblasts 
(NH0B2P11) were transfected with scrambled control, ex3skip or ex9skip AONs, or 
left untransfected ± 500pM glutamate for 48hrs. LDH released upon total lysis of 
viable adherent cells is expressed as a percentage of LDH activity of control cells 
(scrambled, no glutamate). Values are mean ± S.E.M from a single preliminary 
experiment, n=4. In transfected primary osteoblasts, cell number was significantly 
affected by overexpression of EAATl splice variants (P=0.006), by 500pM glutamate 
(P=0.004) and by the interaction between the two factors (P<0.001) (GLM). Post-hoc 
Tukey’s tests revealed a significant decrease in cell number in cells transfected with 
ex3skip and ex9skip AONs, and this was significantly prevented by 500pM glutamate 
in ex3skip transfected cells. Transfection with scrambled control oligoribonucleotides 
significantly increased primary osteoblast cell number relative to untransfected cells 
(GLM P=0.018). Post-hoc Tukey’s tests did not reveal any pair-wise significance for 
this effect at OpM or 500pM glutamate. Significance values **P<0.01.
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Figure 5.13. E ffect o f  antisense mediated E A A Tl exon 3 and exon 9 skipping on 
primary osteoblast cell death at 48hrs post-transfection. Primary osteoblasts 
(NHOB2P11) were transfected with scrambled control, ex3skip or ex9skip AONs, or 
left untransfected ± 500pM glutamate for 48hrs. Cell death was assayed by measuring 
LDH released from dead or dying cells in the culture supernatant and expressed as the 
percentage of total LDH activity (i.e. adherent cell lysate + dead or dying cells in the 
supernatant). Values are mean ± S.E.M from a single preliminary experiment, n=4. In 
transfected primary osteoblasts, cell death was significantly increased by 500pM 
glutamate (GLM P=0.049), however no pair-wise significance was detected (Tukey’s 
test). Transfection with scrambled control oligoribonucleotides significantly 
decreased primary osteoblast cell death relative to untransfected cells (GLM 
P=0.030). Post-hoc Tukey’s tests did not reveal any pair-wise significance for this 
effect at OpM or 500pM glutamate.
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Preliminary findings from transfected primary osteoblasts demonstrated that cell 
number was significantly affected by overexpression of EAATl splice variants (GLM 
with ranked data P=0.006), by 500pM glutamate (GLM with ranked data P=0.004) 
and by the interaction between the two factors (GLM with ranked data P<0.001) 
(Figure 5.12). Post-hoc pair-wise comparisons (Tukey’s tests) revealed a significant 
reduction in cell number in cells overexpressing EAATla and EAATlex9skip to 74 ± 
1.7 % (/M3.001) and 73 ± 3.0 % (P=0.001) of scrambled control cells respectively at 
OpM glutamate. Such a large reduction in cell number is likely to be biologically 
significant however these experiments need to be repeated to validate this. The 
presence of 500jiM  glutamate prevented this decrease and this was significant in 
ex3skip AON transfected cells (P=0.006). Transfection with scrambled control 
oligoribonucleotides significantly increased primary osteoblast cell number relative to 
untransfected cells (GLM P=0.018), but no post-hoc pair-wise comparisons (Tukey’s 
tests) were significant.
In transfected primary osteoblasts, cell death was significantly affected by glutamate 
(GLM P=0.049) but not by overexpression o f EAATl splice variants (GLM P=0.454) 
or by the interaction between the two factors (GLM P=0.539) (Figure 5.13). Analysis 
of all experimental groups showed that incubation of cells with 500pM glutamate 
resulted in a general increase in cell death; however post-hoc Tukey’s tests did not 
detect any pair-wise significance. The increase in cell death was small, 4.6% at most, 
and therefore unlikely to be biologically significant. Transfection with scrambled 
control oligoribonucleotides significantly decreased primary osteoblast cell death 
relative to untransfected cells (GLM P=0.030), although no post-hoc comparisons 
(Tukey’s tests) were significant.
5.3.5 Effect of antisense mediated EAATl exon skipping on gene
expression
5.3.5.1 Osteoblast-like cells
MG-63 and SaOS-2 cells were transfected with scrambled control or antisense 
oligoribonucleotides for 48hrs, or left untransfected. 500pM glutamate was added to 
replicate cultures under each condition at 24hrs post-transfection. Expression levels of 
osteocalcin, osteonectin, OPG and ALP were quantified by QRT-PCR and expressed
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as a percentage of expression in control cells (scrambled, OpM glutamate). Presented 
data are from three independent experiments where n=3.
5.3.5.1.1 Osteocalcin
5.3.5.J.J.J MG-63
In transfected MG-63 cells, osteocalcin expression was significantly affected by 
500pM glutamate (GLM P=0.009) but not by overexpression of EAATl splice 
variants (GLM P=0.099) and there was no interaction between the two factors (GLM 
P=0.167) (Figure 5.14A). Post-hoc comparisons (Tukey’s tests) revealed a significant 
decrease in osteocalcin expression o f 37 ± 7.8 % in scrambled control cells at 500pM 
glutamate compared to cells at OpM glutamate (P=0.037), however a similar effect 
was not detectable in cells overexpressing EAATla (P=0.848) or EAATlex9skip 
(P=0.998) at 500pM glutamate compared to OpM glutamate. There was a trend for 
decreased osteocalcin expression in cells overexpressing the EAATl splice variants in 
the absence of glutamate, and this effect was significant at the 10% level. 
Overexpression of EAATla and EAATlex9skip decreased osteocalcin expression to 
71 ± 3.5 % and 71 ± 9.7 % of scrambled control cells respectively at OpM glutamate. 
The combination of transfection with oligoribonucleotides and 500pM glutamate had 
a significant effect on MG-63 osteocalcin expression relative to untransfected cells 
(GLM P=0.017). Post-hoc pair-wise comparisons (Tukey’s tests) revealed that this 
was a reflection of the down-regulated osteocalcin expression in scrambled control 
cells in response to 500pM glutamate which was not apparent in untransfected cells.
5.3.5.1.1.2 SaOS-2
In transfected SaOS-2 cells, osteocalcin expression was significantly affected by 
overexpression of EAATl splice variants (GLM P—0.027) and the effect of 500pM 
glutamate was close to significance at the 5% level (GLM P=0.054). There was no 
significant interaction between the two factors (GLM P=0.477) (Figure 5.14B). Post- 
hoc comparisons (Tukey’s tests) revealed that overall, osteocalcin expression was 
significantly decreased in cells transfected with ex3skip AON compared to scrambled 
control cells (P=0.025), however pair-wise comparisons within each glutamate
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Figure 5.14. E ffect o f antisense mediated E A A Tl exon 3 and exon 9 skipping on 
osteocalcin mRNA expression in osteoblast-like cells at 48hrs post-transfection. 
Osteoblast-like cells (A, MG-63; B, SaOS-2) were transfected with scrambled control, 
ex3skip or ex9skip AONs for 48hrs, or left untransfected (± 500pM glutamate for last 
24hrs). Expression of osteocalcin mRNA was assessed by QRT-PCR, normalised to 
housekeeping gene levels and expressed as the mean percentage change over control 
cells (scrambled, no glutamate) ± S.E.M from three independent experiments, n=3. MG- 
63 osteocalcin expression was significantly decreased by 500pM glutamate (GLM 
P=0.009) and this was significant in scrambled control cells but not in cells 
overexpressing EAATla or EAATlex9skip (Tukey’s test). SaOS-2 osteocalcin 
expression was significantly affected by overexpression of EAATl splice variants (GLM 
P=0.027) and post-hoc Tukey’s tests revealed a significant decrease in expression in cells 
overexpressing EAATla. Oligoribonucleotide transfection did not affect osteocalcin 
expression relative to untransfected MG-63 or SaOS-2 cells (GLM). Significance values 
*P<0.05.
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treatment group were not statistically significant. The effect of glutamate was close to 
significance reflecting the trend for decreased osteocalcin expression in cells at 
500pM glutamate within each transfection group.
Transfection with oligoribonucleotides had no significant effect on SaOS-2 
osteocalcin expression relative to untransfected cells (GLM i >=0.845).
5.3.5.1.2 Osteonectin
5.3.5.1.2.1 MG-63
In transfected MG-63 cells, osteonectin expression was not significantly affected by 
overexpression of EAATl splice variants (GLM P=0.442) or 500pM glutamate 
(GLM P=0.620) and there was no interaction between the two factors (GLM 
P=0.279) (Figure 5.15A).
Transfection with oligoribonucleotides had no significant effect on MG-63 
osteonectin expression relative to untransfected cells (Shierer Ray P=0.115).
5.3.5.1.2.2 SaOS-2
In transfected SaOS-2 cells, osteonectin expression was not significantly affected by 
overexpression of EAATl splice variants (GLM with log data P=0.753) or 500pM 
glutamate (GLM with log data P=0.873), and there was no interaction between the 
two factors (GLM with log data P=0.740) (Figure 5.15B).
Transfection with oligoribonucleotides had no significant effect on SaOS-2 
osteonectin expression relative to untransfected cells (GLM P=0.071). The effect of 
transfection was close to significant and this appears to be a reflection of the non­
specific increase in osteonectin expression in transfected cells in the absence of 
glutamate compared to untransfected cells.
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Figure 5.15. E ffect o f  antisense mediated E A A T l exon 3 and exon 9 skipping on 
osteonectin mRNA expression in osteoblast-like cells at 48hrs post-transfection. 
Osteoblast-like cells (A, MG-63; B, SaOS-2) were transfected with scrambled control, 
ex3skip or ex9skip AONs for 48hrs, or left untransfected (± 500pM glutamate for last 
24hrs). Expression of osteonectin mRNA was assessed by QRT-PCR, normalised to 
housekeeping gene levels and expressed as the mean percentage change over control 
cells (scrambled, no glutamate) ± S.E.M from three independent experiments, n=3. 
Osteonectin expression was not significantly affected by overexpression of EAATl 
splice variants or 500pM glutamate in MG-63 or SaOS-2 cells (GLM). 
Oligoribonucleotide transfection did not affect osteonectin expression relative to 
untransfected cells in MG-63 (Shierer Ray test) or SaOS-2 cells (GLM).
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5.3.5.1.3 OPG
5.3.5.1.3.1 MG-63
In transfected MG-63 cells, OPG expression was not significantly affected by 
overexpression of EAATl splice variants (GLM P=0.330) or 500pM glutamate 
(GLM P=0.830), and there was no interaction between the two factors (GLM 
P=0.390) (Figure 5.16A).
Transfection with oligoribonucleotides had no significant effect on MG-63 OPG 
expression relative to untransfected cells (GLMP=0.751).
5.3.5.1.3.2 SaOS-2
In transfected SaOS-2 cells, OPG expression was not significantly affected by 
overexpression of EAATl splice variants (Shierer Ray P=0.593) or 500pM glutamate 
(Shierer Ray P=0.206), and there was no interaction between the two factors (Shierer 
Ray / >=0.526) (Figure 5.16B).
Transfection with oligoribonucleotides had no significant effect on SaOS-2 OPG 
expression relative to untransfected cells (Shierer Ray P=0.065). The effect of 
transfection was close to significant reflecting the non-specific increase in OPG 
expression in transfected cells in the absence of glutamate compared to untransfected 
cells.
5.3.5.1.4 ALP
5.3.5.1.4.1 MG-63
In transfected MG-63 cells, ALP expression was not significantly affected by 
overexpression of EAATl splice variants (GLM P=0.522) or 500pM glutamate 
(GLM P=0.783), and there was no interaction between the two factors (GLM 
P=0.591) (Figure 5.17A).
Transfection with oligoribonucleotides had no significant effect on MG-63 ALP 
expression relative to untransfected cells (GLMP=0.790).
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Figure 5.16, E ffect o f  antisense mediated E A A T l exon 3 and exon 9 skipping on 
osteoprotegerin (OPG) mRNA expression in osteoblast-like cells at 48hrs post­
transfection. Osteoblast-like cells (A, MG-63; B, SaOS-2) were transfected with 
scrambled control, ex3skip or ex9skip AONs for 48hrs, or left untransfected (± 
500|iM glutamate for last 24hrs). Expression of OPG mRNA was assessed by QRT- 
PCR, normalised to housekeeping gene levels and expressed as the mean percentage 
change over control cells (scrambled, no glutamate) ± S.E.M from three independent 
experiments, n=3. OPG expression was not significantly affected by overexpression 
of EAATl splice variants or 500|iM glutamate in MG-63 (GLM) or SaOS-2 cells 
(Shierer Ray test). Oligoribonucleotide transfection did not affect OPG expression 
relative to untransfected cells in MG-63 (GLM) or SaOS-2 cells (Shierer Ray test).
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Figure 5.17. Effect o f antisense mediated EAAT1 exon 3 and exon 9 skipping on ALP  
mRNA expression in osteoblast-like cells at 48hrs post-transfection. Osteoblast-like 
cells (A, MG-63; B, SaOS-2) were transfected with scrambled control, ex3skip or 
ex9skip AONs for 48hrs, or left untransfected (± 500pM glutamate for last 24hrs). 
Expression of ALP mRNA was assessed by QRT-PCR, normalised to housekeeping gene 
levels and expressed as the mean percentage change over control cells (scrambled, no 
glutamate) ± S.E.M from three independent experiments, n=3. ALP expression was not 
significantly affected by overexpression of EAAT1 splice variants or 500pM glutamate 
in MG-63 cells (GLM). SaOS-2 ALP expression was significantly decreased across 
transfected groups by 500pM glutamate (GLM P=0.038), however post-hoc pair-wise 
Tukey’s tests did not reach significance. Oligoribonucleotide transfection did not affect 
ALP expression relative to untransfected cells in MG-63 or SaOS-2 cells (GLM).
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5.3.5.1.4.2 SaOS-2
In transfected SaOS-2 cells, ALP expression was significantly affected by 500pM 
glutamate (GLM with log data P=0.038) but not by overexpression of EAAT1 splice 
variants (GLM with log data P=0.642), and there was no interaction between the two 
factors (GLM with log data P—0.619) (Figure 5.17B). 500pM glutamate decreased 
ALP expression in cells overexpressing EAATla and EAATlex9skip compared to 
scrambled control cells, however post-hoc pair-wise comparisons (Tukey’s tests) were 
not statistically significant.
Transfection with oligoribonucleotides had no significant effect on SaOS-2 ALP 
expression relative to untransfected cells (GLM P=0.986).
5.3.5.2 Primary osteoblasts
Gene expression changes were measured in untransfected primary human osteoblasts 
(NHOB2P11) and in the same cells 48hrs post-transfection with scrambled control or 
antisense oligoribonucleotides (Figure 5.18). 500pM glutamate was added to replicate 
cultures under each condition at the point o f transfection and remained in the culture 
medium for the full 48hr duration. Expression levels of osteocalcin and osteonectin 
were quantified by QRT-PCR and expressed as the percentage of gene expression in 
control cells (scrambled, no glutamate). Presented data are from a single preliminary 
experiment where n=4.
5.3.5.2.1 Osteocalcin
In transfected cells, osteocalcin expression was significantly decreased by 500pM 
glutamate (GLM /*=0.047), but unaffected by overexpression of EAAT1 splice 
variants (GLM P=0.992) and there was no interaction between the two factors (GLM 
P=0.983) (Figure 5.18A). Post-hoc comparisons (Tukey’s tests) did not reveal any 
pair-wise significance for the effect of glutamate.
Transfection with oligoribonucleotides had no significant effect on primary osteoblast 
osteocalcin expression relative to untransfected cells (GLM P=0.752).
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Figure 5.18. E ffect o f  antisense mediated EAAT1 exon 3 and exon 9 skipping on 
gene expression in primary human osteoblasts. Primary osteoblasts (NH0B2P11) 
were transfected with scrambled control, ex3skip or ex9skip AONs, or left 
untransfected ± 500pM glutamate for 48hrs. Expression of (A) osteocalcin and (B) 
osteonectin mRNA was assessed by QRT-PCR, normalised to 18S rRNA levels and 
expressed as the mean percentage change over control cells (scrambled, no glutamate) 
± S.E.M from a single preliminary experiment, n=4. In transfected primary 
osteoblasts, expression levels of osteocalcin and osteonectin were significantly 
decreased by 500pM glutamate (GLM P=0.047 and P=0.020 respectively) however 
no pair-wise Tukey’s comparisons reached significance. Oligoribonucleotide 
transfection did not affect osteocalcin or osteonectin expression relative to 
untransfected cells (GLM).
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5. S. 5.2.2 Osteonectin
In transfected cells, osteonectin expression was significantly decreased by 500pM 
glutamate (GLM with ranked data P=0.020), but unaffected by overexpression of 
EAAT1 splice variants (GLM with ranked data P=0.600) and there was no interaction 
between the two factors (GLM with ranked data P=0.997) (Figure 5.18B). Post-hoc 
comparisons (Tukey’s tests) did not reveal any pair-wise significance for the effect of 
glutamate.
Transfection with oligoribonucleotides had no significant effect on primary osteoblast 
osteonectin expression relative to untransfected cells (GLM with log data P=0.751).
5.3.6 Effect of antisense mediated EAAT1 exon skipping on ALP activity
ALP activity of SaOS-2 cells was measured colourimetrically at 48hrs post- 
transfection and normalised to total cell number (total LDH activity within the 
adherent cell lysate). ALP activity is shown as a percentage of ALP activity o f control 
cells (scrambled, OpM glutamate) (Figure 5.19). Presented data are from four 
independent experiments where n=3. SaOS-2 ALP activity was significantly affected 
by overexpression of EAAT1 splice variants (GLM with ranked data T^O.021) and by 
the interaction between glutamate and overexpression of the splice variants (GLM 
with ranked data P=0.042), however glutamate itself did not significantly affect ALP 
activity (GLM with ranked data /M3.378). Post-hoc pair-wise Tukey’s comparisons 
revealed that ALP activity was significantly increased to 216 ± 38.9 % of scrambled 
control cells by overexpression o f EAATlex9skip in the absence of glutamate 
(P=0.006). The same treatment had no effect on ALP activity compared to scrambled 
control cells at 500pM glutamate (P=1.000).
Comparison of scrambled control and untransfected cells revealed that 
oligoribonucleotide transfection did not affect ALP activity (GLM P=0.669).
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Figure 5.19. E ffect o f antisense mediated EAAT1 exon 3 and exon 9 skipping on 
SaOS-2 A LP activity over 48hrs. SaOS-2 cells were transfected with scrambled 
control, ex3skip or ex9skip AONs, or left untransfected, for 48hrs (± 500pM 
glutamate for last 24hrs). ALP activity was measured colourimetrically and 
normalised to cell number (as measured by total cellular LDH activity). ALP activity 
is shown as the mean percentage of control cell ALP activity (scrambled, no 
glutamate) ± S.E.M from four independent experiments, n=3. SaOS-2 ALP activity 
was significantly affected by overexpression of EAAT1 splice variants (GLM 
P=0.021) and by the interaction between glutamate and overexpression of the splice 
variants (GLM P=0.042). Post-hoc pair-wise Tukey’s tests revealed that ALP activity 
was significantly increased by overexpression of EAATlex9skip in the absence of 
glutamate. Oligoribonucleotide transfection did not affect ALP relative to 
untransfected cells (GLM). Significance values **P<0.01.
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S.4 Discussion
5.4.1 Antisense oligoribonucleotides can be used to efficiently induce exon
skipping of EAAT1 in osteoblasts
The manipulation o f EAAT1 expression relative to that of its splice variants has not 
been previously reported. Using antisense oligoribonucleotides targeted to the splice 
acceptor sequences of exons 3 and 9, it has been possible to induce exon skipping and 
increase the expression of EAATla and EAATlex9skip relative to the full-length 
EAAT1 sequence. At the transcript level, both ex3skip and ex9skip AONs induced a 
substantial increase in EAATla and EAATlex9skip respectively in primary human 
osteoblasts and human osteoblast-like cell lines.
Densitometry analysis of the EAATlex9skip:EAATl expression ratio in ex9skip 
AON transfected cells using PCR products resolved on an agarose gel revealed that 
the largest increase in this ratio occurred in SaOS-2 cells, though data at the 24hr 
time-point was very variable and increases observed at other time-points were similar 
across the two osteoblast cell lines. Furthermore, densitometry was utilised here as a 
simple measure to ascertain the efficiency over time of exon skipping and the 
methodology is not quantitative. Indeed, quantitative RT-PCR indicated that the 
largest increase in the EAATlex9skip:EAATl ratio following ex9skip AON 
transfection occurred in MG-63 cells.
The increase in the ratio of EAATlex9skip to full-length EAAT1 transcript in 
response to ex9skip AON transfection is dependent upon the basal proportion of the 
variants in each individual cell line as well as the normal level of transcription of 
EAATl. EAATlex9skip levels in untransfected cells are approximately 13% and 2% 
those of full length EAATl in MG-63 cells and SaOS-2 cells respectively, but SaOS- 
2 cells express considerably higher levels o f full-length EAATl and EAATlex9skip 
compared to MG-63 cells (as shown by QRT-PCR analysis, section 3.3.1.1). The 
same quantity of AON was added to the transfection mix for each cell line, so 
assuming roughly equal amounts of the AON permeated the plasma membrane and 
were available to induce exon skipping in each cell line, the same amount of full- 
length EAATl transcripts would be converted to EAATlex9skip. Although exon 
skipping might occur to the same extent in both cell lines, the effects of this may be
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much greater in MG-63 cells which express low levels of EAATlex9skip under 
normal conditions.
The lack of commercially available antibodies specific to the splice variants prevented 
confirmation of an increase in protein expression corresponding to the increase in 
variant mRNA levels. As a consequence, it is not possible to determine whether the 
experimental data is due to an up-regulation of splice variant protein relative to the 
normal EAATl protein, or due simply to interference with full-length EAATl mRNA 
levels. Evidence that EAATla and EAATlex9skip are translated has been provided 
using specific antibodies to the splice variants by western blotting and by 
immunohistochemistry in the rat CNS (Macnab and Pow 2007a; Sullivan et al. 
2007a), but not in bone. Western blotting analysis using antibodies targeted to 
portions of EAATl present in the full-length protein as well as both splice variant 
proteins have identified lower molecular weight bands that may correlate with 
EAATlex9skip or EAATla (50-55kDa) (Huggett et al. 2000; Macnab et al. 2006; 
Macnab and Pow 2007a). Western blotting using such EAATl antibodies could be 
used to confirm a difference in density ratios for immunoreactive bands corresponding 
to EAATl and its splice variants following exon skipping in osteoblasts.
5.4.2 Scrambled oligoribonucleotide transfection induces non-specific 
effects in human osteoblasts
Transfection with scrambled control oligoribonucleotides induced some significant 
non-specific effects in osteoblast-like cells and primary human osteoblasts. The 
scrambled control oligoribonucleotide was a scrambled version of the ex9skip AON 
and was checked for non-specific hybridisation by BLASTN searches (GenBank 
database sequences), which confirmed that it was unlikely to cause non-specific 
effects. Thus, the non-specific effects observed are likely to be due to the transfection 
agent, Fugene HD.
MG-63 cells exhibited an increase in cell number in response to transfection with the 
scrambled control AON, indicating that the transfection agent influenced the cell 
cycle. This increase was very small (<10% compared to untransfected cells). Many 
transfection agents negatively impact cell viability and physiology (Arbab et al. 2004; 
Schagat and Kopish 2010). Fugene HD has been developed to limit these cytotoxic
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effects (Schagat and Kopish 2010) and no increase in cell number has previously been 
reported in cells treated with Fugene HD.
In some cases, the response to 500jaM glutamate differed between cells transfected 
with scrambled control oligoribonucleotides and untransfected cells. For example, in 
primary human osteoblasts a glutamate induced reduction in osteocalcin and 
osteonectin expression was observed in all transfected cells compared to untransfected 
cells. This effect of the transfection agent complicates interpretation of changes in 
cells transfected with AONs in the presence and absence of glutamate, however all 
comparisons were appropriately made with reference to the scrambled control.
5.4.3 Overexpression of EAATl splice variants decreases Na+-dependent 
glutamate transport activity in osteoblast-like cells
Overexpression of EAATla and EAATl ex9skip significantly reduced Na+-dependent 
glutamate uptake in both MG-63 and SaOS-2 cells, indicating either a reduction in 
functional glutamate transporters at the plasma membrane, a reduction in affinity of 
the transporters for glutamate or a reduction in speed of transport. Overexpression of 
EAATla decreased Na+-dependent glutamate uptake by approximately the same 
extent in both cell lines, whereas overexpression of EAATlex9skip decreased Na+- 
dependent glutamate uptake to a greater extent in SaOS-2 than MG-63 cells. These 
experiments were carried out with lOfiM glutamate which is close to the glutamate 
concentrations in serum and synovial fluid under physiological conditions (Plaitakis et 
al. 1982; McNeamey et al. 2000) suggesting that manipulation of EAATl splice 
variant expression may be physiologically relevant to glutamate uptake in bone. 
Interestingly, transfection of ex9skip AONs induced the greater increase in 
EAATlex9skip:EAATl ratio in MG-63 cells compared to SaOS-2 cells, yet uptake of 
10pM glutamate was affected to a greater extent by this treatment in SaOS-2 cells. 
This may be due to the glutamate concentration used in the uptake experiments since 
the two cell lines exhibit very different saturation curves for glutamate uptake (section 
3.3.3.2.1). Indeed, interpretation of the functionality of the splice variants would be 
better informed by characterisation of the kinetic constants of Na+-dependent 
glutamate uptake in cells transfected with the AONs compared to those transfected 
with the scrambled control oligoribonucleotide. Such information would indicate 
whether the reduction in EAAT activity is a result of decreased affinity of the
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transporter (i.e. increased Km value) or decreased expression of the transporter at the 
plasma membrane (i.e. decreased Vmax value). Possible explanations for the observed 
reduction in EAAT activity following overexpression of the splice variants are; (i) 
that the splice variant transcript or protein is unstable, resulting in a reduction of full- 
length functional EAATl transcript and protein, (ii) that the splice variant is translated 
but retained intracellularly, (iii) that the splice variant is translated and non-functional 
or (iv) that the splice variant is expressed, functional but has reduced activity 
compared to the full-length protein.
5.4.3.1 EAATla
An unstable EAATla transcript is in agreement with the very low mRNA levels of 
EAATla in human osteoblasts but inconsistent with detection of EAATla protein in 
the CNS (Macnab et al. 2006). Furthermore glutamate uptake assays were carried out 
at 48hrs post-transfection, at which point high levels of EAATla mRNA were 
detectable in AON transfected cells by RT-PCR, indicating that the transcript is stable 
over this time period. The stability o f the EAATla protein has not been investigated; 
however its lack of glycosylation and TM2 domain may prevent the correct assembly 
of multimers, resulting in its retention at the ER (Conradt et al. 1995; Yemool et al.
2004).
There is some evidence to support intracellular retention of EAATla. In mouse MLO- 
Y4 osteocyte-like cells and human SaOS-2 cells transfected with GLAST-la tagged 
with GFP, GLAST-la was detected in internal vesicles surrounding the nucleus in 
MLO-Y4 cells (Huggett et al. 2002) and some patchy distribution at the plasma 
membrane was observed in SaOS-2 cells (Mason and Huggett 2002). No localisation 
studies of EAATla have been carried out in MG-63 cells or primary osteoblasts.
The proposed reorientation of EAATla in the plasma membrane generates an 
extracellular C-terminus (Huggett et al. 2000), preventing intracellular protein-protein 
interactions at this region as well as at any loops linking TM domains that are 
intracellular in the full-length protein. Interactions with the EAATl C-terminal 
domain stabilise expression of EAATl at the membrane (Table 6.1). Loss of such 
interactions might reduce the expression of EAATla at the cell surface. Furthermore, 
loss o f these intracellular regions may prevent regulatory protein-protein interactions
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or post-translational modifications such as phosphorylation that affect expression or 
activity of the transporter (discussed further in chapter 6).
Glutamate uptake has been detected in Xenopus laevis oocytes microinjected with 
cRNA encoding the ORF of GLAST-la, demonstrating that the protein retains the 
functional domains required for uptake activity (Mason, Huggett and Daniels 
unpublished data). EAATla retains the C-terminal domain of EAATl which is highly 
conserved and contains a number of residues that are important for glutamate binding 
and transport (Vandenberg et al. 1995; Grunewald et al. 1998; Seal and Amara 1999; 
Bendahan et al. 2000; Grunewald and Kanner 2000; Seal et al. 2000; Borre et al. 
2002; Ryan and Vandenberg 2002), predicting that the protein would be capable of 
glutamate transport (Huggett et al. 2000). Altered regulation of EAATla activity 
compared to full-length EAATl is more likely since the protein will lack crucial 
residues for the uncoupled anion conductance conferring altered ion channel 
properties to the cell (Mason, Huggett, Daniels, unpublished). The anion conductance 
activity of the EAATs is thought to function as a voltage clamp (Billups et al. 1996; 
Eliasof and Jahr 1996), which compensates for the membrane potential changes due to 
electrogenic glutamate uptake by EAATs. Lack of chloride entry might therefore slow 
glutamate transport, providing one explanation for the decreased EAAT activity in 
cell lines over-expressing EAATla.
5.4.3.2 EAATlex9skip
High levels of EAATlex9skip mRNA in human brain and osteoblasts (Vallejo- 
Illarramendi et al. 2005) and the detection of EAATl ex9skip protein expression in the 
CNS (Macnab and Pow 2007b; Sullivan et al. 2007a) suggest that the splice variant 
transcript and protein are stable. However, there is evidence to indicate instability of 
the protein (Vallejo-Illarramendi et al. 2005), and that multimeric complexes between 
EAATl and EAATlex9skip at the ER might assemble incorrectly and are therefore 
targeted for degradation (Hurtley and Helenius 1989; Klausner and Sitia 1990). 
HEK293 cells transiently transfected with the coding sequence of EAATlex9skip 
expressed a protein that was retained primarily within the ER suggesting that the 
splice variant is not expressed at the cell surface, however expression was also 
detected at the plasma membrane (Vallejo-Illarramendi et al. 2005). EAATlex9skip 
has also been detected intracellularly and at the plasma membrane of cortical and
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collicular neurons using EAATlex9skip specific antibodies (Macnab and Pow 
2007a).
No glutamate uptake activity was detected in HEK293 cells transiently transfected 
with the coding sequence of EAATlex9skip (Vallejo-Illarramendi et al. 2005). 
EAATlex9skip lacks specific residues (A446-G459) that have been found to be 
important for glutamate transport (Seal et al. 2001; Leighton et al. 2002; Ryan and 
Vandenberg 2002). The experiments presented in this chapter are consistent with a 
non-functional role for EAATlex9skip in Na+-dependent glutamate transport, 
however experiments were not carried out to test the theory that EAATlex9skip 
negatively regulates the function of full-length EAATl (Vallejo-Illarramendi et al.
2005).
5.4.4 Overexpression of the EAATl splice variants has opposing effects on 
cell number
EAATl splice variants were overexpressed in osteoblasts at 0 and 500pM glutamate. 
It should be noted that experiments in chapter 4 demonstrated an increase in MG-63 
and human primary osteoblast (NHOB2P7, NHOB3P5) cell number in response to 
500pM glutamate (section 4.3.2) that was not apparent in untransfected cells here. 
With respect to MG-63 cells, this may reflect differences in the experimental set-up 
since the experiments in this chapter were carried out using different culture plates 
and 500pM glutamate was added 24hrs later, when cells were more confluent. This is 
consistent with the idea (presented in section 7.3.4) that the effect of glutamate on 
MG-63 cell number is confluence dependent. With respect to the human primary 
osteoblasts, differences observed between the experiments may also reflect an altered 
confluency at the time of glutamate treatment, or that a later passage of this cell line 
(NHOB2P11) was used.
Overexpression of EAATla in the presence of 500pM glutamate resulted in an 
increase in SaOS-2 cell number that was not apparent at OpM glutamate. SaOS-2 cell 
number is not affected by 500pM glutamate over 24-72hrs, but cell number is 
significantly increased by chemical inhibition of EAATs (chapter 4), and this may 
occur via increased levels of extracellular glutamate available to activate NMDA 
receptors which are associated with the proliferative responses of a variety of cells, 
including MC3T3-E1 osteoblast-like cells, to glutamate (Contestabile 2000; Rzeski et
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al. 2001; Fatokun et al. 2006; Parada-Turska et al. 2006; Spitzer 2006; Piepoli et al.
2009). Therefore, the effect of EAATla on SaOS-2 cell number could also be the 
result of an increase in extracellular glutamate concentration due to decreased 
glutamate uptake activity. However overexpression of EAATlex9skip also reduced 
SaOS-2 glutamate uptake, but the same effects on cell number were not observed. The 
effects of exon skipping on glutamate transport were only assessed at lOpM glutamate 
and it is unclear how transport activity might be affected by exon skipping under the 
pathophysiological concentration of 500pM glutamate.
Alternatively, the effect of EAATla on SaOS-2 cell number could be the direct result 
of altered anion conductance and/or intracellular interactions associated with the 
splice variant. The uncoupled chloride conductance of EAATs may modulate 
glutamate receptor activity or operate itself as a receptor, activating intracellular 
signalling cascades in response to glutamate binding (Danbolt 2001; Mason and 
Huggett 2002). The anion conductance associated with glutamate binding might 
negatively regulate the signalling responses that modulate cell proliferation following 
glutamate receptor activation under normal conditions. The potential loss of C- 
terminal intracellular interactions associated with the re-orientated EAATla protein 
may also modulate the proliferative responses of the cell.
Overexpression of EAATlex9skip reduced MG-63 cell number at OpM glutamate, 
indicating that this treatment inhibits proliferation or increases apoptosis (no analysis 
of cell death was carried out). An inhibition of proliferation might indicate that 
overexpression of EAATlex9skip promotes the transition between the proliferation 
stage of osteoblast growth and differentiation, towards the matrix maturation stage 
(Figure 4.18). In support o f this, SaOS-2 cells transfected with ex9skip AONs exhibit 
increased ALP activity, a marker of extracellular matrix deposition and maturation. 
Evidence for an inverse relationship between these stages of osteoblast growth is well 
documented (Lian and Stein 1995; Malaval et al. 1999; Karsenty 2003; Lian and Stein 
2003; Stein et al. 2004) and a role for glutamate and/or the EAATs in this process is 
discussed in section 7.3.3.
Interestingly, it has been suggested that in the CNS, increased expression of 
EAATlex9skip represent neurons that are at risk of dying in response to hypoxic 
insult (Sullivan et al. 2007a). However the mechanism responsible for cell death in 
this case is glutamate-mediated excitotoxicity, which does not occur in human
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osteoblast-like cells in response to 500pM glutamate (sections 4.3.2.1 and 5.3.4.1 and 
Genever and Skerry 2001).
Preliminary data indicated that in scrambled oligoribonucleotide transfected primary 
osteoblasts (NHOB2P11), 500pM glutamate decreased mean cell number and 
increased mean cell death. These effects were mimicked by overexpression of 
EAATla and EAATlex9skip in the absence of exogenous glutamate suggesting that 
overexpression of these splice variants increases extracellular glutamate by reducing 
glutamate uptake, however further repeats of this experiment are required to validate 
these findings. Exon skipping in the presence of 500pM glutamate had no effect on 
cell number or cell death in primary osteoblasts.
5.4.5 Overexpression of the EAATl splice variants affects osteoblast gene 
expression
In osteoblasts, expression o f osteocalcin, osteonectin and ALP were significantly 
affected by 500pM glutamate, and osteocalcin mRNA levels were significantly 
affected by overexpression of EAATl splice variants.
500pM glutamate decreased MG-63 osteocalcin expression, consistent with chapter 4 
(section 4.3.3.2, Figure 4.7). Preliminary data from primary human osteoblasts 
displayed a reduction in both osteocalcin and osteonectin expression in response to 
500pM glutamate across all transfected groups, but this was not apparent in 
untransfected cells, suggesting that Fugene HD transfection agent modified the 
normal response of these cells to extracellular glutamate.
ALP expression was significantly decreased by 500pM glutamate in SaOS-2 cells 
across all transfection groups. No pair-wise statistical comparisons were significant, 
however 500pM glutamate decreased mean ALP mRNA levels to a greater extent in 
cells overexpressing EAATl splice variants in comparison to scrambled control cells. 
In the absence of extracellular glutamate, mean ALP mRNA levels were slightly 
increased by overexpression of EAATlex9skip, and this correlates with the 
significant increase in ALP activity observed in these cells. That 500|nM glutamate 
appears to attenuate this increase in mean ALP expression, suggests that high 
glutamate concentrations may be able to activate inhibitory GluRs or feedback 
signalling pathways.
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In MG-63 cells, overexpression of EAATla and EAATlex9skip in the absence of 
glutamate mimicked the reduced osteocalcin expression in response to 500pM 
glutamate, indicating a mechanism that occurs via reduced glutamate uptake. 
However, antagonists to NMDA receptors down-regulate the mRNA expression of 
osteocalcin in rat calvarial osteoblasts over 7-28 days (Hinoi et al. 2003) and NMDA 
and AMPA up-regulate osteocalcin expression in glutamate-free medium over 3 days 
(Lin et al. 2008). This discrepancy may be explained by the cell line in question, the 
differences in length o f treatment, or the effects of a specific iGluR agonist/antagonist 
over the general effect of extracellular glutamate. With respect to the latter, other 
glutamate receptor subtypes might be expressed at the cell surface which regulate the 
response, such as mGluRs (further discussed in section 7.3.1).
In SaOS-2 cells, overexpression of EAATla at both glutamate concentrations 
significantly reduced osteocalcin expression. This effect was not observed in 
EAATlex9skip overexpressing cells, implicating the region of the protein lost in 
EAATla in the response. EAATla lacks regions important for Cf conductance and if 
re-orientated in the plasma membrane, lacks protein-protein interactions that normally 
occur within the cell. Therefore, one or both of these activities may normally play a 
role in promoting osteocalcin expression in SaOS-2 cells.
5.4.6 Overexpression of EAATlex9skip increases SaOS-2 ALP activity
SaOS-2 ALP activity was significantly increased by overexpression of 
EAATlex9skip and mean SaOS-2 ALP activity was also increased by 500pM 
glutamate in untransfected cells, and cells transfected with the scrambled or ex3skip 
AONs. 500|iM glutamate also increased mean ALP mRNA levels in MG-63 and 
SaOS-2 cells in chapter 4 (section 4.3.3.6, Figure 4.11). Variability in the data may be 
explained by variable transfection efficiencies leading to differences in the extent of 
splice variant overexpression.
Overexpression of EAATlex9skip at OpM glutamate may increase ALP activity in 
osteoblasts by decreasing glutamate uptake which in turn increases the extracellular 
concentration of glutamate available for glutamate receptor activation. Consistent 
with this, antagonists to NMDA and AMPA receptors have previously been shown to 
inhibit ALP activity in rat calvarial osteoblasts (Hinoi et al. 2003; Lin et al. 2008). 
Thus, increased concentrations of extracellular glutamate due to overexpression of
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EAATl ex9skip may activate NMD A/AMP A receptors in SaOS-2 cells leading to 
increased ALP activity.
Overexpression of EAATla also significantly reduced Na+-dependent uptake of 
lOpM glutamate in SaOS-2 cells but had no effect on ALP activity. However, the 
reduction in uptake was much less than detected in cells overexpressing 
EAATl ex9skip.
Longer term studies assessing the role of the splice variants in the regulation of 
mineralisation were attempted (not shown). However, Fugene HD transfection agent 
had an inhibitory effect on either mineralisation itself, or the staining of calcium 
deposits by alizarin red since mineralisation could not be detected in cells transfected 
with any of the AONs. Furthermore, the transient nature of exon skipping using 
AONs is unsuitable to the long-term nature of mineralisation studies. An alternative 
strategy would be to develop an expression vector for the AONs and generate a stable 
cell line.
5.4.7 AONs as a therapeutic tool in bone
Over recent years, antisense mediated exon skipping has shown potential therapeutic 
application towards Duchenne’s Muscular Dystrophy (DMD), which is caused by 
frame-shifting mutations in the dystrophin-coding DMD gene that prevents production 
of functional dystrophin. By targeting the skipping of specific exons within the DMD 
gene using AONs, the reading frame can be restored which leads to production of an 
internally deleted, but largely functional, protein. This could convert the fatal DMD to 
the milder, Beckers MD phenotype (Dunckley et al. 1998; Wilton et al. 1999; van 
Deutekom et al. 2001; Mann et al. 2002), a mechanism that occurs spontaneously in 
some DMD patients (Aartsma-Rus et al. 2006).
Clinical trials in humans have shown that DMD targeted AONs injected 
intramuscularly can successfully restore expression of dystrophin (van Deutekom et 
al. 2007); however this method of delivery is unfeasible for treatment of all muscles in 
the body. Subcutaneous and intravenous AON delivery have been investigated in 
dystrophin-negative mcbc mice and sufficient amounts of the AON reached dystrophic 
muscle to induce expression of functional levels of dystrophin, however the majority 
ended up in the liver or kidneys (Alter et al. 2006; Fletcher et al. 2007). Furthermore, 
the effects of chronic AON treatment have not been investigated (van Ommen et al.
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2008) and toxicology as a result of non-specific hybridisation of the AON is likely to 
be species specific and unclear until investigated in humans (Hoffman 2007; Aartsma- 
Rus et al. 2009).
Therapeutic application of AONs in bone presents similar challenges. Strategies for 
gene therapy towards bone regeneration have investigated a number of approaches 
including transfection of cell populations ex vivo prior to implantation or injection of 
plasmid DNA; however none have yet reached clinical trial (reviewed in (Evans
2010)). Transfection of bone marrow stromal cells and muscle tissue-derived cells 
with a retrovirus encoding BMP-4 prior to seeding on a collagen sponge and 
implantation into a critical-sized rat femur defect has been shown to improve healing 
(Rose et al. 2003). Furthermore, adenoviral delivery of genes encoding BMP-2 or 
TGF-p into a rabbit femoral defect can stimulate bone healing (Baltzer et al. 2000). 
AONs could be delivered to bone via either these mechanisms, or injected 
intramedullary or into a defect space as oligoribonucleotides, as in the DMD studies 
outlined above (van Deutekom et al. 2007; Aartsma-Rus et al. 2009).
The majority of gene therapy studies in bone investigate its feasibility for improving 
the healing of defects such as non-union fracture rather than increasing bone mass 
systemically for the treatment of osteoporosis. Local delivery of gene therapy for bone 
healing has the advantage of not requiring chronic application, since there is no need 
for the activity to persist beyond the time required to achieve healing.
5.4.8 Summary
Overexpression of EAATl splice variants was investigated in osteoblast-like cells and 
primary human osteoblasts to ascertain the importance of the domains encoded by the 
spliced out exons in EAATla and EAATlex9skip in osteoblasts. Antisense RNA 
oligoribonucleotides targeted to the splice acceptor sequences o f EAATl exons 3 and 
9 efficiently induced exon skipping in osteoblasts and increased the expression of 
EAATla and EAATlex9skip relative to the full-length EAATl sequence 
respectively. Overexpression of both splice variants reduced Na+-dependent glutamate 
uptake in osteoblast-like cells. Modulation of EAATl splice variants in this manner 
has not been previously reported in any tissue, and these are the first studies to show 
that altering the ratio of EAATl to its splice variants can have variant specific effects
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on transporter function and osteoblast phenotype. Overexpression of EAATla 
increased SaOS-2 cell number and decreased osteocalcin expression in both 
osteoblast-like cell lines, whereas overexpression of EAATlex9skip reduced cell 
number and osteocalcin expression in MG-63 cells and increased ALP activity in 
SaOS-2 cells. Modulation of EAATla and EAATlex9skip expression therefore 
demonstrates potential for increasing osteoblast proliferation and bone-forming 
activity respectively, which could have therapeutic application to different stages of 
fracture healing.
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6. Functional effects of inhibition of EAATl intracellular
interactions in human osteoblasts
6.1 B ackground
6.1.1 Regulation of neurotransmitter transporter function
Within the CNS, synaptically released neurotransmitters are cleared by transporters 
that are selectively localised to specific membrane domains i.e. pre-synaptic, post- 
synaptic and astrocytic processes. A signalling event is regulated by transporter 
subtype, localisation, capacity and rate of transport - properties that can be modulated 
by protein-protein interactions within the cell and/or post-translational modification of 
the transporter.
6.1.1.1 Protein-protein interactions of neurotransmitter transporters
Intracellular protein-protein interactions are important for regulating the membrane 
trafficking and activity o f neurotransmitter transporters as well as other proteins 
including voltage gated potassium channels and neurotransmitter receptors (Corey et 
al. 1994; Kim et al. 1995; Komau et al. 1995; Dong et al. 1997; Horio et al. 1997; 
Tezuka et al. 1999; Yamada et al. 1999; Torres et al. 2004). Anchoring of transporters 
at specific regions of the membrane requires protein-protein interactions with 
scaffolding proteins. Many transporters contain postsynaptic density-95/discs 
large/zona occludens-1 (PDZ) binding regions at the extreme C-terminus, which allow 
for interactions with scaffolding proteins containing PDZ modules. PDZ domains are 
one of the most common protein motifs involved in scaffolding interactions. For 
example, the PDZ binding domain of the dopamine transporter (DAT) is necessary for 
interaction with protein-interacting-with-C-kinase (PICK) 1 which increases levels of 
DAT at the cell surface and increases dopamine uptake activity, possibly by anchoring 
DAT to the membrane (Torres et al. 2001; Bjerggaard et al. 2004). PICK1 also 
interacts with the C-terminus of the norepinephrine transporter (NET) and GLT-lb 
(Torres et al. 2001; Bassan et al. 2008).
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6.1.1.2 Post-translational modifications of neurotransmitter transporters
Neurotransmitter transporters interact with a variety of intracellular proteins that 
directly influence their activity. PICK1 interacts with protein kinase C (PKC), a 
signalling molecule that modifies the properties of various neurotransmitter 
transporters, suggesting that PICK1 may recruit PKC to transporters such as DAT, 
NET and GLT-lb. Phorbol ester-mediated stimulation of PKC decreases dopamine 
and glycine transporter activity (Kitayama et al. 1994; Sato et al. 1995), whereas cell- 
surface expression and activity o f the GAB A transporter (GAT-1) is increased by the 
same treatment (Corey et al. 1994). Cell surface expression and activity o f EAATl 
and EAAT3 are decreased and increased respectively by phorbol ester-mediated PKC 
activation (Conradt and StofFel 1997; Gonzalez and Ortega 1997; Davis et al. 1998; 
Gonzalez et al. 1999; Trotti et al. 2001; Do et al. 2002; Gonzalez et al. 2002). Various 
other signalling molecules have been implicated in the regulation of neurotransmitter 
transporters including phosphatidylinositol-3-kinase (PI3K), tyrosine kinases and 
protein phosphatase 2 (PP2) (Vaughan et al. 1997; Bauman et al. 2000; Law et al. 
2000; Apparsundaram et al. 2001; Doolen and Zahniser 2001; Zahniser and Doolen 
2001; Carvelli et al. 2002). Signalling molecules such as these allow for rapid changes 
in activity and distribution o f the transporters between the cytoplasm and the plasma 
membrane.
6.1.2 Regulation of EAAT function
The glutamate transporters and their splice variants display differential subcellular 
distribution patterns (reviewed in (Danbolt 2001)) indicating that their spatial 
organisation and insertion into the membrane is tightly regulated. For example, 
EAAT3 is preferentially distributed to apical membranes o f epithelial cells and to the 
perisynaptic region of the post-synaptic density (Cheng et al. 2002). The amino and 
carboxy termini of the glutamate transporters are intracellular and large compared to 
other cytoplasmic regions suggesting that they may be sites for protein-protein 
interactions (Grunewald et al. 1998). A variety of proteins have been identified that 
interact with the glutamate transporters (Table 6.1), and these interactions can regulate 
EAAT localisation, trafficking and activity as well as intracellular signalling.
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6.1.2.1 EAAT localisation/trafficking
6.1.2.1.1 C-terminal domain interactions
Human EAATl and rat and mouse GLAST contain a PDZ-binding motif (ETKM) at 
the C-terminus which is homologous to motifs found in other members of the EAAT 
family (Figure 6.1). In rat whole brain, GLAST coimmunoprecipitates with the 
Na+/H+ exchanger regulatory factor (NHERF) 1 and ezrin (Lee et al. 2007). NHERF1 
contains two PDZ motifs and a C-terminus that binds members of the ezrin-radixin- 
moesin (ERM) family of membrane-cytoskeletal adaptors. The actin cytoskeleton is 
important in regulating the expression of GLAST at the cell surface (Duan et al. 
1999). Interestingly, since actin responds to mechanical load (Vatsa et al. 2008), this 
interaction with GLAST may explain the first report of GLAST regulation in bone in 
response to mechanical load (Mason et al. 1997).
Interactions have also been demonstrated between the C-terminal tail of GLAST and 
an intermediate filament protein glial fibrillary acidic protein (GFAP) (Sullivan et al. 
2007b). GLAST glutamate uptake was significantly increased by the presence of 
GFAP and NHERF 1 as a result of stabilised expression of GLAST at the plasma 
membrane (Sullivan et al. 2007). Furthermore, expression o f GFAP was found to be 
important for GLAST expression at the plasma membrane of astrocytes following 
hypoxic insult (Sullivan et al. 2007b). The interaction between GFAP and GLAST 
was indirect and dependent upon the presence of NHERF 1 and the PDZ binding motif 
of GLAST, suggesting that in astrocytes, NHERF 1 links an intermediate filament 
network beneath the plasma membrane to cell surface GLAST. The importance of 
GFAP in GLAST activity is demonstrated by GFAP knockout mice that display 
reduced glutamate clearance in the CNS and an increased sensitivity to hypoxia 
(Hughes et al. 2004).
Associations have also been demonstrated between the GLAST C-terminus and Sept2 
and Sept4 in Bergmann glial processes surrounding axons and synapses of the mouse 
brain (Kinoshita et al. 2004). Sept2 and Sept4 are members o f the Septin family of 
guanosine triphosphatases (GTPases) which form filaments in a guanosine 
triphosphate (GTP) -form dependent manner. Sept2 binds to GLAST in a guanosine 
diphosphate (GDP) -form dependent manner and constitutive expression of the GDP-
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Table 6.1. Identified protein-protein interactions o f the glutamate transporters. EAAT s interact with a variety of proteins within the cell which 
regulate EAAT localisation, trafficking and activity as well as intracellular signalling processes. Abbreviations, PM, plasma membrane; CoIP,
coimmunoprecipitation; Y2H, Yeast 2 Hybrid.
Interacting
protein
EAAT
domain
Effect on 
glutamate 
transport
Mechanism of activity Cell type and species Reference
Expressed in 
osteoblasts?
EAAT1
GFAP C-term Increased
Intermediate filament protein 
that stabilises GLAST 
expression at the PM in 
association with NHERF1 
and ezrin.
CoIP using rat and pig 
whole brain; activity 
assessed in COS7 
cells
Sullivan et 
al. 2007
mRNA (Chipoy et al. 
2004); Protein 
(Kasantikul and 
Shuangshoti 1989; 
Chipoy et al. 2004)
NHERF1 C-term Increased
PDZ adaptor protein that 
stabilises G AST expression 
at the PM.
CoIP using rat whole 
brain; activity 
assessed in COS7 
cells
Lee et al.
2007, 
Sullivan et 
al. 2007
mRNA (Schroeder et 
al. 2007)
Ezrin C-term Not tested Membrane-cytoskeletal adaptor protein.
CoIP using rat whole 
brain Lee et al. 
2007
mRNA (Khanna et al.
2001; Park et al. 
2006); Protein (Park 
et al. 2006)
Sept2 C-term Decreased
Sept2 is a filament forming 
GTPase. Sept2 binds G AST 
in a GDP-form dependent 
manner and the constitutively 
GDP-bound form causes 
G AST internalisation.
CoIP using mouse 
brain membrane 
extracts and COS7 
cells; activity 
assessed in COS7 
cells and mouse 
Bergmann glial cells
Kinoshita et 
al. 2004 Not reported
Sept4 C-term Not tested
Sept4 is a filament forming 
GTPase which may hetero­
complex with Sept2.
CoIP using mouse 
brain membrane 
extracts
Kinoshita et 
al. 2004 Not reported
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Table 6.1 continued
Interacting
protein
EAAT
domain
Effect on 
glutamate 
transport
Mechanism of activity Cell type and species Reference Expressed in osteoblasts?
EAAT2
Ajuba N-term None
Cytoplasmic protein 
containing LIM domains. Co­
expression of GLT-1 and 
Ajuba recruits Ajuba to the 
PM.
Y2H using rat hippocampal 
cDNA library; CoIP using rat 
whole brain; activity 
assessed in COS cells
Marie et al. 
2002 Not reported
GPS-1 C-term Decreased
GPS-1 is a subunit of the 
COP9 signalosome and may 
be involved in the surface 
trafficking of GLT-1 via its 
leucine zipper-like motif.
Y2H (species/tissue not 
defined); activity assessed 
in HEK cells Watanabe et al. 2003 Not reported
PKCa Notdefined Decreased
Phorbol ester-mediated PKC 
activation decreases GLT-1 a 
expression at the PM.
CoIP using rat brain 
synaptosomes and GLT-1 a 
transfected C6 glioma; 
activity assessed in GLT-1 a 
transfected C6 glioma
Gonzalez 
et al. 2005
Protein (Sanders 
and Stern 1996; 
Lampasso et al. 
2002)
PICK1 C-term None
PDZ domain protein that 
interacts with PKC and GLT- 
1b splice variant. Co­
expression of GLT-1 b and 
PICK1 recruits PICK1 to the 
PM and the interaction 
prevents the PKC mediated 
decrease in GLT-1 b transport 
activity.
Y2H using rat forebrain 
neuronal cDNA library; CoIP 
using rat whole brain and 
GLT-1 b transfected COS7 
cells; activity assessed in 
COS7 cells and rat 
forebrain neuronal cultures
Bassan et 
al. 2008 Not reported
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Table 6.1 continued
Interacting
protein
EAAT
domain
Effect on 
glutamate 
transport
Mechanism of activity Cell type and species Reference
Expressed in 
osteoblasts?
EAAT3
GTRAP3-18 C-term Decreased
GTRAP3-18 decreases the 
substrate affinity of EAAC1 
via a reduction of N-linked 
glycosylation.
Y2H using rat brain 
cDNA; activity 
assessed in HEK, 
COS7 and C6 
glioma cells
Lin et al. 2001, 
Butchbach et al. 
2003, Ruggiero 
et al. 2008
Not reported
PKCa Notdefined Increased
Interaction only detected 
after phorbol ester treatment. 
Phorbol ester-mediated PKC 
activation increases EAAC1 
expression at the PM.
CoIP using C6 
glioma cells Gonzalez et al. 
2002, 2003
Protein (Sanders 
and Stern 1996; 
Lampasso et al. 
2002)
EAAT4
GTRAP48 C-term Increased
GTRAP48 is a Rho GEF. 
Interaction stabilises EAAT4 
expression at the PM.
Y2H using rat whole 
brain cDNA library; 
CoIP using 
GTRAP48 
expressing HEK 
cells
Jackson et al. 
2001 Not reported
GTRAP41 C-term Increased
Possibly an actin-binding 
protein. Stabilises EAAT4 
expression at the PM.
Y2H using rat whole 
brain cDNA library; 
CoIP using 
GTRAP41 
expressing HEK 
cells
Jackson 2001 Not reported
EAAT5 PICK1 C-term Not tested - - Bassan et al. 2008 Not reported
241
Chapter 6
0T—1CO1 PDZ
Human EAAT11 E ----T— K---- M II
Rat GLAST2 E ----T — K-----M II
Mouse GLAST3 E ----T — K-----M II
Human EAAT24 K----R-----E-----K
Human EAAT2b5 E ----T---- C---- 1 1
Rat GLT-16 K----R---- E---- K
Mouse GLT-17 K----R---- E---- K
Rat G LT-1 b8/GLT-1 v9 E ---- T -----C-----1 1
Mouse mGLT-1a7 K---- R-----E-----K
Mouse mGLT-1b7 E ---- T-----C-----1 1
Rat GLT-1 c10 Q— S — W— V 1
Human EAAT311 T —  S — Q— F II
RatEAACI12 T —  S —  Q---- F II
Mouse EAAC113 T —  S —  Q— F II
Human EAAT414 E —  S— A— M II
Rat EAAT415 E ---- S— V-----M II
Mouse EAAT416 E ---- S— V-----M II
Human EAAT517 E ---- T— N-----V 1
Mouse EAAT518 E ---- T-----N-----V 1
PDZ I X — S/T— X—  l/V
PDZ II x — cp— x— cp
9 = h y d rophob ic  re s id u e
Figure 6.1. PDZ domain binding m otifs in glutamate transporter C-terminal 
sequences. The last four amino acids from each EAAT are shown and numbered 
with the PO position allocated to the extreme C-terminal amino acid o f each 
EAAT. All known transporters except human EAAT2, and rat and mouse GLT-1 
(and mouse mGLT-1 a) have PDZ domain interaction motifs at their extreme C- 
termini, if any hydrophobic residue is allowed in the PO position. Figure adapted 
from (Bassan et al. 2008). 1. (Kawakami et al. 1994), 2. (Storck et al. 1992), 3. 
(Tanaka 1993), 4. (Arriza et al. 1994), 5. (Maragakis and Rothstein 2004), 6. 
(Pines et al. 1992), 7. (Utsunomiya-Tate et al. 1997), 8. (Chen et al. 2002), 9. 
(Schmitt et al. 2002), 10. (Rauen et al. 2004), 11. (Smith et al. 1994), 12. (Kanai et 
al. 1995a), 13. (Strausberg et al. 2002), 14. (Fairman et al. 1995), 15. (Cholet et al.
2002), 16. (Yamada et al. 1997), 17. (Arriza et al. 1997), 18. (Blackshaw et al. 
2004)
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form of Sept2 resulted in internalisation of GLAST and a reduction in glutamate 
uptake (Kinoshita et al. 2004).
G protein pathway suppressor-1 (GPS-1) was identified by the Yeast-2-Hybrid (Y2H) 
technique using the C-terminus of GLT-1 as bait (Watanabe et al. 2003). GPS-1 is a 
subunit of the COP9 signalosome and may be involved in the surface trafficking of 
GLT-1 via its leucine zipper-like motif. Coexpression of GPS-1 with GLT-1 in 
HEK293 cells reduced glutamate transport activity, though it was not reported 
whether this effect was due to altered cell surface expression o f GLT-1 (Watanabe et 
al. 2003).
Y2H studies using the C-terminal sequence of EAAT4 identified ‘glutamate 
transporter associated proteins’ (GTRAPs) (Jackson et al. 2001; Lin et al. 2001). The 
EAAT4 C-terminus associates with GTRAP48 and GTRAP41, which promote 
EAAT4 activity by stabilising its expression at the plasma membrane (Jackson et al.
2001). GTRAP48 is a guanine nucleotide exchange factor (GEF) for the small G- 
protein Rho and there is evidence to suggest that GTRAP41 is an actin-binding 
protein, suggesting that interaction of EAAT4 with actin filaments and Rho may be 
involved in stabilising EAAT4 at the membrane (Jackson et al. 2001).
6.1.2.1.2 N-terminal domain interactions
EAATs display poor homology at the N-terminus between subtypes and few 
interacting proteins have been identified. Ajuba, a cytoplasmic protein containing Lin- 
11, Isl-1 and Mec-3 (LIM) domains, is expressed in astrocytes and Bergmann glia and 
known to interact with the N-terminus o f GLT-1. Ajuba is able to activate MAPK and 
may act as a scaffolding protein, linking GLT-1 to the cytoskeleton and various 
signalling pathways (Marie et al. 2002). Co-expression of Ajuba with GLT-1 did not 
alter transport activity but the presence of GLT-1 caused a redistribution of Ajuba 
from the cytoplasm to the plasma membrane.
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6.1.2.2 EAAT activity
6.1.2.2.1 C-terminal domain interactions
Dialysis of whole-cell patch-clamped retinal glia with a competing peptide identical to 
the extreme 8 amino acids of the C-terminus of GLAST, containing the putative PDZ- 
binding domain, increased the affinity o f the transporter for glutamate without 
affecting the maximum glutamate-evoked current ( V m a x )  (Marie and Attwell 1999). 
The authors suggested that the C-terminal peptide disrupted an inhibitory interaction 
that may have been involved in slowing the removal of low concentrations of 
glutamate and therefore regulating the kinetics o f retinal cell light responses. 
Interaction of the C-terminus of EAAC1 and GTRAP3-18 (JWA in human) reduces 
EAAC1 mediated glutamate transport by decreasing substrate affinity via a reduction 
of N-linked glycosylation (Lin et al. 2001; Butchbach et al. 2003; Ruggiero et al. 
2008).
6.1.2.2.2 N-terminal domain interactions
Dialysis o f whole-cell patch-clamped retinal glia with a competing peptide identical to 
the extreme 8 amino acids of the N-terminus of GLAST had no effect upon affinity 
for glutamate or the maximum glutamate-evoked current of the transporter, suggesting 
that any protein-protein interactions at the N-terminus do not regulate GLAST 
transport activity in non-stimulated cells (Marie and Attwell 1999).
Identification of Ajuba, a protein that can activate MAPK signalling, at the N- 
terminus of GLT-1 (Marie et al. 2002) introduced the concept that EAAT protein- 
protein interactions may regulate downstream intracellular signalling pathways, 
supporting a receptor-like function for the transporters. Abe and Saito (2001) 
discovered that glutamate could increase MAPK phosphorylation in rat cortical 
astrocytes in a time- and concentration-dependent manner. This response could be 
mimicked by the transportable glutamate analogues THA and /-PDC but not by 
glutamate receptor agonists, suggesting that EAATs may act as receptors for changes 
in extracellular glutamate concentration (Abe and Saito 2001). The authors could not 
define the region of the protein involved in this activity and did not speculate.
&
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6.1.2.2.3 Other interactions
The amino acid sequence o f the EAATs contains putative phosphorylation sites 
(Figure 1.8, (Kanai et al. 1993; Conradt and Stoffel 1997)) and a number o f studies 
have indicated that phosphorylation can regulate EAAT activity; however the results 
depend on the experimental model used. Furthermore, it is not yet clear if  EAATs are 
phosphorylated directly or regulated by an associated protein that is phosphorylated. 
Table 6.2 summarises the findings relating to the effects o f phosphorylation on EAAT 
activity. It is clear that rapid responses to the cellular environment can be finely tuned 
to regulate EAAT activity via protein kinase-dependent signalling.
Table 6.2. Protein kinase effects on E A A T  transport activity. In vitro studies have 
shown that EAATs are differentially regulated by phosphorylation. Potential 
phosphorylation sites for PKC and PK A  are shown in Figure 1.8, however PKC 
phosphorylation o f EAAT 1 occurs at a non-consensus site (Conradt and Stoffel 1997). 
NC, no change; NT, not tested.
EAAT PKC PI3K PKA
1 I T T
2 ^ (sh o rt-te rm ). ^(long-term ) T I
3 T T T
4 NC NT NT
6.1.2.2.3.1 PKC
In Xenopus Laevis oocytes and HEK293 cells expressing the cloned GLAST cDNA, 
phorbol ester mediated activation o f PKC inhibited glutamate transport activity 
(Conradt and Stoffel 1997). The same treatm ent also reduced GLAST glutamate 
uptake activity in GLAST-rich Bergmann glial cultures (Gonzalez and Ortega 1997) 
and in retinal M uller cells (Gonzalez et al. 1999).
In HEK293 cells, PKC activation by up to lh r phorbol ester treatment did not alter 
plasma membrane expression o f  GLAST, as shown by immunohistochemistry. 
Expression rate and stability o f the transporter were also not affected, as shown by
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metabolic labelling of the protein with [35S]-methionine (Conradt and Stoffel 1997). 
However, long-term treatment (6-24hrs) of GLAST-rich Bergmann glial cultures with 
phorbol esters reduced GLAST protein and mRNA levels (Gonzalez and Ortega 1997; 
Espinoza-Rojo et al. 2000) and phorbol ester-mediated PKC activation in retinal 
Muller cells reduced GLAST expression in the plasma membrane (Wang et al. 2003). 
Mutational studies indicate that PKC does not phosphorylate GLAST at predicted 
consensus PKC sites (GLAST SI 16, T341, T372) (Conradt and Stoffel 1997).
Phorbol ester mediated PKC activation induced a 50% increase in glial glutamate 
uptake from primary cultures o f rat brain cerebral cortex over 3-24hrs and this was 
assumed to be largely due to effects o f PKC on GLT-1, the predominant glial 
transporter in the cerebrum (Casado et al. 1991). The same group later confirmed the 
activation of GLT-1 following phorbol ester treatment and identified that residue 
Serine 113 of GLT-1 was necessary for this effect (Casado et al. 1993). However, 
other studies have observed a reduction in GLT-1 activity following short-term (up to 
30 min) PKC activation in C6 glioma transfected with GLT-1, primary astrocyte 
cultures, and Xenopus Laevis oocytes injected with GLT-1 mRNA and the reduction 
in activity was thought to be the result o f decreased cell surface expression of the 
transporter (Fang et al. 2002; Kalandadze et al. 2002; Zhou and Sutherland 2004; 
Gonzalez et al. 2005).
In C6 glioma, GLT-1 a could be coimmunoprecipitated with the classical PKCa and 
the downregulation o f GLT-1 a cell surface expression in response to phorbol ester 
mediated PKC activation was sensitive to inhibitors of the classical PKC subgroup, 
indicating that PKCa mediates the phorbol ester-induced redistribution of GLT-1 a 
(Gonzalez et al. 2005). Activated PKCa interacts with PICK1 (Staudinger et al. 1995; 
Staudinger et al. 1997; Perez et al. 2001), a PDZ domain protein that may act as an 
adaptor to recruit PKCa into complexes with PICK1 binding target proteins (Perez et 
al. 2001; Hirbec et al. 2002). PICK1 interacts with the C-terminal PDZ binding 
domain of GLT-1 b, a splice variant of GLT-1 a containing an alternative C-terminus, 
but does not interact with GLT-1 a which lacks a PDZ binding domain (Bassan et al. 
2008). GLT-lb colocalises with PICK1 in pyramidal neurons and astrocytes in the 
adult rat cerebral cortex (Mahadomrongkul et al. 2002) and with synaptic markers in 
hippocampal neurons in vitro (Bassan et al. 2008). Coexpression of GLT-lb and 
PICK1 in COS7 cells recruits PICK1 to the plasma membrane (Bassan et al. 2008). In 
rat forebrain neuronal cultures, where GLT-lb is expressed (Wang et al. 1998; Chen
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et al. 2002), phorbol ester mediated PKC activation had no effect on glutamate 
transport activity. However disruption of the GLT-lb-PICKl interaction with a 
competing peptide targeted to the PDZ motif o f GLT-lb decreased transport activity 
in response to phorbol ester treatment, but did not change cell surface expression of 
GLT-la or GLT-lb (Bassan et al. 2008). GLT-lc (Rauen et al. 2004). EAAT5 was 
also found to interact with PICK1 with comparable affinity to GLT-lb (Bassan et al. 
2008), whereas GLAST, EAAC1 and EAAT4 did not show affinity for PICK1 as 
determined by a fluorescent polarisation assay (Bassan et al. 2008).
Phorbol ester-mediated PKC activation increased activity and cell surface expression 
of EAAC1 in C6 glioma cells (Davis et al. 1998; Trotti et al. 2001; Do et al. 2002; 
Gonzalez et al. 2002) and in EAAC1 expressing Xenopus Laevis oocytes (Trotti et al. 
2001; Do et al. 2002). Mutational studies have shown a critical role for S465, at the C- 
terminal o f EAAT3, in mediating this (Baik et al. 2009). Phorbol ester-mediated PKC 
activation in primary cortical neurons also resulted in an increase in EAAC1 cell 
surface expression (Gonzalez et al. 2002; Guillet et al. 2005).
Interestingly, inhibition o f PI3K in EAAC1 expressing C6 glioma cells abolished the 
PKC-dependent increase in cell surface expression, but did not completely eliminate 
the increase in transport activity (Davis et al. 1998), indicating that PKC may regulate 
EAAC1 cell surface expression and catalytic activity independently. Gonzalez et al. 
found, using selective inhibitors for the PKC isoenzymes, that PKCa mediates a PKC- 
dependent increase in cell surface expression of EAAC1 in C6 glioma cells and that 
PKCe mediates a PKC-dependent increase in EAAC1 activity that is independent of 
changes in EAAC1 cell surface expression (Gonzalez et al. 2002). PKCa can be 
coimmunoprecipitated with EAAC1 in C6 glioma cells and in synaptosomes from rat 
cortex, cerebellum, hippocampus and midbrain, however in C6 glioma this interaction 
was dependent upon PKCa activation by phorbol ester treatment (Gonzalez et al.
2003). Confocal microscopy indicated that EAAC1 colocalises with phorbol ester- 
activated PKCa at the plasma membrane of C6 glioma cells (Gonzalez et al. 2003).
In Xenopus laevis oocytes expressing rat EAAT4, phorbol ester treatment enhanced 
the glutamate gated chloride conductance o f this transporter without altering transport 
activity (Fang et al. 2006). This effect was only partially inhibited by the PKC 
inhibitors staurosporine, chelerythrine and calphostin C (Oishi and Yamaguchi 1994; 
Fang et al. 2006). The authors o f this study did not speculate as to which residues of 
EAAT4 might be subject to PKC phosphorylation.
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6.1.2.2.3.2 PI3K
PI3K has also been implicated in EAAT regulation. The Vmax of GLAST in chick 
Bergmann glial cells was increased by treatment with IGF-I and this activation was 
sensitive to inhibition of PI3K, a downstream effector of IGF-I (Gamboa and Ortega
2002). IGF-I increased GLAST activity in this system in a manner that was not 
dependent on de novo protein synthesis, indicating translocation of the transporter to 
the plasma membrane as opposed to increased protein expression of the transporter 
(Gamboa and Ortega 2002).
In primary cortical neuron-enriched cultures from rats, inhibition of PI3K by 
wortmannin decreased cell surface levels o f GLT-1 and EAAC1 (Guillet et al. 2005) 
and inhibited transport activity in EAAC1 expressing C6 glioma cells (Davis et al. 
1998).
6.1.2.2.3.3 PKA
In primary cortical neuron-enriched cultures from rats, inhibition o f PKA by H89 
decreased cell surface expression of GLAST and EAAC1, but increased cell surface 
expression of GLT-1 (Guillet et al. 2005). In contrast, Adolph et al. detected an 
increase in GLAST transport activity in rat primary glial cells treated with the PKA 
inhibitor H89 (Adolph et al. 2007). This enhanced uptake activity was sensitive to 
chemical blocking of actin polymerisation by cytochalasin-B, indicating that 
inhibition of PKA results in increased translocation of GLAST to the plasma 
membrane (Adolph et al. 2007).
6.1.3 Aims
A number of proteins have been identified that interact with or phosphorylate the 
EAAT1 C-terminus; however no interacting proteins have yet been identified for the 
EAAT1 N-terminus or the intracellular loops connecting the transmembrane domains. 
Furthermore, none of the interacting proteins identified and discussed above have 
been assessed for their effects on the ion channel activity of the EAATs. The 
intracellular stretch of amino acids between transmembrane domains 6 and 7 of 
EAAT1 has been noted to show homology to a motif required for binding of IGF-II
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and a-adrenergic receptors to different classes of Ga subunits of heterotrimeric G 
proteins (Gegelashvili and Schousboe 1998). The objectives of the experiments 
presented in this chapter are to modify EAAT activity and/or localisation in human 
osteoblasts using peptides that mimic the intracellular N- and C-termini and the 
stretch of intracellular amino acids between transmembrane domains 6 and 7. These 
peptides are expected to compete with full-length EAAT1 for phosphorylation or 
binding with interacting proteins, and therefore inhibit the effect of intracellular 
proteins on EAAT1 localisation and/or activity. The effect of these competing 
peptides on glutamate transport will be assessed by radiolabelled glutamate uptake 
assay and the effects on bone forming activity will be assessed by measuring cell 
number, gene expression analysis and ALP activity assay.
6.2 Methods
Sequences o f EAAT 1 corresponding to N-terminal, transmembrane 6-7 (TM6-7), and 
C-terminal intracellular domains that were subcloned into pcDNA3.1/V5-Hise- 
TOPO® expression vector (from here on referred to as pcDNA3.1) are detailed in 
section 2.11 and appendix 9.8. The sequences for EAAT1 N-terminus and C-terminus 
were cloned into pcDNA3.1 in frame with the vector V5 and His epitope tags 
(appendix 9.3). The nucleotide sequence o f the EcoRV restriction site mutated during 
cloning of EAAT1 TM6-7, taking the sequence out of frame of the V5 and His 
epitope tags. The mutation had no effect on the translated sequence of the TM6-7 
peptide and introduced new stop codons (shown in appendix 9.3). The general method 
for transfection of pcDNA3.1 expression vector is detailed in section 2.10.2.
6.2.1 Cell culture and transfection
MG-63 osteoblasts were seeded at 2.6 x 104 cells/cm2 in 96-well plates, 48-well 
plates, 8-well chamber slides, and 24-well plates. SaOS-2 cells were seeded at 4.2 x 
104 cells/cm2 in 96-well plates, 48-well plates, 8-well chamber slides and 24-well 
plates. At 80% confluence, the cells were transfected with empty pcDNA3.1 vector or 
pcDNA3.1 vector expressing N-terminal, TM6-7 or C-terminal domains of EAAT 1
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(section 2.10.2), or left untransfected in DMEM containing 5% dFBS and 50pg/ml 
ascorbate.
During optimisation, the transfection medium was supplemented with sodium 
butyrate to increase expression of the peptides (section 6 2.2.2.2). However sodium 
butyrate alone was found to inhibit EAAT glutamate uptake activity (section
6.3.1.4.3), so was not used in experiments where the effect of inhibiting EAAT1 
intracellular domains on EAAT glutamate uptake activity, gene expression, cell 
number or alkaline phosphatase (ALP) activity was assessed.
6.2.2 Confirmation of transfection
6.2.2.1 mRNA expression
RNA was extracted and reverse transcribed from transfected cells (section 2.3) and 
amplified (section 2.4.2) using primers against pcDNA3.1 vector that span the cloning 
site (Table 2.8). These primers yield different sized products depending on the size of 
the DNA insert (Table 2.9).
6.2.2.1.1 Efficiency o f pcDNA3.1 vector expression over time
Cells were transfected in 48-well plates. At 6, 24, 48, and 72hrs post-transfection the 
medium was aspirated, the cells rinsed with cold PBS and homogenised with 0.1ml 
TRIzol® reagent per well for 5 min. The plates were stored at -80°C until RNA 
extractions, reverse transcription and RT-PCR were carried out. RT-PCR (section 
6.2.2.1) was carried out using an optimised 25 cycles of amplification to ensure that 
comparison o f band densities by agarose gel electrophoresis (section 2.4.3) occurred 
during the linear increase in PCR product.
6.2.2.2 Protein expression
6.2.2.2.1 Immunofluorescence
Cells were seeded and transfected in eight-well chamber slides. At 48hrs post­
transfection, the cells were washed with PBS and fixed with 4% paraformaldehyde
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(appendix 9.1) for 15 min. The cells were then washed for 3 x 5 min with PBS prior to 
10 min incubation with 0.2% Triton® X-100 in PBS. Staining and visualisation of the 
cells was as detailed in section 2.6, substituting mouse-anti-V5 (Invitrogen, Paisley, 
UK) as the primary antibody at 1:250 in PBS/0.1% Tween®-20 and goat-anti-mouse 
IgG-FITC conjugate as the secondary antibody at 1:160 in PBS/0.1% Tween®-20. 
One additional difference to the methodology was that fixed cells were incubated with 
the primary antibody for lhr at room temperature as opposed to overnight at 4°C. 
Primary negative controls were performed to confirm that staining was not a result of 
non-specific binding of the secondary antibody.
6.2.2.2.2 Induction o f expression using sodium butyrate
Since no immunoreactive proteins were detected using an antibody against the V5 
epitope, sodium butyrate, a histone deacetylase (HDAC) inhibitor (Davie 2003) that 
can enhance gene expression controlled by mammalian promoters, such as 
cytomegalovirus (CMV), in various different cell types (Cockett et al. 1990; Laubach 
et al. 1996; Shimizu et al. 1997; Chang et al. 1999; Lai et al. 2009) was used.
6.2.2.2.2.1 Effect of sodium butyrate on viable adherent cell number
Since sodium butyrate can significantly induce apoptotic cell death in various cell 
types (Chang et al. 1999), the effect of sodium butyrate on viable adherent cell 
number was assessed. To assess the cytotoxic effects of sodium butyrate, cells were 
incubated with varying concentrations of sodium butyrate for 48hrs. Cells were 
seeded in 96-well plates and at 80% confluence; cells were incubated with sodium 
butyrate (O-lOOmM) in antibiotic-free DMEM containing 5% dFBS and 50pg/ml 
ascorbate. After 48hrs, the medium was aspirated and the cells rinsed with cold PBS 
prior to lysis with lOOpl/well lysis buffer (section 2.5.1). 50pl of lysate was taken for 
LDH assay of cell number (section 2.5.3).
6.2.2.2.2.2 Effect o f sodium butyrate on Na+-dependent glutamate uptake
To determine the effect o f sodium butyrate on endogenous EAAT activity, cells were 
seeded in 24-well plates and at 80% confluence; cells were incubated with lOmM
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sodium butyrate in antibiotic-free DMEM containing 5% dFBS and 50gg/ml 
ascorbate. Cells were cultured for 48hrs in total, however medium was changed in 
replicate cultures at 8 and 24hrs and replaced with fresh antibiotic-free DMEM 
containing 5% dFBS and 50pg/ml ascorbate but lacking sodium butyrate. At 48hrs, 
glutamate uptake activity was assayed in the presence and absence of Na+ to 
determine Na+-dependent uptake (section 2.8 and section 6.2.3 below) and activity 
was compared to control cells cultured for 48hrs in the absence of sodium butyrate.
6.2.3 Effect of inhibition of EAAT1 intracellular interactions on Na+- 
dependent glutamate uptake
Cells were transfected in 24-well plates (section 2.10.2 and 6.2.1). At 48hrs post- 
transfection, glutamate uptake activity was assayed in the presence and absence of 
Na+ to determine Na+-dependent uptake (section 2.8). Culture medium was aspirated 
and the cells pre-incubated with KRH buffer (+ Na+) for lhr and then the buffer 
aspirated and replaced with KRH buffer (± Na+) containing a mix of radiolabelled and 
unlabelled glutamate at lOpM (Table 2.4) for 10 min. Uptake activity was normalised 
to total protein content determined by BCA assay from parallel cultures (section 2.5.2 
and 2.8.2).
6.2.4 Effect of inhibition of EAAT1 intracellular interactions on gene 
expression
Cells were transfected in 24-well plates (section 2.10.2 and 6.2.1). At 24hrs post- 
transfection, the medium o f replicate cultures was supplemented with 500pM 
glutamate. After a further 24hrs (i.e. 48hrs post-transfection) the medium was 
aspirated, cells rinsed with cold PBS and homogenised with 0.2ml TRIzol® reagent 
per well for 5 min. The plates were stored at -80°C until RNA extractions, reverse 
transcription and QRT-PCR amplifications were carried out (section 2.3 and 2.4.4) 
using primers against osteocalcin, osteonectin, osteoprotegerin (OPG), alkaline 
phosphatase (ALP), 18S rRNA, GAPDH and HPRT1 (Table 2.1). Gene expression for 
MG-63 and SaOS-2 cells was normalised to GAPDH and HPRT1 respectively, the 
most stable housekeeping genes of the three as determined using geNorm software for 
this experiment (Vandesompele et al. 2002). Relative QRT-PCR was carried out
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(section 2AA.5) using the Applied Biosystems 7900HT Fast Real-Time PCR system 
(section 2.4.4.1.2) in conjunction with cDNA standard curves (section 2.4.4.2.2). All 
values were expressed relative to control cells transfected with the empty vector at 
OpM glutamate.
6.2.5 Effect of inhibition of EAAT1 intracellular interactions on cell 
number and ALP activity
Cells were transfected in 24-well plates (section 2.10.2 and 6.2.1). At 24hrs post- 
transfection, the medium of replicate wells was supplemented with 500gM glutamate. 
After a further 24hrs (i.e. 48hrs post-transfection) the medium was aspirated and the 
cells rinsed with cold PBS prior to lysis with lOOpl/well lysis buffer (section 2.5.1). 
5pl of lysate was taken for assays o f cell number (LDH Cytotox96 assay) and ALP 
activity (SaOS-2 cells only) (sections 2.5.3 and 2.5.4).
6.2.6 Statistics
Cells transfected with pcDNA3.1 vector expressing EAAT1 intracellular domains 
were compared to empty vector control cells. Statistical comparison between 
untransfected and empty vector control cells was also carried out to display any non­
specific effects of vector transfection
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6.3 Results
6.3.1 Confirmation of pcDNA3.1 vector transfection
6.3.1.1 mRNA expression
RNA isolated from MG-63 cells transfected with empty pcDNA3.1 vector or the same 
vector expressing EAAT1 C-terminal, N-terminal or TM6-7 intracellular domains for 
6, 24 and 48hrs was reverse transcribed and amplified with primers against pcDNA3.1 
vector that span the cloning site. Transfection and expression of the appropriate vector 
was confirmed by the presence of the correct sized transcript at each time-point 
(Figure 6.2).
6.3.1.2 Efficiency of pcDNA3.1 vector expression over time
In order to define the optimum time post-transfection for osteoblast phenotypic assays 
to be carried out; the efficiency of vector expression was observed over time (6-72hrs) 
by limited cycle RT-PCR and resolution of DNA products using agarose gels (Figure
6.3). Only MG-63 and SaOS-2 cells transfected with the empty vector were used to 
assess expression over time since it was assumed that similar conditions would apply 
to all the expression vectors cloned.
Expression of the vector was detected at all time-points assayed and the highest 
expression appeared to be at 24 and 48hrs post-transfection, consistent with the time- 
points of maximum exon skipping observed in optimisation experiments in chapter 5 
(section 5.3.2.1). These results and the desire to design an experiment that would be 
directly comparable to the experiments in chapter 5 led to the decision to assay cells at 
48hrs post-transfection and to assess the effect of extracellular glutamate on 
transfected cells by adding glutamate 24hrs post-transfection, when vector expression 
is likely to be high.
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Figure 6.2. Expression o f  pcDNA3.1 vector in MG-63 cells. Empty pcDNA3.1 and 
pcDNA3.1 vector containing EAAT1 N-terminal, C-terminal and TM6-7 intracellular 
domains were transfected into MG-63 cells and RNA extracted at 6, 24 and 48hrs for 
reverse transcription and amplification by RT-PCR using primers that span the vector 
cloning site. Products were resolved on an agarose gel alongside a low molecular 
weight DNA ladder. 1. Empty vector (246bp), 2. N-terminal (398bp), 3. C-terminal 
(410bp), 4. TM6-7 (329bp).
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Figure 6.3. Expression o f  pcDNA3.1 vector (containing no insert) over 72hrs. 
Empty pcDNA3.1 vector was transfected into (A) MG-63 and (B) SaOS-2 cells. RNA 
was extracted at 6, 24, 48 and 72hrs for reverse transcription and amplification by 25 
cycles o f RT-PCR using primers that span the vector cloning site. Products were 
resolved on an agarose gel alongside a lOObp DNA ladder. Empty vector (246bp).
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6.3.1.3 Protein expression
Neither MG-63 nor SaOS-2 cells transfected with pcDNA3.1 vector expressing the 
EAAT1 N- or C-terminal and stained for immunoreactivity to the V5 epitope 
displayed staining beyond that detected in the primary-negative control (not shown). 
In an attempt to enhance expression of the EAAT1 peptides, the use of sodium 
butyrate was investigated as a supplement to the transfection medium.
6.3.1.4 Induction of expression using sodium butyrate
6.3.1.4.1 Effect o f sodium butyrate on viable adherent cell number
The effect of 0.5-100mM sodium butyrate treatment on viable adherent MG-63 and 
SaOS-2 cell number was assessed at 48hrs (Figure 6.4). Presented data are from a 
angle experiment where n=3. MG-63 cell number rapidly decreased with increasing 
concentrations of sodium butyrate up to lOmM. At lOmM sodium butyrate, MG-63 
cell number was 48 ± 0.7 % of control cells. At concentrations above lOmM sodium 
butyrate, no further decrease in MG-63 cell number was observed. SaOS-2 cell 
number at 0.5 and 2mM sodium butyrate was slightly increased to 107 ± 4.4 % and 
114 ± 4.2 % of control cells respectively. SaOS-2 cell number then rapidly decreased 
at sodium butyrate concentrations between 2 and lOmM, with lOmM sodium butyrate 
decreasing viable adherent cell number to 15 ± 0.7 % of control cells. At 
concentrations above lOmM sodium butyrate, no further decrease in SaOS-2 cell 
number was observed.
6.3.1.4.2 Effect o f lOmM sodium butyrate on pcDNA3.1 vector expression
MG-63 cell number was less affected by sodium butyrate toxicity than SaOS-2 cells. 
These cells were therefore transfected with pcDNA3.1 vector expressing EAAT1 N- 
or C-terminal for 48hrs in the presence of 0 and lOmM sodium butyrate. A 
concentration of lOmM sodium butyrate was chosen to maximise vector expression. 
Transfected cells were stained for the V5 epitope (Figure 6.5).
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Figure 6.4. E ffect o f sodium butyrate on osteoblast viable cell number over 48hrs. 
MG-63 (A) and SaOS-2 (B) osteoblast-like cells were incubated with O-lOOmM 
sodium butyrate for 48hrs. Adherent cell number was assayed by measuring LDH 
released upon total lysis o f viable adherent cells and expressed as the mean percentage 
of LDH activity in viable adherent control cells (OmM sodium butyrate) ± S.E.M from 
a single experiment, n=3.
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Figure 6.5. Immunoreactivity fo r  the V5 epitope in MG-63 cells transfected withpcDNA3.1 vector containing EAAT1 intracellular domains. 
MG-63 cells were transfected with pcDNA3.1 vector containing EAAT1 N-terminal (A-C) and C-terminal (D-F) domains in the presence of 0 or 
lOmM sodium butyrate for 48hrs. Cells were immunostained for the V5 epitope tag on the expressed peptide ( A ,B ,D ,E ) .  Transfected cells (C,F) 
were also probed with secondary antibody alone to determine levels of non-specific staining. Pictures were taken under 800ms exposure.
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In the absence of sodium butyrate, no immunoreactivity for the V5 epitope above that 
detected in the primary-negative control was detected in MG-63 cells transfected with 
pcDNA3.1 vector expressing EAAT1 N- or C-terminal (Figure 6.5A,D). However, 
immunoreactivity for the V5 epitope was clearly detected in MG-63 cells transfected 
with pcDNA3.1 vector expressing EAAT1 N-terminal or C-terminal domains in the 
presence of lOmM sodium butyrate (Figure 6.5B,E), indicating that the peptide is 
expressed and that lOmM sodium butyrate does enhance expression from the 
pcDNA3.1 vector CMV promoter.
6.3.1.4.3 Effect of sodium butyrate on Na+-dependent glutamate uptake
MG-63 cells were incubated with lOmM sodium butyrate for 8, 24 and 48hrs. Total 
incubation time was 48hrs and when sodium butyrate was removed prior to the 48hrs 
end-point, culture medium was replaced with fresh sodium butyrate-free medium. 
Na+-dependent glutamate uptake was normalised to total cellular protein (mg) and 
presented data are from a single experiment where n=4 (Figure 6.6). Na+-dependent 
glutamate uptake in sodium butyrate treated cells was compared to Na+-dependent 
glutamate uptake in untreated cells at 48hrs.
Na+-dependent glutamate uptake was significantly reduced in cells treated with 
sodium butyrate for 24 and 48hrs (one-way ANOVA P<0.001), however 8hrs sodium 
butyrate treatment did not affect glutamate uptake.
Since sodium butyrate treatment alone significantly reduced EAAT activity over the 
required treatment time of 48hrs, and the aim o f these experiments was to modulate 
EAAT1 expression/activity using intracellular peptides, it was concluded that sodium 
butyrate treatment would significantly compromise interpretation of the experimental 
data and it was not used in any further experiments.
6.3.2 Effect of inhibition of EAAT1 intracellular interactions on Na+- 
dependent glutamate uptake
Na+-dependent glutamate uptake was measured in MG-63 and SaOS-2 osteoblast-like 
cells 48hrs post-transfection with empty pcDNA3.1 vector or the same vector 
expressing EAAT1 N-terminal, TM6-7 or C-terminal intracellular domains. Na - 
dependent glutamate uptake was also measured in untransfected cells under the same
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Figure 6.6. E ffect o f  sodium butyrate on Nt?-dependent glutamate uptake in MG- 
63 cells over time. MG-63 cells were incubated with lOmM sodium butyrate and 
cultured for 48hrs; however medium was changed in replicate cultures at 8 and 24hrs 
and replaced with fresh medium. At 48hrs, cells were incubated with lOpM mix of 
radiolabelled and unlabelled glutamate at 37°C for 10 min in KRH buffer ± Na+, 
followed by aspiration of the buffer and rinsing with cold KRH containing 1.5mM 
unlabelled glutamate. Na+-dependent glutamate uptake was normalised to total 
cellular protein (mg). Values are mean ± S.E.M from a single experiment where n=4. 
MG-63 Na+-dependent glutamate uptake was significantly reduced by 10mM sodium 
butyrate treatment for 24 and 48hrs (one-way ANOVA P<0.001). Significance values 
***P<0.001.
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conditions to determine the effects of the transfection procedure. Na+-dependent 
glutamate uptake was normalised to total cellular protein (mg) and expressed as a 
percentage of empty vector control cells. Presented data are from three independent 
experiments where n=3.
6.3.2.1 MG-63
In transfected MG-63 cells, Na+-dependent glutamate uptake was not significantly 
affected by expression of EAAT1 intracellular domains (Kruskal Wallis P=0.26Qi) 
(Figure 6.7). Although not significant, a trend for increased glutamate uptake activity 
was observed in cells expressing EAAT1 N-terminal, TM6-7, and C-terminal 
intracellular domains to 140 ± 12.3 %, 144 ± 19.3 %, and 130 ± 14.8 % of empty 
vector controls respectively.
Na+-dependent glutamate uptake was significantly decreased in empty vector control 
cells relative to untransfected cells (one-way ANOVAP=0.031).
6.3.2.2 SaOS-2
In transfected SaOS-2 cells, Na+-dependent glutamate uptake was not significantly 
affected by expression of EAAT1 intracellular domains (Kruskal Wallis P=0.084) 
(Figure 6.8). Although not significant, a trend for decreased glutamate uptake activity 
was observed in cells expressing EAAT1 N-terminal, TM6-7, and C-terminal 
intracellular domains to 90 ± 5.7 %, 85 ± 5.0 %, and 95 ± 4.2 % of empty vector 
controls respectively.
Na+-dependent glutamate uptake was significantly increased in empty vector control 
cells relative to untransfected cells (Kruskal Wallis P=0.001).
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Figure 6.7. E ffect o f  inhibition o f EAAT1 intracellular interactions on Na+- 
dependent glutamate uptake in MG-63 cells. MG-63 cells were transfected with 
empty pcDNA3.1 or pcDNA3.1 vector containing each EAAT1 intracellular domain 
for 48hrs. MG-63 cells were then incubated with lOpM mix of radiolabelled and 
unlabelled glutamate at 37°C for 10 min in KRH buffer ± Na+, followed by aspiration 
of the buffer and rinsing with cold KRH containing 1.5mM unlabelled glutamate. 
Na+-dependent glutamate uptake was normalised to total cellular protein (mg) and 
expressed as a percentage of empty vector control cells. Values are mean ± S.E.M 
from three independent experiments where n=3. Na+-dependent glutamate uptake was 
not significantly affected by expression of EAAT1 intracellular domains (Kruskal 
Wallis P=0.260), however, Na+-dependent glutamate uptake was significantly 
decreased by transfection with pcDNA3.1 relative to untransfected cells (one-way 
ANOVA P=0.031). Significance values *P<0.05.
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Figure 6,8. E ffect o f  inhibition o f  EAAT1 intracellular interactions on Na+- 
dependent glutamate uptake in SaOS-2 cells. SaOS-2 cells were transfected with 
empty pcDNA3.1 or pcDNA3.1 vector containing each EAAT1 intracellular domain 
for 48hrs. SaOS-2 cells were then incubated with lOpM mix of radiolabelled and 
unlabelled glutamate at 37°C for 10 min in KRH buffer ± Na+, followed by aspiration 
of the buffer and rinsing with cold KRH containing 1.5mM unlabelled glutamate. 
Na+-dependent glutamate uptake was normalised to total cellular protein (mg) and 
expressed as a percentage of empty vector control cells. Values are mean ± S.E.M 
from three independent experiments where n=3. Na+-dependent glutamate uptake was 
not significantly affected by expression of EAAT1 intracellular domains (Kruskal 
Wallis P=0.084), however, Na+-dependent glutamate uptake was significantly 
increased by transfection with pcDNA3.1 relative to untransfected cells (Kruskal 
Wallis P=0.001). Significance values **P<0.01.
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6.3.3 Effect of inhibition of EAAT1 intracellular interactions on cell
number
MG-63 and SaOS-2 cells were transfected with empty pcDNA3.1 or pcDNA3.1 
vector containing EAAT1 N-terminal, TM6-7, and C-terminal intracellular domains 
for 48hrs. 500pM glutamate was added to replicate cultures 24hrs post-transfection. 
Adherent cell number was assayed by measuring LDH released upon total lysis of 
viable adherent cells and expressed as a percentage of LDH activity of viable adherent 
control cells (empty vector, no glutamate). Presented data are from three independent 
experiments where n=3.
6.3.3.1 MG-63
In transfected MG-63 cells, cell number was significantly affected by expression of 
EAAT1 intracellular domains (Shierer Ray P<0.001) but not by 500pM glutamate 
(Shierer Ray P=0.976) and there was no interaction between the two factors (Shierer 
Ray P=0.580) (Figure 6.9). Post-hoc pair-wise comparisons (Mann Whitney U tests) 
revealed that, compared to empty vector controls at 500pM glutamate, cell number 
was significantly increased by transfection with pcDNA3.1 vector expressing EAAT1 
C-terminal domain from 93 ± 3 . 8 %  to 115 ± 3.5 % (P=0.003). Cell number was also 
increased by this treatment at OgM glutamate to 109 ± 4.3 % of empty vector controls, 
however this did not reach statistical significance (P=0.133).
Transfection with pcDNA3.1 empty vector significantly decreased MG-63 cell 
number relative to untransfected cells (Shierer Ray P<0.001) and post-hoc 
comparisons (Mann Whitney U tests) revealed that this occurred at both OpM and 
500gM glutamate (P<0.001 and P=0.008 respectively).
6.3.3.2 SaOS-2
In transfected SaOS-2 cells, cell number was not significantly affected by expression 
of EAAT1 intracellular domains (Shierer Ray P=0.123) or by 500pM glutamate 
(Shierer Ray P=0.455) and there was no interaction between the two factors (Shierer 
Ray P=0.837) (Figure 6.10). Transfection with pcDNA3.1 had no significant effect on 
SaOS-2 cell number relative to untransfected cells (GLM P=0.604).
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Figure 6.9. E ffect o f  inhibition o f EAAT1 intracellular interactions on MG-63 
osteoblast-like cell number over 48hrs. MG-63 cells were transfected with empty 
pcDNA3.1 or pcDNA3.1 vector containing each EAAT1 intracellular domain for 
48hrs. Adherent cell number was assayed by measuring LDH released upon total lysis 
of viable adherent cells and expressed as the mean percentage of LDH activity of 
viable adherent control cells (empty vector, no glutamate) ± S.E.M from three 
independent experiments, n=3. MG-63 cell number was significantly affected by 
expression of EAAT1 intracellular domains (Shierer Ray P<0.001), but not by 
glutamate concentration. Post-hoc pair-wise Mann Whitney U tests revealed that cell 
number was significantly increased in MG-63 cells transfected with pcDNA3.1 vector 
expressing EAAT1 C-terminal domain compared to empty vector controls at 500pM 
glutamate. Transfection with pcDNA3.1 significantly decreased MG-63 cell number 
relative to untransfected cells (Shierer Ray P<0.00\). Significance values **/><0.01, 
***p<0 ooi.
I
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Figure 6.10. E ffect o f  inhibition o f EAAT1 intracellular interactions on SaOS-2 
osteoblast-like cell number over 48hrs. SaOS-2 cells were transfected with empty 
pcDNA3.1 or pcDNA3.1 vector containing each EAAT1 intracellular domain for 
48hrs. Adherent cell number was assayed by measuring LDH released upon total lysis 
of viable adherent cells and expressed as the mean percentage of LDH activity of 
viable adherent control cells (empty vector, no glutamate) ± S.E.M from three 
independent experiments, n=3. SaOS-2 cell number was not significantly affected by 
expression of EAAT 1 intracellular domains or glutamate (Shierer Ray test). Empty 
vector transfection did not affect SaOS-2 cell number relative to untransfected cells 
(GLM).
267
Chapter 6
6.3.4 Effect of inhibition of EAAT1 intracellular interactions on gene
expression
MG-63 and SaOS-2 cells were transfected with empty pcDNA3.1 or pcDNA3.1 
vector containing EAAT1 N-terminal, TM6-7, and C-terminal intracellular domains 
for 48hrs. 500pM glutamate was added to replicate cultures 24hrs post-transfection. 
Expression levels o f  osteocalcin, osteonectin, OPG and ALP were quantified by QRT- 
PCR and expressed as a percentage o f  gene expression in control cells (empty vector, 
no glutamate). Presented data are from three independent experiments where n=3.
6.3.4.1 Osteocalcin
6.3.4.1.1 MG-63
In transfected MG-63 cells, osteocalcin expression was significantly affected by 
expression o f  EAAT1 intracellular domains (GLM P=0.001) but not by 500pM  
glutamate (GLM P=0.480) and there was no interaction between the two factors 
(GLM P=0.45S) (Figure 6.11 A). Post-hoc comparisons (Tukey’s tests) did not reveal 
any pair-wise significance between cells transfected with pcDNA3.1 expressing 
EAAT1 intracellular domains compared to empty vector control cells at the 5% level. 
However compared to empty vector control cells at OpM glutamate, osteocalcin levels 
were increased in cells transfected with pcDNA3.1 vector containing EAAT1 N- 
terminal domain to 125 ± 13.6 % and decreased in cells transfected with pcDNA3.1 
vector containing EAAT1 TM6-7 and C-terminal domain to 79 ± 7.9 % to 83 ± 9.7 % 
respectively. Transfection with pcDNA3.1 had no significant effect on MG-63 
osteocalcin expression relative to untransfected cells (GLM with ranked data 
P=0.951).
6.3.4.1.2 SaOS-2
In transfected SaOS-2 cells, osteocalcin expression was significantly affected by 
expression o f EAAT1 intracellular domains (GLM P=0.028) but not by 500pM  
glutamate (GLM P=0.656) and there was no interaction between the two factors 
(GLM P=0.578) (Figure 6.1 IB). Post-hoc comparisons (Tukey’s tests) did not reveal
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Figure 6.11. E ffect o f inhibition o f EAAT1 intracellular interactions on osteocalcin 
mRNA expression in osteoblast-like cells at 48hrs post-transfection. Osteoblast-like 
cells (A, MG-63; B, SaOS-2) were transfected with empty pcDNA3.1 or pcDNA3.1 
vector containing each EAAT1 intracellular domain for 48hrs and expression o f  mRNA 
for osteocalcin was assessed by QRT-PCR. Osteocalcin levels were normalised to 
housekeeping gene levels and expressed as the mean percentage change over control 
cells (empty vector, no glutamate) ± S.E.M from three independent experiments, n=3. 
MG-63 and SaOS-2 osteocalcin levels were significantly affected by expression o f  
EAAT1 intracellular domains (GLM P=Q.001 (MG-63) and P—0.02S (SaOS-2)), however 
no pair-wise Tukey’s comparisons were statistically significant. Vector transfection did 
not affect osteocalcin expression relative to untransfected cells in MG-63 or SaOS-2 cells 
(GLM).
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any pair-wise significance between groups transfected with the vector at the 5% level. 
However compared to empty vector control cells at OpM glutamate, mean osteocalcin 
levels were decreased in cells expressing EAAT1 C-terminal domain at OpM 
glutamate to 83 ± 9.7 % and compared to empty vector control cells at 500pM 
glutamate, mean osteocalcin levels were increased in cells expressing EAAT1 N- 
terminal domain at 500pM glutamate from 83 ± 11.0 % to 112 ± 7:5 %. Transfection 
with pcDNA3.1 had no significant effect on SaOS-2 osteocalcin expression relative to 
untransfected cells (GLMP=0.210).
6.3.4.2 Osteonectin
6J.4.2.1 MG-63
In transfected MG-63 cells, osteonectin expression was not significantly affected by 
expression of EAAT1 intracellular domains (GLM with ranked data P=0.544) or by 
500pM glutamate (GLM with ranked data P=0.557) and there was no interaction 
between the two factors (GLM with ranked data P=0.800) (Figure 6.12A). However, 
transfection with pcDNA3.1 empty vector resulted in an increase in osteonectin 
mRNA levels relative to untransfected cells (Shierer Ray P=0.003). Post-hoc pair­
wise comparisons (Mann Whitney U tests) revealed pair-wise significance for this 
increase at OpM (P=0.006) but not at 500pM glutamate (P=0.194).
6.3A.2.2 SaOS-2
In transfected SaOS-2 cells, osteonectin expression was not significantly affected by 
expression ofEAATl intracellular domains (GLMP=0.446) or by 500pM glutamate 
(GLM P=0.136) and there was no interaction between the two factors (GLM 
P=0.990) (Figure 6.12B). However, transfection with pcDNA3.1 resulted in a non­
specific increase in osteonectin mRNA levels relative to untransfected cells (GLM 
with log data P=0.028). Post-hoc pair-wise comparisons (Tukey’s tests) did not reveal 
pair-wise significance for this increase at OjiM (P=0.192) or 500pM glutamate 
(P=0.618).
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Figure 6.12. Effect o f  inhibition o f  EAAT1 intracellular interactions on osteonectin 
mRNA expression in osteoblast-like cells at 48hrs post-transfection. Osteoblast-like 
cells (A, MG-63; B, SaOS-2) were transfected with empty pcDNA3.1 or pcDNA3.1 
vector containing each EAAT1 intracellular domain for 48hrs and expression of 
mRNA for osteonectin was assessed by QRT-PCR. Osteonectin levels were 
normalised to housekeeping gene levels and expressed as the mean percentage change 
over control cells (empty vector, no glutamate) ± S.E.M from three independent 
experiments, n=3. Osteonectin expression was not significantly affected by expression 
of EAAT1 intracellular domains or glutamate in MG-63 cells or SaOS-2 cells (GLM). 
Transfection with empty pcDNA3.1 significantly increased osteonectin expression 
relative to untransfected cells in both MG-63 and SaOS-2 cells (Shierer Ray test 
P=0.003 and GLM P=0.028 respectively). Pair-wise significance for this increase was 
only observed in MG-63 cells at OpM glutamate. Significance values **P<0.01.
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6.3.43 OPG
6.3.4.3.1 MG-63
In transfected MG-63 cells, OPG expression was not significantly affected by 
expression of EAAT1 intracellular domains (Shierer Ray P=0.290) or by 500pM 
glutamate (Shierer Ray P=0.496) and there was no interaction between the two factors 
(Shierer Ray P=0.890) (Figure 6.13A). However, transfection with pcDNA3.1 
resulted in a non-specific increase in OPG mRNA relative to untransfected cells 
(GLMP<0.001) and post-hoc comparisons (Tukey’s tests) revealed that this occurred 
at both OpM and 500gM glutamate (P=0.018 and P=0.024 respectively).
6.3.4.3.2 SaOS-2
In transfected SaOS-2 cells, OPG expression was significantly affected by expression 
of EAAT1 intracellular domains (GLM with ranked data P =0.030) but not by 500juM 
glutamate (GLM with ranked data P=0.142) and there was no interaction between the 
two factors (GLM with ranked data P=0.392) (Figure 6.13B). Compared to empty 
vector control cells at OpM glutamate, mean OPG expression was decreased in cells 
expressing EAAT1 N-terminal (P=0.267), TM6-7 (P=0.213), and C-terminal 
(P=0.192) domains, although post-hoc pair-wise comparisons (Tukey’s tests) were 
not significant. Each peptide had different effects at 500pM glutamate.
Transfection with pcDNA3.1 resulted in a non-specific increase in OPG mRNA levels 
relative to untransfected cells (GLM with ranked data P<0.001). Post-hoc pair-wise 
comparisons (Tukey’s tests) revealed pair-wise significance for this increase at OpM 
(P<0.001), but not at 500pM glutamate (P=0.386). A significant effect of the 
interaction between transfection and glutamate was also apparent between 
untransfected and empty vector control cells (GLM with ranked data P=0.049). This 
reflects the increased OPG expression in response to 500jiM glutamate observed in 
untransfected cells (Tukey’s P=0.140) which is lost in empty vector transfected cells 
(Tukey’s P=0.903) due to the non-specific increase in OPG expression as a result of 
transfection.
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Figure 6.13. E ffect o f  inhibition o f EAAT1 intracellular interactions on osteoprotegerin 
(OPG) mRNA expression in osteoblast-like cells at 48hrs post-transfection. Osteoblast­
like cells (A, MG-63; B, SaOS-2) were transfected with empty pcDNA3.1 or pcDNA3.1 
vector containing each EAAT1 intracellular domain for 48hrs and expression of mRNA for 
OPG was assessed by QRT-PCR. OPG levels were normalised to housekeeping gene levels 
and expressed as the mean percentage change over control cells (empty vector, no 
glutamate) ± S.E.M from three independent experiments, n=3. MG-63 OPG expression was 
not significantly affected by EAAT1 intracellular domains or glutamate (Shierer Ray test). 
SaOS-2 OPG expression was significantly affected by expression of EAAT1 intracellular 
domains (GLM P=0.030), however no post-hoc Tukey’s comparisons were significant. 
Transfection with pcDNA3.1 significantly increased OPG expression relative to 
untransfected cells (GLM P<0.001 (MG-63) and P<0.001 (SaOS-2)). Significance values 
L*P<0.05, ***P<0.001.
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6.3AA  ALP
6.3.4.4.1 MG-63
In transfected MG-63 cells, ALP expression was not significantly affected by 
expression of EAAT1 intracellular domains (GLM P=0.681) or by 500pM glutamate 
(GLM P=0.188) and there was no interaction between the two factors (GLM 
P=0.391) (Figure 6.14A). Transfection with pcDNA3.1 had no significant effect on 
MG-63 ALP expression relative to untransfected cells (GLM P=0.939). A general 
effect for 500pM glutamate increasing ALP expression was detectable when 
untransfected cells were compared with empty vector control cells (GLM P=0.044), 
however post-hoc comparisons (Tukey’s tests) did not reveal any pair-wise 
significance.
6.3.4.4.2 SaOS-2
In transfected SaOS-2 cells, ALP expression was not significantly affected by 
expression of EAAT1 intracellular domains (GLM with log data .P=0.090) or 500pM 
glutamate (GLM with log data P=0.368) and there was no interaction between the two 
factors (GLM with log data P=0.620) (Figure 6.14B). However, compared to empty 
vector control cells mean ALP expression was decreased in SaOS-2 cells transfected 
with pcDNA3.1 vector containing EAAT1 C-terminal domain at both glutamate 
concentrations, and by EAAT1 TM6-7 domain at OpM glutamate.
Transfection with pcDNA3.1 had no significant effect on SaOS-2 ALP expression 
relative to untransfected cells (GLM P=0.095).
6.3.5 Effect of inhibition of EAAT1 intracellular interactions on ALP 
activity
SaOS-2 cells were transfected with empty pcDNA3.1 or pcDNA3.1 vector containing 
EAAT1 N-terminal, TM6-7, and C-terminal intracellular domains for 48hrs. 500pM 
glutamate was added to replicate cultures 24hrs post-transfection. ALP activity was 
measured colourimetrically and normalised to total cell number (total LDH activity 
within the adherent cell lysate). ALP activity is shown as the percentage of ALP
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Figure 6.14. E ffect o f inhibition o f EAAT1 intracellular interactions on ALP  
mRNA expression in osteoblast-like cells at 48hrs post-transfection. Osteoblast-like 
cells (A, MG-63; B, SaOS-2) were transfected with empty pcDNA3.1 or pcDNA3.1 
vector containing each EAAT1 intracellular domain for 48hrs and expression of 
mRNA for ALP was assessed by QRT-PCR. ALP levels were normalised to 
housekeeping gene levels and expressed as the mean percentage change over control 
cells (empty vector, no glutamate) ± S.E.M from three independent experiments, n=3. 
ALP expression was not significantly affected by expression of EAAT1 intracellular 
domains or glutamate in MG-63 or SaOS-2 cells (GLM). Vector transfection did not 
affect ALP expression relative to untransfected cells in MG-63 or SaOS-2 cells 
(GLM).
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activity of control cells (empty vector, no glutamate) (Figure 6.15). Presented data are 
from three independent experiments where n=3.
In transfected SaOS-2 cells, ALP activity was not significantly affected by expression 
of EAAT1 intracellular domains (Shierer Ray P=0.907), 500pM glutamate (Shierer 
Ray P=0.5S9) and there was no interaction between the two factors (Shierer Ray 
P=0.859). SaOS-2 ALP activity was also not significantly affected by transfection 
with pcDNA3.1 vector compared to untransfected cells (GLM P=0.333).
6.4 Discussion
6.4.1 Background
The intention of the experiments presented in this chapter was to introduce peptides 
into osteoblasts that mimic the sequences of EAAT1 that might be involved in 
protein-protein interactions within the cell. These experiments were carried out to 
determine whether this method of modulating of EAAT1 activity might enhance 
osteoblast bone-forming activity.
Transfection and expression of EAAT1 intracellular domains resulted in statistically 
significant effects upon MG-63 cell number, osteocalcin expression in both MG-63 
and SaOS-2 cells and OPG expression in SaOS-2 cells. Expression of each peptide in 
osteoblast-like cells was detected at the mRNA level, however achieving detectable 
quantities of the peptide proved problematic.
Many of the identified interactions for EAAT1 and other members of the EAAT 
family have so far been shown to modulate EAAT localisation and/or glutamate 
transport activity; however there is also evidence to suggest that EAAT protein 
interactions can modulate the EAAT uncoupled anion conductance or lead to 
intracellular signalling events (Abe and Saito 2001; Marie et al. 2002; Fang et al.
2006). Competing peptides to EAAT1 intracellular domains therefore have the 
potential to target some, or all, of the activities o f the glutamate transporter. 
Interestingly, the intracellular C-terminus has been shown to confer differences in 
chloride permeability between EAAT1 and EAAT2 in conjunction with other EAAT 
regions, suggesting that the C-terminus may associate with other intracellular domains
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Figure 6.IS, E ffect o f inhibition o f EAAT1 intracellular interactions on SaOS-2 
ALP activity over 48hrs, SaOS-2 cells were transfected with empty pcDNA3.1 or 
pcDNA3.1 vector containing each EAAT1 intracellular domain for 48hrs. ALP 
activity was measured colourimetrically and normalised to cell number (as measured 
by total cellular LDH activity). ALP activity is shown as the mean percentage of 
control cell ALP activity (empty vector, no glutamate) ± S.E.M from three 
independent experiments, n=3. SaOS-2 ALP activity was not significantly affected by 
expression of different EAAT1 intracellular domains, glutamate or the interaction 
between the two factors (Shierer Ray test). SaOS-2 ALP activity of empty vector 
control cells also did not display any significant non-specific effects compared to 
untransfected cells (GLM).
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to influence the conformation of the anion pore (Mitrovic et al. 1998). Therefore, 
competing peptides to intracellular regions may also influence the conformation of the 
transporter.
Many of the studies that have identified proteins that interact with the EAATs have 
been carried out using brain tissue or CNS-derived cells, and it must be considered 
that post-translational regulation of EAATs might differ between cells of the CNS and 
osteoblasts. Only some of the identified EAAT-interacting proteins have also been 
shown to be expressed in osteoblasts (Table 6.1), such as NHERF1 (Schroeder et al. 
2007) and ezrin (Khanna et al. 2001; Park et al. 2006). It is possible that other proteins 
of the same family or different proteins entirely, play a more prominent role in 
osteoblasts. For example, GFAP is an intermediate filament protein that interacts with 
the C-terminus of GLAST in pig and rat whole brain (Sullivan et al. 2007b). GFAP 
interacts with NHERF1 and ezrin to regulate the transport activity of the protein. 
GFAP is expressed in osteoblasts at low but constitutive levels (Kasantikul and 
Shuangshoti 1989; Chipoy et al. 2004), however the expression of another 
intermediate filament protein, vimentin, is high in pre-osteoblasts and regulated 
during differentiation (Lian et al. 2009). Furthermore, vimentin expression is 
upregulated in clonal SW982 synoviocytes following activation of iGluRs 
(McNeamey et al. 2009). Vimentin also colocalises with NHERF1 in rat cochleal glial 
cells (Kanjhan et al. 2006) and siRNA mediated knockdown of vimentin in MG-63 
osteoblast-like cells reduced Na+-dependent glutamate uptake (Brakspear, Harper, 
Blain, Mason, unpublished).
The competing peptides expressed encompass large regions of the EAAT1 sequence, 
making it highly likely that more than a single protein-protein interaction or 
phosphorylation event was prevented. The intracellular N- and C-terminal amino acid 
sequences of EAAT 1 display poor homology across the EAAT family, suggesting that 
these peptides will not compete for intracellular interactions with other EAAT 
subtypes. However, the class of PDZ domain binding motifs at the C-terminus of 
EAAT1 (ETKM) is shared by EAAT3 (TSQF) and EAAT4 (ESAM) (class II motifs) 
presenting the possibility that these transporters interact with proteins belonging to the 
same PDZ family. The TM6-7 sequence o f EAAT 1 is highly homologous across the 
EAAT family (homologies of 81% in EAAT2, 76% in EAAT3, 76% in EAAT4 and 
71% in EAAT5) and therefore this peptide is likely to compete for intracellular 
interactions of this region with all EAATs expressed.
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6.4.2 pcDNA3.1 as a tool for generating intracellular competing peptides 
against EAAT1 domains in osteoblasts
Our experiments have shown that transfected osteoblast-like cells express mRNA 
from pcDNA3.1 vector up to 72hrs post-transfection. However expression of the 
translated peptide could not be confirmed in the absence of the HD AC inhibitor 
sodium butyrate.
The sequences for EAAT1 N- and C-terminal domains were cloned in frame with the 
vector V5 and His tag epitopes. However, due to the small size of the peptides, 
western blotting was not attempted. Visualisation of the peptides by coomassie blue 
staining or silver staining following resolution of transfected cell lysate by sodium 
dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) (not shown) did 
not reveal bands of the appropriate molecular weight in either the presence or absence 
of sodium butyrate. Either these methods were not sensitive enough for the small size 
of the peptides or the peptides were expressed at very low levels.
Immunostaining for the V5 epitope did detect pcDNA3.1 vector expressing EAAT1 
N- and C-terminal domains upon addition o f lOmM sodium butyrate. However, 
sodium butyrate treatment considerably reduced MG-63 and SaOS-2 viability and 
reduced EAAT glutamate uptake activity in MG-63 cells. Sodium butyrate-induced 
cell death and inhibition of proliferation has been observed in other cell types, 
particularly cancer cell lines (Mandal and Kumar 1996; Mandal et al. 1997; Pajak et 
al. 2007). Interestingly, HDAC inhibitors have previously been shown to promote 
expression of GLT-1 and GLAST in rat primary astrocytes (Sheldon and Robinson 
2007; Aguirre et al. 2008; Allritz et al. 2009) and increase glial glutamate uptake 
activity under toxic conditions (Wu et al. 2008).
Since sodium butyrate treatment inhibited EAAT activity in MG-63 cells, we were 
unable to use it to induce expression from the vector in experiments where the effect 
of the peptides on osteoblast phenotype was assessed. Since high levels of vector 
mRNA were detected in the absence of sodium butyrate, but anti-V5 immunostaining 
was not successful, it is likely that the peptides were expressed at very low levels. 
Thus large effects on the osteoblast phenotype were not expected but transfection of 
osteoblast-like cells with pcDNA3.1 expressing EAAT1 intracellular domains did 
result in significant effects upon cell number and gene expression indicative of the 
„ expression of functional peptides. Future optimisation of sodium butyrate
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concentration and length of treatment may identify a set of conditions to maximise 
cell viability and peptide expression whilst maintaining EAAT activity.
Other methods to generate the competing peptides were considered. A synthetic 
peptide generated with a fluorophore tag would allow for detection of its 
accumulation within the cell; however synthesis of the long peptides used here was 
too costly. Cloning of the EAAT1 sequences into a bacterial expression vector 
followed by purification of the expressed peptide was also considered, and in 
retrospect, represented the most appropriate method to ensure generation of the 
peptide.
Direct peptide delivery into the cell would improve the experimental design of these 
studies since control cells transfected with the empty vector exhibited significant 
differences in EAAT activity, cell number and gene expression compared to 
untransfected cells. Since the empty vector does not contain a start codon and 
therefore cannot express a peptide, the non-specific effects observed must be the 
result of either the transfection agent or the foreign DNA. Some non-specific effects 
were also observed in osteoblasts transfected with the scrambled AON using Fugene 
HD transfection agent (section 5.4.2). Although AON non-specific effects were rarely 
statistically significant, the non-specific effects observed with the empty vector were. 
Thus, introduction of foreign DNA into osteoblast-like cells elicits significant non­
specific effects, possibly due to the increased transcriptional activity of the vector or 
the immunogenicity o f the plasmid DNA backbone, which has been observed in other 
cell types (Sato et al. 1996; Tudor et al. 2005).
6.4.3 Inhibition of EAATI intracellular interactions influences the 
osteoblast phenotype
6.4.3.1 Na+-dependent glutamate uptake
Expression of pcDNA3.1 containing EAATI intracellular domains had no significant 
effects upon Na+-dependent glutamate uptake in MG-63 and SaOS-2; however these 
findings were complicated by the effects o f empty vector transfection. Transfection of 
MG-63 cells with pcDNA3.1 vector containing EAATI N-terminal, TM6-7, or C- 
terminal domains displayed a trend for increasing Na+-dependent glutamate uptake, 
whereas transfection of SaOS-2 cells with pcDNA3.1 vector containing EAATI N-
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terminal or TM6-7 domains displayed a trend for decreasing Na+-dependent glutamate 
uptake. These findings suggest that the intracellular interactions of EAATI that 
regulate the activity of the transporter differ between the two cell lines, and that in 
general, the intracellular interactions of EAATI might act to slow the removal of 
extracellular glutamate in MG-63 cells but to accelerate its removal in SaOS-2 cells. 
A difference in the regulation of transport activity between the two cell lines is 
consistent with chapter 3 (Figure 3.15 and 3.16) where glutamate pre-incubation had 
contrasting effects on glutamate uptake activity without altering EAAT transcription. 
However, kinetic characterisation of KM and Vmax values for glutamate uptake under 
each experimental condition is necessary to determine the mechanisms responsible for 
these differential effects.
Surprisingly, inhibition o f EAATI C-terminal intracellular interactions had the least 
effect on mean glutamate transport in both cell types. Most of the proteins identified 
to interact with the EAATs do so at the C-terminus and have a role in regulating the 
expression of the transporter at the plasma membrane (Table 6.1). It might therefore 
be expected that interruption of these interactions with EAATI in osteoblast-like cells 
would significantly influence glutamate transport activity. Many C-terminal 
interacting proteins identified for EAATI stabilise its expression at the cell surface 
(Lee et al. 2007; Sullivan et al. 2007b) suggesting that a loss of these interactions 
would decrease glutamate uptake activity. Interestingly, the EAATI C-terminal 
competing peptide increased mean Na+-dependent glutamate uptake in MG-63 cells, 
suggesting that an inhibitory intracellular interaction was prevented. This is consistent 
with findings in retinal glia where a competing peptide identical to the extreme C- 
terminus of GLAST increased the affinity o f the transporter for glutamate (Marie and 
Attwell 1999) and also correlates with the action of the septin GTPases which interact 
with the GLAST C-terminus and decrease glutamate transport activity (Kinoshita et 
al. 2004) and GTRAP3-18 which reduces the affinity o f EAAC1 for glutamate via an 
interaction with the transporter C-terminus (Lin et al. 2001; Butchbach et al. 2003; 
Ruggiero et al. 2008). It is possible that the inhibition of EAATI C-terminal 
interactions did have a greater effect on glutamate uptake in MG-63 and SaOS-2 cells 
which could not be detected at only one concentration of glutamate, since interruption 
of proteins that stabilise cell-surface expression EAATI would affect the Vmax of 
glutamate transport, and kinetic constants of uptake were not determined.
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6.4.3.2 Cell number
Inhibiting EAATI intracellular interactions by competing peptides differentially 
affected adherent MG-63 and SaOS-2 cell number, which is unsurprising in light of 
the contrasting effects o f these treatments on glutamate transport activity in the two 
cell lines.
At 500pM glutamate, cell number was significantly increased in MG-63 cells 
transfected with the EAATI C-terminal domain compared to empty vector controls. 
NMDA receptor activation has previously been implicated in the regulation of 
MC3T3-E1 osteoblast-like cell number (Fatokun et al. 2006) and the proliferation of 
neurons, cancer cells, chondrocyte-like cells and synovial fibroblasts (Contestabile 
2000; Rzeski et al. 2001; Parada-Turska et al. 2006; Spitzer 2006; Piepoli et al. 2009), 
suggesting that the increase in MG-63 cell number in response to the EAATI C- 
terminal peptide might be the result of sustained high concentrations of extracellular 
glutamate available to activate receptors, possibly via decreased EAAT activity. Na+- 
dependent glutamate uptake was not reduced in MG-63 cells expressing the EAATI 
C-terminal peptide, indicating that this explanation is unlikely, however the uptake 
kinetics of higher glutamate concentrations are not known.
A receptor-like function for the EAATs has been suggested whereby the transporter 
responds to glutamate binding by activating intracellular signalling events (Abe and 
Saito 2001; Mason 2004a). Such a function for EAATI might regulate cell 
proliferation in response to glutamate and be modulated in MG-63 cells by an 
intracellular protein that interacts with the EAATI C-terminal, and candidate proteins 
for such a function are shown in table 6.1. A receptor-like function for EAATI may 
also occur in response to activation of the uncoupled anion conductance of the 
transporter, which might be lost in cells expressing the EAATI C-terminal peptide 
due to inhibition of associations between the EAATI intracellular domains important 
for conformation of the anion pore (Mitrovic et al. 1998).
Transfection of SaOS-2 cells with the EAATI C-terminal domain had no effect on 
cell number, suggesting that either the peptides are not expressed at a high enough 
level to have a significant effect in SaOS-2 cells (where EAATI mRNA levels and the 
rate of glutamate transport is much greater than in MG-63 cells), or that the 
intracellular EAATI interactions differ between the two osteoblast-like cell lines.
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6.4.3.3 Gene expression
Significant differences in gene expression were observed in MG-63 and SaOS-2 cells 
transfected with pcDNA3.1 vector expressing the competing peptides. These effects 
differed between the transfection groups suggesting that the peptides are expressed 
and functional within the cell.
Osteocalcin expression was significantly affected by expression of EAATI 
intracellular domains in both cell types. Compared to empty vector control cells, 
expression of the EAATI N-terminal domain slightly increased mean osteocalcin 
expression in MG-63 cells in the absence of glutamate, while a decrease was detected 
in MG-63 cells expressing the EAATI TM6-7 domain at both glutamate 
concentrations and the EAATI C-terminal domain at OpM glutamate. Decreased 
osteocalcin expression may reflect an increased proliferative phenotype of MG-63 
cells expressing the EAATI C-terminal domain.
In SaOS-2 cells, mean osteocalcin mRNA levels were also increased in cells 
expressing the EAATI N-terminal domain compared to empty vector control cells; 
however this was only apparent at 500pM glutamate. The EAATI C-terminal domain 
appeared to decrease SaOS-2 osteocalcin levels, though only in the absence of 
glutamate. While the expression pattern of osteocalcin in response to EAATI 
competing peptides was similar between the two cell types, the biggest effects 
observed were via EAATI TM6-7 and C-terminal domains in MG-63 and via EAATI 
N-terminal domain in SaOS-2.
SaOS-2 OPG expression was significantly decreased by expression of all three 
EAATI intracellular domains in the absence of exogenous glutamate and by EAATI 
TM6-7 and C-terminal domains in the presence of 500pM glutamate. 500pM 
glutamate increased mean OPG mRNA levels in untransfected SaOS-2 cells (shown 
here and Figure 4.1 OB) indicating a glutamate responsive signalling pathway leading 
to upregulated OPG expression. A reduction in OPG mRNA levels in cells expressing 
either the TM6-7 or C-terminal domain of EAATI at 500pM glutamate implicates the 
intracellular interactions of these regions in the signalling event. Since each EAATI 
peptide had a similar effect on OPG expression at OpM glutamate in these cells, it is 
possible that these regions of EAATI are important for the tertiary structure of the 
protein, potentially implicating the anion pore of EAATI in this response (Mitrovic et 
al. 1998).
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6.4.3.4 ALP activity
SaOS-2 ALP activity was not affected by expression of EAATI intracellular domains 
in either the presence or absence o f glutamate, suggesting that intracellular 
interactions of these regions of EAATI are not important for the regulation of ALP 
activity in these cells. Consistent with this finding, competing peptides also had no
significant effect on SaOS-2 ALP mRNA levels. Antagonists to NMDA and AMPA
receptors have previously been shown to inhibit ALP activity in rat calvarial 
osteoblasts (Hinoi et al. 2003; Lin et al. 2008), suggesting that competing peptides to 
EAATI in SaOS-2 cells do not increase the level of glutamate available to act on 
NMD A/AMP A receptors, despite the decrease in mean Na+-dependent glutamate 
uptake activity induced by transfection with pcDNA3.1 expressing these EAATI 
domains.
6.4.3.5 Inferences from these findings in osteoblast-like cells
Many differences were detected between the responses of the ceil lines MG-63 and 
SaOS-2 to the transfection of pcDNA3.1 vector expressing EAATI competing 
peptides. This may suggest that EAATI interacts with different proteins in each cell 
line, with the inference that these differences reflect changes that occur during 
osteoblast differentiation. However, the EAAT expression profile differs between the 
two cell lines and is also likely to shape the response to EAATI competing peptides. 
Interestingly, expression of EAATI competing peptides significantly affected 
osteocalcin expression in both cell lines and similar patterns of expression changes 
could be observed. This finding may indicate a common mechanism for EAATI 
mediated regulation of osteocalcin expression between the two cell lines, and 
therefore possibly throughout osteoblast differentiation.
Expression of EAATI TM6-7 and C-terminal peptides decreased MG-63 osteocalcin 
expression while the EAATI C-terminal peptide increased MG-63 cell number in 
response to 500pM glutamate, potentially implicating the intracellular interactions of 
these domains in the regulation of the osteoblast proliferative stage of maturation.
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6.4.4 Peptides as a therapeutic tool in bone
There is increasing interest from the pharmaceutical industry in the development of 
peptide therapeutics. This follows improvements in manufacturing and large scale 
production methods; however synthesis of peptides remains costly and challenging in 
comparison to small molecule drugs. The advantages of peptide therapeutics are high 
activity, specificity and potency, low toxicity and they do not accumulate in tissues. 
Some examples of currently available peptide therapeutics are leuprolide acetate 
(Lupron) and goserelin acetate (Zoladex), which mimic gonadotropin-releasing 
hormone and are used for the treatment of advanced prostate cancer and 
endometriosis, exenatide (Byetta), which is an insulin secretagogue that is used for the 
treatment of type 2 diabetes, and enfuvirtide (Fuzeon) which mimics the fusion 
machinery of HTV-1 and therefore inhibits virus fusion.
Teriparatide (Forteo) was FDA approved in 2002 as a peptide therapeutic for the 
treatment of osteoporosis. Teriparatide is a recombinant peptide identical to the 34 N- 
terminal amino acids of human PTH, a major regulator of calcium and phosphate 
metabolism in bone and kidney. Teriparatide has a similar affinity for the PTH 
receptor as full-length PTH, and can therefore stimulate new bone formation when 
intermittently administered at a low dose (Dempster et al. 2001; Neer et al. 2001; 
Rubin and Bilezikian 2003; Sato et al. 2004). Since peptides have low stability in 
vivo, a short half-life and low oral bioavailability, teriparatide, and most other peptide 
therapeutics, are injected subcutaneously. The cost and difficult administration of 
these molecules makes it necessary that the therapeutic offers considerable benefits. 
Another potential method for peptide delivery to bone is local application of the 
molecules in conjunction with an absorbable collagen sponge. A similar process is 
used in the application of rhBMP-2 and rhBMP-7 currently in clinical use for spinal 
fusion and the treatment of non-union fracture (section 1.2.1.5.2.1). This strategy has 
also been employed successfully to deliver synthetic peptides based on the sequence 
of BMP-2 (Choi et al. 2010) or osteopontin (Egusa et al. 2009) to rat calvarial defects.
6.4.4.1 Competitive peptides to EAATI as a therapeutic tool in bone
The peptide sequences of EAATI that have been investigated in this chapter are 
intracellular. The hydrophilic nature of peptides makes membrane transport
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problematic and as a result, the majority of therapeutic peptide candidates target 
extracellular molecules. However, there is increasing interest in the use of cell 
penetrating peptides (CPPs) to deliver therapeutic molecules across the cell 
membrane. CPPs were discovered following the identification of sequences required 
for the cellular uptake of proteins such as the transcription-transactivating (Tat) 
protein of HIV-1 (Frankel and Pabo 1988). CPPs are short peptides that have either 
polycationic or amphipathic sequences and can be used to deliver a variety of 
different molecules into the cell including nucleic acids, large proteins, liposomes and 
small peptides (reviewed in (Heitz et al. 2009)). Use of CPPs in humans has reached 
clinical trial in some cases, for example phase II clinical trials of a CPP-based 
formulation of cyclosporine A (Psorban) for the topical treatment of psoriasis are 
currently underway (Rothbard et al. 2000; Price 2003).
CPPs have been used to transport proteins into rat and mouse calvarial osteoblasts in 
vitro (Dolgilevich et al. 2002; Sun et al. 2005) and represent a means of delivering the 
EAATI competing peptides into the cell, both in vitro and in vivo in conjunction with 
a collagen sponge. Local delivery of such a molecule for in vivo application would be 
necessary since the CPP would transport the peptide into cells indiscriminately, 
reducing the level of the therapeutic reaching bone and also leading to potential side 
effects since the glutamate signalling pathway functions in many central and 
peripheral tissues (reviewed in (Skerry and Genever 2001; Hinoi et al. 2004)). After 
generating a bacterial expression vector containing the EAATI sequences of interest 
in frame with a CPP sequence during the course of this PhD, time constraints 
prevented the purification and testing of these peptides in osteoblasts. Repeating the 
experiments presented in this chapter using a CPP-linked EAATI peptide would lead 
to a more reliable conclusion as to whether these molecules would be useful 
therapeutically, since the quantity o f competing peptide within the cell could be 
defined and optimised and the effects of transfection could be avoided.
The intracellular N- and C-terminal domains of EAATI expressed within the cell 
lines were fairly long at ~50 amino acids. For therapeutic use the peptide would 
preferably be shorter in order to reduce the chance of any non-specific effects and also 
to reduce the costs associated with synthesis. Therefore, if any of the EAATI 
sequences investigated in this chapter were to be pursued as a therapeutic peptide, the 
region of the sequence conferring the activity would need to be identified.
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The experiments presented in this chapter have shown that inhibition of EAATI C- 
terminal intracellular interactions can increase cell number of ‘pre-osteoblast’ MG-63 
cells, which may be useful in the context of fracture repair since atrophic non-unions 
are typified by insufficient availability of bone forming cells, preventing normal bone 
healing from occurring (Megas 2005) (section 1.2.1.5.2). Expression of EAATI N- 
terminal competing peptides increased osteocalcin in both cell lines suggesting that 
this peptide may represent a means of increased osteoblast differentiation, relevant to 
diseases of low bone mineral density (BMD) such as osteoporosis. Furthermore, 
inhibition of EAATI intracellular interactions decreased OPG expression in SaOS-2 
cells and a mechanism for reducing expression of OPG may have therapeutic 
application in fracture repair for the enhancement of bone remodelling and the 
replacement of the woven bone callus or the enhancement of osteoclast activity in 
diseases of high bone mass (section 1.2.1.1 and Table 1.1).
6.4.5 Summary
Expression of competing peptides to intracellular domains of EAATI was 
investigated in osteoblast-like cells to ascertain the importance of EAATI 
intracellular interactions in osteoblast proliferation and activity. In MG-63 cells, 
competing peptides to EAATI C-terminal domain significantly increased cell number 
at 500jiM glutamate. Osteocalcin mRNA levels were affected similarly in both cell 
lines at 0 and 500pM glutamate with the EAATI N-terminal domain increasing 
expression and the EAATI TM6-7 and C-terminal domains decreasing expression. 
SaOS-2 OPG mRNA levels were significantly decreased by competing peptides to 
each EAATI intracellular domain at OpM glutamate. Large differences in osteoblast 
glutamate transport were detected in response to expression of EAATI intracellular 
domains; however these were not significant due to the variances associated with the 
transient transfections. Thus, optimisation of peptide expression and increased 
replicates are necessary to further investigate these findings.
Peptide-specific significant effects were observed demonstrating that the peptides 
were expressed and functional and that intracellular interactions of EAATI modulate 
osteoblast cell number and gene expression.
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7. General discussion
7.1 Background
New strategies to replace or repair traumatised or diseased bone is a major 
socioeconomic and clinical need in an ageing demographic. More than one million 
fractures occur in the UK each year and 5-10% of these experience problems in 
healing (Gaston and Simpson 2007). Furthermore, one in two women and one in five 
men over the age of 50 in the UK will fracture a bone as a result of osteoporosis (van 
Staa et al. 2001) and osteoporosis related fractures cost the health service an annual 
sum of over £1 billion (Torgensen 2001; PRODIGY 2006).
Glutamate was first linked to bone when a gene screening experiment designed to 
identify genes regulated following osteogenic mechanical loading of the rat ulna 
identified GLAST (Mason et al. 1997). GLAST (EAATI) was constitutively 
expressed in osteocytes of control bone but absent in the loaded limb, implicating the 
transporter in the response of bone to mechanical load. Activation of ionotropic 
glutamate receptors can regulate the phenotype of osteoblasts and osteoclasts in vitro 
(Chenu et al. 1998; Peet et al. 1999; Itzstein et al. 2000; Hinoi et al. 2003; Ho et al. 
2005) and bone mass in vivo (Burford et al. 2004; Lin et al. 2008; Skerry 2008). 
Mechanical loading plays a key role in the physiology of bone, allowing bone to 
functionally adapt to its environment (Lanyon 1996), however characterisation of the 
signalling events linking load to bone formation is incomplete. Identification and 
therapeutic exploitation of the mechanoresponse offers the opportunity to prevent and 
treat bone loss. This thesis has investigated the potential of targeting the glutamate 
signalling pathway in bone to this purpose. The hypothesis of this PhD was that 
inhibition of glutamate transporter activity in bone cells could be used to mimic 
mechanical stimulation and enhance osteoblast differentiation and/or bone forming 
activity, representing a new target for anabolic therapies in bone. The aims were to 
characterise EAAT expression and activity in human osteoblasts and to determine 
whether modulation of EAAT activity could enhance the osteoblast bone-forming 
phenotype in vitro. Potential therapeutic targeting of EAATs in bone for the treatment 
of osteoporosis or non-union fracture has been previously proposed (Mason et al. 
1997; Mason 2004), but not comprehensively tested. EAATs are the gate-keepers of
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the glutamate response and therefore offer the opportunity to modulate glutamate 
signalling without the potential side-effects associated with targeting particular 
glutamate receptor subtypes.
Since EAATs may exhibit multiple activities (glutamate uptake and release, glutamate 
gated Cl' conductance and a receptor-like function) (reviewed in (Danbolt 2001; 
Mason 2004a)) in osteoblasts, the particular activity relevant to mechanically-induced 
bone formation is unknown. Therefore, each EAAT activity was inhibited in 
osteoblasts, and the effects on osteoblast activity assessed in vitro. This was done 
using broad range chemical EAAT inhibitors, antisense mediated EAATI exon 
skipping and competitive peptides to intracellular regions of EAATI thought to be 
involved in protein-protein interactions (illustrated in Figures 7.1 and 7.2).
7.2 EAATs are expressed and functional in human osteoblasts
Transcripts for EAATs 1-3 and two splice variants of EAATI (EAATla and 
EAATlex9skip) were detected in human bone, primary osteoblasts and osteoblast­
like cell lines (MG-63 and SaOS-2) by RT-PCR. This confirms reports of the 
expression of EAATs 1-3 and EAAT la  in osteoblasts (Mason et al. 1997; Huggett et 
al. 2000; Huggett et al. 2002; Kalariti et al. 2004; Takarada et al. 2004; Kalariti et al.
2007); however this is the first report o f EAATIex9skip expression in human bone 
tissue and osteoblasts.
We have quantified EAAT transcription in osteoblasts by QRT-PCR for the first time 
and shown that EAATI is expressed at higher levels than EAAT3 (~300-fold higher 
in MG-63 and -50,000-fold higher in SaOS-2) while EAAT2 expression was too low 
to quantify accurately. Expression of EAATs 1 and 3 was confirmed in primary 
human osteoblasts and osteoblast-like cells by immunofluorescence, and functional 
EAAT expression was demonstrated by Na+-dependent glutamate uptake into these 
cells. EAAT function has been previously demonstrated in rat calvarial osteoblasts 
(Takarada et al. 2004) but not in human osteoblasts. In human osteoblast-like cells, 
Na+-dependent glutamate uptake was concentration dependent, sensitive to 
pharmacological EAAT inhibition (f-PDC, TBOA) and extracellular glutamate 
concentration (10-500pM). The role of extracellular glutamate in the regulation of 
EAAT activity has not been previously investigated in osteoblast-like cells.
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Figure 7.1. Schematic diagram o f glutamate signalling in osteoblasts. Osteoblasts 
release glutamate which may activate glutamate receptors in an autocrine and 
paracrine manner. Osteoblasts express functional NMDA and AMPA ionotropic 
glutamate receptors (iGluRs), which upon glutamate binding allow an influx of Na+ 
and Ca2+, and metabotropic glutamate receptors (mGluRs) which activate G-protein 
coupled pathways. Activation of osteoblast iGluRs leads to glutamate release, 
proliferation, and increased Runx2 activity (Hinoi et al. 2002b; Hinoi et al. 2003; Ho 
et al. 2005; Fatokun et al. 2006). Activation of mGluRs is known to inhibit NMDA 
receptor signals in osteoblasts through PLC activated pathways (Gu and Publicover 
2000). High concentrations of extracellular glutamate prevent cystine uptake through 
the cystine/glutamate antiporter which can lead to suppression of proliferation and 
reduced Runx2 activity due to GSH depletion in osteoblasts (Uno et al. 2007; 
Takarada-Iemata et al. 2010), and may also lead to ROS-mediated cell death (Murphy 
et al. 1989; Cho and Bannai 1990). EAATs are expressed and functional in osteoblasts 
where they transport glutamate against its concentration gradient. Inhibition of 
glutamate transport (by t-PDC, TBOA and overexpression of EAATIa and 
EAATlex9skip) can increase the levels of extracellular glutamate available to activate 
GluRs and inhibit the cystine/glutamate antiporter. Glutamate binding to EAATs also 
activates an uncoupled chloride flux which may function as a voltage clamp, 
compensating for the membrane potential changes due to electrogenic glutamate 
uptake by EAATs (Billups et al. 1996; Eliasof and Jahr 1996), or may act directly as a 
receptor or modulate glutamate receptor activation by regulating ion influx (Danbolt 
2001; Mason and Huggett 2002). Chloride conductance of all EAATs is inhibited by 
TBOA and the region of EAATI important for chloride flux is lost in EAATIa. A 
variety of proteins have been identified which interact with the intracellular domains 
of EAATI and these interactions can be experimentally inhibited using competing 
peptides. EAATI C-terminal interactions can also be inhibited by overexpression of 
EAATIa which is proposed to reorientate in the plasma membrane downstream of the 
N-terminus (Huggett et al. 2000). Glutamate transport through EAATs has been 
shown to activate MAPK (Abe and Saito 2001) which can increase Runx2 activation 
(Xiao et al. 2000). Phospholipase C (PLC), diacylglycerol (DAG), cyclic adenosine 
monophosphate (cAMP), protein kinase C (PKC), inositol triphosphate (IP3), alkaline 
phosphatase (ALP), reactive oxygen species (ROS), mitogen activated protein kinase 
(MAPK), excitatory amino acid transporter (EAAT), glutathione (GSH).
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Figure 7.2. Diagram o f the effects o f modulating EAAT1 activity in osteoblast-like cells based on findings from  this thesis. In both cell lines 
(MG-63 and SaOS-2), inhibition of glutamate transport through EAATs (by f-PDC, TBOA, EAATlex9skip and EAATIa) increases the 
concentration of extracellular glutamate available to activate receptors. The phenotypic effects of receptor activation are likely to differ 
depending on which receptor subtype is activated, and EAAT1 specific inhibition may have different effects to inhibition of all EAATs in this 
regard. Increased extracellular glutamate can also inhibit cystine uptake through the cystine/glutamate antiporter, compete with /-PDC and 
TBOA for EAAT binding sites and regulate the activity of the transporter. (A) In MG-63 cells, inhibition of the EAAT1 Cl' conductance by 
TBOA or overexpression of EAATIa decreased mean OPG mRNA expression. Inhibition of EAAT1 N-terminal interactions increased 
osteocalcin mRNA levels whereas inhibition of EAAT 1 TM6-7 and C-terminal interactions decreased osteocalcin mRNA levels. The C-terminal 
competing peptide also increased cell number at 500pM glutamate and this may occur via increased EAAT1 activity preventing the activation of 
a particular nearby receptor subtype. Glutamate transport through the EAATs may increase ALP mRNA levels and this was prevented by EAAT 
inhibitors. (B) In SaOS-2 cells, overexpression of EAATIa increased cell number at 500pM glutamate and decreased osteocalcin mRNA levels 
at both physiological and pathophysiological glutamate concentrations. EAATIa may inhibit osteocalcin expression via the loss of a C-terminal 
interaction which increases osteocalcin expression through a mechanism that is activated by TBOA. Competing peptides to EAAT1 intracellular 
interactions inhibited OPG mRNA expression whereas glutamate transport through EAATs increased OPG mRNA expression, and this was 
inhibited by /-PDC.
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These studies indicate that EAAT1 is the dominant glutamate transporter in 
osteoblasts, demonstrating that regulation of EAAT1 expression in osteocytes in 
response to mechanical load (Mason et al. 1997) is likely to be physiologically 
relevant. Interestingly, the EAAT expression profile of osteoclasts (Table 1.4) reveals 
that these cells express EAAT2 and EAAT4 (Hinoi et al. 2007; Takarada and Yoneda
2008), in contrast to the predominant EAAT1 and EAAT3 expression of osteoblasts, 
though expression of EAAT4 has not been investigated in osteoblasts. This will aid 
cell-type specific targeting of the EAATs in bone. Cell-type specific EAAT 
expression patterns are present within the CNS and other peripheral tissues 
(Gegelashvili and Schousboe 1997; Danbolt 2001; Berger and Hediger 2006), 
demonstrating that the transporters exhibit broader functional roles than simply the 
maintenance of low concentrations of extracellular glutamate.
7.2.1 Novel characterisation of EAAT1 splice variants in bone
Characterisation of EAAT expression in bone has largely ignored the existence of 
multiple splice variants (section 5.1.1), with the exception of the EAAT1 splice 
variant EAATIa (Huggett et al. 2000; Huggett et al. 2002). In the osteoblast cell lines 
studied, EAATIa expression was very low, whilst levels of the dominant negative 
EAATlex9skip were much higher, comparable to levels detected in the brain 
(Vallejo-Illarramendi et al. 2005). Furthermore, the higher expression levels of 
EAATlex9skip relative to full-length EAAT1 in MG-63 (13% of full-length EAAT1 
levels) compared to SaOS-2 cells (2% of full-length EAAT1 levels) suggests that this 
splice variant might be down-regulated during osteoblast maturation. This could be 
tested by analysing EAAT1 splicing during osteogenic differentiation of MSCs. A 
reduction in the expression of a dominant negative transporter would be expected to 
increase the cells capacity to transport glutamate, consistent with previous suggestions 
that osteoblasts acquire a more active glutamatergic signalling phenotype as they 
mature (Genever and Skerry 2001).
These are the first studies to utilise antisense mediated exon skipping techniques to 
overexpress the ratio of EAAT 1 splice variant to full-length EAAT1 in bone cells, and 
we have shown that overexpression of EAATIa and EAATlex9skip reduces Na+- 
dependent uptake of 10fiM glutamate in MG-63 and SaOS-2 cells. A reduction in 
glutamate transport in cells overexpressing EAATlex9skip is consistent with the
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reported dominant negative role of this variant (Vallejo-Illarramendi et al. 2005). 
However EAATIa was thought to be a functional transporter as only domains 
important for the glutamate-gated Cl' conductance are absent (Mason, Huggett, 
Daniels, unpublished). The reduced glutamate transport activity in cells 
overexpressing EAATIa either implicate EAAT1 exon 3 directly in the regulation of 
glutamate transport or reveal how loss of the Cl' conductance of EAAT1 in 
osteoblasts, which normally compensates for the membrane potential changes due to 
electrogenic glutamate uptake by EAATs (Billups et al. 1996; Eliasof and Jahr 1996), 
can slow glutamate transport.
7.3 Regulation of EAAT activity modifies the osteoblast phenotype
The majority of glutamate signalling research within bone and other peripheral tissues 
has focused on the activity o f the glutamate receptors. That the EAATs might also 
play a direct role in regulating the phenotype of bone cells has been hypothesised 
(Mason 2004a) and some studies have begun to investigate this theory, reporting that 
f-PDC prevents bone formation of calvarial osteoblasts in vitro (Taylor 2002). The 
experiments presented here have clearly shown that modulating EAAT activity at both 
physiological and pathophysiological glutamate concentrations can modify the 
osteoblast phenotype. Interestingly, some effects of EAAT modulation did not mimic 
exogenous glutamate treatment, providing evidence for the first time that specific 
transporter-mediated pathways might be active in osteoblasts, either through 
glutamate transport, chloride conductance or protein-protein interactions.
The main effects of the experimental modulations of EAAT activity in MG-63 and 
SaOS-2 osteoblast-like cells at physiological and pathophysiological concentrations of 
glutamate are summarised in tables 7.1 and 7.2 and Figure 7.2. Data from human 
primary osteoblasts are not included since these cells were not tested with every 
experimental treatment; but are discussed in the following sections where appropriate. 
No exogenous glutamate was added to the medium to achieve the physiological 
concentration of glutamate (28jnM in serum (Mally et al. 1996), 6pM in synovial fluid 
(Plaitakis et al. 1982; McNearney et al. 2000)) since it was known that osteoblasts 
spontaneously release glutamate (Genever and Skerry 2001). The pathophysiological 
concentration of glutamate chosen here (500pM) reflects the glutamate levels in the
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Table 7.1. Summary o f  the effects o f  modulating EAAT activity at physiological glutamate concentrations on the osteoblast phenotype. Changes in 
expression/activity of MG-63 (black) and SaOS-2 (grey) are shown as increases ( |) , decreases ( j)  or no change (-) relative to respective controls (no 
inhibitor/scrambled AON/empty vector, OpM glutamate). NT, not tested. Significance values *P<0.05, **P<0.01, ***P<0.001, n.s (not significant) by 
pair-wise post-hoc comparisons. Trends non-significant by post-hoc test but significant by ANOVA are indicated in brackets.
Intracellular interactions
Ion channel
Ex9skip r-PDC TBOA Ex3skip C-term TM6-7 N-term
Cell number 1* g n.s. £ * * * g n.s.t*
g n.s.
-
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gn.s.
g n.s. t*
g n.s.
V
- n.s. <*•>
I  n S’(#)
gn.s. (**} g n.s.
Osteonectin - - gn.s. - - - -mRNA - - - - "
OPGmRNA g n.s.
g n.s. gn.s. g n.s. 
gn.s.{+) gn.s. g n.s.
ALPmRNA g n.s.
gn.s.
m g n.s. g n.s. I
ALP activity NTg ** NT I  *
NT
I*
NT NT NT NT
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NT
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NT
NT
NT
NT
NT
NT
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Table 7.2. Summary o f  the effects o f  modulating EAAT activity at pathophysiological glutamate concentrations on the osteoblast phenotype.
Changes in expression/activity o f MG-63 (black) and SaOS-2 (grey) are shown as increases ( |) , decreases (j)  or no change (-) relative to respective 
controls (no inhibitor/scrambled AON/empty vector, 500pM glutamate). NT, not tested. Significance values *P<0.05, **P<0.01, ***/><0.001, n.s (not 
significant) by pair-wise post-hoc comparisons. Trends non-significant by post-hoc test but significant by ANOVA are indicated in brackets.
__________ - — -_ Transport . .  |ntrace| |U|ar interactions
Ion channel
Ex9skip r-PDC TBOA Ex3skip C-term TM6-7 N-term
Cell number  ^n.s.  ^n.s. I* H **
j  **
OsteocalcinmRNA  ^n.s. V
jn.s. (*+) 
m ■g^n.s.
Osteonectin ■ - I * - - m -mRNA m  ^n.s. - - m -
OPG m  ^n.s. - - f n.s. ■ -mRNA m 1 * ■ J^ n.s. m
ALPmRNA
m n.s. ^  ** I* ■ n.s. mm
NT NT NT NT NT NT NTALP activity - - - - - - -
Mineralisation NT
NT
NT*^** NT NT
NT
NT
NT
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synovial fluid o f patients with inflamed joints due to OA, RA and gout (McNeamey et 
al. 2004) and are associated with peripheral pain (Carlton 2 0 0 1 ) and inflammation 
(Flood et al. 2007).
The treatments have been categorised within the table by the EAAT activity 
influenced, however these are not rigid classifications (as shown in Table 7.3). For 
instance, TBOA and EAATlex9skip inhibit glutamate transport and may therefore 
prevent any intracellular interactions associated with the conformational changes that 
occur upon glutamate transport. Furthermore, EAATlex9skip lacks residues within 
exon 9 known to be important for glutamate binding (Figure 1.8) (Seal and Amara 
1998; Zhang and Kanner 1999; Leighton et al. 2006), which may influence the 
glutamate gated CT conductance. Therefore, explanations exist as to why findings are 
not consistent across the groups as they are categorised in tables 7.1 and 7.2. The 
pertinent findings from these data will now be discussed.
Table 7.3. Known and potential effects o f experimental modulation o f EAAT  
activity and specificity o f these treatments to EAAT1. Each experimental modulation 
of EAAT activity is shown in conjunction with the EAAT activities that are known to 
be inhibited (Y), may be inhibited (?) or are unlikely to be influenced (N). EAAT1 
specificity is also shown.
Transport Anionconductance
Intracellular
interactions
EAAT1
specific
/-PDC Y N ? N
TBOA Y Y ? N
Ex3skip Y Y Y Y
Ex9skip Y ? ? Y
N-term peptide N N Y Y
TM 6-7 peptide N ? Y N
C-term peptide ? ? Y ?
7.3.1 Targeting of EAAT1 elicits different effects to targeting all EAATs in 
osteoblasts
Inhibition o f glutamate transport in osteoblasts was achieved by chemical inhibitors 
(/-PDC and TBOA) and by overexpression o f  the dominant-negative EAATlex9skip. 
While /-PDC and TBOA inhibit transport through all expressed EAATs, the effects o f
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overexpressing EAATlex9skip is expected to be specific to EAAT1 . This may 
explain why these treatments resulted in contrasting effects on the cell phenotype. In 
the absence o f exogenous glutamate, overexpression o f  EA ATlex9 skip decreased 
MG-63 cell number and mean osteocalcin expression levels while increasing SaOS-2 
ALP activity, whereas EAAT inhibitors increased MG-63 and SaOS-2 cell number, 
increased SaOS-2 osteocalcin expression and decreased SaOS-2 ALP activity (Table
7.1).
Such effects could be the result o f  differences in expression, activity or localisation o f  
the EAAT subtypes expressed. Transcript levels for EAATs 1-3 in MG-63 and SaOS- 
2 cells decrease in magnitude in the order o f  EAAT1>EAAT3>EAAT2 (EAATs 4  
and 5 were not investigated). EAAT inhibitor concentrations (lOOpM) were sufficient 
to inhibit all EAAT subtypes (Table 2.3), though with ~ 10-fold greater affinity for 
EAATs 2, 4 and 5 (/-PDC) or EAATs 2-5 (TBOA) compared to EAAT1 . The low  
mRNA expression o f  EAAT 2 (unquantifiable levels) suggests that inhibitors may be 
influencing the osteoblast phenotype via EAATs 3, 4 or 5. Thus detailed investigation 
o f EAATs 3-5 in osteoblasts may be warranted. This may be particularly relevant for 
MG-63 cells which express EAAT1 at only 300-fold higher levels than EAAT3 but it 
seems unlikely that inhibition o f transport specifically through EAAT1 would yield 
different effects to inhibiting transport through all EAATs in SaOS-2 cells, given that 
EAAT1 expression is -5 0 ,000-fold higher than EAAT3 and that both subtypes 
display similar affinities for L-glutamate in Xenopus oocytes and HEK293 cells 
(Arriza et al. 1994; Jensen and Brauner-Osbome 2004). Therefore a role for EAATs 4 
and 5 should be investigated in SaOS-2 cells.
It is known that the uptake kinetics and glutamate gated C f conductance can vary 
across the EAAT subtypes, as can post-translational regulation by phosphorylation 
and protein-protein interactions (reviewed in (Danbolt 2001)), indicating that each 
EAAT subtype might have differential functional roles. For example, glial EAATs (1 
and 2) are responsible for the bulk o f  glutamate transport in the CNS (Danbolt 2001; 
O'Shea 2002; Kanai and Hediger 2004) whereas neuronal EAATs (3 and 4) are 
thought to have more specialised roles that are poorly characterised.
The localisation o f  different EAAT subtypes within the cell is tightly regulated 
(reviewed in (Danbolt 2001; Amara and Fontana 2002)). Inhibition o f  EAATs close to 
certain glutamate receptor subtypes will allow glutamate spill-over and receptor 
activation, modulating intracellular signalling events. For example glutamate uptake
299
Chapter 7
through EAAT4 limits mGluR activation and signalling at purkinje neurons in the 
cerebellum (Wadiche and Jahr 2005). EAAT1 may be located close to a particular 
receptor subtype in osteoblasts such that overexpression o f  EAAT 1 ex9skip decreases 
glutamate uptake in the vicinity o f  this receptor leading to its activation and 
intracellular signalling regulating cell proliferation, ALP activity and osteocalcin 
expression. This would not be apparent with more general chemical inhibition o f  
EAATs. Activation o f NMD A receptors can modulate these effects in osteoblasts 
(Hinoi et al. 2003; Ho et al. 2005; Fatokun et al. 2006; Lin et al. 2008) but 
colocalisation o f EAAT1 with NMD A  receptors has not been investigated in bone 
cells or the CNS, and may be a useful area for future work. Interestingly, GLAST has 
been implicated in restricting the activation o f  mGluRs in neurons from murine 
hippocampal slices (Huang et al. 2004). Therefore EAAT1 may be located close to 
mGluRs in osteoblasts which are activated upon specific inhibition o f  glutamate 
uptake by EAAT1. Such mGluRs may directly signal to decrease cell number and 
increase ALP activity or they may inhibit activation o f  NMD A receptors which signal 
to increase cell number and decrease ALP activity under these conditions. Gu and 
Publicover have shown that NM DA currents in osteoblasts that were rapidly lost upon 
treatment with lOOpM glutamate could be restored by blockade o f mGluRs with 
MCPG, indicating that inhibitory cross talk occurs between mGluRs and NMDA  
receptors in osteoblasts (Gu and Publicover 2000).
The differing effects o f  chemical EAAT inhibitors and overexpression o f  
EAATlex9skip in these cells may also be explained by differences in the mode and 
timing o f  inhibition. For instance, the inhibitors are likely to be most active at the 
point o f treatment, whereas exon skipping becomes increasingly effective, and 
confluence-dependent changes in osteoblasts may affect the responses.
7.3.2 Modulation o f EAAT activity regulates expression o f osteocalcin in 
osteoblasts
Of all the transcripts quantified as markers o f  osteoblast activity, osteocalcin 
expression was most consistently affected by each method o f  EAAT modulation. 
Each experimental condition inhibited different EAAT activities, highlighting the 
possibility that osteocalcin expression might be regulated by more than one 
mechanism involving EAATs. Effects were cell type specific and since MG-63 cells
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represent an early osteoblast phenotype and SaOS- 2  cells display a late osteoblast 
phenotype this supports the theory that glutamate signalling is dependent on 
osteoblast maturation stage (discussed further in section 7 .3 .4 ).
7.3.2.1 MG-63 cells
Osteocalcin expression was significantly reduced in MG-63 cells following 24hr 
incubation with 500pM glutamate. Osteocalcin expression is regulated by the 
transcription factor Runx2 (Ducy and Karsenty 1995; Merriman et al. 1995) and 
500jiM glutamate also decreased human primary osteoblast Runx2 expression. Others 
have shown that high concentrations o f  extracellular glutamate, leading to inhibition 
o f the cystine/glutamate antiporter, downregulates Runx2 activity due to a depletion 
of GSH early in osteoblast differentiation (Takarada-Iemata et al. 2010). This 
mechanism may explain the observed effects on osteocalcin in MG-63 cells, which 
exhibit a pre-osteoblast phenotype and on Runx2 in primary osteoblasts after 24hrs 
culture but not at 5 days.
Overexpression o f  EAATIa and EAATlex9skip in MG-63 cells appeared to mimic 
the glutamate-induced down-regulation o f  osteocalcin expression. Overexpression o f  
either splice variant decreased glutamate uptake, thus increasing the levels o f  
extracellular glutamate, known to inhibit the cystine/glutamate antiporter leading to 
decreased osteocalcin expression through depletion o f  GSH (Takarada-Iemata et al. 
2010). In support o f this, EAATs and the antiporter colocalise in human corneal 
epithelium (Langford et al. 2010) and rat lens (Lim et al. 2005). However EAAT 
inhibitors alone, which also reduce glutamate uptake, did not mimic the glutamate- 
induced down-regulation o f  osteocalcin expression. It is possible that /-PDC and 
TBOA do not sustain their inhibitory activity over time or at the specific location o f  
the antiporter and, in the case o f  /-PDC, accumulate intracellularly preventing the 
sustained inhibition o f extracellular glutamate uptake. Inhibitors o f the 
cystine/glutamate antiporter, such as homocysteic acid, could be used to test the 
hypothesis that the glutamate-induced down-regulation o f  osteocalcin and Runx2 in 
MG-63 and primary human osteoblasts is the result o f reversal o f  the 
cystine/glutamate antiporter.
At physiological glutamate concentrations, mean MG-63 osteocalcin expression was 
increased by inhibition o f  EAAT 1 N-terminal interactions but decreased by inhibition
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o f EAAT1 TM6-7 and C-terminal interactions. Each EAAT1 competing peptide 
increased mean uptake activity o f  lOpM glutamate, suggesting that these effects are 
not mediated by increased extracellular glutamate inhibiting the cystine/glutamate 
antiporter, although kinetic characterisation o f  the glutamate uptake saturation curves 
with each peptide is necessary to be certain o f  this. Therefore, an EAAT-mediated 
mechanism involving intracellular interactions with EAAT1 TM 6-7 and/or C- 
terminus may positively regulate the expression o f  osteocalcin. This is consistent with 
the observed decrease in osteocalcin expression when overexpressing either EAAT1 
splice variant since intracellular interactions downstream o f  TM2 (EAATIa) and at 
the C-terminus (EAATlex9skip) are likely to be altered.
These findings suggest that MG-63 osteocalcin expression may be regulated by both 
the effects o f extracellular glutamate on the cystine/glutamate antiporter and by an 
EAAT 1-mediated mechanism that is dependent on intracellular interactions o f the 
protein but not dependent on the extracellular glutamate concentration.
7.3.2.2 SaOS-2 cells
SaOS-2 cells exhibit a late-osteoblast phenotype (Pautke et al. 2004; Shapira and 
Halabi 2009). SaOS-2 cells display low levels o f  Na+-independent compared to Na+- 
dependent glutamate transport (section 3.3.3.1.1), suggesting that in comparison to the 
EAATs, the cystine/glutamate antiporter does not play a major role in the uptake o f 1- 
250pM extracellular glutamate in SaOS-2 cells. Inhibition o f EAAT glutamate 
transport by f-PDC and TBOA at physiological glutamate concentrations increased 
SaOS-2 osteocalcin expression. In rat calvarial osteoblasts, NMDA receptor activation 
increases Runx2 activity and expression o f  osteocalcin (Hinoi et al. 2003; Lin et al. 
2008), suggesting that in SaOS-2 cells, EAAT inhibition increases the level o f  
extracellular glutamate available to activate NM DA receptors. However, 500pM  
glutamate alone and in combination with EAAT inhibitors had no effect on SaOS-2 
osteocalcin expression, indicating that at physiological glutamate concentrations, 
there is a transporter-mediated effect on osteocalcin expression in these cells that is 
independent o f  extracellular glutamate.
Since TBOA caused the largest increase in SaOS-2 osteocalcin expression and is 
known to block the glutamate gated anion conductance o f  EAATs (Shimamoto et al. 
1998; Seal et al. 2001; Ryan and Vandenberg 2002), this may suggest that the
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chloride flux downregulates osteocalcin expression. However overexpression o f  
EAATIa, which lacks domains required for glutamate gated anion conductance, 
significantly decreased SaOS-2 osteocalcin expression. This suggests that the effect o f  
TBOA may be due to inhibition o f  anion conductance o f  EAATs 2-5. Alternatively, 
the data are consistent with an intracellular interaction o f  EAAT 1, lost in EAATIa, 
therefore down-stream o f  the N-terminus that is activated upon binding o f  TBOA (but 
not /-PDC or glutamate), leading to increased osteocalcin expression. TBOA is non- 
transportable, unlike glutamate and /-PDC, and may remain bound extracellularly for 
longer, sustaining an intracellular interaction response that increases osteocalcin 
expression. Further evidence for this hypothesis is provided by inhibition o f  EAAT 1 
C-terminal intracellular interactions, which leads to decreased mean osteocalcin 
mRNA levels in SaOS-2 cells. Potential mediators o f  this response include ezrin, 
GFAP, NHERF1 and Sept2/4 which are known to bind to the C-terminus o f EAAT 1 
(Table 6.1) (Kinoshita et al. 2004; Lee et al. 2007; Sullivan et al. 2007b).
This possible receptor-like function for EAATs leading to increased osteocalcin 
expression is potentially important in bone biology and the mechanism should be 
further investigated. There is some evidence linking EAAT activity with MAPK 
activation (Abe and Saito 2001; Marie et al. 2002) and MAPK activity has been 
associated with regulation o f  osteocalcin expression in MC3T3-E1 osteoblast-like 
cells, through direct phosphorylation o f  Runx2 (Xiao et al. 2000). EAAT activation o f  
MAPK was dependent on glutamate transport (Abe and Saito 2001) or via an N- 
terminal EAAT interaction (Marie et al. 2002). This mechanism does not explain our 
data in SaOS-2 cells since increased osteocalcin expression was observed with TBOA 
which inhibits transport and preventing EAAT1 N-terminal interactions using 
competing peptides had no effect at physiological glutamate concentrations and 
increased mean osteocalcin levels at pathophysiological glutamate concentrations. To 
determine whether EAAT1 activation o f  MAPK activity is relevant to this response, 
SaOS-2 cells treated with TBOA in the presence and absence o f competing peptides 
to EAAT1 intracellular domains could be analysed by western blotting for 
phosphorylated MAPK.
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7.3.3 Modulation of EAAT activity may influence coupling of proliferation 
and differentiation in osteoblasts
Proliferation and differentiation towards a bone-forming phenotype are negatively 
coupled in osteoblasts (Lian and Stein 1995; Karsenty 2003) (Figure 4.18). The 
expression o f genes associated with proliferation decreases as bone matrix genes are 
upregulated during osteoblast maturation (Malaval et al. 1999; Karsenty 2003; Lian 
and Stein 2003; Stein et al. 2004). Osteosarcoma cells such as MG-63 and SaOS-2 
exhibit a dysregulation o f  sequential gene expression that normally occurs during 
osteoblast differentiation and the genes associated with each development stage are 
expressed simultaneously (Lian and Stein 1993). However the data presented here and 
discussed below indicate that modulation o f  EAAT activity may influence the 
coupling o f  proliferation and differentiation in osteoblast-like cells. Experiments with 
primary human osteoblasts at early and late differentiation stages did not validate all 
the findings in MG-63 and SaOS-2 cells; however insufficient experiments and 
replicates were carried out to comprehensively test this.
Further understanding o f  the regulatory mechanisms that govern the relationship 
between proliferation and differentiation in osteoblasts could provide valuable 
guidance for the diagnosis and targeted treatment o f skeletal disorders such as bone 
cancers, where aberrations in this relationship have occurred. Furthermore, prolonging 
the proliferative stage o f osteoblast development prior to differentiation may have 
application to fracture repair where it would be advantageous to ensure an adequate 
quantity o f osteoblasts is available to fill the defect. The role o f EAATs in regulating 
the coupling o f  osteoblast proliferation and differentiation should be further 
investigated by comprehensively determining the effects o f EAAT modulation at each 
stage o f primary osteoblast maturation (Figure 4.18).
7.3.3 .1  MG-63 cells
At physiological glutamate concentrations, /-PDC and TBOA increased mean MG-63 
cell number. It is not possible to say whether inhibitors increased proliferation or 
decreased apoptosis, particularly since glutamate signalling through ionotropic 
glutamate receptors is known to mediate both neural progenitor cell proliferation
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(Haydar et al.,2000; Bai et al. 2003) and survival (Ikonomidou et al. 1999). However, 
EAAT inhibitors did not significantly affect human primary osteoblast cell death. 
NMDA receptor activation causes proliferation o f MC3T3-E1 osteoblast-like cells 
(Fatokun et al. 2006) as well as neuronal progenitor cells, cancer cells, chondrocyte­
like cells and synovial fibroblasts (Contestabile 2 0 0 0 ; Rzeski et al. 2 0 0 1 ; Parada- 
Turska et al. 2006; Spitzer 2006; Piepoli et al. 2009). This suggests that EAAT 
inhibitors increase MG-63 cell number by increasing the concentration o f  
extracellular glutamate available to activate NM DA receptors.
In contrast to the effects o f  /-PDC and TBOA, overexpression o f  EAATlex9skip 
(which specifically inhibits glutamate transport through EAAT1) decreased MG-63 
cell number at physiological glutamate concentrations. Thus EAAT1 directly 
increases MG-63 cell number, independently o f the extracellular glutamate 
concentration, possibly through localisation close to particular inhibitory glutamate 
receptor subtypes (section 7.3.1). Overexpression o f  EAATIa did not decrease MG- 
63 cell number at physiological glutamate concentrations, indicating differences 
between the two splice variants in their mechanism o f  EAAT 1 inhibition. 
Pathophysiological glutamate concentrations (500pM) only increased cell number 
when added during the proliferative stage o f  osteoblast growth. For example, 500jiM  
glutamate increased MG-63 cell number in experiments presented in chapter 4 but not 
in untransfected cells in chapters 5 or 6  where glutamate was added 24hrs later when 
cells were more confluent. Changes in components o f the glutamate signalling system 
may occur as osteoblasts grow and mature (discussed further in section 7.3.4).
Loss o f C-terminal interactions using competing peptides increased MG-63 cell 
number in the presence o f  500pM glutamate indicating that the EAAT1 C-terminal 
may interact with other proteins within the cell directly to downregulate cell number. 
Alternatively, since loss o f  C-terminal intracellular interactions increased mean 
glutamate uptake activity in MG-63 cells, this may reduce the activation o f  nearby 
glutamate receptor subtypes that signal to inhibit the increase in cell number. The C- 
terminal competing peptide may also disrupt the conformation o f  the anion pore 
(Mitrovic et al. 1998). The glutamate-gated chloride conductance may negatively 
regulate proliferation under normal conditions by modulating ion entry following 
NMDA receptor activation. However, blocking the glutamate-gated chloride 
conductance o f all EAATs using TBOA prevented the glutamate-induced increase in
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MGt63 cell number, suggesting that the mechanism responsible may be specific to 
EAAT1.
7.3.3.2 SaOS-2 cells
EAAT inhibition by /-PDC and TBOA significantly increased SaOS-2 cell number, 
suggesting that reduced glutamate uptake increases the extracellular glutamate 
available to activate the NM DA receptors responsible for increasing cell number. 
EAAT inhibitors also decreased SaOS-2 ALP activity and mineralisation suggesting 
that these treatments may prolong the proliferation stage o f osteoblast maturation, 
preventing the upregulation o f  genes associated with matrix maturation and 
mineralisation. Prolonging o f  the proliferation stage o f  osteoblast maturation has 
previously been observed in primary human and rat osteoblasts subjected dynamic 
cell stretching (Stanford et al. 1995a; Kaspar et al. 2000) and TGF-p (Lian and Stein 
1993). Inconsistent with this however, is the increase in SaOS-2 osteocalcin 
expression, a marker o f  late osteoblasts, in response to TBOA and this may reflect the 
dysregulation o f proliferation and differentiation in osteosarcoma cell lines.
In contrast, overexpression o f  EAATlex9skip (which specifically inhibits glutamate 
transport through EAAT1) increased SaOS-2 ALP activity at physiological glutamate 
concentrations. Thus specific inhibition o f EAAT1 may drive osteoblast 
differentiation from the proliferative stage to the non-proliferating matrix maturation 
stage, inferring that EAAT1 activity specifically decreases ALP activity, 
independently o f  glutamate receptor activation by extracellular glutamate. 
Overexpression o f  EAATIa did not have the same effects, again suggesting 
differences between the two splice variants.
Pathophysiological glutamate concentrations alone did not affect SaOS-2 cell number; 
however overexpression o f  EAATIa increased SaOS-2 cell number at 500fiM 
glutamate. Overexpression o f  EAATIa decreased SaOS-2 glutamate uptake, 
suggesting that the increase in cell number may be due to increased activation o f  
NMDA receptors. However, overexpression o f EAAT lex9skip, which inhibited 
SaOS-2 uptake o f lOpM glutamate to a greater extent compared to overexpression o f  
EAATIa (Figure 5.9), had no effect on SaOS-2 cell number at pathophysiological 
glutamate concentrations. This suggests the existence o f  an alternative mechanism 
relating glutamate to cell number that is dependent upon regions o f the EAAT1
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protein lost in EAATIa. EAATIa is thought to reorient in the plasma membrane thus 
preventing any C-terminal intracellular interactions (Huggett et al. 2 0 0 0 ). Consistent 
with this, loss o f  C-terminal interactions using competing peptides increased MG-63 
cell number in the presence o f  500pM glutamate.
7.3.4 Evidence for maturation-specific glutamatergic signalling in 
osteoblasts
Modulation o f  EAAT activity often differentially affected MG-63 and SaOS-2 cells, 
suggesting that cells with a pre-osteoblast phenotype (MG-63) respond differently to 
cells with a late osteoblast phenotype (SaOS-2). The confluence dependent effects o f  
glutamate (discussed in section 7.3.3.1) and the differences in the short- and long-term 
effects o f EAAT inhibitors on primary osteoblast ALP activity also support the theory 
that glutamate signalling may have different effects in osteoblasts depending on the 
maturation stage. The differentiation stage o f  osteoblasts is also known to regulate the 
response to 1,25-dihydroxyvitamin D 3 and PTH (Majeska and Rodan 1982; Isogai et 
al. 1996).
The effect o f  osteoblast differentiation stage on the response to glutamate and/or 
EAAT inhibitors may reflect altered levels o f glutamate receptor/transporter 
expression, the expression o f particular receptor/transporter subtypes, or differences in 
glutamate release or transporter activities. The evidence from this thesis and other 
publications to support this is discussed below.
This thesis has highlighted the differences between MG-63 and SaOS-2 cells in 
EAAT expression and activity, in the regulation o f  EAAT activity by extracellular 
glutamate, and the ratio o f EAAT 1 to its splice variant EAATlex9skip. Other studies 
have shown that total glutamate uptake decreases as rat calvarial osteoblasts mature in 
culture from 7 to 21 days (Takarada et al. 2004). This is in contrast to MG-63 and 
SaOS-2 cells which are thought to represent a pre- and late-osteoblast phenotype 
respectively, since SaOS-2 cells display greater total and Na+-dependent glutamate 
uptake activity than MG-63 cells (section 3.3.3.1.1). These differences could be due to 
species or culture conditions.
In addition to the EAATs, osteoblast differentiation also alters glutamate release, 
receptor expression and the response to glutamate receptor activation and 
cystine/glutamate antiporter activity. For example, glutamate release increases during
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maturation o f MC3T3-E1 osteoblast-like cells (Genever and Skerry 2001). Although 
again this is in contrast to the maturation phenotypes o f  MG-63 and SaOS-2 cells 
since SaOS-2 cells exhibit lower rates o f  glutamate release (-3 .7  nmoles/mg protein) 
than MG-63 cells (-7  nmoles/mg protein) (Genever and Skerry 2001). In rat calvarial 
osteoblasts, expression o f  NR1 mRNA remained constant over 7-28 days in vitro, 
whereas expression o f  NR2D mRNA was reduced by -50%  in osteoblasts cultured for 
21 and 28 days compared to 7 days (Hinoi et al. 2003).
There appear to be two opposing mechanisms linking glutamate to osteoblast 
differentiation. Osteoblast differentiation o f  bone marrow stromal cells was prevented 
by high concentrations o f  glutamate which inhibit the cystine/glutamate antiporter and 
reduce GSH levels (Takarada-Iemata et al. 2010), whereas studies from Hinoi et al. 
demonstrate that NMDA receptor activation is associated with increased Runx2 and 
ALP activity o f  rat calvarial osteoblasts if  added to the culture after the proliferative 
stage o f maturation (Hinoi et al. 2003). These data suggest that high concentrations o f  
glutamate can inhibit osteoblast differentiation o f  bone marrow stromal cells in 
association with GSH depletion but that glutamate signalling through specific 
glutamate receptors increases differentiation and bone forming activity o f  committed 
osteoblasts. These differences may reflect changes in the expression and activity o f  
glutamate signalling components during maturation o f osteoblasts, or the effects of 
different glutamate concentrations i.e. pathophysiological concentrations inhibit the 
cystine/glutamate antiporter whereas physiological concentrations activate glutamate 
receptors. The latter possibility is highly relevant to pathological situations associated 
with high glutamate concentrations such as OA, RA, gout (McNeamey et al. 2004) 
and may be important in fresh bone fractures. Enhanced knowledge o f maturation- 
stage dependent glutamate signalling in bone would be useful for the therapeutic 
targeting o f EAATs or other glutamatergic signalling components in the treatment o f  
bone disorders or fracture.
7.4 A role fo r EAATs in the  regulation o f bone rem odelling?
The mechanisms that couple osteoblast and osteoclast activities in bone remodelling 
(section 1.2) are poorly understood but could be exploited therapeutically to inhibit 
bone resorption while simultaneously promoting bone formation. Osteoclast
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differentiation and resorption is regulated by osteoblasts via the OPG/RANK/RANK- 
L system (section 1.1.1.2) (Yasuda et al. 1998a; Yasuda et al. 1998b) and the data in 
this thesis indicate that modulation o f  EAAT activity affects expression o f  OPG in 
SaOS-2 osteoblasts. Mean OPG mRNA levels were increased in SaOS-2 cells in 
response to 24hr incubation with 500pM glutamate and this was prevented by /-PDC. 
Thus glutamate uptake through the transporter may promote expression o f  OPG. A 
reduction in OPG mRNA levels in SaOS-2 cells expressing either the TM6-7 or C- 
terminal domain o f  EAAT 1 at 500pM glutamate, or all three peptides at physiological 
glutamate levels, implicates these regions in the signalling event. Since each EAAT1 
peptide had a similar effect on OPG expression in SaOS-2 cells, it is possible that the 
glutamate-induced increase in OPG expression requires the tertiary structure o f  
EAAT1 protein, possibly to form the anion pore (Mitrovic et al. 1998). This is the 
first report linking the glutamate signalling pathway in bone to the regulation o f  OPG 
expression.
The role o f  glutamate in the processes that couple osteoblast and osteoclast activity is 
shown in Figure 7.3. Evidence is provided by expression o f glutamatergic signalling 
components in each cell type (Table 1.3 and 1.4), activation o f glutamate receptors 
that regulate osteoclast and osteoblast differentiation and activity (Chenu et al. 1998; 
Peet et al. 1999; Itzstein et al. 2000; Hinoi et al. 2003; Ho et al. 2005; Lin et al. 2008), 
glutamate release by both cell types (Genever and Skerry 2001; Morimoto et al. 2006) 
and the fact that inhibition o f the cystine/glutamate antiporter inhibits differentiation 
of both osteoclasts (Hinoi et al. 2007) and osteoblasts (Takarada-Iemata et al. 2010). 
Modulation o f  EAAT activity in vivo will therefore affect multiple bone cell types and 
strategies to target cell type specific EAAT activity may need to be employed in 
further studies.
A role for osteoblast expressed EAATs in regulating the expression o f  OPG, and 
therefore the differentiation and activity o f  osteoclasts, could be further tested by 
specifically inhibiting SaOS-2 EAATs (by siRNA) in co-cultures o f osteoblasts and 
pre-osteoclasts and analysing RANKL expression and osteoclast differentiation and 
activity.
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Figure 7.3. Hypothetical model o f glutamate signalling in hone and the potential effects o f EAAT modulation in vivo. Opening of stretch and 
voltage sensitive calcium channels (SSCC, VSCC) in osteocytes in response to mechanical load increases intracellular Ca2+ which may induce 
glutamate release into junctions with neighbouring osteocytes (Mason 2004a). EAAT1 expression is downregulated in mechanically loaded 
osteocytes (Mason et al. 1997). Glutamate is released into the bone microenvironment by osteocytes close to the bone surface where it binds to 
NMDA receptors to induce differentiation of osteoblast progenitors through increased Runx2 activity and to regulate osteoblast proliferation, gene 
expression and activity during maturation (Hinoi et al. 2003; Ho et al. 2005). Glutamate also activates AMPA receptors on osteoblasts to cause 
glutamate release (Hinoi et al. 2002b). Released glutamate may activate neighbouring osteoblasts or osteoclasts. Osteoblasts express high levels of 
EAAT1 and lower levels of EAAT3, which regulate the extracellular glutamate concentration. Findings from this thesis suggest that EAAT1 may 
be located close to specific inhibitory mGluRs and that an EAAT 1-mediated mechanism regulates expression of osteocalcin (OC), demonstrating 
that these transporters represent therapeutic targets for increasing osteoblast bone-forming activity. Furthermore, accumulation of glutamate 
through the transporter may increase expression of osteoprotegerin (OPG). OPG is a soluble decoy receptor for osteoblast-expressed RANKL and 
an inhibitor of osteoclast differentiation (Yasuda et al. 1998a; Yasuda et al. 1998b). Binding of RANKL to its receptor RANK, present on 
osteoclasts, promotes osteoclast differentiation and activity. NMDA receptor activation also promotes NF-kB stimulated osteoclast differentiation 
(Peet et al. 1999; Merle et al. 2003) and increases the activity of mature bone-resorbing osteoclasts (Chenu et al. 1998; Itzstein et al. 2000; 
Mentaverri et al. 2003). Osteoclasts express EAATs 2 and 4 (Hinoi et al. 2007; Takarada and Yoneda 2008), the activity of which could be 
modulated in vivo by some of the methods developed in this thesis. Preventing osteoclast glutamate accumulation through EAATs may influence 
the bone-resorbing activity of the cell since mature osteoclasts release glutamate in conjunction with bone degradation products by transcytosis and 
released glutamate can act on autorgeulatory mGluRs, preventing further glutamate release by osteoclasts (Morimoto et al. 2006). Glutamate 
signals may therefore contribute to the mechanoresponse and the coupling process during bone remodelling. Alterations in bone mass are probably 
governed by the net effects of signalling on all bone cell types and modulation of EAAT activity in vivo is likely to affect multiple cell types. Figure 
adapted from (Mason 2004a).
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7.5 Do EAATs play a role in regulating bone form ation?
A role for glutamate in the regulation of bone mass has been highlighted by transgenic 
models lacking components of the signalling pathway, including VGLUT1' ' and bone 
specific NMDAR1 subunit knockouts, which display reduced bone mass (Hinoi et al. 
2007; Skerry 2008). Furthermore, glutamate receptor activation has been implicated 
in osteoblast and osteoclast differentiation and activity (Chenu et al. 1998; Peet et al. 
1999; Itzstein et al. 2000; Hinoi et al. 2003; Merle et al. 2003; Ho et al. 2005; Lin et 
al. 2008; Olkku and Mahonen 2008), and mechanical load, a potent osteogenic 
stimulus, can regulate expression of GLAST and glutamate receptors in bone in vivo 
(Mason et al. 1997; Ho et al. 2005; Szczesniak et al. 2005). These findings provide 
evidence that glutamate signalling regulates bone formation and remodelling and that 
modulation of the transporters can influence this.
The role of EAATs in the regulation of bone formation has not been comprehensively 
tested in vitro and the lack of an effect on bone growth in the GLAST knockout 
mouse has led some researchers to believe that GLAST activity does not play a major 
role in bone growth (Gray et al. 2001). However, redundancy amongst the transporters 
expressed was not taken into account, nor were the effects of modelling versus 
remodelling or the response to challenge (Chenu et al. 2001; Skerry et al. 2001). The 
studies presented in this thesis strongly suggest that EAAT activity in osteoblasts 
regulates the bone forming phenotype.
7.5.1 Could therapeutic modulation of EAATs enhance bone formation?
Inhibition of each EAAT activity has shown the potential to increase osteoblast cell 
number and/or bone-forming activity, demonstrating potential for therapeutic 
enhancement of bone mass. TBOA increased cell number and osteocalcin expression 
in SaOS-2 cells at physiological glutamate levels and increased ALP activity and 
mineralisation of primary human osteoblasts at pathophysiological glutamate 
concentrations. Overexpression of EAATIa also increased cell number in SaOS-2 
cells at 500pM glutamate and overexpression of EAATlex9skip increased SaOS-2 
ALP activity in the absence of exogenous glutamate. Furthermore, competing 
peptides to EAAT1 C-terminal domain increased MG-63 cell number at 500pM
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glutamate while inhibition of EAAT1 N-terminal interactions increased mean 
osteocalcin expression in MG-63 cells at OpM glutamate and in SaOS-2 cells at 
500pM glutamate.
These effects varied between different cell lines, time in culture (section 7.3.4) and 
glutamate concentration, indicating that therapeutic modulation of EAAT activity 
should be targeted to a particular osteoblast maturation stage and pathological state 
with respect to glutamate concentration.
Glutamate concentration is increased in inflamed joints (Lawand et al. 2000; 
McNearney et al. 2004) however the glutamate concentration that osteoblasts are 
exposed to at the defect site of a fresh or non-union fracture or in osteoporosis is 
currently unknown. Glutamate concentrations might be expected to increase during 
the initial inflammatory stage of fracture repair (section 1.2.1.5.1); however such 
concentrations may then dissipate under conditions of non-union. Therefore to define 
the most appropriate therapeutic strategy for targeting EAATs in bone, information 
regarding glutamate levels at the site o f treatment is required. Alternatively, glutamate 
itself, or specific agonists, could be directly delivered with the therapeutic to achieve 
the appropriate conditions.
Whilst potential for therapeutic targeting of EAATs in bone has been revealed here, 
the data are complex and require further investigation. The data suggest that EAATs 
may finely tune the glutamate response in a manner that depends on osteoblast 
differentiation stage, EAAT subtype expression and localisation as well as which 
specific EAAT activity predominates. To further investigate the potential for EAAT 
modulation in bone repair, these experimental methodologies should be applied to a 
model of human primary osteoblast differentiation, to determine the appropriate 
maturation stage to target at physiological and pathophysiological glutamate 
concentrations, and then ultimately an in vivo model. The experiments here indicate 
that the primary outputs to measure in such in vitro studies are osteocalcin and OPG 
expression and ALP activity. The in vivo model chosen will depend on the dosing and 
delivery of a particular therapeutic agent but could comprise a rodent model of 
fracture repair or a model of post-menopausal bone loss in ovariectomised mice. 
However, effects in vivo are likely to differ from in vitro since modulation of 
glutamatergic signalling has the potential to affect each ceil type in bone (illustrated in 
Figure 7.3) as well as other tissues and nerves.
313
Chapter 7
7.5.1.1 Therapeutic strategies in bone
7.5.7.7.1 Non-union fracture
Atrophic non-unions are typified by insufficient availability of bone forming cells, 
preventing normal bone healing from occurring (Megas 2005) (section 1.2.1.5.2). 
Therefore, treatments to increase the number or activity of osteoblasts available to fill 
the defect would be advantageous.
Data from this thesis (section 7.5.1), demonstrates that inhibition of each EAAT 
activity can increase osteoblast cell number and/or bone-forming activity, suggesting 
that therapeutic targeting of EAATs may have application to fracture repair.
Local delivery of a therapeutic for fracture healing does not require chronic 
application, since there is no need for the activity to persist beyond the time required 
to achieve healing, therefore each of our methods to inhibit EAAT activity displays 
therapeutic potential. One method for site-specific delivery to bone is the application 
of the molecules incorporated in an absorbable collagen sponge. This process is 
currently used clinically in the application of rhBMP-2 and rhBMP-7 for spinal fusion 
and the treatment of non-union fracture (section 1.2.1.5.2.1), and is appropriate for the 
delivery of chemical EAAT inhibitors, AONs and competing peptides with CPP tags. 
Alternative delivery strategies include the direct injection of the molecules into the 
defect space or, with respect to AONs and peptides, the injection of viral vectors 
expressing the sequences. This method has the advantage of being non-surgical.
7.5.7.7.2 Osteoporosis
Osteoporosis is a disorder of uncoupled bone remodelling, where insufficient bone is 
formed in response to increased resorption (section 1.2.1.2). The majority of current 
therapeutics for osteoporosis target bone resorption and there is a pressing need for 
the development of anabolic bone agents. Methods that regulate EAATs to increase 
osteoblast bone forming activity may reflect potential therapies for osteoporosis. 
These include TBOA and competing peptides to the EAAT1 N-terminal domain 
which increased expression o f osteocalcin at both physiological and 
pathophysiological glutamate concentrations, and overexpression of EAATlex9skip 
which increased SaOS-2 ALP activity at physiological glutamate levels.
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Osteoporosis is a systemic disease and therefore requires systemic delivery of a 
therapeutic. Since glutamate signalling pathways are functional in several sites of the 
body besides the CNS and bone (reviewed in (Skerry and Genever 2001; Hinoi et al. 
2004)), a targeted delivery strategy for EAAT modulation to mineralised tissues 
would need to be employed to avoid adverse systemic effects. One way to achieve this 
might be tagging the therapeutic to bisphosphonates (section 1.2.1.4) which 
selectively adsorb to mineral surfaces (Jung et al. 1973), thus forming a new type of 
drug that is both anabolic and anti-resorptive. However, linking the drug to targeting 
compounds would increase its size, thus potentially reducing its oral bioavailability, 
necessitating injection.
AONs could be delivered systemically by injecting into the blood and targeted to bone 
by viral vectors expressing the sequence under a bone specific promoter, such as the 
Runx2 or osteocalcin promoter. The promoter used would depend on the appropriate 
maturation stage of the osteoblast to target.
7.5.1.1.3 Osteolysis
Osteolysis is the most significant long-term complication associated with artificial 
joint replacement and is characterised by bone resorption leading to implant loosening 
and failure (reviewed in (Purdue et al. 2007)). Methods to improve the 
osteoconduction and osteoinduction of the implant, or to reduce the activity of 
osteoclasts in the vicinity o f the implant, could prevent osteolysis and implant 
loosening
The data in this thesis shows that modulation of EAAT activity increases osteoblast 
cell number and markers of bone formation, strategies that could be osteoinductive. 
Furthermore, overexpression of EAAT lex9skip and competing peptides to the 
EAAT1 C-terminal domain increased expression of OPG in SaOS-2 and MG-63 cells 
respectively. Since OPG inhibits osteoclast differentiation and activation, these 
molecules could prevent the bone resorption that typifies osteolysis.
Delivery of therapeutics for osteolysis could involve tethering peptides to the surface 
of the implant or incorporation into a bone void filler for revision surgeries.
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7.5.1.1.4 Osteosclerosis
Sclerosing bone dysplasias are characterised by increased bone density (section
1.2.1.1), so methods to reduce osteoblast activity or increase osteoclast activity could 
be potential treatments for these diseases.
Our data shows that chemical EAAT inhibition reduces ALP activity and 
mineralisation of SaOS-2 cells, suggesting that these inhibitors may be exploited 
therapeutically to reduce bone formation. However, these effects were not apparent in 
primary osteoblasts.
SaOS-2 OPG expression was decreased by /-PDC and competing peptides to each 
EAAT1 intracellular domain tested. Methods to decrease OPG expression in 
osteoblasts could be used to increase osteoclast differentiation and activity and 
therefore increase bone resorption.
Osteosclerosis is a systemic disorder, and therefore presents the same problems of 
therapeutic targeting to bone as discussed with reference to osteoporosis (section 
7.5.1.1.2). Furthermore, these disorders are characterised by genetic defects and as 
such would require chronic treatment, which may not be suited to application of the 
peptides which have a short half-life in vivo.
7.5.2 Non-bone therapeutic applications
7.5.2.1 Ectopic calcification
Ectopic calcification is the inappropriate mineralisation of soft tissues including 
kidney, cardiovascular tissues, skin and tendons (reviewed in (Giachelli 1999)). 
Therefore, although experiments designed to analyse the effects of EAAT inhibitors 
on mineralisation gave contradicting results in SaOS-2 and primary human 
osteoblasts, a consistent and considerable decrease in SaOS-2 mineralisation was 
detected. It may therefore be useful to investigate the activity of these inhibitors in 
conditions such as these, where mineralisation is undesirable.
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7.5.2.2 Osteosarcoma
Osteosarcoma is the most common form of primary bone cancer and occurs primarily 
in developing bones. The MG-63 cell line used in these studies is osteosarcoma 
derived and overexpression of EAATlex9skip and chemical EAAT inhibition 
decreased MG-63 cell number at physiological and pathophysiological glutamate 
concentrations respectively. Methods to inhibit the growth of cancer cells are 
therapeutically advantageous and glutamate receptor antagonists are currently being 
investigated to this purpose (Rzeski et al. 2002). These studies indicate that targeting 
of EAATs in osteosarcoma may also represent a therapeutic strategy.
7.5.2.3 CNS pathologies
The methods developed here to characterise EAAT activity in osteoblasts may prove 
beneficial for the understanding, prevention and treatment of CNS pathologies such as 
ischemic brain damage (Kuwahara et al. 1992; Rossi et al. 2000), epilepsy (Meldrum 
1994; Tanaka et al. 1997; Meldrum et al. 1999; Guo et al. 2010), ALS (Rothstein et al. 
1995; Rothstein et al. 1996; Howland et al. 2002), Alzheimer’s disease (Scott et al. 
1995; Scott et al. 2002; Maragakis and Rothstein 2004) and Parkinson’s disease 
(Blandini et al. 1996; Chase et al. 2000) which are characterised by a dysregulation of 
glutamatergic signalling. In the CNS, EAATs control the extracellular concentration 
of glutamate, preventing excitotoxicity and neuronal injury (Marcaggi and Attwell 
2004). Trafficking of EAATs is poorly understood and competing peptides to EAAT1 
may help identify interactions that are important for cell surface expression of the 
transporter in glial cells which undergo extensive cytoskeletal reorganisation during 
development and injury to the brain (Pekny and Nilsson 2005). SaOS-2 glutamate 
uptake was down-regulated following exposure to extracellular glutamate (Figure 
3.16) with no alterations in EAAT transcription (Figure 3.3), and identification of the 
intracellular interactions important for this response may provide a target for 
maintaining glutamate transport under conditions of excitotoxic levels of glutamate in 
the CNS. Furthermore, characterisation of EAAT1 splicing following ischemia, or 
forced overexpression of the splice variants in glial cells in vitro, may be useful in the 
context of ischemic stroke injury. ATP levels drop in ischemia and the 
electrochemical gradients cannot be maintained, leading to reversed operation of
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EAATs and glutamate release (Rossi et al. 2000), a major contributor to the 
neurotoxicity associated with stroke-induced ischemic brain damage (Kuwahara et al. 
1992; Rossi et al. 2000). Inhibition of EAAT transport activity would prevent 
glutamate release under these conditions. We and others have shown that 
overexpression of EAATlex9skip inhibits glutamate uptake and Sullivan et al. 
detected EAAT lex9skip expression in neurons and regions that are susceptible to 
damage in the hypoxic pig brain (Sullivan et al. 2007a), suggesting that 
EAATlex9skip expression may represent a protective mechanism.
7.6 Effects o f m odulating EAAT activity beyond the glutam ate 
signalling pathw ay
The findings from this PhD have largely been discussed in the context of glutamate 
signalling; however it is likely that modulation of EAAT activity will have broader 
effects within the cell. Inhibition of EAAT uptake under conditions of high 
extracellular glutamate levels will reduce the intracellular accumulation of glutamate, 
reducing the driving force behind the cystine/glutamate antiporter, which has been 
shown to be important for osteoblast proliferation and differentiation (Iemata et al. 
2007; Takarada-Iemata et al. 2010). In bone, such effects are likely to affect pre­
osteoblasts since MG-63 cells displayed high levels of Na+-independent glutamate 
uptake and decreased expression of osteocalcin in response to 500pM glutamate.
In addition, the intracellular glutamate concentration is regulated during osteoblast 
differentiation through the action of glutamine synthetase (GS) which converts 
glutamate to glutamine (Olkku and Mahonen 2008) and inhibition of osteoblast 
EAAT activity may disrupt this regulated control over intracellular glutamate 
concentration. During osteogenic differentiation of rat MSCs, GS activity declines 
rapidly at the onset of mineralisation and this change in activity is reflected by 
increased intracellular glutamate concentrations (Olkku and Mahonen 2008; Zheng 
and Quirion 2009). In our studies, inhibition of glutamate transport decreased 
mineralisation of SaOS-2 cells and this may occur as a consequence of reduced 
intracellular glutamate concentrations, consistent with these studies from Olkku and 
Mahonen. However a similar effect was not detectable in primary osteoblasts.
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Evidence from the CNS suggests interplay between the glutamate signalling pathway 
and other signalling pathways that are present in bone such as IGF, adenosine and 
calcium (Gama et al. 2001; Ferre et al. 2002; Fuxe et al. 2003; Domenici et al. 2004; 
Ciruela et al. 2006). IGF has been implicated in mechanical load-induced osteogenesis 
(section 1.3) and adenosine and calcium receptors can also function in bone cells to 
influence bone formation (Dvorak and Riccardi 2004; Dvorak et al. 2004; Evans et al. 
2006). Activation of PLC by PTH in rat femoral osteoblasts prevented calcium influx 
through NMDA receptors suggesting interplay between these two pathways in bone 
(Gu and Publicover 2000). Furthermore, the canonical Wnt signalling pathway 
negatively regulates the activity of GS in MG-63 cells, thus increasing the 
intracellular glutamate concentration (Olkku and Mahonen 2008). Therefore, the 
effects of modulating EAAT activity are complex and widespread.
7.7 C ritique  o f the  experim ental approaches taken
MG-63 and SaOS-2 cell lines exhibit different maturational phenotypes and were 
purposely chosen to investigate whether EAAT modulation was more effective at a 
particular stage of osteoblast differentiation. Osteosarcoma-derived cells are 
commonly accepted and widely published as appropriate in vitro osteoblast models 
(Bilbe et al. 1996), however they lack the sequential gene expression that 
accompanies osteoblast differentiation (Lian and Stein 1993). Therefore it is 
necessary to confirm that the differences in the expression and activity of glutamate 
signalling components between these cell lines reflect the normal changes that occur 
during osteoblast differentiation. To do this, human primary osteoblasts were used, 
but proved too expensive to obtain adequate replicates. It would be informative to 
profile EAAT expression and activity as well as the effects of modulating EAAT 
activity in primary osteoblasts, preferably over maturation in culture. Primary 
osteoblasts from rodents are easier to obtain, however from a therapeutic perspective, 
showing proof of concept in human cells is more relevant than the same results in a 
non-human cell. Therefore, differentiating human osteoblasts should be used to 
answer the outstanding questions generated by this thesis.
These studies largely ignored the possibility that EAATs 4 and 5 might be expressed 
in osteoblasts since EAAT4 had not been detected in any peripheral tissue other than
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placenta (Matthews et al. 1998) at the beginning of this PhD (Table 1.2) and 
expression of EAAT 5 is primarily restricted to the retina (Arriza et al. 1997; Pow and 
Barnett 2000). EAAT4 mRNA and protein expression have recently been 
demonstrated in osteoclasts (Hinoi et al. 2007; Takarada and Yoneda 2008) 
suggesting that this transporter might play a more active role in bone than was 
initially considered. EAAT5 mRNA was looked for and not detected in osteoclasts 
(Takarada and Yoneda 2008). It would be informative to quantify mRNA levels of 
EAATs 4 and 5 in human osteoblasts to determine more accurately the EAAT 
expression profile in these cells. Table 7.3 shows the experimental treatments utilised 
in this thesis which were not specific to EAAT1 and may therefore influence the 
activity of EAATs 4 and 5 should they be expressed in osteoblasts.
It is difficult to obtain an accurate view of the effects of altering EAAT activity in a 
system where glutamate is spontaneously released (Genever and Skerry 2001). 
Furthermore, the possibility exists that glutamate might also be released in vitro by 
medium displacement in osteoblasts due to its mechanoresponsiveness.
7.8 F u tu re  directions
7.8.1 Kinetic characterisation of glutamate uptake in cells overexpressing 
EAAT1 splice variants and competing peptides to EAAT1 
intracellular domains
Overexpression of EAAT1 splice variants and competing peptides to EAAT1 
intracellular domains altered Na+-dependent uptake of lOpM glutamate in osteoblast­
like cells. Kinetic characterisation of the Na+-dependent glutamate uptake saturation 
curve in treated cells would further characterise the effect of the splice variants and 
competing peptides on EAAT1 activity. Such data would enhance our understanding 
of the transporter in all tissues where EAATs are expressed, particularly those where 
EAATs are known to be important in the pathogenesis of disease. Knowledge of the 
mechanisms regulating EAAT activity are poorly documented and very little is known 
regarding the physiological role of EAAT la and EAATlex9skip. In our experiments, 
overexpression of EAAT la  reduced glutamate transport despite the variant retaining 
the regions of the protein important for glutamate binding and transport (Huggett et al.
I,;:
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2000) and evidence to suggest it is a functional transporter (Mason, Huggett, Daniels, 
unpublished). Therefore kinetic characterisation may help elucidate the importance of 
the ion channel domain, lost in EAAT la, for glutamate uptake.
7.8.2 Is EAAT1 localised close to a particular receptor in osteoblasts and
does this change during maturation?
EAAT localisation in the CNS can shape the synaptic event by regulating the local 
extracellular glutamate concentration available to activate glutamate receptors. Data 
from this thesis has suggested that inhibiting all EAATs may have different effects to 
inhibiting EAAT1 specifically and one explanation for this could be that EAAT1 is 
localised close to a particular receptor subtype that it important in the response of 
osteoblasts to glutamate. This hypothesis could be tested by immunofluorescent co­
localisation of EAAT 1 in osteoblasts with candidate glutamate receptor subtypes that 
are known to be expressed in osteoblasts (Table 1.3).
7.8.3 Does inhibition of EAATs sensitise osteoblasts to mechanical load?
The hypothesis behind this PhD was that inhibition of EAAT activity could mimic the 
osteogenic response of osteoblasts to mechanical load; however it is also possible that 
inhibition of EAAT activity actually primes the cells to be more responsive to 
mechanical load. It would be interesting to modulate EAAT activity in osteoblasts 
alone in a collagen gel, or in co-culture with osteocytes (Mason et al. 2008), subject to 
mechanical load and assess the effects on differentiation and bone-forming activity.
7.9 Concluding rem ark s
Glutamatergic signalling in bone is highly complex involving different receptors, 
transporters and various cell types. Its functional significance has been demonstrated 
in the literature and in this thesis. Many signalling pathways have been linked to load- 
induced bone formation and rather than any one factor that controls these events, it is 
probably an interplay of many signals. These data demonstrate that high-affinity 
glutamate transporters (EAATs) are expressed and functional in human osteoblasts
i
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and that their modulation in vitro can affect osteoblast cell number and bone-forming 
activity. Furthermore, methods have been identified to therapeutically modulate 
EAAT activity in vitro that may have in vivo application for the treatment of 
traumatised or diseased bone.
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Appendices
9. Appendices
9.1 Solutions
9.1.1 General solutions
Phosphate Buffered Saline (PBS)
8g of Sodium Chloride (NaCl)
0.2g of Potassium Chloride (KC1)
1.44g of Sodium phosphate, dibasic, anhydrous (Na2HP0 4 )
0.24g of Potassium phosphate, monobasic, anhydrous (K H 2PO 4 )
Dissolved in 800ml (IH2O and pH adjusted to 7.4 with 1M Hydrochloric acid. 
Volume made up to 1L with dH20 and solution sterilised by autoclaving.
4% Paraformaldehyde/PBS
4g paraformaldehyde was dissolved in 100ml PBS with heating. The pH was 
raised (to pH 7-8) by adding a few drops of IN NaOH until the solution 
cleared. Solution was used fresh.
9.1.2 Molecular biology
LB agar
LB agar tablets (Sigma) were dissolved in dH20 (50ml/tablet) by autoclaving 
twice. The solution was allowed to cool slightly before adding ampicillin to 
100gg/ml, IPTG to 0.5mM and X-galactosidase to 40pg/ml. Agar was poured 
into 10cm plates and allowed to solidify aseptically. Plates stored at 4°C.
LB broth
LB broth tablets (Sigma) were dissolved in dH2<3 (50ml/tablet) by autoclaving 
once. The solution was allowed to cool before adding ampicillin to lOOpg/ml. 
Stored at 4°C.
Tris-Borate EDTA buffer (TBE)
10X TBE was obtained from Promega and diluted 1:10 in dH20.
9.1.3 Glutamate uptake
Kreb s-Ringer-HEPE S buffer (KRH)
Prepared fresh, volume adjusted to 1L and pH adjusted to 7.4. Filter sterilised 
and stored at 4°C.
Stock solution Volume for 1 litre Final concentration
NaCl, 1.25M (73.05 g/1) 100ml 125mM
KC1, 70mM (5.22 g/1) 50ml 3.5mM
CaCl2*2H20, 30mM (4.41 g/1) 50ml 1.5mM
MgS04, 24mM (2.89 g/1) 50ml 1.2mM
KH2PO4 , 24mM (3.27 g/1) 50ml 1.2mM
HEPES, 1M, pH 7.4 10ml lOmM
D-glucose, 1M (180.2 g/1) 2 ml 2mM
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9.2 Q RT-PCR standard curves and dissociation curves
9.2.1 S tra tagene (C a rd iff U n ive rs ity )
9.2.1.1 Example standard curve 
GAPDH
34
32
30
28
20
24-
20
18
10
14- '*
12
Initial Q uantity  (cop ies)
9.2.1.2 Dissociation curves 
18S rRNA
D iss o c ia t io n  C u rv e
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GAPDH
D is s o c ia t io n  C u rv e
HPRT1
D iss o c ia t io n  C u rv e
------------------------
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Osteocalcin
D is s o c ia t io n  C u rv e
Osteonectin
D iss o c ia t io n  C u rv e
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EAAT1 (+EAATlex9skip)
D iss o c ia t io n  C u rv e
i>'«—'
EAATlex9skip
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EAAT3
D iss o c ia t io n  C u rv e
_________________
Standard Curve Plot
9.2.2 Applied Biosystems (Smith & Nephew Research Centre, York)
9.2.2.1 Example standard curve
GAPDH
Standard Curve Plot 
Detector:
Legend
■ S tandards 
y  Unknowns
Hide Unknowns
S tandard  Curve
S lope: -3 .3964228 
Y-Inter: 14 .166149 
R2: 0 .9956287
1.0 E-3 1.0 E-2 1.0 E-1 1.0
Quantity
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9.2.2.2 Dissociation curves
18S rRNA
t t J  #6.0 TOO 76.0 00 0 MO Mi) MO
T em perrtu re  (°C)
Detedor |lred_^_ Plot: Derivelivej^j Step SStage 3. atap 3
GAPDH
Tem perature  f € )
Detector jfttel * I Plot jDoti«U*»_^J S e n  Stage 3, step 3 " 3
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HPRT1
Osteocalcin
60 J  66 il 70 0 76 a  60 0 MO 00.0
Tem perature CQ
Deled or ( f r e d j j  Plot ,0«riv*rB_^j Step Stage 3, step 3_f]
T em perature C°C)
Detector ffrad '+ j Plot fcerwalivq Step Stage 3, step 3 ^~]
367
Appendices
Osteonectin
Dissociation Ciave
60 jO 68 jO 70.0 78 0 60J> 88 0 000 08090J9 _
T em perature CO  
Delector l = Z  Ptat iDenvaHre •*’1 Step: Stage 3, step 3 _* j
Alkaline phosphatase
2J0»fr1
2J00&1
1J00E-I
| 1 aooti
IJWM
?oooe-2
00 0 68.0 70 0 78J) 600 ««0 00.0 080
T em peralura f O  
Delector jl r e d ^ J  Ptat D erive**.^] Step Stage 3. step 3 y
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Osteoprotegerin
PtesnaattonCuree
» 0  MO 700 78 0 » 0  MO OOJJ 950
T am par a tu re  <*C>
Detector jfrad ^  j Ptot IDerivefeve * |  Step: {siaqe3 ,s tep3  ^  1
Runx2
.100 61
10O&1
80.0
T em perature  (°C>
Detector |f re d _ ^  Ptot Derivative Step Staoe 3, s te p 3
369
Appendices
Type I collagen
Association Cure
4DQ0 E*2
85.0 70.0 7SJ) 90.0 »  0 90.0 95.0
Temperature <<C>
Detector Itred 1 Ptot jPenvaivB Step jstape 3. step 3 ^  |
370
Appendices
9.3 V ector m aps and sequence reference points
PGEM®-T
Xmnl 1994
Seal
1 8 7 5 /
Nael
2692
f1 ori
Apal
Aatll
Sphl
BstZI
Ncol
Sacll
Amp pGEM®-T
Vector
(3000bp)
lacZ
BstZI
Pstl
Sail
Ndel
Sac I
BstXI
Nsil
ori
t  SP6
1 start 
14 
20 
26 
31 
37 
46
55
62
62
73
75
82
94
103 g 
112 s' 
126 >
17  Transcription Start 
|---------- — ►
5' . . . TGTAA TACGA CTCAC TATAG GGCGA ATTGG GCCCG ACGTC GCATG CTCCC GGCCG 
3 '. . . ACATT ATGCT GAGTG ATATC CCGCT TAACC CGGGC TGCAG CGTAC GAGGG CCGGC
T7 Promoter 1 I I________ I__I________ I I__________ I
Apal Aatll Sphl BstZI
CCATG GCCGC GGGATT3', 
GGTAC CGGCG CCCTA \
c loned  insert)«
Ncol Sacll
ATCAC TAGTG CGGCC GCCTG CAGGT CGACC ATATG 
TTAGTG ATCAC GCCGG CGGAC GTCCA GCTGG TATAC
IL
Spel Not! Pstl Sail
BstZI
Sacl BstXI Nsil
SP6 Promoter
Ndel
SP6 Transcription Start
■< 1
GGAGA GCTCC CAACG CGTTG GATGC ATAGC TTGAG TATTC TATAG TGTCA CCTAA AT . . .  3' 
CCTCT CGAGG GTTGC GCAAC CTACG TATCG AACTC ATAAG ATATC ACAGT GGATT TA . .  . 5'
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pcDNA3. l/V5-Hisc-TOPO
pen
Product
pcDNA3.1/ 
V5-His-TOPO
5523 bp
CAAT TATA 3 end at CMV promotery  I Putative transcript o ra l  start
761 CCCA 77GACG CAAA7GGGCG GTAGGCG7GT ACGG7 GGGAG GTC'CATATAA GCAGAGC7CT CTGGC7AAC7 AGAGAACCCA
■ ■ —-   TT promoter/pnming_5«e______ Mnd III Kpn I BarrtH 1
841 C T G C 77A C 7G  G C 77A 7C G A A  A 77A A 7A CG A  CTCAC7ATAG GGAGACCCAA GC7GGCTAG7 7AA GCT7GG7 ACCGAGCTCG
BstX. I EcoR V ffsIX I N o t  II   I I i
921 GA7CCAC7AG 7C C A G 7G 7G G  7GG AA 77GCC C 7 7 ^ M E 3 J ^ B 3 A g  GGC A A - T c ”  CCA GA7 A7C CAG CAC AG7  GGC
ACC77A ACG G G A F I ^ K 2 - ^ B t 7C  CCG 7 7 A  AG7
L y s  G l y  A s n  S e x  A l a  A s p  l i e  G i n  H i s  S e r  G l y
Xho I Xba I D ra II A pal S ac ll B®« I  V5 eptope__________________________
987 GGC CGC 7CG  AG 7 C 7A  GAG GGC CCG CGG 7 7 C  GAA GG7 AAG C C 7 A7C C C 7 AAC CC7 CTC C7C GG7 CTC
G l y  A r g  S e r  S e r  L e u  G l u  G l y  P r o  A r g  P h e  G i u  G l y  L y s  P r o  H e  P r o  A s n  P r o  L e u  L e u  G l y  L e u
Ago I ________ Poiytvstdine region_________ Pmo I ______ BGH Reverse
10 5 3  GA 7 7 C 7  ACG CG 7 ACC GG 7 CA7 C A 7 CAC CAT CAC CAT 7GA G77TAAACCC GC7GA7CAGC C7CGAC7G7G
A s p  S e r  7 h i  A r g  7 h r  G l y  H i s  H i s  H i s  H i s  H a s  H a s  • • • -------------------
pnmog srte
1122 C C T T C 7 A G 7 7  GCCAGCCATC 7 G 7 T G 7 T 7 G C  CCC7CCCCCG 7G C C T 7C C T 7 GACCC7GGAA GG7GCCAC7C CCACTGTCCT
BGH potyadenytaton  signal
1202 7 7 C C 7 A A 7 A A  AA7GAGGAAA 77G C A 7C G C A  7 7 G 7 C 7 G A G 7  A G G 7G 7CA 77 C7A7TC7G GG GGG7GGGGTG GGGCAGGAC
 Vector prim ers
^  (spanning the cloning site)
EAAT1 N - and C-terminal were cloned into pcDNA3.1 in frame with the vector V5 and His 
epitope tags. The nucleotide sequence o f  the EcoRV restriction site mutated during cloning o f  
EAAT1 TM6-7 (loss o f  2 nucleotides), taking the sequence out o f frame o f the V5 and His 
epitope tags, but having no effect on the translated sequence o f the TM6-7 peptide and 
introducing new stop codons.
BamHI M e t  e a a t i  T M 6 -7
GAGCTCGGATCCGAT^XQGGCCTACCCATCACCTTCAAG^CNGCTGGAAGAGAACAATGGCGTGGAC
aagcgcgtcaocagaJTCgtggatccagcacagtggcggccgctcgagtctagagggcccgcggu
Mutated EcoRV site
g g a I t a a P P t a T t a a T g T g g g M c g a T a c o g q t a c S ^ t c a I t c a I ^ J  
STOP STOP
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9.4 Generation of standard curves with plasmid DNA templates for
absolute QRT-PCR
Mass of a single plasmid can be defined as;
m = [n] [ 1.096x1 O'21 (g/bp)]
where n = plasmid size (bp)
= PGEM-T vector size (3000bp) + insert size, 
m = mass (g)
Example:
1 pi of plasmid DNA solution to be pipetted into each PCR reaction containing lxlO8 
copies of plasmid.
Mass of plasmid that contains lx l 08 copies
= (lx l 08 copies) x (mass of a single plasmid)
Plasmid DNA diluted to workable concentrations then the following formula used to 
calculate the volume needed to prepare the lxlO8 copies/pl standard dilution.
C i V i = C 2 V 2
where
Ci=concentration of stock plasmid (g/pl) containing lx l 08 copies/gl, V2=volume 
required of plasmid at lx l 08 copies/pl.
C2=concentration of stock plasmid (g/pl), V2=volume of stock plasmid required to 
generate plasmid concentration (Ci) of volume (Vi).
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9.5 C alculation of alkaline phosphatase activity
Enzyme a c tiv ity  (nm oles/m in/cell) = _____________V(ul) x O Um w (cm 1) x  1000_______
e x  incubation time (m in) x  cell number (LD H  OD492nm)
where e is the molar extinction coefficient (M^.cm*1) which for pNPP is 1.78 x 104 M*
I.cm'1. OD405nm (cm’1) is the absorbance at 405nm divided by the light-path length 
(cm). V is the final assay volume, i.e. 225pi for a 96-well assay. OD492nm is the 
absorbance of that sample at 492nm following incubation with components of 
Cytotox96 (Promega) to assay for cell number (normalised for sample volume across 
assays).
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9.6 Time-course for glutamate uptake in SaOS-2 cells and primary
human osteoblasts (NHOB2P9)
350
300
250
200
CL
150
100
20
Time (min)
14-C glutamate accumulation in SaOS-2 osteoblasts over time. Osteoblasts were 
incubated with lOpM mix of radiolabelled and unlabelled glutamate at 4 or 37°C for 
different periods of up to 30 min in KRH buffer, followed by aspiration of buffer and 
subsequent rinsing with buffer containing unlabeled glutamate at 1.5 mM. Values 
represent uptake (in pmol) from single wells at 37°C and 4°C.
35
o
Ea.
o»
3a.s
3
to
E3s
0
353020 25151050
Time (min)
14-C glutamate accumulation in primary human osteoblasts (NHOB2P9) over time. 
Osteoblasts were incubated with lOpM mix of radiolabelled and unlabelled glutamate 
at 37°C for different periods of up to 30 min in KRH buffer, followed by aspiration of 
buffer and subsequent rinsing with buffer containing unlabeled glutamate at 1.5 mM. 
Values represent uptake (in pmol) from 4 replicate wells at 37°C ± S.E.M.
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9.7 Standard curve of alizarin red S dissolved in 5% perchloric
acid
Absorbance was measured at 450nm
1.6
1.4 y = 0.0069x-0.0135 
R2= 0.9993
1.0
0.8
0.6
0.4
0.2
0.0
150 25050 100 200
- 0.2 J
Alizarin red  (|jg)
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9.8 EAAT1 topology and amino acid sequence with the coding
sequences for the amino acids cloned into pcDNA3.1/V5-His@- 
TOPO® underlined
The boxes above the sequence correspond to the transmembrane domains.
EAATl G lycosylation
sites
Re-entrant 
loop 2
Re-entrant 
loop 1
C-terminal portion important 
for transport function
1 MTKSNGEEPKMGGRMERFQQGVRKRTLLAKKKVQNITKEDVKSYLFRNAFVLLTVTAVIV
61 GTILGFTLRPYRMSYREVKYFSFPGELLMRMLQMLVLPLIISSLVTGMAALDSKAS GKMG
121 M R A W Y  Y M T T T I I A W I G I 1 1 V I I I H P G K G T K E N M H R E G K I V R V T A A D A F L D L IRNMF P P
181 NLVEACFKQFKTNYEKRSFKVPIQANETLVGAVINNVSEAMETLTRITEELVPVPGSVNG
2 41 VNAL G L W F  SMC F GFVIGNMKEQGQALRE F FDS LNE AIMRL VAVIMWYAPVGIL FLIAGK
□  I   I
301 IVEME DMGVIGGQ L AMYT VT VIVGL LIH AVI VL P L L Y FL VT RKN PWVFIGGL L QALIT AL
361 GTSSSS ATLPITFKCLEENNGVDK RVTRFVL PVGATI NMD GT AL YE AL AAIFIAQVNNFE
421 L N F G Q I I T I S ITATAASIGAAGIPQAGLVTMVIVLTSVGLPTDDITLIIAVDWFLDRLRT
481 TTNVLGDSLGAGIVEHLSRHELKNRDVEMGNSVIEENEMKKPYQLIAQDNETEKPIDSET
541 KM
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ORAL PRESENTATIONS
Speaker
July 2010, B ritish  Orthopaedic Research Society (BORS) annual meeting in  C ardiff, UK. 
Invited to  present a ta lk  entitled ‘Glutamate transporters: a new anabolic therapy in  
bone?’ .
A p ril 2010, R N A C a rd iff jo in t meeting w ith  the B risto l RNA club. Talk entitled ‘Antisense- 
mediated exon skipping o f EAAT1 in human osteoblasts’ .
September 2009, Annual meeting o f C a rd iff Institute o f Tissue Engineering and Repair 
(C ITER). Ta lk entitled ‘Lost in  space -  can we use glutamate to rescue mechanically 
compromised bone?’ .
February 2009, Connective Tissue B io logy Laboratories Seminar Series, C a rd iff University. 
Ta lk entitled ‘Do glutamate transporters regulate bone form ation’ .
June 2008, Bone Research Society (BRS) jo in t meeting w ith  Bone Orthopaedic Research 
Society (BORS) in  Manchester, UK. Invited to  present an oral poster entitled 
‘Glutamate transporter inh ibitors influence osteoblast gene expression’ .
A p ril 2008, Connective Tissue B io logy Laboratories Seminar Series, C ard iff University. Talk 
entitled ‘Glutamate signalling in  bone’ .
Co-author
Mason D.J, W hatling G, Kotw al R.S, Brakspear K , Roberts H , W ilson C, W illiam s R, Sultan 
J and H o lt C .A. (2010). Can jo in t realignment surgery reveal mechanically regulated 
signals that influence pain and pathology in  humans? European Orthopaedic Research 
Society meeting, Davos, Switzerland.
Mason D.J, Brakspear K , W ilson C, W illiam s R and Kotw al R. (2009). Expression o f 
glutamate receptors and transporters in  human subchondral bone in  osteoarthritis. 
B ritish  Association o f Knee Surgeons Annual M eeting, Edinburgh, UK. J Bone Joint 
Surg B r Proceedings; 92-B: 411.
Kotwal R.S, Brakspear K , W ilson C, W illiam s R  and Mason D.J. (2009). Expression o f 
glutamate receptors and transporters in  human meniscus: correlation w ith  anatomical 
locations, pain or pathology. B ritish  Association o f Knee Surgeons Annual Meeting, 
Edinburgh, U K . J Bone Joint Surg B r Proceedings; 92-B: 411.
BOOK CHAPTERS
Mason D, D illingham  C, Evans B, Brakspear K , Jaen K  and Ralphs J. (2009) Interactions 
between osteocytes and osteoblasts in  a novel 3D co-culture system. ‘B io 
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